assay_id,doc_id,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_strain,assay_tissue,assay_cell_type,assay_subcellular_fraction,tid,relationship_type,confidence_score,curated_by,src_id,src_assay_id,chembl_id,cell_id,bao_format,tissue_id,variant_id
1.0,11087.0,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615117,,BAO_0000019,,
2.0,684.0,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615118,,BAO_0000219,,
3.0,15453.0,,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615119,,BAO_0000019,,
4.0,17841.0,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0,,,,,104729.0,H,4.0,Autocuration,1.0,,CHEMBL615120,,BAO_0000249,,
5.0,17430.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001.0,N,1.0,Intermediate,1.0,,CHEMBL615121,163.0,BAO_0000219,,
6.0,17430.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001.0,N,1.0,Intermediate,1.0,,CHEMBL615122,163.0,BAO_0000219,,
7.0,13799.0,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0,,,143B,,80001.0,N,1.0,Intermediate,1.0,,CHEMBL615123,163.0,BAO_0000219,,
8.0,17774.0,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0,,,143B,,80001.0,N,1.0,Expert,1.0,,CHEMBL615124,163.0,BAO_0000219,,
9.0,3801.0,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,143B,,80001.0,N,1.0,Intermediate,1.0,,CHEMBL615125,163.0,BAO_0000219,,
10.0,17430.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001.0,N,1.0,Intermediate,1.0,,CHEMBL615126,163.0,BAO_0000219,,
11.0,17430.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001.0,N,1.0,Intermediate,1.0,,CHEMBL615127,163.0,BAO_0000219,,
12.0,17774.0,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0,,,143B,,80001.0,N,1.0,Expert,1.0,,CHEMBL615128,163.0,BAO_0000219,,
13.0,11324.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185.0,N,1.0,Intermediate,1.0,,CHEMBL857900,,BAO_0000218,,
14.0,11324.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185.0,N,1.0,Intermediate,1.0,,CHEMBL615129,,BAO_0000218,,
15.0,11324.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185.0,N,1.0,Intermediate,1.0,,CHEMBL615130,,BAO_0000218,,
16.0,11324.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185.0,N,1.0,Intermediate,1.0,,CHEMBL615131,,BAO_0000218,,
17.0,11347.0,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100122.0,D,9.0,Expert,1.0,,CHEMBL884521,,BAO_0000357,,
18.0,16474.0,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615132,,BAO_0000357,,
19.0,10091.0,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615133,,BAO_0000019,,
20.0,16474.0,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615134,,BAO_0000357,,
21.0,16474.0,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615135,,BAO_0000357,,
22.0,16474.0,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615136,,BAO_0000357,,
23.0,16474.0,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615137,,BAO_0000357,,
24.0,16474.0,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615138,,BAO_0000357,,
25.0,14352.0,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL836324,,BAO_0000219,,
26.0,5646.0,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615139,,BAO_0000357,,
27.0,5646.0,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615140,,BAO_0000357,,
28.0,10997.0,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12426.0,H,8.0,Autocuration,1.0,,CHEMBL615141,,BAO_0000219,,
29.0,6309.0,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,soya bean,3847.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615142,,BAO_0000357,,
30.0,167.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615143,,BAO_0000357,,
31.0,167.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615144,,BAO_0000357,,
32.0,11087.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL872867,,BAO_0000357,,
33.0,11087.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615145,,BAO_0000357,,
34.0,13622.0,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615146,,BAO_0000357,,
35.0,13622.0,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL615147,,BAO_0000357,,
36.0,11347.0,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615148,,BAO_0000019,,
37.0,5926.0,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615149,,BAO_0000019,,
38.0,4567.0,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615150,,BAO_0000019,,
39.0,3782.0,Dissociation constant towards 16S rRNA construct A,B,,,,,,,,,22222.0,M,3.0,Intermediate,1.0,,CHEMBL615151,,BAO_0000225,,
40.0,3782.0,Dissociation constant towards 16S rRNA construct B,B,,,,,,,,,22222.0,M,3.0,Intermediate,1.0,,CHEMBL615152,,BAO_0000225,,
41.0,4466.0,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263.0,M,3.0,Expert,1.0,,CHEMBL615153,,BAO_0000225,,
42.0,6592.0,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263.0,M,3.0,Expert,1.0,,CHEMBL615154,,BAO_0000225,,
43.0,898.0,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053.0,H,8.0,Autocuration,1.0,,CHEMBL615155,,BAO_0000019,,
44.0,898.0,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053.0,H,8.0,Autocuration,1.0,,CHEMBL615156,,BAO_0000019,,
45.0,13163.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001.0,H,8.0,Autocuration,1.0,,CHEMBL615157,,BAO_0000019,,
46.0,13163.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001.0,H,8.0,Autocuration,1.0,,CHEMBL615158,,BAO_0000019,,
47.0,10691.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971.0,D,9.0,Expert,1.0,,CHEMBL615159,,BAO_0000019,,
48.0,10691.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971.0,D,9.0,Expert,1.0,,CHEMBL615172,,BAO_0000019,,
49.0,10691.0,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971.0,D,9.0,Expert,1.0,,CHEMBL615173,,BAO_0000019,,
50.0,10691.0,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971.0,D,9.0,Expert,1.0,,CHEMBL615174,,BAO_0000019,,
51.0,898.0,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053.0,H,8.0,Autocuration,1.0,,CHEMBL884518,,BAO_0000019,,
52.0,912.0,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,,,,,11512.0,H,8.0,Autocuration,1.0,,CHEMBL615175,,BAO_0000357,,
53.0,912.0,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,,,,,11512.0,H,8.0,Autocuration,1.0,,CHEMBL615176,,BAO_0000357,,
54.0,912.0,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,,,,,11512.0,H,8.0,Autocuration,1.0,,CHEMBL615177,,BAO_0000357,,
55.0,15103.0,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104740.0,D,5.0,Autocuration,1.0,,CHEMBL615178,,BAO_0000249,,
56.0,5116.0,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615179,506.0,BAO_0000219,,
57.0,14578.0,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104835.0,D,7.0,Autocuration,1.0,,CHEMBL615180,,BAO_0000219,,
58.0,14578.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104821.0,D,7.0,Autocuration,1.0,,CHEMBL615181,,BAO_0000219,,
59.0,14578.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104848.0,D,7.0,Autocuration,1.0,,CHEMBL615182,,BAO_0000219,,
60.0,4787.0,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Expert,1.0,,CHEMBL615183,506.0,BAO_0000219,,
61.0,4787.0,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615184,506.0,BAO_0000219,,
62.0,3547.0,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615185,506.0,BAO_0000219,,
63.0,3547.0,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615186,506.0,BAO_0000219,,
64.0,6726.0,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615187,506.0,BAO_0000219,,
65.0,3455.0,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Expert,1.0,,CHEMBL885343,506.0,BAO_0000219,,
66.0,5726.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615188,506.0,BAO_0000219,,
67.0,5726.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615189,506.0,BAO_0000219,,
68.0,5726.0,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615190,506.0,BAO_0000219,,
69.0,3395.0,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615191,506.0,BAO_0000219,,
70.0,3415.0,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Expert,1.0,,CHEMBL615192,506.0,BAO_0000219,,
71.0,3415.0,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Expert,1.0,,CHEMBL827083,506.0,BAO_0000219,,
72.0,17099.0,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Expert,1.0,,CHEMBL615193,506.0,BAO_0000219,,
73.0,17099.0,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615194,506.0,BAO_0000219,,
74.0,17099.0,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615195,506.0,BAO_0000219,,
75.0,17099.0,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002.0,N,1.0,Intermediate,1.0,,CHEMBL615196,506.0,BAO_0000219,,
76.0,17721.0,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0,,,Jurkat,,81072.0,N,1.0,Intermediate,1.0,,CHEMBL615197,503.0,BAO_0000219,,
77.0,1229.0,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL615198,,BAO_0000019,,
78.0,11347.0,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100121.0,D,9.0,Expert,1.0,,CHEMBL615199,,BAO_0000357,,
79.0,17117.0,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231.0,H,8.0,Expert,1.0,,CHEMBL615200,,BAO_0000357,,
80.0,17117.0,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231.0,H,8.0,Expert,1.0,,CHEMBL615201,,BAO_0000357,,
81.0,17117.0,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,,,,,11231.0,H,8.0,Expert,1.0,,CHEMBL615202,,BAO_0000357,,
82.0,11375.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231.0,H,8.0,Autocuration,1.0,,CHEMBL615203,,BAO_0000251,,
83.0,11375.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231.0,H,8.0,Autocuration,1.0,,CHEMBL615204,,BAO_0000251,,
84.0,11375.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231.0,H,8.0,Autocuration,1.0,,CHEMBL615205,,BAO_0000251,,
85.0,11375.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231.0,H,8.0,Autocuration,1.0,,CHEMBL615206,,BAO_0000251,,
86.0,11375.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0,,Liver,,Microsomes,12083.0,H,8.0,Autocuration,1.0,,CHEMBL615207,,BAO_0000251,2107.0,
87.0,791.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0,,,,,11231.0,H,8.0,Autocuration,1.0,,CHEMBL827084,,BAO_0000019,,
88.0,791.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0,,,,,11231.0,H,8.0,Autocuration,1.0,,CHEMBL615208,,BAO_0000019,,
89.0,791.0,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0,,,,,11231.0,H,8.0,Autocuration,1.0,,CHEMBL615209,,BAO_0000019,,
90.0,11375.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083.0,D,9.0,Autocuration,1.0,,CHEMBL615210,,BAO_0000251,2107.0,
91.0,11375.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083.0,D,9.0,Autocuration,1.0,,CHEMBL615211,,BAO_0000251,2107.0,
92.0,153.0,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083.0,D,9.0,Autocuration,1.0,,CHEMBL615212,,BAO_0000251,2107.0,
93.0,8269.0,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,,,,,11377.0,H,8.0,Expert,1.0,,CHEMBL615213,,BAO_0000357,,
94.0,8269.0,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,,,,,11377.0,H,8.0,Expert,1.0,,CHEMBL615273,,BAO_0000357,,
95.0,17653.0,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Expert,1.0,,CHEMBL615274,726.0,BAO_0000219,,
96.0,14277.0,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL615275,726.0,BAO_0000219,,
97.0,1717.0,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL615276,726.0,BAO_0000219,,
98.0,14091.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL615277,726.0,BAO_0000219,,
99.0,14091.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL615326,726.0,BAO_0000219,,
100.0,17653.0,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0,,,,,50606.0,N,1.0,Expert,1.0,,CHEMBL883130,,BAO_0000218,,
101.0,13105.0,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL884519,726.0,BAO_0000219,,
102.0,1717.0,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL615327,726.0,BAO_0000219,,
103.0,13105.0,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL615328,726.0,BAO_0000219,,
104.0,13600.0,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615329,,BAO_0000218,,
105.0,13467.0,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615330,,BAO_0000218,,
106.0,17477.0,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0,,,2.2.15,,50606.0,N,1.0,Expert,1.0,,CHEMBL615331,,BAO_0000218,,
107.0,1593.0,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615332,,BAO_0000218,,
108.0,1593.0,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615333,,BAO_0000218,,
109.0,15089.0,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615334,,BAO_0000218,,
110.0,15089.0,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615335,,BAO_0000218,,
111.0,1593.0,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615336,,BAO_0000218,,
112.0,1593.0,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615337,,BAO_0000218,,
113.0,13600.0,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615338,,BAO_0000218,,
114.0,13467.0,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615339,,BAO_0000218,,
115.0,13467.0,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587.0,N,1.0,Intermediate,1.0,,CHEMBL615340,,BAO_0000218,,
116.0,14764.0,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL615341,726.0,BAO_0000219,,
117.0,6531.0,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0,,,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615342,,BAO_0000251,,
118.0,17322.0,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615343,,BAO_0000019,,
119.0,17072.0,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0,,,2008,,80612.0,N,1.0,Intermediate,1.0,,CHEMBL615344,388.0,BAO_0000219,,
120.0,16936.0,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,2008,,80612.0,N,1.0,Intermediate,1.0,,CHEMBL615345,388.0,BAO_0000219,,
121.0,16936.0,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0,,,2008,,80612.0,N,1.0,Intermediate,1.0,,CHEMBL615346,388.0,BAO_0000219,,
122.0,17146.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0,,,2008,,80612.0,N,1.0,Intermediate,1.0,,CHEMBL615347,388.0,BAO_0000219,,
123.0,17146.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0,,,2008,,80612.0,N,1.0,Intermediate,1.0,,CHEMBL615348,388.0,BAO_0000219,,
124.0,10797.0,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/R,,80613.0,N,1.0,Intermediate,1.0,,CHEMBL827085,561.0,BAO_0000219,,
125.0,10797.0,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/R,,80613.0,N,1.0,Intermediate,1.0,,CHEMBL615349,561.0,BAO_0000219,,
126.0,10797.0,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/S,,80614.0,N,1.0,Intermediate,1.0,,CHEMBL615350,389.0,BAO_0000219,,
127.0,10797.0,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/S,,80614.0,N,1.0,Intermediate,1.0,,CHEMBL615351,389.0,BAO_0000219,,
128.0,4823.0,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0,,,,,100256.0,S,2.0,Expert,1.0,,CHEMBL615352,,BAO_0000220,,
129.0,12912.0,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0,,,,,100256.0,S,2.0,Intermediate,1.0,,CHEMBL615353,,BAO_0000220,,
130.0,2957.0,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,,,,,100256.0,S,2.0,Expert,1.0,,CHEMBL615354,,BAO_0000220,,
131.0,2957.0,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,,,,,100256.0,S,2.0,Expert,1.0,,CHEMBL615355,,BAO_0000220,,
132.0,3260.0,Inhibitory activity against 20S proteosome,B,,,,,,,,,100256.0,S,2.0,Intermediate,1.0,,CHEMBL615356,,BAO_0000220,,
133.0,3451.0,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615357,,BAO_0000019,,
134.0,13885.0,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL615358,726.0,BAO_0000219,,
135.0,13885.0,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020.0,N,1.0,Intermediate,1.0,,CHEMBL827086,726.0,BAO_0000219,,
136.0,3676.0,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615359,,BAO_0000019,,
137.0,6043.0,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,,,,,235.0,H,8.0,Autocuration,1.0,,CHEMBL615360,,BAO_0000357,,
138.0,11140.0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0,,Heart,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615361,,BAO_0000218,948.0,
139.0,10543.0,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640.0,H,8.0,Autocuration,1.0,,CHEMBL615362,,BAO_0000019,,
140.0,10543.0,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640.0,H,8.0,Expert,1.0,,CHEMBL615363,,BAO_0000019,,
141.0,10543.0,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,,,,,19640.0,H,8.0,Autocuration,1.0,,CHEMBL615364,,BAO_0000357,,
142.0,10543.0,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640.0,H,8.0,Expert,1.0,,CHEMBL615365,,BAO_0000019,,
143.0,11365.0,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360.0,N,1.0,Intermediate,1.0,,CHEMBL615366,524.0,BAO_0000219,,
144.0,11365.0,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360.0,N,1.0,Intermediate,1.0,,CHEMBL615367,524.0,BAO_0000219,,
145.0,11803.0,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0,,,PBL,,80384.0,N,1.0,Intermediate,1.0,,CHEMBL615368,554.0,BAO_0000219,,
146.0,11803.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615369,,BAO_0000019,,
147.0,11803.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615370,,BAO_0000019,,
148.0,12278.0,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,,,,,191.0,H,8.0,Autocuration,1.0,,CHEMBL615673,,BAO_0000357,,
149.0,8249.0,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615674,,BAO_0000019,,
150.0,8249.0,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615675,,BAO_0000019,,
151.0,8249.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615676,635.0,BAO_0000219,,
152.0,8249.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615677,635.0,BAO_0000219,,
153.0,8249.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615678,635.0,BAO_0000219,,
154.0,8249.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615679,635.0,BAO_0000219,,
155.0,8249.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615680,,BAO_0000019,,
156.0,8249.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615681,,BAO_0000019,,
157.0,16992.0,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,,,,,104290.0,H,6.0,Autocuration,1.0,,CHEMBL857972,,BAO_0000249,,
158.0,10543.0,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0,,,,,50264.0,N,1.0,Intermediate,1.0,,CHEMBL857899,,BAO_0000218,,
159.0,17833.0,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human herpesvirus 3,10335.0,,,,,50527.0,N,1.0,Intermediate,1.0,,CHEMBL615371,,BAO_0000218,,
160.0,17290.0,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,vericilla zoster virus,10335.0,,,HEL,,50527.0,N,1.0,Expert,1.0,,CHEMBL615372,468.0,BAO_0000218,,
161.0,17290.0,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,vericilla zoster virus,10335.0,,,,,50527.0,N,1.0,Intermediate,1.0,,CHEMBL615373,,BAO_0000218,,
162.0,17290.0,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,vericilla zoster virus,10335.0,,,,,50527.0,N,1.0,Intermediate,1.0,,CHEMBL615374,,BAO_0000218,,
163.0,10932.0,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0,,,,,50145.0,N,1.0,Intermediate,1.0,,CHEMBL615375,,BAO_0000218,,
164.0,9707.0,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615376,,BAO_0000019,,
165.0,2346.0,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0,,,,,11143.0,H,8.0,Expert,1.0,,CHEMBL615377,,BAO_0000249,,
166.0,2205.0,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0,,,,,18077.0,H,8.0,Expert,1.0,,CHEMBL615378,,BAO_0000357,,
167.0,11900.0,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0,,,1-87 tumor cell line,,80609.0,N,1.0,Intermediate,1.0,,CHEMBL615379,832.0,BAO_0000219,,
168.0,14864.0,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL615380,,BAO_0000219,,
169.0,16474.0,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615381,,BAO_0000357,,
170.0,16474.0,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615382,,BAO_0000357,,
171.0,16474.0,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615383,,BAO_0000357,,
172.0,16474.0,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615384,,BAO_0000357,,
173.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615385,,BAO_0000357,,
174.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615386,,BAO_0000357,,
175.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615387,,BAO_0000357,,
176.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615388,,BAO_0000357,,
177.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615214,,BAO_0000357,,
178.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL827087,,BAO_0000357,,
179.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615215,,BAO_0000357,,
180.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615216,,BAO_0000357,,
181.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615217,,BAO_0000357,,
182.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615218,,BAO_0000357,,
183.0,3094.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0,,,,,100171.0,D,9.0,Autocuration,1.0,,CHEMBL615219,,BAO_0000357,,
184.0,10413.0,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615220,,BAO_0000019,,
185.0,16929.0,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0,,,C3H 10T1/2,,80049.0,N,1.0,Intermediate,1.0,,CHEMBL615221,294.0,BAO_0000219,,
186.0,1229.0,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL615222,,BAO_0000019,,
187.0,16587.0,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11489.0,H,8.0,Autocuration,1.0,,CHEMBL615223,,BAO_0000357,,
188.0,16587.0,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11862.0,H,8.0,Autocuration,1.0,,CHEMBL615224,,BAO_0000357,,
189.0,16587.0,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,,,,,11862.0,H,8.0,Autocuration,1.0,,CHEMBL615225,,BAO_0000357,,
190.0,16587.0,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,,,,,11489.0,H,8.0,Autocuration,1.0,,CHEMBL615226,,BAO_0000357,,
191.0,16587.0,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,,,,,11862.0,H,8.0,Autocuration,1.0,,CHEMBL615227,,BAO_0000357,,
192.0,8058.0,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0,,,,,12347.0,D,9.0,Expert,1.0,,CHEMBL615228,,BAO_0000019,,
193.0,9065.0,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0,,,,,100120.0,D,9.0,Expert,1.0,,CHEMBL615229,,BAO_0000357,,
194.0,8865.0,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0,,Adrenal gland,,,100120.0,D,9.0,Expert,1.0,,CHEMBL615230,,BAO_0000357,2369.0,
195.0,9066.0,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120.0,D,9.0,Expert,1.0,,CHEMBL615231,,BAO_0000357,,
196.0,8394.0,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120.0,D,9.0,Expert,1.0,,CHEMBL884520,,BAO_0000357,,
197.0,8394.0,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0,,,,,100120.0,D,9.0,Expert,1.0,,CHEMBL615232,,BAO_0000357,,
198.0,6431.0,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,,,,,10328.0,H,8.0,Autocuration,1.0,,CHEMBL615233,,BAO_0000019,,
199.0,6431.0,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490.0,H,8.0,Autocuration,1.0,,CHEMBL827088,,BAO_0000357,,
200.0,6431.0,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490.0,H,8.0,Autocuration,1.0,,CHEMBL615234,,BAO_0000357,,
201.0,9295.0,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615235,,BAO_0000019,,
202.0,10193.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615236,,BAO_0000019,,
203.0,13622.0,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615237,,BAO_0000019,,
204.0,12079.0,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615238,,BAO_0000019,,
205.0,13622.0,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615239,,BAO_0000019,,
206.0,12079.0,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0,,,,,11134.0,D,9.0,Autocuration,1.0,,CHEMBL615240,,BAO_0000019,,
207.0,13500.0,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,,,,,11835.0,H,8.0,Expert,1.0,,CHEMBL615241,,BAO_0000019,,
208.0,13723.0,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,,,,,11601.0,H,8.0,Expert,1.0,,CHEMBL615242,,BAO_0000357,,
209.0,16474.0,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615243,,BAO_0000019,,
210.0,1630.0,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615244,,BAO_0000019,,
211.0,167.0,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615245,,BAO_0000019,,
212.0,16474.0,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615246,,BAO_0000019,,
213.0,167.0,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615247,,BAO_0000019,,
214.0,16474.0,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,,,,,11134.0,H,8.0,Autocuration,1.0,,CHEMBL615248,,BAO_0000019,,
215.0,10091.0,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,,,,,11601.0,H,8.0,Autocuration,1.0,,CHEMBL615249,,BAO_0000357,,
216.0,11966.0,Tested for inhibition against porcine 12-LO,B,,,,,,,,,11601.0,H,8.0,Autocuration,1.0,,CHEMBL615250,,BAO_0000357,,
217.0,951.0,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615251,,BAO_0000019,,
218.0,10997.0,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615252,,BAO_0000019,,
219.0,10193.0,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,,,,,12052.0,H,8.0,Expert,1.0,,CHEMBL828340,,BAO_0000019,,
220.0,10193.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615253,,BAO_0000019,,
221.0,10193.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615254,,BAO_0000019,,
222.0,10193.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615255,,BAO_0000019,,
223.0,10193.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615256,,BAO_0000019,,
224.0,10193.0,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615257,,BAO_0000019,,
225.0,11087.0,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,,,,,12052.0,H,8.0,Autocuration,1.0,,CHEMBL615258,,BAO_0000019,,
226.0,15569.0,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007.0,N,1.0,Intermediate,1.0,,CHEMBL615259,621.0,BAO_0000219,,
227.0,12989.0,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007.0,N,1.0,Expert,1.0,,CHEMBL615260,621.0,BAO_0000219,,
228.0,16745.0,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,41M,,80007.0,N,1.0,Intermediate,1.0,,CHEMBL615261,621.0,BAO_0000219,,
229.0,15569.0,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007.0,N,1.0,Intermediate,1.0,,CHEMBL615262,621.0,BAO_0000219,,
230.0,12989.0,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007.0,N,1.0,Expert,1.0,,CHEMBL615263,621.0,BAO_0000219,,
231.0,12989.0,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0,,,41M,,80007.0,N,1.0,Expert,1.0,,CHEMBL838393,621.0,BAO_0000219,,
232.0,16745.0,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,41M,,80007.0,N,1.0,Intermediate,1.0,,CHEMBL615264,621.0,BAO_0000219,,
233.0,6210.0,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0,,,,,84.0,D,9.0,Expert,1.0,,CHEMBL615265,,BAO_0000357,,
234.0,6210.0,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0,,,,,68.0,D,9.0,Expert,1.0,,CHEMBL615266,,BAO_0000357,,
235.0,6226.0,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,,,,,68.0,H,8.0,Expert,1.0,,CHEMBL615267,,BAO_0000357,,
236.0,17855.0,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201.0,H,8.0,Expert,1.0,,CHEMBL615268,,BAO_0000357,,
237.0,17855.0,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,,,,,10201.0,H,8.0,Expert,1.0,,CHEMBL615269,,BAO_0000357,,
238.0,17855.0,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201.0,H,8.0,Expert,1.0,,CHEMBL615270,,BAO_0000357,,
239.0,10413.0,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220.0,H,8.0,Autocuration,1.0,,CHEMBL615271,,BAO_0000357,,
240.0,10413.0,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615272,,BAO_0000357,,
241.0,10413.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615103,,BAO_0000357,,
242.0,10413.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615104,,BAO_0000357,,
243.0,10413.0,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220.0,H,8.0,Autocuration,1.0,,CHEMBL615105,,BAO_0000357,,
244.0,10413.0,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220.0,H,8.0,Autocuration,1.0,,CHEMBL872866,,BAO_0000357,,
245.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615106,,BAO_0000357,,
246.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615107,,BAO_0000019,,
247.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615108,,BAO_0000357,,
248.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615109,,BAO_0000357,,
249.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615110,,BAO_0000357,,
250.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL840105,,BAO_0000019,,
251.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615111,,BAO_0000019,,
252.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615112,,BAO_0000019,,
253.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615113,,BAO_0000019,,
254.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615114,,BAO_0000019,,
255.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615115,,BAO_0000357,,
256.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615116,,BAO_0000019,,
257.0,7323.0,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,,,,,11303.0,H,8.0,Autocuration,1.0,,CHEMBL615698,,BAO_0000357,,
258.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615699,,BAO_0000019,,
259.0,7587.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615700,,BAO_0000019,,
260.0,13750.0,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0,,,,,100249.0,H,8.0,Expert,1.0,,CHEMBL615701,,BAO_0000357,,
261.0,7662.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615702,,BAO_0000019,,
262.0,7662.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615703,,BAO_0000019,,
263.0,7662.0,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615704,,BAO_0000019,,
264.0,12211.0,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL615705,,BAO_0000019,,
265.0,12211.0,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL615706,,BAO_0000019,,
266.0,12211.0,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL615707,,BAO_0000221,2116.0,
267.0,12211.0,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL615708,,BAO_0000019,,
268.0,15453.0,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,,,,,121.0,H,8.0,Autocuration,1.0,,CHEMBL615709,,BAO_0000357,,
269.0,11884.0,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615710,,BAO_0000218,,
270.0,7185.0,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL615711,,BAO_0000019,,
271.0,6876.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0,,,,,121.0,D,9.0,Expert,1.0,,CHEMBL615712,,BAO_0000357,,
272.0,6876.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0,,,,,121.0,D,9.0,Expert,1.0,,CHEMBL836325,,BAO_0000357,,
273.0,11863.0,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,,,,,12198.0,H,8.0,Autocuration,1.0,,CHEMBL615713,,BAO_0000019,,
274.0,11863.0,Inhibition constant of high-affinity 5-HT uptake,B,,,,,,,,,12198.0,H,8.0,Autocuration,1.0,,CHEMBL615714,,BAO_0000357,,
275.0,11863.0,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,,,,,12198.0,H,8.0,Autocuration,1.0,,CHEMBL615715,,BAO_0000019,,
276.0,11863.0,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,,,,,12198.0,H,8.0,Autocuration,1.0,,CHEMBL615716,,BAO_0000019,,
277.0,4639.0,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL615717,,BAO_0000019,,
278.0,15796.0,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL881818,,BAO_0000019,,
279.0,15796.0,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL884540,,BAO_0000357,,
280.0,12801.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744.0,D,5.0,Autocuration,1.0,,CHEMBL615718,,BAO_0000224,,
281.0,12801.0,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615719,,BAO_0000224,,
282.0,12120.0,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,,,,Membranes,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615720,,BAO_0000249,,
283.0,12120.0,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,,,,Membranes,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615721,,BAO_0000249,,
284.0,11963.0,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615722,,BAO_0000019,,
285.0,11701.0,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615723,,BAO_0000019,,
286.0,9995.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615724,,BAO_0000221,10000000.0,
287.0,9995.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615725,,BAO_0000221,10000000.0,
288.0,9995.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615726,,BAO_0000221,10000000.0,
289.0,16394.0,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615727,,BAO_0000218,,
290.0,11574.0,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL615728,,BAO_0000019,,
291.0,15779.0,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL857971,449.0,BAO_0000219,,
292.0,15363.0,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL615729,,BAO_0000357,,
293.0,15363.0,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL615730,,BAO_0000019,,
294.0,15329.0,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL615731,,BAO_0000019,,
295.0,15329.0,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL615732,,BAO_0000019,,
296.0,15329.0,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL615733,,BAO_0000019,,
297.0,15329.0,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL615734,,BAO_0000019,,
298.0,15329.0,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL615735,,BAO_0000019,,
299.0,15329.0,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL615736,,BAO_0000019,,
300.0,273.0,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL615737,,BAO_0000221,2116.0,
301.0,273.0,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL615738,,BAO_0000221,2116.0,
302.0,273.0,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL615739,,BAO_0000221,2116.0,
303.0,12092.0,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL615278,,BAO_0000357,,
304.0,1317.0,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,10623.0,D,9.0,Expert,1.0,,CHEMBL615279,,BAO_0000019,,
305.0,12409.0,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Expert,1.0,,CHEMBL615280,,BAO_0000357,,
306.0,11126.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615281,,BAO_0000019,,
307.0,11126.0,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615282,,BAO_0000019,,
308.0,11126.0,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615283,,BAO_0000019,,
309.0,11126.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0,,,HL-60,,80156.0,N,1.0,Autocuration,1.0,,CHEMBL615284,649.0,BAO_0000219,,
310.0,11126.0,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615285,,BAO_0000019,,
311.0,11126.0,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615286,,BAO_0000019,,
312.0,17807.0,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0,,,Oocytes,,104703.0,D,7.0,Autocuration,1.0,,CHEMBL615287,,BAO_0000219,,
313.0,16575.0,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,,,,,100256.0,S,2.0,Intermediate,1.0,,CHEMBL615288,,BAO_0000220,,
314.0,15407.0,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,,,,,100256.0,S,2.0,Intermediate,1.0,,CHEMBL615289,,BAO_0000220,,
315.0,10797.0,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL615290,478.0,BAO_0000219,,
316.0,10797.0,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL884522,478.0,BAO_0000219,,
317.0,3469.0,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615291,,BAO_0000019,,
318.0,16037.0,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,,,,,22222.0,M,3.0,Intermediate,1.0,,CHEMBL615292,,BAO_0000225,,
319.0,16037.0,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,,,,,22222.0,M,3.0,Intermediate,1.0,,CHEMBL615293,,BAO_0000225,,
320.0,16037.0,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222.0,M,3.0,Intermediate,1.0,,CHEMBL615294,,BAO_0000225,,
321.0,16037.0,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222.0,M,3.0,Intermediate,1.0,,CHEMBL615295,,BAO_0000225,,
322.0,16524.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL825021,,BAO_0000019,,
323.0,16524.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615296,,BAO_0000019,,
324.0,16524.0,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615297,,BAO_0000019,,
325.0,16758.0,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615298,,BAO_0000019,,
326.0,16758.0,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615299,,BAO_0000019,,
327.0,16758.0,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615300,,BAO_0000019,,
328.0,14360.0,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,,,,,241.0,H,8.0,Autocuration,1.0,,CHEMBL615301,,BAO_0000357,,
329.0,14360.0,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0,,,,,241.0,D,9.0,Expert,1.0,,CHEMBL615302,,BAO_0000357,,
330.0,9964.0,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615303,,BAO_0000019,,
331.0,9964.0,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615304,,BAO_0000019,,
332.0,9964.0,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615305,,BAO_0000019,,
333.0,9964.0,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615306,,BAO_0000218,,
334.0,9964.0,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615307,,BAO_0000218,,
335.0,9964.0,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615308,,BAO_0000218,,
336.0,9964.0,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615309,,BAO_0000218,,
337.0,9964.0,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615310,,BAO_0000019,,
338.0,9964.0,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615311,,BAO_0000019,,
339.0,9964.0,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615312,,BAO_0000019,,
340.0,9964.0,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615313,,BAO_0000019,,
341.0,9964.0,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615314,,BAO_0000019,,
342.0,9964.0,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615315,,BAO_0000019,,
343.0,9964.0,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615316,,BAO_0000218,,
344.0,9964.0,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615317,,BAO_0000218,,
345.0,9964.0,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615318,,BAO_0000218,,
346.0,9964.0,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615319,,BAO_0000218,,
347.0,9964.0,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615320,,BAO_0000019,,
348.0,9964.0,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,,,,,12132.0,H,8.0,Autocuration,1.0,,CHEMBL615321,,BAO_0000019,,
349.0,3796.0,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615322,,BAO_0000019,,
350.0,4251.0,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL615323,,BAO_0000357,,
351.0,4251.0,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL615407,,BAO_0000357,,
352.0,4251.0,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL857267,,BAO_0000357,,
353.0,4251.0,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL615408,,BAO_0000357,,
354.0,166.0,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL615409,,BAO_0000357,,
355.0,17861.0,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL615410,,BAO_0000357,,
356.0,166.0,Inhibition constant against 3-dehydroquinate synthase,B,,,,,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL615411,,BAO_0000357,,
357.0,166.0,Association rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL615412,,BAO_0000357,,
358.0,166.0,Rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690.0,H,8.0,Autocuration,1.0,,CHEMBL615413,,BAO_0000357,,
359.0,3548.0,Inhibitory activity against fuc-TVII,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615414,,BAO_0000019,,
360.0,9877.0,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615415,,BAO_0000251,2107.0,
361.0,9877.0,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615416,,BAO_0000251,2107.0,
362.0,9877.0,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615417,,BAO_0000251,2107.0,
363.0,9877.0,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615418,,BAO_0000251,2107.0,
364.0,9877.0,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615419,,BAO_0000251,2107.0,
365.0,9877.0,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615420,,BAO_0000251,2107.0,
366.0,9877.0,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615421,,BAO_0000251,2107.0,
367.0,9877.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615422,,BAO_0000251,2107.0,
368.0,9877.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615423,,BAO_0000251,2107.0,
369.0,9877.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL872868,,BAO_0000251,2107.0,
370.0,9877.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236.0,D,9.0,Autocuration,1.0,,CHEMBL615424,,BAO_0000251,2107.0,
371.0,3003.0,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,,,,,104832.0,H,4.0,Autocuration,1.0,,CHEMBL825022,,BAO_0000224,,
372.0,3003.0,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,,,,,104832.0,H,4.0,Autocuration,1.0,,CHEMBL615425,,BAO_0000224,,
373.0,3003.0,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,,,,,104832.0,H,4.0,Autocuration,1.0,,CHEMBL615426,,BAO_0000224,,
374.0,17185.0,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0,,,,,10612.0,D,9.0,Expert,1.0,,CHEMBL615427,,BAO_0000357,,
375.0,6072.0,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616.0,N,1.0,Intermediate,1.0,,CHEMBL615428,844.0,BAO_0000219,,
376.0,6072.0,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616.0,N,1.0,Intermediate,1.0,,CHEMBL615429,844.0,BAO_0000219,,
377.0,5018.0,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0,,,MC-38,,80617.0,N,1.0,Intermediate,1.0,,CHEMBL615430,700.0,BAO_0000219,,
378.0,2852.0,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL615431,,BAO_0000019,,
379.0,8663.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,,,B16,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615432,798.0,BAO_0000218,,
380.0,8663.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,,,B16,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615433,798.0,BAO_0000218,,
381.0,3245.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Human rhinovirus 14,12131.0,,,,,12464.0,D,9.0,Expert,1.0,,CHEMBL615434,,BAO_0000019,,
382.0,3245.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0,,,,,50085.0,N,1.0,Intermediate,1.0,,CHEMBL615435,,BAO_0000218,,
383.0,3877.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0,,,,,50679.0,N,1.0,Intermediate,1.0,,CHEMBL615436,,BAO_0000218,,
384.0,3877.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0,,,,,50679.0,N,1.0,Intermediate,1.0,,CHEMBL615437,,BAO_0000218,,
385.0,5861.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464.0,D,9.0,Expert,1.0,,CHEMBL615438,,BAO_0000019,,
386.0,5861.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464.0,D,9.0,Expert,1.0,,CHEMBL615439,,BAO_0000019,,
387.0,5861.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464.0,D,9.0,Expert,1.0,,CHEMBL615440,,BAO_0000019,,
388.0,5861.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Human rhinovirus 14,12131.0,,,,,12464.0,D,9.0,Expert,1.0,,CHEMBL615441,,BAO_0000019,,
389.0,13748.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0,,,,,50665.0,N,1.0,Intermediate,1.0,,CHEMBL615641,,BAO_0000218,,
390.0,13748.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0,,,,,50665.0,N,1.0,Intermediate,1.0,,CHEMBL872065,,BAO_0000218,,
391.0,13748.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0,,,,,50665.0,N,1.0,Intermediate,1.0,,CHEMBL825023,,BAO_0000218,,
392.0,13748.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0,,,,,50665.0,N,1.0,Intermediate,1.0,,CHEMBL615642,,BAO_0000218,,
393.0,13748.0,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0,,,,,12464.0,H,8.0,Expert,1.0,,CHEMBL615643,,BAO_0000357,,
394.0,17699.0,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615644,,BAO_0000019,,
395.0,7145.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0,,,3EM 37,,80619.0,N,1.0,Intermediate,1.0,,CHEMBL615645,833.0,BAO_0000218,,
396.0,7145.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0,,,3EM 37,,80619.0,N,1.0,Intermediate,1.0,,CHEMBL615646,833.0,BAO_0000218,,
397.0,7145.0,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0,,,3EM 37,,80619.0,N,1.0,Intermediate,1.0,,CHEMBL615647,833.0,BAO_0000218,,
398.0,7145.0,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0,,,3EM 37,,80619.0,N,1.0,Intermediate,1.0,,CHEMBL615648,833.0,BAO_0000218,,
399.0,7145.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619.0,N,1.0,Intermediate,1.0,,CHEMBL615649,833.0,BAO_0000218,,
400.0,7145.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619.0,N,1.0,Intermediate,1.0,,CHEMBL615650,833.0,BAO_0000218,,
401.0,5325.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615651,847.0,BAO_0000218,,
402.0,5325.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615652,847.0,BAO_0000218,,
403.0,5325.0,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Expert,1.0,,CHEMBL615653,847.0,BAO_0000218,,
404.0,16169.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615654,847.0,BAO_0000219,,
405.0,16169.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615655,847.0,BAO_0000219,,
406.0,16169.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL825024,847.0,BAO_0000219,,
407.0,16169.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615656,847.0,BAO_0000219,,
408.0,16169.0,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615657,847.0,BAO_0000219,,
409.0,16169.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615658,847.0,BAO_0000219,,
410.0,16169.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615659,847.0,BAO_0000219,,
411.0,16169.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615660,847.0,BAO_0000219,,
412.0,16169.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615661,847.0,BAO_0000219,,
413.0,16169.0,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615662,847.0,BAO_0000219,,
414.0,16169.0,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615663,847.0,BAO_0000219,,
415.0,16169.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615664,847.0,BAO_0000219,,
416.0,16169.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615665,847.0,BAO_0000219,,
417.0,16169.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615666,847.0,BAO_0000219,,
418.0,16169.0,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615667,847.0,BAO_0000219,,
419.0,16169.0,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615668,847.0,BAO_0000219,,
420.0,16169.0,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615669,847.0,BAO_0000219,,
421.0,16169.0,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615670,847.0,BAO_0000219,,
422.0,16169.0,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL836739,847.0,BAO_0000219,,
423.0,16169.0,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615671,847.0,BAO_0000219,,
424.0,16169.0,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615672,847.0,BAO_0000219,,
425.0,16169.0,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615791,847.0,BAO_0000219,,
426.0,16169.0,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615792,847.0,BAO_0000219,,
427.0,16169.0,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615793,847.0,BAO_0000219,,
428.0,16169.0,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615794,847.0,BAO_0000219,,
429.0,16169.0,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620.0,N,1.0,Intermediate,1.0,,CHEMBL615795,847.0,BAO_0000219,,
430.0,15547.0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0,,,3LLD122,,80621.0,N,1.0,Intermediate,1.0,,CHEMBL615590,971.0,BAO_0000219,,
431.0,8663.0,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615591,,BAO_0000218,,
432.0,8663.0,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615592,,BAO_0000218,,
433.0,8663.0,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615593,,BAO_0000218,,
434.0,8663.0,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615594,,BAO_0000218,,
435.0,4504.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615595,723.0,BAO_0000219,,
436.0,4504.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615596,723.0,BAO_0000219,,
437.0,12695.0,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,,,NIH3T3,,11169.0,H,8.0,Expert,1.0,,CHEMBL615597,723.0,BAO_0000219,,
438.0,12695.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615598,723.0,BAO_0000219,,
439.0,12695.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615599,723.0,BAO_0000219,,
440.0,17642.0,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615600,723.0,BAO_0000219,,
441.0,17642.0,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615601,723.0,BAO_0000219,,
442.0,12340.0,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615602,723.0,BAO_0000219,,
443.0,12340.0,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615603,723.0,BAO_0000219,,
444.0,12716.0,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615604,723.0,BAO_0000219,,
445.0,6277.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615605,723.0,BAO_0000219,,
446.0,6277.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615606,723.0,BAO_0000219,,
447.0,6277.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL884526,723.0,BAO_0000219,,
448.0,6277.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615607,723.0,BAO_0000219,,
449.0,6277.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615608,723.0,BAO_0000219,,
450.0,6277.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615609,723.0,BAO_0000219,,
451.0,6277.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615682,723.0,BAO_0000219,,
452.0,6277.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615683,723.0,BAO_0000219,,
453.0,17780.0,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615684,723.0,BAO_0000218,,
454.0,12751.0,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0,,,,,104860.0,D,7.0,Autocuration,1.0,,CHEMBL615685,,BAO_0000219,,
455.0,12380.0,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615686,723.0,BAO_0000219,,
456.0,14892.0,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615687,723.0,BAO_0000219,,
457.0,12695.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL884523,723.0,BAO_0000219,,
458.0,12695.0,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,,,,,11169.0,H,8.0,Expert,1.0,,CHEMBL615688,,BAO_0000019,,
459.0,12695.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615689,723.0,BAO_0000219,,
460.0,12695.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615690,723.0,BAO_0000219,,
461.0,12695.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,,,,,11169.0,H,8.0,Expert,1.0,,CHEMBL615691,,BAO_0000019,,
462.0,12695.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,,,,,11169.0,H,8.0,Expert,1.0,,CHEMBL615692,,BAO_0000019,,
463.0,6277.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615693,723.0,BAO_0000219,,
464.0,6277.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615324,723.0,BAO_0000219,,
465.0,4959.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,9.0,D,9.0,Expert,1.0,,CHEMBL615325,723.0,BAO_0000219,,
466.0,4959.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,9.0,D,9.0,Expert,1.0,,CHEMBL615490,723.0,BAO_0000219,,
467.0,4959.0,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,188.0,D,9.0,Expert,1.0,,CHEMBL615491,723.0,BAO_0000219,,
468.0,4959.0,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,188.0,D,9.0,Expert,1.0,,CHEMBL615492,723.0,BAO_0000219,,
469.0,12082.0,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615493,723.0,BAO_0000219,,
470.0,12082.0,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615494,723.0,BAO_0000219,,
471.0,12082.0,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615495,723.0,BAO_0000219,,
472.0,12082.0,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615496,723.0,BAO_0000219,,
473.0,2643.0,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615497,723.0,BAO_0000219,,
474.0,11926.0,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615498,723.0,BAO_0000219,,
475.0,15204.0,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615499,723.0,BAO_0000219,,
476.0,15992.0,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL835522,723.0,BAO_0000219,,
477.0,16279.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615500,723.0,BAO_0000219,,
478.0,16279.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615501,723.0,BAO_0000219,,
479.0,16279.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615502,723.0,BAO_0000219,,
480.0,16279.0,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615503,723.0,BAO_0000219,,
481.0,16279.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615504,723.0,BAO_0000219,,
482.0,16279.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615505,723.0,BAO_0000219,,
483.0,12831.0,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Expert,1.0,,CHEMBL615506,723.0,BAO_0000219,,
484.0,13497.0,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951.0,N,1.0,Intermediate,1.0,,CHEMBL615507,723.0,BAO_0000219,,
485.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615508,620.0,BAO_0000218,,
486.0,13618.0,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615509,620.0,BAO_0000219,,
487.0,11902.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615510,620.0,BAO_0000219,,
488.0,11902.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615511,620.0,BAO_0000219,,
489.0,11902.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615512,620.0,BAO_0000219,,
490.0,14840.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615513,620.0,BAO_0000218,,
491.0,14840.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615514,620.0,BAO_0000218,,
492.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615515,620.0,BAO_0000219,,
493.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615516,620.0,BAO_0000219,,
494.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615517,620.0,BAO_0000219,,
495.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615518,620.0,BAO_0000219,,
496.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615519,620.0,BAO_0000219,,
497.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615520,620.0,BAO_0000218,,
498.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615521,620.0,BAO_0000218,,
499.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615522,620.0,BAO_0000218,,
500.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615523,620.0,BAO_0000218,,
501.0,13715.0,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615524,620.0,BAO_0000218,,
502.0,13715.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615525,620.0,BAO_0000218,,
503.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615526,620.0,BAO_0000218,,
504.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615527,620.0,BAO_0000218,,
505.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615528,620.0,BAO_0000218,,
506.0,13715.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615529,620.0,BAO_0000218,,
507.0,13715.0,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615530,620.0,BAO_0000218,,
508.0,13715.0,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615531,620.0,BAO_0000218,,
509.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615532,620.0,BAO_0000219,,
510.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615533,620.0,BAO_0000219,,
511.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615534,620.0,BAO_0000219,,
512.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615535,620.0,BAO_0000218,,
513.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615536,620.0,BAO_0000218,,
514.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615537,620.0,BAO_0000218,,
515.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615538,620.0,BAO_0000218,,
516.0,13715.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL836166,620.0,BAO_0000218,,
517.0,6411.0,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,,,3T3-L1,,11214.0,H,8.0,Expert,1.0,,CHEMBL615539,620.0,BAO_0000219,,
518.0,6411.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615540,620.0,BAO_0000219,,
519.0,6411.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,,,3T3-L1,,11214.0,H,8.0,Expert,1.0,,CHEMBL615541,620.0,BAO_0000219,,
520.0,3966.0,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615542,620.0,BAO_0000219,,
521.0,3966.0,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Intermediate,1.0,,CHEMBL615543,620.0,BAO_0000219,,
522.0,15556.0,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615544,620.0,BAO_0000219,,
523.0,5845.0,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615545,620.0,BAO_0000219,,
524.0,14422.0,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615546,620.0,BAO_0000219,,
525.0,5845.0,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615547,620.0,BAO_0000219,,
526.0,14508.0,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615548,620.0,BAO_0000219,,
527.0,14508.0,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615549,620.0,BAO_0000219,,
528.0,14508.0,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006.0,N,1.0,Expert,1.0,,CHEMBL615550,620.0,BAO_0000219,,
529.0,6349.0,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622.0,N,1.0,Intermediate,1.0,,CHEMBL615551,1118.0,BAO_0000219,,
530.0,15899.0,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622.0,N,1.0,Expert,1.0,,CHEMBL615552,1118.0,BAO_0000219,,
531.0,15899.0,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622.0,N,1.0,Expert,1.0,,CHEMBL615553,1118.0,BAO_0000219,,
532.0,15899.0,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622.0,N,1.0,Expert,1.0,,CHEMBL615554,1118.0,BAO_0000219,,
533.0,15899.0,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622.0,N,1.0,Intermediate,1.0,,CHEMBL615555,1118.0,BAO_0000219,,
534.0,17038.0,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622.0,N,1.0,Expert,1.0,,CHEMBL615556,1118.0,BAO_0000219,,
535.0,12421.0,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615557,,BAO_0000019,,
536.0,12947.0,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615558,,BAO_0000019,,
537.0,12947.0,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL872066,,BAO_0000019,,
538.0,4896.0,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0,,,,,11607.0,D,9.0,Expert,1.0,,CHEMBL615559,,BAO_0000019,,
539.0,6148.0,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615560,,BAO_0000019,,
540.0,16432.0,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615561,,BAO_0000019,,
541.0,4978.0,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,,,,,11607.0,H,8.0,Expert,1.0,,CHEMBL857062,,BAO_0000019,,
542.0,4978.0,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,,,,,11607.0,H,8.0,Expert,1.0,,CHEMBL615562,,BAO_0000019,,
543.0,3723.0,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615563,,BAO_0000019,,
544.0,3518.0,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615564,,BAO_0000357,,
545.0,4164.0,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615565,,BAO_0000019,,
546.0,3518.0,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615566,,BAO_0000019,,
547.0,4164.0,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0,,,,,11607.0,D,9.0,Expert,1.0,,CHEMBL615567,,BAO_0000019,,
548.0,3518.0,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615568,,BAO_0000019,,
549.0,3518.0,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615569,,BAO_0000357,,
550.0,4978.0,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615570,,BAO_0000019,,
551.0,4978.0,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,,,,,11607.0,H,8.0,Autocuration,1.0,,CHEMBL615571,,BAO_0000019,,
552.0,6455.0,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,,,,,104733.0,H,4.0,Autocuration,1.0,,CHEMBL615572,,BAO_0000224,,
553.0,2222.0,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615573,,BAO_0000019,,
554.0,13020.0,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615574,,BAO_0000019,,
555.0,13021.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615575,,BAO_0000019,,
556.0,14532.0,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,,,,,10619.0,H,8.0,Autocuration,1.0,,CHEMBL615576,,BAO_0000357,,
557.0,14118.0,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10619.0,H,8.0,Autocuration,1.0,,CHEMBL615577,,BAO_0000357,,
558.0,11884.0,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615578,,BAO_0000221,10000000.0,
559.0,13969.0,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615579,,BAO_0000357,,
560.0,13392.0,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615580,,BAO_0000357,,
561.0,14430.0,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615581,,BAO_0000019,,
562.0,12248.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615582,,BAO_0000221,10000000.0,
563.0,12249.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615583,,BAO_0000221,10000000.0,
564.0,9995.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615584,,BAO_0000221,10000000.0,
565.0,9995.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL833691,,BAO_0000221,10000000.0,
566.0,9995.0,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615585,,BAO_0000221,10000000.0,
567.0,9995.0,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615586,,BAO_0000221,10000000.0,
568.0,9995.0,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL884524,,BAO_0000221,10000000.0,
569.0,12249.0,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615587,,BAO_0000221,10000000.0,
570.0,11799.0,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615588,,BAO_0000221,10000000.0,
571.0,14331.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL615589,,BAO_0000249,,
572.0,11884.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0,,Hippocampus,,,51.0,H,8.0,Expert,1.0,,CHEMBL615442,,BAO_0000221,10000000.0,
573.0,14331.0,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615443,,BAO_0000221,10000000.0,
574.0,11701.0,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615444,,BAO_0000221,10000000.0,
575.0,11701.0,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,,Hippocampus,,,51.0,H,8.0,Expert,1.0,,CHEMBL615445,,BAO_0000221,10000000.0,
576.0,12248.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615446,,BAO_0000221,10000000.0,
577.0,12248.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615447,449.0,BAO_0000219,,
578.0,12248.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Expert,1.0,,CHEMBL615448,,BAO_0000221,10000000.0,
579.0,12249.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Expert,1.0,,CHEMBL615449,,BAO_0000221,10000000.0,
580.0,12248.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615450,449.0,BAO_0000219,,
581.0,11799.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51.0,H,8.0,Expert,1.0,,CHEMBL615451,,BAO_0000221,10000000.0,
582.0,634.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615452,,BAO_0000357,,
583.0,9995.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615453,,BAO_0000221,10000000.0,
584.0,9995.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615454,,BAO_0000221,10000000.0,
585.0,9995.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615455,,BAO_0000221,10000000.0,
586.0,9995.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615456,,BAO_0000221,10000000.0,
587.0,9995.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615457,,BAO_0000221,10000000.0,
588.0,12210.0,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,,Hippocampus,,,51.0,H,8.0,Expert,1.0,,CHEMBL615458,,BAO_0000218,10000000.0,
589.0,13311.0,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Expert,1.0,,CHEMBL615459,,BAO_0000221,10000000.0,
590.0,2331.0,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL615460,449.0,BAO_0000219,,
591.0,1375.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615461,,BAO_0000019,,
592.0,1375.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615462,,BAO_0000019,,
593.0,11574.0,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615463,,BAO_0000221,10000000.0,
594.0,12867.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615464,,BAO_0000221,2116.0,
595.0,12867.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615465,,BAO_0000221,2116.0,
596.0,12867.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615466,,BAO_0000221,2116.0,
597.0,12867.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615467,,BAO_0000221,2116.0,
598.0,12867.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615468,,BAO_0000221,2116.0,
599.0,12867.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615469,,BAO_0000221,2116.0,
600.0,11574.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615470,,BAO_0000357,,
601.0,13114.0,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615471,,BAO_0000357,,
602.0,13181.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615472,,BAO_0000357,,
603.0,10639.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0,,Hippocampus,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL883242,,BAO_0000221,10000000.0,
604.0,10639.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0,,Hippocampus,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL615473,,BAO_0000221,10000000.0,
605.0,11883.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0,,,CHO,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL615474,449.0,BAO_0000218,,
606.0,17785.0,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615475,,BAO_0000357,,
607.0,1558.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,,,HeLa,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615476,308.0,BAO_0000219,,
608.0,1558.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,,,HeLa,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615477,308.0,BAO_0000219,,
609.0,15740.0,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615478,,BAO_0000019,,
610.0,17624.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615160,449.0,BAO_0000219,,
611.0,17624.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51.0,H,8.0,Expert,1.0,,CHEMBL615161,449.0,BAO_0000219,,
612.0,17624.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615162,449.0,BAO_0000219,,
613.0,17624.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615163,449.0,BAO_0000219,,
614.0,17624.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Expert,1.0,,CHEMBL615164,449.0,BAO_0000219,,
615.0,17624.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Expert,1.0,,CHEMBL615165,449.0,BAO_0000219,,
616.0,17624.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615166,449.0,BAO_0000219,,
617.0,14256.0,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615167,,BAO_0000219,,
618.0,3445.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51.0,D,9.0,Expert,1.0,,CHEMBL615168,308.0,BAO_0000219,,
619.0,3445.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0,,,HeLa,,51.0,D,9.0,Expert,1.0,,CHEMBL615169,308.0,BAO_0000219,,
620.0,17200.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL615170,449.0,BAO_0000219,,
621.0,17200.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL615171,449.0,BAO_0000219,,
622.0,15180.0,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615694,,BAO_0000019,,
623.0,15180.0,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615695,,BAO_0000019,,
624.0,16026.0,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615696,,BAO_0000019,,
625.0,2759.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615697,449.0,BAO_0000219,,
626.0,2759.0,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL859410,449.0,BAO_0000219,,
627.0,2759.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615841,449.0,BAO_0000219,,
628.0,2759.0,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL615842,449.0,BAO_0000219,,
629.0,2759.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL835003,449.0,BAO_0000219,,
630.0,2759.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615843,449.0,BAO_0000219,,
631.0,2759.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL615979,449.0,BAO_0000219,,
632.0,2759.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615980,449.0,BAO_0000219,,
633.0,2759.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL615981,449.0,BAO_0000219,,
634.0,3445.0,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL615982,,BAO_0000019,,
635.0,5272.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL615983,,BAO_0000019,,
636.0,5272.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL615984,,BAO_0000019,,
637.0,5272.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL615985,,BAO_0000019,,
638.0,17624.0,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615986,449.0,BAO_0000219,,
639.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615987,449.0,BAO_0000219,,
640.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615988,449.0,BAO_0000219,,
641.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51.0,H,8.0,Expert,1.0,,CHEMBL615989,449.0,BAO_0000219,,
642.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615990,449.0,BAO_0000219,,
643.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615991,449.0,BAO_0000219,,
644.0,17624.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615992,449.0,BAO_0000219,,
645.0,17624.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615993,449.0,BAO_0000219,,
646.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51.0,H,8.0,Expert,1.0,,CHEMBL615994,449.0,BAO_0000219,,
647.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615995,449.0,BAO_0000219,,
648.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615996,449.0,BAO_0000219,,
649.0,17624.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615997,449.0,BAO_0000219,,
650.0,6563.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615998,,BAO_0000019,,
651.0,6563.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615999,,BAO_0000019,,
652.0,6563.0,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616000,,BAO_0000019,,
653.0,17296.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616001,722.0,BAO_0000219,,
654.0,6876.0,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616002,,BAO_0000019,,
655.0,6876.0,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616003,,BAO_0000019,,
656.0,5272.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616004,,BAO_0000019,,
657.0,5272.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616005,,BAO_0000019,,
658.0,5548.0,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616006,,BAO_0000019,,
659.0,5548.0,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616007,,BAO_0000019,,
660.0,5548.0,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616008,,BAO_0000019,,
661.0,5548.0,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616009,,BAO_0000019,,
662.0,5929.0,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616010,,BAO_0000019,,
663.0,5929.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616011,,BAO_0000019,,
664.0,5929.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL615740,,BAO_0000019,,
665.0,16245.0,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615741,,BAO_0000019,,
666.0,5640.0,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615742,,BAO_0000019,,
667.0,5640.0,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615743,,BAO_0000019,,
668.0,14509.0,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615744,449.0,BAO_0000219,,
669.0,14509.0,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,,,CHO,,51.0,H,8.0,Expert,1.0,,CHEMBL615745,449.0,BAO_0000219,,
670.0,15331.0,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615746,,BAO_0000357,,
671.0,15331.0,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615747,,BAO_0000357,,
672.0,6563.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615748,,BAO_0000019,,
673.0,6563.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615749,,BAO_0000019,,
674.0,6563.0,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615750,,BAO_0000019,,
675.0,6563.0,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616259,,BAO_0000019,,
676.0,6563.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616260,,BAO_0000019,,
677.0,5272.0,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616261,,BAO_0000019,,
678.0,5272.0,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616262,,BAO_0000019,,
679.0,5272.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616263,,BAO_0000019,,
680.0,5272.0,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616264,,BAO_0000019,,
681.0,5272.0,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616265,,BAO_0000019,,
682.0,5272.0,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616266,,BAO_0000019,,
683.0,5272.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616267,,BAO_0000019,,
684.0,5272.0,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616268,,BAO_0000019,,
685.0,16146.0,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616269,,BAO_0000357,,
686.0,17624.0,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL884528,449.0,BAO_0000219,,
687.0,13706.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,,,HEK293,,105.0,D,9.0,Expert,1.0,,CHEMBL616270,722.0,BAO_0000219,,
688.0,15250.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616271,449.0,BAO_0000219,,
689.0,17624.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616272,449.0,BAO_0000219,,
690.0,6861.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616273,,BAO_0000357,,
691.0,17200.0,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616274,,BAO_0000357,,
692.0,17624.0,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616275,449.0,BAO_0000219,,
693.0,17624.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616276,449.0,BAO_0000219,,
694.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616277,,BAO_0000218,,
695.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616278,,BAO_0000218,,
696.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616279,,BAO_0000218,,
697.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616280,,BAO_0000218,,
698.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616281,,BAO_0000218,,
699.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616282,,BAO_0000218,,
700.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616283,,BAO_0000218,,
701.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616284,,BAO_0000218,,
702.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616285,,BAO_0000218,,
703.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616286,,BAO_0000218,,
704.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616287,,BAO_0000218,,
705.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616288,,BAO_0000218,,
706.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL616289,,BAO_0000218,,
707.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615610,,BAO_0000218,,
708.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615611,,BAO_0000218,,
709.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615612,,BAO_0000218,,
710.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615613,,BAO_0000218,,
711.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615614,,BAO_0000218,,
712.0,12058.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615615,,BAO_0000218,,
713.0,11440.0,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,,,,,105093.0,H,4.0,Autocuration,1.0,,CHEMBL615616,,BAO_0000019,,
714.0,6238.0,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,,Hypothalamus,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL615617,,BAO_0000249,1898.0,
715.0,10046.0,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL615618,,BAO_0000019,,
716.0,10046.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL615619,,BAO_0000019,,
717.0,10046.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL615620,,BAO_0000019,,
718.0,167.0,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL615621,,BAO_0000357,,
719.0,167.0,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL615622,,BAO_0000357,,
720.0,11520.0,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615623,,BAO_0000019,,
721.0,11520.0,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615624,,BAO_0000019,,
722.0,11520.0,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615625,,BAO_0000019,,
723.0,11520.0,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL767045,,BAO_0000019,,
724.0,135.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL615626,,BAO_0000019,,
725.0,135.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL615627,,BAO_0000019,,
726.0,11311.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL615628,,BAO_0000019,,
727.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL615629,,BAO_0000357,,
728.0,12281.0,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0,,,,,55.0,D,9.0,Expert,1.0,,CHEMBL615630,,BAO_0000357,,
729.0,11311.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL615631,,BAO_0000219,,
730.0,12576.0,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087.0,H,8.0,Autocuration,1.0,,CHEMBL615632,,BAO_0000218,,
731.0,12281.0,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,,,,,17087.0,H,8.0,Autocuration,1.0,,CHEMBL615633,,BAO_0000357,,
732.0,12576.0,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087.0,H,8.0,Autocuration,1.0,,CHEMBL615634,,BAO_0000218,,
733.0,11089.0,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL615635,,BAO_0000019,,
734.0,11006.0,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL615636,,BAO_0000357,,
735.0,11481.0,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL615637,,BAO_0000357,,
736.0,10864.0,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL615638,702.0,BAO_0000219,,
737.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615639,702.0,BAO_0000219,,
738.0,11311.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615640,702.0,BAO_0000219,,
739.0,11311.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615796,,BAO_0000019,,
740.0,11311.0,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615845,,BAO_0000219,,
741.0,11006.0,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615846,,BAO_0000357,,
742.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615847,702.0,BAO_0000219,,
743.0,11311.0,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615848,,BAO_0000357,,
744.0,11481.0,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615849,,BAO_0000019,,
745.0,11006.0,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615850,,BAO_0000357,,
746.0,11006.0,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615851,,BAO_0000357,,
747.0,11311.0,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615852,,BAO_0000219,,
748.0,11006.0,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL615853,,BAO_0000019,,
749.0,4288.0,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,,Prostate gland,,,120.0,H,8.0,Autocuration,1.0,,CHEMBL884527,,BAO_0000357,2367.0,
750.0,7587.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL872871,,BAO_0000019,,
751.0,7587.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615854,,BAO_0000019,,
752.0,7587.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL767046,,BAO_0000019,,
753.0,11249.0,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,,,,,10732.0,H,8.0,Autocuration,1.0,,CHEMBL615855,,BAO_0000357,,
754.0,8003.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0,,,,,12198.0,D,9.0,Expert,1.0,,CHEMBL615856,,BAO_0000019,,
755.0,8003.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198.0,D,9.0,Expert,1.0,,CHEMBL615857,,BAO_0000019,,
756.0,8003.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198.0,D,9.0,Expert,1.0,,CHEMBL615858,,BAO_0000019,,
757.0,12416.0,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615859,,BAO_0000221,10000000.0,
758.0,16293.0,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615860,,BAO_0000357,,
759.0,13047.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615861,,BAO_0000019,,
760.0,13047.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615862,,BAO_0000019,,
761.0,13047.0,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615863,,BAO_0000019,,
762.0,13047.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615864,,BAO_0000019,,
763.0,10085.0,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615865,,BAO_0000221,10000000.0,
764.0,10085.0,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615866,,BAO_0000221,10000000.0,
765.0,10085.0,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615867,,BAO_0000221,10000000.0,
766.0,9841.0,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615868,,BAO_0000249,,
767.0,8822.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0,,,,,104744.0,D,5.0,Autocuration,1.0,,CHEMBL615869,,BAO_0000249,,
768.0,9806.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744.0,D,5.0,Autocuration,1.0,,CHEMBL615870,,BAO_0000019,,
769.0,9806.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,104744.0,D,5.0,Autocuration,1.0,,CHEMBL615871,,BAO_0000019,,
770.0,8868.0,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615872,,BAO_0000224,,
771.0,9036.0,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,,Hippocampus,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL833492,,BAO_0000221,10000000.0,
772.0,11374.0,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,,Hippocampus,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615873,,BAO_0000221,10000000.0,
773.0,10881.0,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615479,,BAO_0000224,,
774.0,8822.0,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615480,,BAO_0000019,,
775.0,9806.0,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0,,,,,104744.0,D,5.0,Autocuration,1.0,,CHEMBL615481,,BAO_0000249,,
776.0,15463.0,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL872869,,BAO_0000019,,
777.0,15463.0,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615482,,BAO_0000019,,
778.0,14542.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615483,,BAO_0000221,955.0,
779.0,14542.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615484,,BAO_0000221,955.0,
780.0,8569.0,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615485,,BAO_0000019,,
781.0,10062.0,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,104744.0,D,5.0,Autocuration,1.0,,CHEMBL615486,,BAO_0000224,,
782.0,4771.0,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615487,,BAO_0000224,,
783.0,10062.0,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615488,,BAO_0000224,,
784.0,10062.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615489,,BAO_0000224,,
785.0,10062.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615389,,BAO_0000224,,
786.0,15463.0,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615390,,BAO_0000019,,
787.0,15463.0,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615391,,BAO_0000019,,
788.0,9098.0,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615392,,BAO_0000224,,
789.0,3070.0,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615393,,BAO_0000019,,
790.0,14542.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,,Brain,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615394,,BAO_0000221,955.0,
791.0,14542.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615395,,BAO_0000221,955.0,
792.0,6398.0,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615396,,BAO_0000224,,
793.0,1344.0,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,,Brain,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615397,,BAO_0000221,955.0,
794.0,11963.0,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615398,,BAO_0000019,,
795.0,8908.0,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615399,,BAO_0000019,,
796.0,9098.0,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615400,,BAO_0000019,,
797.0,8841.0,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0,,,,,104744.0,D,5.0,Autocuration,1.0,,CHEMBL615401,,BAO_0000019,,
798.0,8814.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615402,,BAO_0000019,,
799.0,11752.0,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615403,,BAO_0000019,,
800.0,11642.0,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,,Brain,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615404,,BAO_0000221,955.0,
801.0,11642.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,,,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615781,,BAO_0000019,,
802.0,9231.0,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,,Brain,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615782,,BAO_0000220,955.0,
803.0,11351.0,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104744.0,H,4.0,Autocuration,1.0,,CHEMBL615783,,BAO_0000221,955.0,
804.0,4639.0,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL873481,,BAO_0000019,,
805.0,1205.0,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL615784,,BAO_0000019,,
806.0,10025.0,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615785,,BAO_0000357,,
807.0,13241.0,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615786,,BAO_0000249,,
808.0,16245.0,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615787,,BAO_0000218,,
809.0,16245.0,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615788,,BAO_0000218,,
810.0,12438.0,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL767044,,BAO_0000019,,
811.0,16245.0,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615789,,BAO_0000218,,
812.0,16245.0,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615790,,BAO_0000218,,
813.0,15740.0,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615813,,BAO_0000019,,
814.0,15535.0,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615814,,BAO_0000219,,
815.0,15535.0,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615815,,BAO_0000219,,
816.0,15535.0,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615816,,BAO_0000219,,
817.0,9888.0,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615817,,BAO_0000249,,
818.0,10085.0,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615818,,BAO_0000221,10000000.0,
819.0,10085.0,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615819,,BAO_0000221,10000000.0,
820.0,17331.0,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,,,,Membranes,10576.0,H,8.0,Expert,1.0,,CHEMBL615820,,BAO_0000249,,
821.0,10845.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615821,,BAO_0000221,10000000.0,
822.0,10845.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615822,,BAO_0000221,10000000.0,
823.0,10845.0,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615823,,BAO_0000221,10000000.0,
824.0,10845.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615824,,BAO_0000221,10000000.0,
825.0,10845.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615825,,BAO_0000221,10000000.0,
826.0,13730.0,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615826,,BAO_0000357,,
827.0,13508.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615827,,BAO_0000249,,
828.0,13508.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615828,,BAO_0000249,10000000.0,
829.0,12073.0,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615829,,BAO_0000221,10000000.0,
830.0,4671.0,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615830,,BAO_0000221,10000000.0,
831.0,13631.0,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615831,,BAO_0000221,10000000.0,
832.0,12438.0,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615832,,BAO_0000357,,
833.0,10483.0,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615833,,BAO_0000019,,
834.0,10483.0,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615834,,BAO_0000221,10000000.0,
835.0,12352.0,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,,,,,10576.0,H,8.0,Intermediate,1.0,,CHEMBL615835,,BAO_0000249,,
836.0,14732.0,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615836,,BAO_0000249,10000000.0,
837.0,11049.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615837,,BAO_0000019,,
838.0,11049.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615838,,BAO_0000019,,
839.0,13657.0,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615839,,BAO_0000249,,
840.0,11473.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL884525,,BAO_0000019,,
841.0,2014.0,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615840,,BAO_0000249,,
842.0,3086.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615405,,BAO_0000221,10000000.0,
843.0,15854.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615406,,BAO_0000019,,
844.0,10922.0,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615900,,BAO_0000221,10000000.0,
845.0,13346.0,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615901,,BAO_0000221,10000000.0,
846.0,15311.0,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615902,,BAO_0000357,,
847.0,10922.0,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615903,,BAO_0000221,10000000.0,
848.0,10025.0,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615904,,BAO_0000357,,
849.0,10025.0,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615905,,BAO_0000357,,
850.0,9742.0,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615906,,BAO_0000019,,
851.0,9742.0,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615907,,BAO_0000019,,
852.0,12304.0,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615908,,BAO_0000019,,
853.0,15789.0,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615909,,BAO_0000221,10000000.0,
854.0,9912.0,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615910,,BAO_0000019,,
855.0,9912.0,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615911,,BAO_0000019,,
856.0,9912.0,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615912,,BAO_0000019,,
857.0,16693.0,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615913,,BAO_0000019,,
858.0,13276.0,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615914,,BAO_0000357,,
859.0,12678.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615915,,BAO_0000221,10000000.0,
860.0,11825.0,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615916,,BAO_0000357,,
861.0,12443.0,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615917,,BAO_0000357,,
862.0,13830.0,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615918,,BAO_0000357,,
863.0,14286.0,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615919,,BAO_0000249,10000000.0,
864.0,14356.0,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615920,,BAO_0000221,10000000.0,
865.0,15306.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615921,,BAO_0000357,,
866.0,15306.0,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615922,,BAO_0000357,,
867.0,16616.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL881290,,BAO_0000249,,
868.0,3651.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615923,,BAO_0000221,10000000.0,
869.0,14331.0,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615924,,BAO_0000221,10000000.0,
870.0,14331.0,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615925,,BAO_0000221,10000000.0,
871.0,14178.0,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615926,,BAO_0000357,,
872.0,10639.0,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615927,,BAO_0000019,,
873.0,12306.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615928,,BAO_0000221,10000000.0,
874.0,1348.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615929,,BAO_0000357,,
875.0,13605.0,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615930,,BAO_0000221,10000000.0,
876.0,17624.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615931,449.0,BAO_0000219,,
877.0,17624.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615932,449.0,BAO_0000219,,
878.0,17624.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615933,449.0,BAO_0000219,,
879.0,15267.0,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615934,,BAO_0000357,,
880.0,16532.0,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615935,,BAO_0000357,,
881.0,6563.0,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615936,,BAO_0000019,,
882.0,4751.0,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615937,449.0,BAO_0000219,,
883.0,15463.0,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615938,,BAO_0000357,,
884.0,3805.0,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615797,,BAO_0000357,,
885.0,5640.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615798,,BAO_0000357,,
886.0,6563.0,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL872870,,BAO_0000357,,
887.0,5548.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615799,,BAO_0000357,,
888.0,6347.0,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615800,,BAO_0000357,,
889.0,17296.0,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615801,722.0,BAO_0000219,,
890.0,13047.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615802,,BAO_0000019,,
891.0,15740.0,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615803,,BAO_0000357,,
892.0,5640.0,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL835002,,BAO_0000019,,
893.0,5640.0,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615804,,BAO_0000019,,
894.0,17211.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,,,HeLa,,51.0,H,8.0,Expert,1.0,,CHEMBL615805,308.0,BAO_0000219,,
895.0,4751.0,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615806,449.0,BAO_0000219,,
896.0,6491.0,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL615807,,BAO_0000357,,
897.0,4707.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615808,,BAO_0000357,,
898.0,13910.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL615809,,BAO_0000357,,
899.0,16190.0,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,,,HeLa,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615810,308.0,BAO_0000219,,
900.0,16633.0,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615811,,BAO_0000357,,
901.0,11898.0,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615812,449.0,BAO_0000219,,
902.0,11898.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615751,449.0,BAO_0000219,,
903.0,14331.0,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615752,,BAO_0000357,,
904.0,17624.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,,,CHO,,51.0,H,8.0,Expert,1.0,,CHEMBL615753,449.0,BAO_0000219,,
905.0,17624.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615754,449.0,BAO_0000219,,
906.0,3307.0,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615755,,BAO_0000357,,
907.0,6563.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL615756,449.0,BAO_0000219,,
908.0,14165.0,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615757,,BAO_0000019,,
909.0,5732.0,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615758,,BAO_0000357,,
910.0,13366.0,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615759,,BAO_0000357,,
911.0,17626.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615760,,BAO_0000357,,
912.0,6588.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,,,HeLa,,51.0,H,8.0,Expert,1.0,,CHEMBL615761,308.0,BAO_0000219,,
913.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL872104,,BAO_0000357,,
914.0,15463.0,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615762,,BAO_0000357,,
915.0,15463.0,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615763,,BAO_0000357,,
916.0,14770.0,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615764,,BAO_0000357,,
917.0,16245.0,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,,,Cell line,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615765,1167.0,BAO_0000219,,
918.0,16245.0,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615766,,BAO_0000019,,
919.0,5548.0,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615767,,BAO_0000357,,
920.0,5548.0,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615768,,BAO_0000357,,
921.0,5548.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615769,,BAO_0000357,,
922.0,6876.0,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615770,,BAO_0000357,,
923.0,2598.0,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615771,,BAO_0000357,,
924.0,17785.0,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615772,,BAO_0000357,,
925.0,6013.0,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615773,,BAO_0000357,,
926.0,5929.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615774,,BAO_0000357,,
927.0,16633.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615775,,BAO_0000357,,
928.0,1558.0,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615776,,BAO_0000357,,
929.0,16026.0,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL615777,,BAO_0000357,,
930.0,12469.0,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615778,,BAO_0000219,,
931.0,15874.0,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL615779,,BAO_0000357,,
932.0,15874.0,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL615780,,BAO_0000357,,
933.0,3935.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616298,,BAO_0000357,,
934.0,15818.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616299,,BAO_0000357,,
935.0,13706.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616300,485.0,BAO_0000219,,
936.0,13729.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,51.0,H,8.0,Expert,1.0,,CHEMBL616301,485.0,BAO_0000219,,
937.0,15413.0,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616302,,BAO_0000019,,
938.0,15413.0,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616117,,BAO_0000019,,
939.0,15413.0,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616118,,BAO_0000019,,
940.0,15413.0,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616119,,BAO_0000019,,
941.0,3445.0,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51.0,D,9.0,Expert,1.0,,CHEMBL616120,308.0,BAO_0000219,,
942.0,15740.0,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616121,,BAO_0000357,,
943.0,15740.0,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616122,,BAO_0000357,,
944.0,17626.0,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616123,,BAO_0000357,,
945.0,4234.0,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616124,,BAO_0000357,,
946.0,5640.0,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616125,,BAO_0000357,,
947.0,5272.0,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616126,,BAO_0000357,,
948.0,4622.0,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616127,449.0,BAO_0000219,,
949.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616128,,BAO_0000019,,
950.0,3025.0,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616129,,BAO_0000357,,
951.0,15315.0,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616130,,BAO_0000357,,
952.0,15267.0,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616131,,BAO_0000357,,
953.0,17158.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,,,HeLa,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616132,308.0,BAO_0000219,,
954.0,14214.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51.0,D,9.0,Expert,1.0,,CHEMBL616133,308.0,BAO_0000219,,
955.0,17133.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616134,,BAO_0000357,,
956.0,16532.0,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616135,,BAO_0000357,,
957.0,2391.0,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616136,,BAO_0000357,,
958.0,14447.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616137,,BAO_0000019,,
959.0,14447.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL872105,,BAO_0000019,,
960.0,15086.0,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616138,,BAO_0000357,,
961.0,13051.0,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616139,,BAO_0000357,,
962.0,16026.0,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616140,,BAO_0000019,,
963.0,17085.0,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616141,,BAO_0000019,,
964.0,17133.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616142,,BAO_0000357,,
965.0,17133.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616143,,BAO_0000357,,
966.0,17211.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616144,308.0,BAO_0000219,,
967.0,17211.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,,,HeLa,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616145,308.0,BAO_0000219,,
968.0,17211.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616012,308.0,BAO_0000219,,
969.0,17211.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616013,308.0,BAO_0000219,,
970.0,16394.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616014,,BAO_0000019,,
971.0,16394.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616015,,BAO_0000019,,
972.0,16394.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616016,,BAO_0000019,,
973.0,16394.0,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616017,,BAO_0000218,,
974.0,16394.0,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616018,,BAO_0000019,,
975.0,15740.0,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616019,,BAO_0000019,,
976.0,15740.0,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616020,,BAO_0000019,,
977.0,15740.0,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL858018,,BAO_0000357,,
978.0,17296.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616021,722.0,BAO_0000219,,
979.0,5640.0,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616022,,BAO_0000019,,
980.0,5640.0,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616023,,BAO_0000019,,
981.0,5640.0,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616024,,BAO_0000019,,
982.0,5640.0,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616025,,BAO_0000019,,
983.0,2759.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616026,449.0,BAO_0000219,,
984.0,16394.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616027,,BAO_0000019,,
985.0,16394.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616028,,BAO_0000019,,
986.0,3445.0,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616029,,BAO_0000019,,
987.0,4316.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,,,CHO,,51.0,H,8.0,Expert,1.0,,CHEMBL616030,449.0,BAO_0000219,,
988.0,4316.0,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616031,,BAO_0000019,,
989.0,15180.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616032,,BAO_0000019,,
990.0,15180.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616033,,BAO_0000019,,
991.0,15042.0,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616034,,BAO_0000019,,
992.0,15042.0,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616035,,BAO_0000019,,
993.0,15042.0,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616036,,BAO_0000019,,
994.0,15042.0,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616037,,BAO_0000019,,
995.0,15042.0,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616038,,BAO_0000019,,
996.0,15042.0,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616039,,BAO_0000019,,
997.0,15042.0,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616040,,BAO_0000019,,
998.0,15180.0,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51.0,D,9.0,Expert,1.0,,CHEMBL616041,308.0,BAO_0000219,,
999.0,15180.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51.0,D,9.0,Expert,1.0,,CHEMBL616042,308.0,BAO_0000219,,
1000.0,15180.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51.0,D,9.0,Expert,1.0,,CHEMBL616043,308.0,BAO_0000219,,
1001.0,16245.0,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616044,,BAO_0000019,,
1002.0,16026.0,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616045,,BAO_0000019,,
1003.0,17296.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616046,722.0,BAO_0000219,,
1004.0,2759.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616047,449.0,BAO_0000219,,
1005.0,2759.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616048,449.0,BAO_0000219,,
1006.0,2759.0,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL616049,449.0,BAO_0000219,,
1007.0,2759.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616050,449.0,BAO_0000219,,
1008.0,15419.0,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616051,,BAO_0000219,,
1009.0,15419.0,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616212,,BAO_0000219,,
1010.0,16026.0,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616213,,BAO_0000019,,
1011.0,1414.0,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616214,,BAO_0000219,,
1012.0,1414.0,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616215,,BAO_0000219,,
1013.0,12861.0,Binding activity radioligand.,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616216,,BAO_0000357,,
1014.0,12861.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616217,,BAO_0000019,,
1015.0,5104.0,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616218,,BAO_0000357,,
1016.0,5105.0,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616219,,BAO_0000357,,
1017.0,16312.0,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616220,,BAO_0000357,,
1018.0,15180.0,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL833493,,BAO_0000357,,
1019.0,5033.0,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616221,,BAO_0000357,,
1020.0,16909.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL616222,449.0,BAO_0000219,,
1021.0,2590.0,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616223,,BAO_0000019,,
1022.0,2590.0,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616224,,BAO_0000019,,
1023.0,16394.0,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616225,,BAO_0000019,,
1024.0,4540.0,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,51.0,D,9.0,Expert,1.0,,CHEMBL616226,722.0,BAO_0000219,,
1025.0,17296.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616227,722.0,BAO_0000219,,
1026.0,17296.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616228,722.0,BAO_0000219,,
1027.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616229,722.0,BAO_0000219,,
1028.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616230,722.0,BAO_0000219,,
1029.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616231,722.0,BAO_0000219,,
1030.0,6166.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616232,,BAO_0000357,,
1031.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616233,722.0,BAO_0000219,,
1032.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL857973,722.0,BAO_0000219,,
1033.0,15316.0,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616234,,BAO_0000219,,
1034.0,14875.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616235,,BAO_0000357,,
1035.0,14727.0,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,HeLa,,51.0,H,8.0,Expert,1.0,,CHEMBL616236,308.0,BAO_0000219,,
1036.0,14727.0,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616237,,BAO_0000019,,
1037.0,15146.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616238,722.0,BAO_0000219,,
1038.0,5213.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616239,722.0,BAO_0000219,,
1039.0,16429.0,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616240,,BAO_0000219,,
1040.0,15042.0,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0,,,HeLa,,51.0,D,9.0,Expert,1.0,,CHEMBL616241,308.0,BAO_0000219,,
1041.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616242,722.0,BAO_0000219,,
1042.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,,,HEK293,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616243,722.0,BAO_0000219,,
1043.0,17200.0,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616244,,BAO_0000357,,
1044.0,13051.0,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Autocuration,1.0,,CHEMBL616245,,BAO_0000357,,
1045.0,5486.0,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616246,,BAO_0000357,,
1046.0,5254.0,Binding affinity against 5-HT1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616247,,BAO_0000357,,
1047.0,5254.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616248,,BAO_0000357,,
1048.0,15331.0,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616249,,BAO_0000357,,
1049.0,13506.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616250,,BAO_0000357,,
1050.0,15267.0,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616251,,BAO_0000357,,
1051.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616252,,BAO_0000218,,
1052.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616253,,BAO_0000218,,
1053.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616254,,BAO_0000218,,
1054.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616255,,BAO_0000218,,
1055.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863.0,D,9.0,Expert,1.0,,CHEMBL832872,,BAO_0000218,,
1056.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616256,,BAO_0000218,,
1057.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616257,,BAO_0000218,,
1058.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616258,,BAO_0000218,,
1059.0,16616.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616384,,BAO_0000218,,
1060.0,10297.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,,Hippocampus,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616385,,BAO_0000221,10000000.0,
1061.0,13704.0,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,,,,,11863.0,H,8.0,Expert,1.0,,CHEMBL616386,,BAO_0000357,,
1062.0,10297.0,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616387,,BAO_0000221,10000000.0,
1063.0,10297.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616388,,BAO_0000221,10000000.0,
1064.0,10297.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616389,,BAO_0000221,10000000.0,
1065.0,10297.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616390,,BAO_0000221,10000000.0,
1066.0,217.0,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616391,,BAO_0000357,,
1067.0,10297.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616392,,BAO_0000221,10000000.0,
1068.0,4921.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616393,,BAO_0000357,,
1069.0,4921.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616394,,BAO_0000357,,
1070.0,4996.0,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616395,,BAO_0000019,,
1071.0,12918.0,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616396,,BAO_0000357,,
1072.0,5333.0,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL872907,,BAO_0000019,,
1073.0,4437.0,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616397,,BAO_0000019,,
1074.0,1742.0,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616398,,BAO_0000019,,
1075.0,16688.0,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616399,,BAO_0000357,,
1076.0,12861.0,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL857065,,BAO_0000357,,
1077.0,12861.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616400,,BAO_0000019,,
1078.0,12861.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616401,,BAO_0000019,,
1079.0,12490.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,,,,,10624.0,H,8.0,Expert,1.0,,CHEMBL616402,,BAO_0000019,,
1080.0,11828.0,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616403,,BAO_0000019,,
1081.0,11866.0,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616404,,BAO_0000221,10000000.0,
1082.0,12827.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616405,,BAO_0000249,,
1083.0,12918.0,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616406,,BAO_0000019,,
1084.0,12919.0,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616407,,BAO_0000019,,
1085.0,13047.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616408,,BAO_0000019,,
1086.0,15796.0,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616409,,BAO_0000249,,
1087.0,3651.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616410,,BAO_0000221,10000000.0,
1088.0,188.0,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616411,,BAO_0000357,,
1089.0,16616.0,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616412,,BAO_0000249,,
1090.0,16616.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616413,,BAO_0000249,10000000.0,
1091.0,12306.0,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616414,,BAO_0000221,10000000.0,
1092.0,17167.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616415,,BAO_0000221,10000000.0,
1093.0,14776.0,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616416,,BAO_0000019,,
1094.0,12158.0,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616417,,BAO_0000357,,
1095.0,13481.0,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616418,,BAO_0000357,,
1096.0,13427.0,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616419,,BAO_0000219,,
1097.0,10210.0,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616420,,BAO_0000357,,
1098.0,10205.0,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616421,,BAO_0000249,,
1099.0,10205.0,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616422,,BAO_0000249,,
1100.0,10205.0,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,,,,Membranes,10576.0,H,8.0,Expert,1.0,,CHEMBL616423,,BAO_0000249,,
1101.0,12280.0,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616424,,BAO_0000357,,
1102.0,17386.0,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616425,,BAO_0000357,,
1103.0,13654.0,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616426,,BAO_0000357,,
1104.0,14423.0,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616427,,BAO_0000221,10000000.0,
1105.0,15412.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616428,,BAO_0000221,10000000.0,
1106.0,12073.0,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616290,,BAO_0000221,10000000.0,
1107.0,4101.0,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616052,,BAO_0000357,,
1108.0,10062.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616053,,BAO_0000357,,
1109.0,6238.0,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616054,,BAO_0000249,,
1110.0,16273.0,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616055,,BAO_0000357,,
1111.0,11139.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616056,,BAO_0000357,,
1112.0,16796.0,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616057,,BAO_0000019,,
1113.0,9548.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616058,,BAO_0000221,955.0,
1114.0,10381.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616059,,BAO_0000221,955.0,
1115.0,13408.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616060,,BAO_0000249,,
1116.0,13825.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616061,,BAO_0000221,10000000.0,
1117.0,11147.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616062,,BAO_0000221,10000000.0,
1118.0,10552.0,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616063,,BAO_0000249,,
1119.0,10552.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616064,,BAO_0000249,2435.0,
1120.0,17136.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616065,,BAO_0000249,,
1121.0,5778.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616066,,BAO_0000249,,
1122.0,13481.0,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616067,,BAO_0000221,10000000.0,
1123.0,13481.0,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616068,,BAO_0000221,10000000.0,
1124.0,13630.0,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Intermediate,1.0,,CHEMBL616069,,BAO_0000221,10000000.0,
1125.0,16245.0,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616070,,BAO_0000249,,
1126.0,14509.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616071,,BAO_0000221,10000000.0,
1127.0,14509.0,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616072,,BAO_0000221,10000000.0,
1128.0,14509.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616073,,BAO_0000221,10000000.0,
1129.0,14509.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616074,,BAO_0000221,10000000.0,
1130.0,14256.0,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616075,,BAO_0000019,,
1131.0,11139.0,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616076,,BAO_0000357,,
1132.0,11047.0,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616077,,BAO_0000019,,
1133.0,11047.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616078,,BAO_0000019,,
1134.0,11047.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616079,,BAO_0000019,,
1135.0,2395.0,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576.0,D,9.0,Expert,1.0,,CHEMBL616080,485.0,BAO_0000219,,
1136.0,9699.0,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616081,,BAO_0000357,,
1137.0,12028.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616082,,BAO_0000221,10000000.0,
1138.0,12028.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616083,,BAO_0000221,10000000.0,
1139.0,5815.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616084,,BAO_0000019,,
1140.0,16616.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616085,,BAO_0000019,,
1141.0,5815.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616086,,BAO_0000019,,
1142.0,2761.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616087,,BAO_0000221,10000000.0,
1143.0,13133.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616088,,BAO_0000357,,
1144.0,10444.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616089,,BAO_0000019,,
1145.0,13278.0,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616090,,BAO_0000357,,
1146.0,15874.0,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616091,,BAO_0000357,,
1147.0,10552.0,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,Membranes,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616092,,BAO_0000249,2435.0,
1148.0,11130.0,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616093,,BAO_0000357,,
1149.0,11130.0,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616094,,BAO_0000218,,
1150.0,14542.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,,Brain,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616095,,BAO_0000221,955.0,
1151.0,13670.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616096,,BAO_0000357,,
1152.0,9888.0,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616097,,BAO_0000249,,
1153.0,3678.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616098,,BAO_0000249,,
1154.0,11332.0,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616099,,BAO_0000221,10000000.0,
1155.0,11332.0,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616100,,BAO_0000221,10000000.0,
1156.0,1185.0,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616101,,BAO_0000357,,
1157.0,2014.0,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616102,,BAO_0000249,,
1158.0,1185.0,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616103,,BAO_0000357,,
1159.0,14429.0,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616104,,BAO_0000019,,
1160.0,16288.0,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616105,,BAO_0000019,,
1161.0,5432.0,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616106,,BAO_0000019,,
1162.0,14429.0,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616107,,BAO_0000019,,
1163.0,13672.0,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616108,,BAO_0000357,,
1164.0,11296.0,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616109,,BAO_0000221,10000000.0,
1165.0,11296.0,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616110,,BAO_0000357,,
1166.0,14749.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,,,CHO,,10576.0,H,8.0,Expert,1.0,,CHEMBL616111,449.0,BAO_0000219,,
1167.0,15086.0,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616112,,BAO_0000019,,
1168.0,13462.0,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616113,,BAO_0000221,10000000.0,
1169.0,15363.0,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616114,,BAO_0000019,,
1170.0,15363.0,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616115,,BAO_0000019,,
1171.0,10796.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616116,,BAO_0000357,,
1172.0,12816.0,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Brain,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615844,,BAO_0000221,955.0,
1173.0,13542.0,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615939,,BAO_0000221,10000000.0,
1174.0,13308.0,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615940,,BAO_0000019,,
1175.0,13541.0,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615941,,BAO_0000221,10000000.0,
1176.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615942,,BAO_0000221,10000000.0,
1177.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615943,,BAO_0000221,10000000.0,
1178.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615944,,BAO_0000221,10000000.0,
1179.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615945,,BAO_0000221,10000000.0,
1180.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615946,,BAO_0000221,10000000.0,
1181.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615947,,BAO_0000221,10000000.0,
1182.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615948,,BAO_0000221,10000000.0,
1183.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615949,,BAO_0000221,10000000.0,
1184.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615950,,BAO_0000221,10000000.0,
1185.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615951,,BAO_0000221,10000000.0,
1186.0,10058.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615952,,BAO_0000221,10000000.0,
1187.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615953,,BAO_0000221,10000000.0,
1188.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615954,,BAO_0000221,10000000.0,
1189.0,10058.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615955,,BAO_0000221,10000000.0,
1190.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615956,,BAO_0000221,10000000.0,
1191.0,10058.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615957,,BAO_0000221,10000000.0,
1192.0,12879.0,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615958,,BAO_0000019,,
1193.0,11964.0,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615959,,BAO_0000019,,
1194.0,11964.0,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615960,,BAO_0000019,,
1195.0,11964.0,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615961,,BAO_0000019,,
1196.0,9548.0,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615962,,BAO_0000221,955.0,
1197.0,9098.0,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615963,,BAO_0000019,,
1198.0,9098.0,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615964,,BAO_0000019,,
1199.0,9098.0,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615965,,BAO_0000019,,
1200.0,13248.0,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,,,CHO,,10576.0,H,8.0,Expert,1.0,,CHEMBL615966,449.0,BAO_0000219,,
1201.0,3147.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615967,,BAO_0000249,,
1202.0,13949.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615968,,BAO_0000019,,
1203.0,11883.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,,,CHO,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615969,449.0,BAO_0000218,,
1204.0,11883.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615970,,BAO_0000218,,
1205.0,11883.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615971,,BAO_0000357,,
1206.0,15535.0,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10576.0,H,8.0,Expert,1.0,,CHEMBL615972,,BAO_0000249,,
1207.0,15535.0,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615973,,BAO_0000249,,
1208.0,15535.0,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615974,,BAO_0000249,,
1209.0,16372.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL615975,449.0,BAO_0000219,,
1210.0,14608.0,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615976,,BAO_0000249,,
1211.0,4795.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL872106,,BAO_0000221,10000000.0,
1212.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615977,,BAO_0000357,,
1213.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615978,,BAO_0000357,,
1214.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616166,,BAO_0000357,,
1215.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616167,,BAO_0000357,,
1216.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616168,,BAO_0000357,,
1217.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616169,,BAO_0000357,,
1218.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616170,,BAO_0000357,,
1219.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616171,,BAO_0000357,,
1220.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616172,,BAO_0000357,,
1221.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616173,,BAO_0000357,,
1222.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616174,,BAO_0000357,,
1223.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616175,,BAO_0000357,,
1224.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616176,,BAO_0000357,,
1225.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616177,,BAO_0000357,,
1226.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616178,,BAO_0000357,,
1227.0,9742.0,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616179,,BAO_0000019,,
1228.0,12073.0,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616180,,BAO_0000357,,
1229.0,4101.0,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616181,,BAO_0000357,,
1230.0,15360.0,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616182,,BAO_0000019,,
1231.0,11576.0,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616183,,BAO_0000221,10000000.0,
1232.0,5834.0,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615874,,BAO_0000019,,
1233.0,2395.0,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576.0,D,9.0,Expert,1.0,,CHEMBL615875,485.0,BAO_0000219,,
1234.0,1375.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615876,,BAO_0000019,,
1235.0,1375.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615877,,BAO_0000019,,
1236.0,3967.0,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615878,,BAO_0000357,,
1237.0,12884.0,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615879,,BAO_0000357,,
1238.0,2343.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL615880,,BAO_0000357,,
1239.0,11511.0,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615881,,BAO_0000019,,
1240.0,11511.0,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL615882,,BAO_0000019,,
1241.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615883,,BAO_0000218,,
1242.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615884,,BAO_0000218,,
1243.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615885,,BAO_0000218,,
1244.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615886,,BAO_0000218,,
1245.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615887,,BAO_0000218,,
1246.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615888,,BAO_0000218,,
1247.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615889,,BAO_0000218,,
1248.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615890,,BAO_0000218,,
1249.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615891,,BAO_0000218,,
1250.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615892,,BAO_0000218,,
1251.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615893,,BAO_0000218,,
1252.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615894,,BAO_0000218,,
1253.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615895,,BAO_0000218,,
1254.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615896,,BAO_0000218,,
1255.0,16394.0,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615897,,BAO_0000218,,
1256.0,16616.0,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL615898,,BAO_0000249,,
1257.0,16796.0,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL615899,,BAO_0000019,,
1258.0,16796.0,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616291,,BAO_0000019,,
1259.0,15629.0,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616292,,BAO_0000357,,
1260.0,13241.0,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616293,,BAO_0000249,,
1261.0,12073.0,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616294,,BAO_0000221,10000000.0,
1262.0,14286.0,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616295,,BAO_0000249,10000000.0,
1263.0,14542.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,,Brain,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616296,,BAO_0000221,955.0,
1264.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616297,,BAO_0000019,,
1265.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616605,,BAO_0000019,,
1266.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616606,,BAO_0000019,,
1267.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616607,,BAO_0000019,,
1268.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616608,,BAO_0000019,,
1269.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616609,,BAO_0000019,,
1270.0,13630.0,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616610,,BAO_0000019,,
1271.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616611,,BAO_0000019,,
1272.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616612,,BAO_0000019,,
1273.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616613,,BAO_0000019,,
1274.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616614,,BAO_0000019,,
1275.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616615,,BAO_0000019,,
1276.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616616,,BAO_0000019,,
1277.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616617,,BAO_0000019,,
1278.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616618,,BAO_0000019,,
1279.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616619,,BAO_0000019,,
1280.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616620,,BAO_0000019,,
1281.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616621,,BAO_0000019,,
1282.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616622,,BAO_0000019,,
1283.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616146,,BAO_0000019,,
1284.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL832873,,BAO_0000019,,
1285.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616147,,BAO_0000019,,
1286.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL872872,,BAO_0000019,,
1287.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616148,,BAO_0000019,,
1288.0,9783.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616149,,BAO_0000221,10000000.0,
1289.0,9783.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616150,,BAO_0000221,10000000.0,
1290.0,14331.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616151,,BAO_0000249,,
1291.0,15260.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL872873,,BAO_0000221,10000000.0,
1292.0,15260.0,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616670,,BAO_0000221,10000000.0,
1293.0,15260.0,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616671,,BAO_0000221,10000000.0,
1294.0,16616.0,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL884861,,BAO_0000249,,
1295.0,15629.0,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616672,,BAO_0000357,,
1296.0,15086.0,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616673,,BAO_0000019,,
1297.0,5717.0,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616674,,BAO_0000019,,
1298.0,12652.0,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616675,,BAO_0000357,,
1299.0,14608.0,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616676,,BAO_0000221,10000000.0,
1300.0,12306.0,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616677,,BAO_0000221,10000000.0,
1301.0,12306.0,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616678,,BAO_0000221,10000000.0,
1302.0,15247.0,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616679,,BAO_0000357,,
1303.0,17529.0,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616680,,BAO_0000221,10000000.0,
1304.0,14826.0,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616681,,BAO_0000221,10000000.0,
1305.0,14826.0,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616682,,BAO_0000221,10000000.0,
1306.0,13241.0,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616683,,BAO_0000221,10000000.0,
1307.0,14093.0,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616684,,BAO_0000221,10000000.0,
1308.0,14093.0,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616685,,BAO_0000221,10000000.0,
1309.0,14442.0,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616686,,BAO_0000221,955.0,
1310.0,9919.0,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616687,,BAO_0000357,,
1311.0,9919.0,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616688,,BAO_0000357,,
1312.0,11440.0,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616689,,BAO_0000221,10000000.0,
1313.0,11257.0,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616690,,BAO_0000357,,
1314.0,10330.0,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616691,,BAO_0000357,,
1315.0,17331.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616692,,BAO_0000221,10000000.0,
1316.0,16567.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616693,,BAO_0000249,,
1317.0,12058.0,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616694,,BAO_0000019,,
1318.0,9699.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616695,,BAO_0000221,10000000.0,
1319.0,9547.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616696,,BAO_0000357,,
1320.0,10330.0,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616697,,BAO_0000357,,
1321.0,14331.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616698,,BAO_0000357,,
1322.0,14060.0,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616949,,BAO_0000019,,
1323.0,14744.0,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616950,,BAO_0000221,10000000.0,
1324.0,13506.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL832875,,BAO_0000357,,
1325.0,10862.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616951,,BAO_0000221,955.0,
1326.0,10862.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616952,,BAO_0000221,955.0,
1327.0,10062.0,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616953,,BAO_0000357,,
1328.0,12073.0,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616954,,BAO_0000357,,
1329.0,14875.0,GTPgammaS radioligand binding assay,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616955,,BAO_0000357,,
1330.0,2391.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616956,,BAO_0000357,,
1331.0,2391.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616957,,BAO_0000019,,
1332.0,2391.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616958,,BAO_0000019,,
1333.0,2391.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616959,,BAO_0000357,,
1334.0,2391.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616960,,BAO_0000357,,
1335.0,2391.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616961,,BAO_0000019,,
1336.0,17211.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,,,HeLa,,106.0,H,8.0,Expert,1.0,,CHEMBL616962,308.0,BAO_0000219,,
1337.0,17211.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,,,HeLa,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616963,308.0,BAO_0000219,,
1338.0,6491.0,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616524,,BAO_0000357,,
1339.0,16190.0,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616525,449.0,BAO_0000219,,
1340.0,14165.0,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL872908,,BAO_0000019,,
1341.0,14165.0,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616526,,BAO_0000019,,
1342.0,4234.0,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616527,,BAO_0000357,,
1343.0,6328.0,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616528,,BAO_0000219,,
1344.0,14770.0,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616529,,BAO_0000357,,
1345.0,2598.0,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616530,,BAO_0000357,,
1346.0,6897.0,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616531,,BAO_0000357,,
1347.0,6897.0,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616532,,BAO_0000357,,
1348.0,6013.0,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616533,,BAO_0000357,,
1349.0,5843.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616534,,BAO_0000357,,
1350.0,14454.0,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616535,,BAO_0000357,,
1351.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616536,,BAO_0000357,,
1352.0,3935.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616537,,BAO_0000357,,
1353.0,13729.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,106.0,H,8.0,Expert,1.0,,CHEMBL616538,485.0,BAO_0000219,,
1354.0,14251.0,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616539,,BAO_0000019,,
1355.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616540,,BAO_0000019,,
1356.0,3025.0,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616429,,BAO_0000357,,
1357.0,15315.0,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616430,,BAO_0000357,,
1358.0,14214.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616431,,BAO_0000219,,
1359.0,3804.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616432,,BAO_0000357,,
1360.0,2391.0,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616433,,BAO_0000357,,
1361.0,4175.0,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616434,,BAO_0000357,,
1362.0,17296.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616435,449.0,BAO_0000219,,
1363.0,17085.0,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616436,,BAO_0000019,,
1364.0,17211.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616437,308.0,BAO_0000219,,
1365.0,17211.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,,,HeLa,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616438,308.0,BAO_0000219,,
1366.0,17211.0,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616439,308.0,BAO_0000219,,
1367.0,15926.0,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616440,,BAO_0000357,,
1368.0,16312.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,,,CHO-K1,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616441,485.0,BAO_0000219,,
1369.0,5843.0,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616442,,BAO_0000357,,
1370.0,5843.0,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616443,,BAO_0000357,,
1371.0,16312.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,,,CHO-K1,,106.0,H,8.0,Expert,1.0,,CHEMBL616444,485.0,BAO_0000219,,
1372.0,15926.0,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616445,,BAO_0000357,,
1373.0,15926.0,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616446,,BAO_0000357,,
1374.0,4540.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,106.0,D,9.0,Expert,1.0,,CHEMBL616447,449.0,BAO_0000219,,
1375.0,6166.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616448,,BAO_0000357,,
1376.0,17296.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616449,449.0,BAO_0000219,,
1377.0,17296.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616450,449.0,BAO_0000219,,
1378.0,17296.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL857974,449.0,BAO_0000219,,
1379.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616451,449.0,BAO_0000219,,
1380.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616452,449.0,BAO_0000219,,
1381.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616453,449.0,BAO_0000219,,
1382.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616454,449.0,BAO_0000219,,
1383.0,14875.0,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616455,,BAO_0000357,,
1384.0,15146.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616456,449.0,BAO_0000219,,
1385.0,5213.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616457,,BAO_0000357,,
1386.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616458,449.0,BAO_0000219,,
1387.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616459,449.0,BAO_0000219,,
1388.0,14454.0,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616460,,BAO_0000019,,
1389.0,14454.0,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616461,,BAO_0000019,,
1390.0,14875.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616462,449.0,BAO_0000219,,
1391.0,14875.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616463,449.0,BAO_0000219,,
1392.0,15250.0,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616464,,BAO_0000019,,
1393.0,15250.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616465,449.0,BAO_0000219,,
1394.0,15086.0,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,17105.0,H,8.0,Autocuration,1.0,,CHEMBL832874,,BAO_0000357,,
1395.0,3025.0,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616184,,BAO_0000019,,
1396.0,14998.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616185,,BAO_0000019,,
1397.0,14998.0,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0,,,,,106.0,H,8.0,Intermediate,1.0,,CHEMBL616186,,BAO_0000019,,
1398.0,14998.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616187,,BAO_0000019,,
1399.0,13969.0,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616188,,BAO_0000357,,
1400.0,13392.0,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577.0,D,9.0,Intermediate,1.0,,CHEMBL873475,,BAO_0000357,,
1401.0,3651.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0,,Striatum,,,10577.0,D,9.0,Expert,1.0,,CHEMBL616189,,BAO_0000019,2435.0,
1402.0,10025.0,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616190,,BAO_0000357,,
1403.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616191,,BAO_0000357,,
1404.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616192,,BAO_0000357,,
1405.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616193,,BAO_0000357,,
1406.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616194,,BAO_0000357,,
1407.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616195,,BAO_0000357,,
1408.0,13863.0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616196,,BAO_0000357,,
1409.0,4622.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616197,,BAO_0000249,10000000.0,
1410.0,14911.0,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Intermediate,1.0,,CHEMBL616198,,BAO_0000019,,
1411.0,12678.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616199,,BAO_0000221,10000000.0,
1412.0,12678.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616200,,BAO_0000221,10000000.0,
1413.0,14235.0,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616201,,BAO_0000221,10000000.0,
1414.0,14949.0,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616202,,BAO_0000221,10000000.0,
1415.0,14949.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616203,,BAO_0000221,10000000.0,
1416.0,14949.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616204,,BAO_0000221,10000000.0,
1417.0,14949.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616205,,BAO_0000221,10000000.0,
1418.0,14949.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616206,,BAO_0000221,10000000.0,
1419.0,16118.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616207,,BAO_0000249,,
1420.0,3268.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616208,,BAO_0000249,,
1421.0,3268.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616209,,BAO_0000249,,
1422.0,16117.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616210,,BAO_0000357,,
1423.0,9783.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616211,,BAO_0000221,10000000.0,
1424.0,9783.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616504,,BAO_0000221,10000000.0,
1425.0,14356.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616505,,BAO_0000221,10000000.0,
1426.0,15740.0,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616506,,BAO_0000019,,
1427.0,12306.0,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL872107,,BAO_0000221,10000000.0,
1428.0,13348.0,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616507,,BAO_0000221,10000000.0,
1429.0,10394.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616303,,BAO_0000249,,
1430.0,15260.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616304,,BAO_0000221,10000000.0,
1431.0,10046.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616305,,BAO_0000221,10000000.0,
1432.0,15260.0,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,,Hippocampus,,,10576.0,H,8.0,Intermediate,1.0,,CHEMBL616306,,BAO_0000221,10000000.0,
1433.0,12851.0,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616307,,BAO_0000357,,
1434.0,2148.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL881829,,BAO_0000221,10000000.0,
1435.0,13134.0,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616308,,BAO_0000357,,
1436.0,12462.0,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616309,,BAO_0000019,,
1437.0,12462.0,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616310,,BAO_0000019,,
1438.0,12462.0,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,,,CHO,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616311,449.0,BAO_0000219,,
1439.0,11933.0,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616312,,BAO_0000357,,
1440.0,11933.0,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616313,,BAO_0000357,,
1441.0,403.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616314,,BAO_0000221,10000000.0,
1442.0,15538.0,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616315,,BAO_0000221,10000000.0,
1443.0,15538.0,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616567,,BAO_0000221,10000000.0,
1444.0,15538.0,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616568,,BAO_0000221,10000000.0,
1445.0,12464.0,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,,,,,10576.0,H,8.0,Intermediate,1.0,,CHEMBL616569,,BAO_0000019,,
1446.0,1455.0,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616570,,BAO_0000357,,
1447.0,12652.0,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616571,,BAO_0000357,,
1448.0,12639.0,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616572,,BAO_0000221,10000000.0,
1449.0,13949.0,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616573,,BAO_0000249,,
1450.0,12463.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616574,,BAO_0000357,,
1451.0,14829.0,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616575,,BAO_0000221,10000000.0,
1452.0,14829.0,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL872108,,BAO_0000221,10000000.0,
1453.0,12092.0,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616576,,BAO_0000357,,
1454.0,403.0,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616577,,BAO_0000249,,
1455.0,403.0,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616578,,BAO_0000249,,
1456.0,3967.0,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616579,,BAO_0000357,,
1457.0,12771.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616580,,BAO_0000019,,
1458.0,15086.0,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616581,,BAO_0000019,,
1459.0,14909.0,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616582,,BAO_0000221,10000000.0,
1460.0,14949.0,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616583,,BAO_0000221,10000000.0,
1461.0,2309.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616584,,BAO_0000221,10000000.0,
1462.0,4170.0,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616585,,BAO_0000357,,
1463.0,11642.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616586,,BAO_0000221,10000000.0,
1464.0,11642.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616587,,BAO_0000221,10000000.0,
1465.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616588,,BAO_0000221,10000000.0,
1466.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616589,,BAO_0000221,10000000.0,
1467.0,12953.0,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616590,,BAO_0000221,10000000.0,
1468.0,12903.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,,,CHO,,10576.0,H,8.0,Expert,1.0,,CHEMBL616591,449.0,BAO_0000219,,
1469.0,12536.0,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616592,,BAO_0000357,,
1470.0,10058.0,The inhibition activity of 5-HT1A at 1 uM,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616593,,BAO_0000357,,
1471.0,12902.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,CHO-K1,,10576.0,H,8.0,Expert,1.0,,CHEMBL616594,485.0,BAO_0000219,,
1472.0,14057.0,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616595,,BAO_0000249,,
1473.0,11296.0,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616596,,BAO_0000357,,
1474.0,11296.0,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616597,,BAO_0000221,10000000.0,
1475.0,11296.0,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616598,,BAO_0000221,10000000.0,
1476.0,16616.0,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616599,,BAO_0000249,,
1477.0,16616.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616600,,BAO_0000249,10000000.0,
1478.0,16567.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616601,,BAO_0000019,,
1479.0,16567.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616602,,BAO_0000019,,
1480.0,16567.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616603,,BAO_0000019,,
1481.0,16567.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616604,,BAO_0000019,,
1482.0,17136.0,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616316,,BAO_0000249,,
1483.0,17136.0,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616317,,BAO_0000249,,
1484.0,16616.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616318,,BAO_0000019,,
1485.0,17331.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616319,,BAO_0000221,10000000.0,
1486.0,17331.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616320,,BAO_0000221,10000000.0,
1487.0,17167.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616321,,BAO_0000221,10000000.0,
1488.0,15740.0,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616322,,BAO_0000019,,
1489.0,15740.0,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616323,,BAO_0000019,,
1490.0,4671.0,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616324,,BAO_0000357,,
1491.0,10058.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616325,,BAO_0000221,10000000.0,
1492.0,10058.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616326,,BAO_0000221,10000000.0,
1493.0,10058.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616327,,BAO_0000221,10000000.0,
1494.0,12073.0,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616328,,BAO_0000357,,
1495.0,2759.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL858110,,BAO_0000249,,
1496.0,2759.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616329,,BAO_0000249,,
1497.0,2759.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616330,,BAO_0000249,,
1498.0,2759.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616331,,BAO_0000249,,
1499.0,2759.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616332,,BAO_0000249,,
1500.0,9737.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL857063,,BAO_0000249,955.0,
1501.0,9737.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616333,,BAO_0000019,,
1502.0,5717.0,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616334,,BAO_0000019,,
1503.0,12253.0,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616335,,BAO_0000221,10000000.0,
1504.0,14025.0,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616336,,BAO_0000019,,
1505.0,10425.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616337,,BAO_0000249,,
1506.0,14998.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616338,,BAO_0000019,,
1507.0,13694.0,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616339,,BAO_0000221,10000000.0,
1508.0,13694.0,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616340,,BAO_0000221,10000000.0,
1509.0,4342.0,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616341,,BAO_0000357,,
1510.0,12936.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616342,,BAO_0000357,,
1511.0,13144.0,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616343,,BAO_0000019,,
1512.0,13343.0,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616344,,BAO_0000019,,
1513.0,12132.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616345,,BAO_0000357,,
1514.0,15419.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616346,,BAO_0000019,,
1515.0,1479.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616347,,BAO_0000221,10000000.0,
1516.0,14287.0,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616348,,BAO_0000019,,
1517.0,13116.0,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616349,,BAO_0000357,,
1518.0,2759.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576.0,D,9.0,Expert,1.0,,CHEMBL616152,,BAO_0000249,,
1519.0,2759.0,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616153,,BAO_0000249,,
1520.0,14748.0,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616154,,BAO_0000019,,
1521.0,12304.0,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616155,,BAO_0000019,,
1522.0,12409.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616156,,BAO_0000221,10000000.0,
1523.0,12409.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576.0,D,9.0,Expert,1.0,,CHEMBL616157,,BAO_0000221,10000000.0,
1524.0,13267.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616158,,BAO_0000221,10000000.0,
1525.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616159,,BAO_0000357,,
1526.0,14256.0,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL616160,,BAO_0000357,,
1527.0,16567.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616161,,BAO_0000019,,
1528.0,15740.0,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616162,,BAO_0000019,,
1529.0,13278.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL616163,,BAO_0000357,,
1530.0,1970.0,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10626.0,H,8.0,Expert,1.0,,CHEMBL616164,,BAO_0000249,,
1531.0,10034.0,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,,Brain,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616165,,BAO_0000221,955.0,
1532.0,13348.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616355,,BAO_0000019,,
1533.0,13630.0,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616356,,BAO_0000019,,
1534.0,10862.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616357,,BAO_0000221,955.0,
1535.0,12058.0,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL616358,,BAO_0000019,,
1536.0,4639.0,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616359,,BAO_0000357,,
1537.0,15453.0,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616360,,BAO_0000357,,
1538.0,4820.0,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616361,,BAO_0000357,,
1539.0,1089.0,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616362,,BAO_0000357,,
1540.0,386.0,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,,,,Brain membranes,51.0,H,8.0,Autocuration,1.0,,CHEMBL616363,,BAO_0000249,,
1541.0,6011.0,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616364,,BAO_0000357,,
1542.0,5014.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616365,,BAO_0000357,,
1543.0,4402.0,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616366,,BAO_0000357,,
1544.0,17066.0,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL872906,,BAO_0000357,,
1545.0,17515.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616367,,BAO_0000357,,
1546.0,2474.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616368,,BAO_0000357,,
1547.0,4775.0,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616369,,BAO_0000357,,
1548.0,14294.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616370,,BAO_0000357,,
1549.0,14294.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL616371,,BAO_0000357,,
1550.0,12249.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616372,449.0,BAO_0000219,,
1551.0,11376.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL616373,,BAO_0000219,,
1552.0,2474.0,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616374,,BAO_0000218,,
1553.0,13311.0,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616375,,BAO_0000221,10000000.0,
1554.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616376,,BAO_0000357,,
1555.0,1633.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,,,,,51.0,H,8.0,Expert,1.0,,CHEMBL857064,,BAO_0000357,,
1556.0,11866.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616377,,BAO_0000357,,
1557.0,4373.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616378,,BAO_0000357,,
1558.0,4687.0,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616379,,BAO_0000357,,
1559.0,16946.0,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616380,,BAO_0000357,,
1560.0,13291.0,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616381,,BAO_0000357,,
1561.0,14159.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616382,,BAO_0000357,,
1562.0,10812.0,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616383,,BAO_0000357,,
1563.0,3032.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,11863.0,D,9.0,Expert,1.0,,CHEMBL616350,449.0,BAO_0000219,,
1564.0,16655.0,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616351,,BAO_0000357,,
1565.0,14532.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616352,,BAO_0000357,,
1566.0,13944.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616353,,BAO_0000357,,
1567.0,13033.0,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616354,,BAO_0000357,,
1568.0,10321.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616508,,BAO_0000357,,
1569.0,2968.0,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616559,,BAO_0000357,,
1570.0,13964.0,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616560,,BAO_0000357,,
1571.0,15527.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616561,,BAO_0000357,,
1572.0,12248.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616562,449.0,BAO_0000219,,
1573.0,12249.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616563,449.0,BAO_0000219,,
1574.0,15120.0,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616564,,BAO_0000357,,
1575.0,13313.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616565,,BAO_0000357,,
1576.0,2613.0,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616566,,BAO_0000218,,
1577.0,16700.0,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616989,,BAO_0000357,,
1578.0,2201.0,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL857975,,BAO_0000357,,
1579.0,1274.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863.0,D,9.0,Expert,1.0,,CHEMBL616990,,BAO_0000357,,
1580.0,1317.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616991,,BAO_0000357,,
1581.0,12146.0,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616992,,BAO_0000357,,
1582.0,14059.0,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863.0,H,8.0,Autocuration,1.0,,CHEMBL616993,,BAO_0000357,,
1583.0,14025.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616994,,BAO_0000019,,
1584.0,14025.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616995,,BAO_0000019,,
1585.0,14447.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105571.0,D,9.0,Intermediate,1.0,,CHEMBL616996,722.0,BAO_0000219,,
1586.0,3025.0,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616997,,BAO_0000218,,
1587.0,3025.0,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616998,,BAO_0000218,,
1588.0,15329.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616999,,BAO_0000019,,
1589.0,15329.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617000,,BAO_0000019,,
1590.0,15847.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617001,,BAO_0000019,,
1591.0,15847.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL858111,,BAO_0000019,,
1592.0,14165.0,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617002,,BAO_0000019,,
1593.0,14214.0,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617003,,BAO_0000019,,
1594.0,14214.0,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617004,,BAO_0000019,,
1595.0,14214.0,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL617005,,BAO_0000019,,
1596.0,13729.0,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0,,,CHO-K1,,106.0,D,9.0,Expert,1.0,,CHEMBL616623,485.0,BAO_0000219,,
1597.0,3025.0,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616624,449.0,BAO_0000219,,
1598.0,2391.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL883243,,BAO_0000357,,
1599.0,2391.0,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616625,,BAO_0000019,,
1600.0,14956.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616626,449.0,BAO_0000219,,
1601.0,2598.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616627,449.0,BAO_0000219,,
1602.0,2598.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616628,449.0,BAO_0000219,,
1603.0,2598.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616629,449.0,BAO_0000219,,
1604.0,2598.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616630,449.0,BAO_0000219,,
1605.0,14956.0,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL616631,,BAO_0000019,,
1606.0,14956.0,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616632,,BAO_0000019,,
1607.0,14214.0,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL616633,,BAO_0000357,,
1608.0,3463.0,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616634,449.0,BAO_0000219,,
1609.0,15331.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616635,,BAO_0000357,,
1610.0,16146.0,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL885358,,BAO_0000357,,
1611.0,14159.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,106.0,D,9.0,Expert,1.0,,CHEMBL616636,449.0,BAO_0000219,,
1612.0,14158.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616637,449.0,BAO_0000219,,
1613.0,14159.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616638,,BAO_0000357,,
1614.0,15250.0,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616639,449.0,BAO_0000219,,
1615.0,15250.0,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616640,449.0,BAO_0000219,,
1616.0,15331.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616641,449.0,BAO_0000219,,
1617.0,15332.0,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616642,449.0,BAO_0000219,,
1618.0,14956.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616643,449.0,BAO_0000219,,
1619.0,3805.0,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616644,,BAO_0000357,,
1620.0,14875.0,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616645,,BAO_0000357,,
1621.0,14454.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616646,,BAO_0000019,,
1622.0,14454.0,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616647,,BAO_0000019,,
1623.0,16288.0,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616509,,BAO_0000357,,
1624.0,16288.0,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616510,,BAO_0000357,,
1625.0,16312.0,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616511,,BAO_0000357,,
1626.0,1348.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616512,,BAO_0000357,,
1627.0,5834.0,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616513,,BAO_0000357,,
1628.0,13366.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616514,,BAO_0000019,2435.0,
1629.0,1414.0,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616515,,BAO_0000357,,
1630.0,14998.0,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616516,,BAO_0000019,,
1631.0,11473.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616517,,BAO_0000357,,
1632.0,11473.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616518,,BAO_0000357,,
1633.0,10639.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616519,,BAO_0000357,,
1634.0,10639.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616520,,BAO_0000357,,
1635.0,1375.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616521,,BAO_0000357,,
1636.0,1375.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616522,,BAO_0000357,,
1637.0,16532.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL884531,,BAO_0000357,,
1638.0,11147.0,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616523,,BAO_0000357,,
1639.0,13366.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616731,,BAO_0000019,2435.0,
1640.0,10444.0,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616732,,BAO_0000019,,
1641.0,16532.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616733,,BAO_0000357,,
1642.0,16532.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616734,,BAO_0000357,,
1643.0,12827.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616735,,BAO_0000249,,
1644.0,12827.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616736,,BAO_0000249,,
1645.0,12919.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616737,,BAO_0000019,,
1646.0,14025.0,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616738,,BAO_0000019,,
1647.0,12919.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616739,,BAO_0000019,,
1648.0,12919.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616740,,BAO_0000019,,
1649.0,12919.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616741,,BAO_0000019,,
1650.0,14447.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616742,722.0,BAO_0000219,,
1651.0,1375.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616743,,BAO_0000019,,
1652.0,1375.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616744,,BAO_0000019,,
1653.0,12409.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616745,,BAO_0000019,,
1654.0,12409.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616746,,BAO_0000019,,
1655.0,12409.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616747,,BAO_0000019,,
1656.0,12409.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616748,,BAO_0000019,,
1657.0,12409.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616648,,BAO_0000019,,
1658.0,11574.0,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616649,,BAO_0000357,,
1659.0,1558.0,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616650,,BAO_0000357,,
1660.0,12409.0,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616651,,BAO_0000218,,
1661.0,12409.0,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616652,,BAO_0000218,,
1662.0,12409.0,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616653,,BAO_0000218,,
1663.0,12409.0,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616654,,BAO_0000218,,
1664.0,12253.0,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616655,,BAO_0000019,,
1665.0,12936.0,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616656,,BAO_0000357,,
1666.0,13181.0,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616657,,BAO_0000019,,
1667.0,12409.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0,,Striatum,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616658,,BAO_0000357,2435.0,
1668.0,10639.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570.0,D,9.0,Intermediate,1.0,,CHEMBL616659,,BAO_0000357,,
1669.0,5254.0,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL616660,,BAO_0000357,,
1670.0,13051.0,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616661,,BAO_0000357,,
1671.0,3463.0,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616662,,BAO_0000019,,
1672.0,15315.0,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616663,,BAO_0000019,,
1673.0,6011.0,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616664,,BAO_0000019,,
1674.0,14159.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL881820,449.0,BAO_0000219,,
1675.0,14159.0,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616665,449.0,BAO_0000219,,
1676.0,15250.0,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616666,449.0,BAO_0000219,,
1677.0,15250.0,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616667,449.0,BAO_0000219,,
1678.0,15331.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616668,449.0,BAO_0000219,,
1679.0,15332.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL616669,449.0,BAO_0000219,,
1680.0,15332.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL617040,449.0,BAO_0000219,,
1681.0,3294.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617041,449.0,BAO_0000219,,
1682.0,14158.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL617042,449.0,BAO_0000219,,
1683.0,14956.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL617043,449.0,BAO_0000219,,
1684.0,12469.0,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617044,,BAO_0000019,,
1685.0,3463.0,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL617045,449.0,BAO_0000219,,
1686.0,15250.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL617046,449.0,BAO_0000219,,
1687.0,15250.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL617047,449.0,BAO_0000219,,
1688.0,14956.0,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL617048,,BAO_0000019,,
1689.0,14159.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616897,,BAO_0000019,,
1690.0,14159.0,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616898,,BAO_0000019,,
1691.0,14499.0,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL858201,449.0,BAO_0000219,,
1692.0,15315.0,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616899,,BAO_0000019,,
1693.0,3294.0,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616900,,BAO_0000219,,
1694.0,3463.0,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616901,449.0,BAO_0000219,,
1695.0,15331.0,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616902,,BAO_0000357,,
1696.0,14159.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL616903,449.0,BAO_0000219,,
1697.0,14158.0,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616904,449.0,BAO_0000219,,
1698.0,14159.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616905,,BAO_0000357,,
1699.0,15250.0,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616906,449.0,BAO_0000219,,
1700.0,15250.0,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616907,449.0,BAO_0000219,,
1701.0,15331.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616908,449.0,BAO_0000219,,
1702.0,15332.0,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL616909,449.0,BAO_0000219,,
1703.0,14499.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL616910,449.0,BAO_0000219,,
1704.0,15332.0,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616911,449.0,BAO_0000219,,
1705.0,14956.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL616912,449.0,BAO_0000219,,
1706.0,3805.0,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616913,,BAO_0000357,,
1707.0,6011.0,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL616914,449.0,BAO_0000219,,
1708.0,16190.0,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616915,449.0,BAO_0000219,,
1709.0,14165.0,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616916,,BAO_0000019,,
1710.0,4234.0,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616917,,BAO_0000357,,
1711.0,15527.0,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616918,,BAO_0000357,,
1712.0,6328.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616919,,BAO_0000219,,
1713.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616920,,BAO_0000357,,
1714.0,14770.0,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL872914,,BAO_0000357,,
1715.0,2598.0,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616921,,BAO_0000357,,
1716.0,6897.0,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616922,,BAO_0000357,,
1717.0,6013.0,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616923,,BAO_0000357,,
1718.0,5843.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616924,,BAO_0000357,,
1719.0,14454.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL875909,,BAO_0000357,,
1720.0,14454.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616925,,BAO_0000357,,
1721.0,14454.0,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616926,,BAO_0000357,,
1722.0,15818.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616927,,BAO_0000357,,
1723.0,13729.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,105.0,H,8.0,Expert,1.0,,CHEMBL616928,485.0,BAO_0000219,,
1724.0,6011.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616929,,BAO_0000219,,
1725.0,4234.0,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616930,,BAO_0000357,,
1726.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616931,,BAO_0000019,,
1727.0,3025.0,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616932,,BAO_0000357,,
1728.0,15315.0,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616933,,BAO_0000357,,
1729.0,14214.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616934,,BAO_0000219,,
1730.0,3804.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616935,,BAO_0000357,,
1731.0,16700.0,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616936,,BAO_0000357,,
1732.0,2391.0,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616937,,BAO_0000357,,
1733.0,4175.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616938,,BAO_0000357,,
1734.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616939,,BAO_0000019,,
1735.0,17085.0,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616940,,BAO_0000019,,
1736.0,15926.0,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616941,,BAO_0000357,,
1737.0,16312.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,,,CHO-K1,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616942,485.0,BAO_0000219,,
1738.0,16312.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,,,CHO-K1,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616943,485.0,BAO_0000219,,
1739.0,14956.0,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,,,CHO,,104802.0,H,4.0,Autocuration,1.0,,CHEMBL616944,449.0,BAO_0000219,,
1740.0,3294.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616945,,BAO_0000019,,
1741.0,12861.0,Binding activity radioligand.,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616946,,BAO_0000357,,
1742.0,12861.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616947,,BAO_0000019,,
1743.0,16312.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO-K1,,105.0,H,8.0,Expert,1.0,,CHEMBL616948,485.0,BAO_0000219,,
1744.0,5104.0,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616851,,BAO_0000357,,
1745.0,5105.0,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616852,,BAO_0000357,,
1746.0,14499.0,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616853,,BAO_0000357,,
1747.0,15926.0,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616854,,BAO_0000357,,
1748.0,4540.0,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,105.0,D,9.0,Expert,1.0,,CHEMBL616855,449.0,BAO_0000219,,
1749.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616856,449.0,BAO_0000219,,
1750.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616857,449.0,BAO_0000219,,
1751.0,6166.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616858,,BAO_0000357,,
1752.0,15779.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616859,449.0,BAO_0000219,,
1753.0,15779.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616860,449.0,BAO_0000219,,
1754.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616861,722.0,BAO_0000219,,
1755.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616541,722.0,BAO_0000219,,
1756.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,,,HEK293,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616542,722.0,BAO_0000219,,
1757.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616543,449.0,BAO_0000219,,
1758.0,14875.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL616544,,BAO_0000357,,
1759.0,15146.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616545,449.0,BAO_0000219,,
1760.0,5213.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616546,,BAO_0000357,,
1761.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616547,449.0,BAO_0000219,,
1762.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616548,449.0,BAO_0000219,,
1763.0,14454.0,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616549,,BAO_0000019,,
1764.0,14454.0,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616550,,BAO_0000019,,
1765.0,5254.0,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL857066,,BAO_0000357,,
1766.0,5254.0,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616551,,BAO_0000357,,
1767.0,10639.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616552,,BAO_0000357,,
1768.0,10639.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL832876,,BAO_0000019,,
1769.0,12352.0,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616553,,BAO_0000019,,
1770.0,9098.0,Binding affinity towards 5-HT1B was determined,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616554,,BAO_0000357,,
1771.0,14430.0,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616555,,BAO_0000019,,
1772.0,13657.0,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616556,,BAO_0000019,,
1773.0,13657.0,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616557,,BAO_0000019,,
1774.0,15854.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616558,,BAO_0000019,,
1775.0,10639.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10577.0,D,9.0,Expert,1.0,,CHEMBL616749,,BAO_0000019,,
1776.0,10025.0,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616750,,BAO_0000357,,
1777.0,10025.0,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616751,,BAO_0000357,,
1778.0,14286.0,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616752,,BAO_0000249,,
1779.0,3651.0,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616753,,BAO_0000019,2435.0,
1780.0,14178.0,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577.0,D,9.0,Expert,1.0,,CHEMBL616754,,BAO_0000357,,
1781.0,10639.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616755,,BAO_0000019,,
1782.0,13605.0,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616756,,BAO_0000019,2435.0,
1783.0,5834.0,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616757,,BAO_0000019,2435.0,
1784.0,10922.0,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616758,,BAO_0000357,2435.0,
1785.0,14286.0,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616759,,BAO_0000249,,
1786.0,11825.0,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616760,,BAO_0000357,,
1787.0,14826.0,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616761,,BAO_0000019,2435.0,
1788.0,9699.0,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616762,,BAO_0000019,2435.0,
1789.0,14423.0,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616763,,BAO_0000019,,
1790.0,10062.0,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL872909,,BAO_0000357,,
1791.0,10062.0,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616764,,BAO_0000357,,
1792.0,12280.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577.0,D,9.0,Expert,1.0,,CHEMBL616765,,BAO_0000357,,
1793.0,15412.0,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616766,,BAO_0000357,2435.0,
1794.0,15412.0,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616767,,BAO_0000357,2435.0,
1795.0,10062.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616768,,BAO_0000357,,
1796.0,11147.0,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616769,,BAO_0000357,,
1797.0,9547.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616770,,BAO_0000019,,
1798.0,10444.0,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616771,,BAO_0000019,,
1799.0,12469.0,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,,Striatum,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616772,,BAO_0000019,2435.0,
1800.0,9098.0,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616773,,BAO_0000019,,
1801.0,9098.0,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616774,,BAO_0000019,,
1802.0,9699.0,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616775,,BAO_0000357,,
1803.0,10394.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616776,,BAO_0000249,,
1804.0,12092.0,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616777,,BAO_0000357,,
1805.0,16700.0,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616778,,BAO_0000357,,
1806.0,403.0,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,10577.0,D,9.0,Expert,1.0,,CHEMBL616779,,BAO_0000249,,
1807.0,12771.0,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577.0,D,9.0,Expert,1.0,,CHEMBL616780,,BAO_0000357,,
1808.0,11642.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616781,,BAO_0000019,,
1809.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616782,,BAO_0000357,,
1810.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616783,,BAO_0000357,,
1811.0,12953.0,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,,Striatum,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616784,,BAO_0000019,2435.0,
1812.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616785,,BAO_0000357,,
1813.0,9737.0,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL857067,,BAO_0000249,955.0,
1814.0,9737.0,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616786,,BAO_0000019,,
1815.0,9737.0,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616787,,BAO_0000249,955.0,
1816.0,12827.0,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616788,,BAO_0000357,,
1817.0,5033.0,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616789,,BAO_0000357,,
1818.0,9786.0,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,10577.0,D,9.0,Expert,1.0,,CHEMBL616790,,BAO_0000019,,
1819.0,13116.0,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577.0,H,8.0,Expert,1.0,,CHEMBL616791,,BAO_0000357,,
1820.0,16429.0,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616792,,BAO_0000019,,
1821.0,12409.0,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0,,,,,10577.0,D,9.0,Expert,1.0,,CHEMBL616793,,BAO_0000249,,
1822.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616794,,BAO_0000357,,
1823.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL616795,,BAO_0000357,,
1824.0,5486.0,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616796,,BAO_0000019,,
1825.0,4639.0,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616797,,BAO_0000357,,
1826.0,386.0,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,,,,Brain membranes,106.0,H,8.0,Autocuration,1.0,,CHEMBL616798,,BAO_0000249,,
1827.0,2474.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616799,,BAO_0000357,,
1828.0,6011.0,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616800,,BAO_0000357,,
1829.0,5014.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616801,,BAO_0000357,,
1830.0,17515.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616802,,BAO_0000357,,
1831.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616803,,BAO_0000357,,
1832.0,1633.0,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,,,,,106.0,H,8.0,Expert,1.0,,CHEMBL857068,,BAO_0000357,,
1833.0,1633.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616804,,BAO_0000357,,
1834.0,4373.0,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616805,,BAO_0000357,,
1835.0,4687.0,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616806,,BAO_0000357,,
1836.0,11574.0,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616807,,BAO_0000357,,
1837.0,10321.0,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616808,,BAO_0000357,,
1838.0,15527.0,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616809,,BAO_0000357,,
1839.0,17200.0,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616810,,BAO_0000357,,
1840.0,14423.0,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,104802.0,H,4.0,Autocuration,1.0,,CHEMBL616811,,BAO_0000224,,
1841.0,5834.0,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616812,,BAO_0000357,,
1842.0,11473.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616813,,BAO_0000357,,
1843.0,11473.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616814,,BAO_0000357,,
1844.0,10639.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616815,,BAO_0000357,,
1845.0,10639.0,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616816,,BAO_0000357,,
1846.0,14331.0,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616817,,BAO_0000357,,
1847.0,10796.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616818,,BAO_0000357,,
1848.0,9098.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL616819,,BAO_0000357,,
1849.0,14331.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL616820,,BAO_0000357,,
1850.0,11828.0,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL616821,,BAO_0000019,,
1851.0,11866.0,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616822,,BAO_0000357,,
1852.0,13047.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616823,,BAO_0000019,,
1853.0,188.0,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616824,,BAO_0000357,,
1854.0,11825.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616825,,BAO_0000357,,
1855.0,11825.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616826,,BAO_0000357,,
1856.0,11624.0,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Expert,1.0,,CHEMBL616827,,BAO_0000019,,
1857.0,11139.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616828,,BAO_0000357,,
1858.0,11147.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616829,,BAO_0000357,,
1859.0,10444.0,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616830,,BAO_0000019,,
1860.0,11624.0,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Expert,1.0,,CHEMBL616831,,BAO_0000357,,
1861.0,11662.0,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616832,,BAO_0000019,,
1862.0,11662.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616833,,BAO_0000019,,
1863.0,11662.0,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Expert,1.0,,CHEMBL616834,,BAO_0000019,,
1864.0,11662.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL829595,,BAO_0000019,,
1865.0,9098.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616835,,BAO_0000357,,
1866.0,10394.0,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL872910,,BAO_0000249,,
1867.0,11933.0,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL616836,,BAO_0000357,,
1868.0,12092.0,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616837,,BAO_0000357,,
1869.0,12253.0,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616466,,BAO_0000019,,
1870.0,12253.0,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0,,,HEK293,,12689.0,D,9.0,Autocuration,1.0,,CHEMBL616467,722.0,BAO_0000219,,
1871.0,1558.0,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616468,,BAO_0000357,,
1872.0,2474.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616469,,BAO_0000357,,
1873.0,2474.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL616470,,BAO_0000357,,
1874.0,11574.0,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL616471,,BAO_0000357,,
1875.0,1558.0,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL616472,,BAO_0000357,,
1876.0,13944.0,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL616473,,BAO_0000357,,
1877.0,13033.0,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL616474,,BAO_0000357,,
1878.0,10321.0,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL616475,,BAO_0000357,,
1879.0,11866.0,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL616476,,BAO_0000357,,
1880.0,14454.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616477,,BAO_0000019,,
1881.0,11574.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616478,,BAO_0000224,,
1882.0,11574.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616479,,BAO_0000224,,
1883.0,13631.0,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616480,,BAO_0000019,,
1884.0,9630.0,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL616481,,BAO_0000019,,
1885.0,8822.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL616482,,BAO_0000249,,
1886.0,9064.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL884713,,BAO_0000221,955.0,
1887.0,8868.0,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616483,,BAO_0000224,,
1888.0,9064.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616484,,BAO_0000224,,
1889.0,9806.0,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616485,,BAO_0000019,,
1890.0,9098.0,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616486,,BAO_0000224,,
1891.0,8868.0,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616487,,BAO_0000224,,
1892.0,12765.0,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616488,,BAO_0000224,,
1893.0,11049.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616489,,BAO_0000019,,
1894.0,11049.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616490,,BAO_0000019,,
1895.0,11049.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616491,,BAO_0000019,,
1896.0,11049.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616492,,BAO_0000019,,
1897.0,11049.0,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616493,,BAO_0000019,,
1898.0,11473.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616494,,BAO_0000019,,
1899.0,11473.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616495,,BAO_0000019,,
1900.0,3086.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616496,,BAO_0000019,,
1901.0,11049.0,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616497,,BAO_0000019,,
1902.0,11049.0,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616498,,BAO_0000019,,
1903.0,10639.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616499,,BAO_0000019,,
1904.0,10922.0,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616500,,BAO_0000019,,
1905.0,9064.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL616501,,BAO_0000221,955.0,
1906.0,10748.0,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,,Brain,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616502,,BAO_0000221,955.0,
1907.0,11614.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL884529,,BAO_0000249,,
1908.0,11615.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616503,,BAO_0000249,,
1909.0,11615.0,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616964,,BAO_0000224,,
1910.0,11614.0,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616965,,BAO_0000249,,
1911.0,11702.0,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616966,,BAO_0000224,,
1912.0,11702.0,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616967,,BAO_0000224,,
1913.0,11702.0,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL616968,,BAO_0000224,,
1914.0,11702.0,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616969,,BAO_0000224,,
1915.0,13346.0,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL884530,,BAO_0000019,,
1916.0,10025.0,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616970,,BAO_0000224,,
1917.0,10025.0,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616971,,BAO_0000224,,
1918.0,10025.0,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616972,,BAO_0000224,,
1919.0,9036.0,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616973,,BAO_0000224,,
1920.0,9036.0,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616974,,BAO_0000224,,
1921.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616975,,BAO_0000019,,
1922.0,12304.0,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616976,,BAO_0000019,,
1923.0,13276.0,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616977,,BAO_0000224,,
1924.0,11825.0,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616978,,BAO_0000224,,
1925.0,12443.0,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616979,,BAO_0000224,,
1926.0,13830.0,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616980,,BAO_0000224,,
1927.0,9592.0,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616981,,BAO_0000249,,
1928.0,9592.0,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616982,,BAO_0000249,,
1929.0,10881.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616983,,BAO_0000224,,
1930.0,13605.0,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616984,,BAO_0000019,,
1931.0,11624.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL616985,,BAO_0000224,,
1932.0,4101.0,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616986,,BAO_0000224,,
1933.0,4101.0,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616987,,BAO_0000224,,
1934.0,15360.0,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL616988,,BAO_0000019,,
1935.0,11576.0,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617243,,BAO_0000019,,
1936.0,5834.0,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617244,,BAO_0000019,,
1937.0,2395.0,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617245,485.0,BAO_0000219,,
1938.0,11965.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617246,,BAO_0000249,,
1939.0,3967.0,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617546,,BAO_0000224,,
1940.0,11130.0,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,,,,Brain membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617547,,BAO_0000249,,
1941.0,13427.0,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617548,,BAO_0000219,,
1942.0,9443.0,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617549,,BAO_0000224,,
1943.0,9443.0,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617550,,BAO_0000224,,
1944.0,11825.0,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617551,,BAO_0000224,,
1945.0,12120.0,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617552,,BAO_0000249,,
1946.0,12120.0,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617553,,BAO_0000249,,
1947.0,11963.0,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,,Thoracic aorta,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617554,,BAO_0000019,1515.0,
1948.0,9069.0,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617555,,BAO_0000019,,
1949.0,8868.0,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617556,,BAO_0000224,,
1950.0,17200.0,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL617557,,BAO_0000357,,
1951.0,17200.0,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL617558,,BAO_0000357,,
1952.0,13969.0,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,17106.0,H,8.0,Expert,1.0,,CHEMBL617559,,BAO_0000357,,
1953.0,13392.0,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,,,,,17106.0,D,9.0,Expert,1.0,,CHEMBL617560,,BAO_0000357,,
1954.0,1742.0,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617561,,BAO_0000249,,
1955.0,1742.0,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617562,,BAO_0000249,,
1956.0,14331.0,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,,Striatum,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617563,,BAO_0000357,2435.0,
1957.0,12861.0,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617564,,BAO_0000019,,
1958.0,12861.0,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,,,,,17106.0,H,8.0,Expert,1.0,,CHEMBL617565,,BAO_0000019,,
1959.0,12861.0,Binding activity radioligand.,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL856076,,BAO_0000357,,
1960.0,12861.0,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617566,,BAO_0000019,,
1961.0,12861.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106.0,H,8.0,Expert,1.0,,CHEMBL875911,,BAO_0000019,,
1962.0,12861.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617567,,BAO_0000019,,
1963.0,675.0,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617568,,BAO_0000249,,
1964.0,12490.0,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,,,,,17106.0,H,8.0,Expert,1.0,,CHEMBL617569,,BAO_0000019,,
1965.0,11828.0,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,,,,,17106.0,H,8.0,Expert,1.0,,CHEMBL617570,,BAO_0000249,,
1966.0,11866.0,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617571,,BAO_0000357,,
1967.0,773.0,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617572,,BAO_0000357,,
1968.0,13047.0,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL617573,,BAO_0000357,,
1969.0,13047.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617574,,BAO_0000019,,
1970.0,13047.0,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL617575,,BAO_0000357,,
1971.0,188.0,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,,,,,10578.0,H,8.0,Autocuration,1.0,,CHEMBL617576,,BAO_0000357,,
1972.0,10639.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,,,,,10578.0,H,8.0,Autocuration,1.0,,CHEMBL617577,,BAO_0000019,,
1973.0,12438.0,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,,,,,10578.0,H,8.0,Autocuration,1.0,,CHEMBL617578,,BAO_0000019,,
1974.0,12438.0,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10578.0,H,8.0,Autocuration,1.0,,CHEMBL617579,,BAO_0000357,,
1975.0,15854.0,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10578.0,H,8.0,Expert,1.0,,CHEMBL617580,,BAO_0000019,,
1976.0,10394.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10578.0,H,8.0,Autocuration,1.0,,CHEMBL617581,,BAO_0000249,,
1977.0,12092.0,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10578.0,H,8.0,Autocuration,1.0,,CHEMBL617582,,BAO_0000357,,
1978.0,3389.0,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,,,,,10578.0,H,8.0,Expert,1.0,,CHEMBL617583,,BAO_0000019,,
1979.0,6011.0,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617584,,BAO_0000357,,
1980.0,4639.0,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617585,,BAO_0000357,,
1981.0,2474.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL875912,,BAO_0000357,,
1982.0,5014.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617586,,BAO_0000357,,
1983.0,17515.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617587,,BAO_0000357,,
1984.0,11866.0,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617588,,BAO_0000357,,
1985.0,4687.0,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL857980,,BAO_0000357,,
1986.0,12146.0,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617589,,BAO_0000357,,
1987.0,10321.0,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617590,,BAO_0000357,,
1988.0,13267.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617591,722.0,BAO_0000219,,
1989.0,1274.0,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Expert,1.0,,CHEMBL617592,,BAO_0000357,,
1990.0,15250.0,,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617593,,BAO_0000357,,
1991.0,13706.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617594,485.0,BAO_0000219,,
1992.0,13706.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617595,485.0,BAO_0000219,,
1993.0,13706.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617596,722.0,BAO_0000219,,
1994.0,13706.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617597,722.0,BAO_0000219,,
1995.0,13047.0,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617598,,BAO_0000019,,
1996.0,13366.0,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL872916,,BAO_0000357,,
1997.0,13366.0,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL617599,,BAO_0000357,,
1998.0,1558.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617091,,BAO_0000357,,
1999.0,12902.0,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,,,CHO-K1,,105.0,H,8.0,Expert,1.0,,CHEMBL617092,485.0,BAO_0000219,,
2000.0,13706.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617093,485.0,BAO_0000219,,
2001.0,13706.0,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617094,,BAO_0000019,,
2002.0,13706.0,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617095,,BAO_0000019,,
2003.0,14251.0,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617096,,BAO_0000019,,
2004.0,14251.0,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617097,,BAO_0000019,,
2005.0,14251.0,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617098,,BAO_0000019,,
2006.0,13313.0,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617301,,BAO_0000357,,
2007.0,13313.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617302,,BAO_0000357,,
2008.0,13366.0,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617303,,BAO_0000357,,
2009.0,13051.0,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL617304,,BAO_0000357,,
2010.0,12903.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,105.0,H,8.0,Expert,1.0,,CHEMBL617305,449.0,BAO_0000219,,
2011.0,12469.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0,,,,,105.0,D,9.0,Autocuration,1.0,,CHEMBL617306,,BAO_0000219,,
2012.0,5619.0,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL617307,,BAO_0000357,,
2013.0,13047.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617308,,BAO_0000019,,
2014.0,16633.0,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617309,,BAO_0000357,,
2015.0,16633.0,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617310,,BAO_0000357,,
2016.0,16633.0,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617311,,BAO_0000357,,
2017.0,16633.0,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617312,,BAO_0000357,,
2018.0,3269.0,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL617313,,BAO_0000357,,
2019.0,12409.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL617314,,BAO_0000357,,
2020.0,13706.0,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617315,,BAO_0000019,,
2021.0,13706.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617316,722.0,BAO_0000219,,
2022.0,13706.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617317,722.0,BAO_0000219,,
2023.0,12903.0,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617318,449.0,BAO_0000219,,
2024.0,13047.0,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL617319,,BAO_0000019,,
2025.0,13366.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL617320,,BAO_0000357,,
2026.0,13366.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL617321,,BAO_0000357,,
2027.0,13366.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106.0,D,9.0,Expert,1.0,,CHEMBL617322,,BAO_0000357,,
2028.0,13366.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616862,,BAO_0000357,,
2029.0,13366.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616863,,BAO_0000357,,
2030.0,12469.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,,,CHO,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616864,449.0,BAO_0000219,,
2031.0,13706.0,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616865,485.0,BAO_0000219,,
2032.0,13706.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616866,485.0,BAO_0000219,,
2033.0,13706.0,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616867,,BAO_0000019,,
2034.0,12902.0,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,,,CHO-K1,,106.0,H,8.0,Expert,1.0,,CHEMBL616868,485.0,BAO_0000219,,
2035.0,13051.0,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL616869,,BAO_0000357,,
2036.0,12903.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106.0,H,8.0,Expert,1.0,,CHEMBL616870,449.0,BAO_0000219,,
2037.0,1558.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,,,CHO-K1,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616871,485.0,BAO_0000219,,
2038.0,1558.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,,,CHO-K1,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616872,485.0,BAO_0000219,,
2039.0,1558.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,,,CHO-K1,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616873,485.0,BAO_0000219,,
2040.0,1558.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,,,CHO-K1,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616838,485.0,BAO_0000219,,
2041.0,1558.0,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616839,,BAO_0000357,,
2042.0,13047.0,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,106.0,H,8.0,Autocuration,1.0,,CHEMBL616840,,BAO_0000019,,
2043.0,13313.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616841,,BAO_0000357,,
2044.0,13313.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL616842,,BAO_0000357,,
2045.0,12409.0,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105.0,H,8.0,Expert,1.0,,CHEMBL857976,,BAO_0000357,,
2046.0,15250.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616843,449.0,BAO_0000219,,
2047.0,1348.0,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0,,,,,10618.0,D,9.0,Expert,1.0,,CHEMBL616844,,BAO_0000357,,
2048.0,1348.0,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616845,,BAO_0000357,,
2049.0,4234.0,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0,,,,,10618.0,D,9.0,Expert,1.0,,CHEMBL616846,,BAO_0000357,,
2050.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616847,,BAO_0000357,,
2051.0,10444.0,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616848,,BAO_0000019,,
2052.0,3935.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616849,,BAO_0000357,,
2053.0,15818.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL872911,,BAO_0000357,,
2054.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616850,,BAO_0000019,,
2055.0,12936.0,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,10618.0,D,9.0,Expert,1.0,,CHEMBL616699,449.0,BAO_0000219,,
2056.0,6166.0,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616700,,BAO_0000357,,
2057.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616701,449.0,BAO_0000219,,
2058.0,15779.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616702,449.0,BAO_0000219,,
2059.0,15779.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616703,449.0,BAO_0000219,,
2060.0,13181.0,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616704,,BAO_0000357,,
2061.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616705,449.0,BAO_0000219,,
2062.0,14875.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616706,,BAO_0000357,,
2063.0,15146.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616707,449.0,BAO_0000219,,
2064.0,5213.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616708,,BAO_0000357,,
2065.0,12146.0,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616709,,BAO_0000357,,
2066.0,13267.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616710,449.0,BAO_0000219,,
2067.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616711,449.0,BAO_0000219,,
2068.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616712,449.0,BAO_0000219,,
2069.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616713,,BAO_0000357,,
2070.0,4373.0,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616714,,BAO_0000357,,
2071.0,14159.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616715,,BAO_0000357,,
2072.0,16633.0,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618.0,H,8.0,Autocuration,1.0,,CHEMBL616716,,BAO_0000357,,
2073.0,17085.0,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616717,,BAO_0000019,,
2074.0,17085.0,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279.0,H,8.0,Expert,1.0,,CHEMBL616718,,BAO_0000019,,
2075.0,16209.0,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL875905,,BAO_0000019,,
2076.0,16209.0,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616719,,BAO_0000019,,
2077.0,17085.0,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279.0,H,8.0,Expert,1.0,,CHEMBL616720,,BAO_0000019,,
2078.0,14159.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616721,,BAO_0000357,,
2079.0,15250.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616722,449.0,BAO_0000219,,
2080.0,3805.0,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616723,,BAO_0000357,,
2081.0,16190.0,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616724,449.0,BAO_0000219,,
2082.0,16190.0,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616725,,BAO_0000357,,
2083.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616726,,BAO_0000357,,
2084.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616727,,BAO_0000357,,
2085.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616728,,BAO_0000357,,
2086.0,6866.0,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL616729,,BAO_0000357,,
2087.0,17085.0,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279.0,H,8.0,Expert,1.0,,CHEMBL616730,,BAO_0000019,,
2088.0,16312.0,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617125,,BAO_0000357,,
2089.0,6166.0,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL857977,,BAO_0000357,,
2090.0,15779.0,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617126,449.0,BAO_0000219,,
2091.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617127,449.0,BAO_0000219,,
2092.0,14875.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617128,,BAO_0000357,,
2093.0,15146.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617129,449.0,BAO_0000219,,
2094.0,5213.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617130,,BAO_0000357,,
2095.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617131,449.0,BAO_0000219,,
2096.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617132,449.0,BAO_0000219,,
2097.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617133,449.0,BAO_0000219,,
2098.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617134,,BAO_0000357,,
2099.0,4373.0,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617135,,BAO_0000357,,
2100.0,5014.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279.0,H,8.0,Autocuration,1.0,,CHEMBL617136,,BAO_0000357,,
2101.0,11662.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617137,,BAO_0000019,,
2102.0,11662.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617138,,BAO_0000019,,
2103.0,11662.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617139,,BAO_0000019,,
2104.0,14093.0,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617140,,BAO_0000019,,
2105.0,11200.0,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617141,,BAO_0000218,,
2106.0,11200.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL858112,,BAO_0000019,,
2107.0,12352.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,,,,,17005.0,H,8.0,Intermediate,1.0,,CHEMBL617142,,BAO_0000019,,
2108.0,13657.0,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617143,,BAO_0000019,,
2109.0,14331.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617144,,BAO_0000019,,
2110.0,14331.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617145,,BAO_0000019,,
2111.0,14331.0,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617146,,BAO_0000019,,
2112.0,12685.0,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617147,,BAO_0000019,,
2113.0,14389.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617148,,BAO_0000019,,
2114.0,14386.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617149,,BAO_0000019,,
2115.0,5732.0,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617150,,BAO_0000224,,
2116.0,16293.0,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617151,,BAO_0000224,,
2117.0,2078.0,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617201,,BAO_0000224,,
2118.0,5486.0,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL617202,,BAO_0000357,,
2119.0,11820.0,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826.0,H,4.0,Autocuration,1.0,,CHEMBL617203,,BAO_0000218,,
2120.0,10297.0,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,,,,,104826.0,H,4.0,Autocuration,1.0,,CHEMBL617204,,BAO_0000019,,
2121.0,13704.0,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,,,,,104826.0,H,4.0,Autocuration,1.0,,CHEMBL617205,,BAO_0000224,,
2122.0,10297.0,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826.0,D,5.0,Autocuration,1.0,,CHEMBL617206,,BAO_0000019,,
2123.0,11820.0,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826.0,H,4.0,Autocuration,1.0,,CHEMBL617207,,BAO_0000218,,
2124.0,10297.0,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826.0,D,5.0,Autocuration,1.0,,CHEMBL617208,,BAO_0000019,,
2125.0,11555.0,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104826.0,H,4.0,Autocuration,1.0,,CHEMBL617209,,BAO_0000224,,
2126.0,11555.0,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,,,,,104826.0,H,4.0,Autocuration,1.0,,CHEMBL617210,,BAO_0000224,,
2127.0,11555.0,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,,,,,104826.0,H,4.0,Autocuration,1.0,,CHEMBL617211,,BAO_0000224,,
2128.0,10297.0,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826.0,D,5.0,Autocuration,1.0,,CHEMBL617212,,BAO_0000019,,
2129.0,16688.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617213,,BAO_0000224,,
2130.0,16688.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617214,,BAO_0000224,,
2131.0,5333.0,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617215,,BAO_0000221,,
2132.0,4437.0,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617216,,BAO_0000221,,
2133.0,5033.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617217,,BAO_0000357,,
2134.0,15267.0,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617218,,BAO_0000019,,
2135.0,15267.0,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL872913,,BAO_0000019,,
2136.0,11820.0,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,,,,,104826.0,H,4.0,Autocuration,1.0,,CHEMBL617219,,BAO_0000019,,
2137.0,9069.0,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL873482,,BAO_0000224,,
2138.0,9162.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617220,,BAO_0000019,,
2139.0,9162.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617221,,BAO_0000019,,
2140.0,9162.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617222,,BAO_0000019,,
2141.0,10428.0,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL875906,,BAO_0000019,,
2142.0,9628.0,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617223,,BAO_0000019,,
2143.0,12704.0,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617224,,BAO_0000224,,
2144.0,15453.0,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617225,,BAO_0000224,,
2145.0,188.0,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617226,,BAO_0000224,,
2146.0,10349.0,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617227,,BAO_0000224,,
2147.0,10349.0,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617228,,BAO_0000224,,
2148.0,8868.0,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617229,,BAO_0000224,,
2149.0,10025.0,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617230,,BAO_0000224,,
2150.0,10025.0,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617231,,BAO_0000224,,
2151.0,11702.0,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617232,,BAO_0000224,,
2152.0,11702.0,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617233,,BAO_0000224,,
2153.0,11702.0,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617234,,BAO_0000224,,
2154.0,11702.0,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617235,,BAO_0000019,,
2155.0,11702.0,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617236,,BAO_0000019,,
2156.0,10085.0,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617237,,BAO_0000221,10000000.0,
2157.0,10085.0,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617238,,BAO_0000221,10000000.0,
2158.0,9630.0,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617239,,BAO_0000221,955.0,
2159.0,11070.0,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617240,,BAO_0000019,,
2160.0,9841.0,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617241,,BAO_0000249,,
2161.0,9841.0,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686.0,H,4.0,Autocuration,1.0,,CHEMBL875907,,BAO_0000249,,
2162.0,13291.0,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617242,,BAO_0000019,,
2163.0,10590.0,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617152,,BAO_0000019,,
2164.0,9064.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617153,,BAO_0000221,955.0,
2165.0,12268.0,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617154,,BAO_0000249,,
2166.0,13508.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,,Brain,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617155,,BAO_0000221,955.0,
2167.0,11279.0,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617156,,BAO_0000019,,
2168.0,11200.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617157,,BAO_0000019,,
2169.0,11200.0,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617158,,BAO_0000019,,
2170.0,11200.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617159,,BAO_0000019,,
2171.0,11200.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617160,,BAO_0000019,,
2172.0,11200.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL858113,,BAO_0000019,,
2173.0,9231.0,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,,Brain,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617247,,BAO_0000220,955.0,
2174.0,9737.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617248,,BAO_0000019,,
2175.0,9737.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617249,,BAO_0000249,955.0,
2176.0,9737.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617250,,BAO_0000019,,
2177.0,9737.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617251,,BAO_0000019,,
2178.0,11828.0,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617252,,BAO_0000019,,
2179.0,12253.0,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617006,,BAO_0000019,,
2180.0,12253.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617007,,BAO_0000019,,
2181.0,11279.0,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617008,,BAO_0000019,,
2182.0,11866.0,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617009,,BAO_0000019,,
2183.0,14424.0,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617010,,BAO_0000224,,
2184.0,15180.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL857978,,BAO_0000019,,
2185.0,15180.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617011,,BAO_0000019,,
2186.0,9786.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617012,,BAO_0000019,,
2187.0,12132.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617013,,BAO_0000224,,
2188.0,5486.0,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617014,,BAO_0000249,,
2189.0,15316.0,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617015,,BAO_0000019,,
2190.0,16429.0,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617016,,BAO_0000019,,
2191.0,14617.0,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617017,,BAO_0000224,,
2192.0,11351.0,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617018,,BAO_0000221,955.0,
2193.0,11279.0,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617019,,BAO_0000019,,
2194.0,9523.0,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617020,,BAO_0000019,,
2195.0,9523.0,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617021,,BAO_0000019,,
2196.0,9523.0,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617022,,BAO_0000019,,
2197.0,9523.0,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617023,,BAO_0000019,,
2198.0,9523.0,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617024,,BAO_0000019,,
2199.0,9523.0,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617025,,BAO_0000019,,
2200.0,9523.0,Hill coefficient of compound was determined,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617026,,BAO_0000224,,
2201.0,4771.0,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617027,,BAO_0000019,,
2202.0,5033.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617028,,BAO_0000019,,
2203.0,10845.0,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617029,,BAO_0000019,,
2204.0,10845.0,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL875908,,BAO_0000019,,
2205.0,16288.0,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617030,,BAO_0000357,,
2206.0,16288.0,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617031,,BAO_0000019,,
2207.0,16190.0,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617032,,BAO_0000019,,
2208.0,12463.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617033,,BAO_0000224,,
2209.0,9699.0,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617034,,BAO_0000224,,
2210.0,9699.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617035,,BAO_0000224,,
2211.0,11662.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617036,,BAO_0000019,,
2212.0,1205.0,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617037,,BAO_0000224,,
2213.0,11376.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617038,,BAO_0000219,,
2214.0,11376.0,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617039,,BAO_0000219,,
2215.0,4639.0,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617161,,BAO_0000224,,
2216.0,2222.0,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617162,,BAO_0000224,,
2217.0,1558.0,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617163,,BAO_0000224,,
2218.0,1089.0,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617164,,BAO_0000224,,
2219.0,386.0,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,,,,Brain membranes,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617165,,BAO_0000249,,
2220.0,2474.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617166,,BAO_0000224,,
2221.0,17066.0,Binding affinity towards 5-HT2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617167,,BAO_0000224,,
2222.0,959.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL872912,,BAO_0000224,,
2223.0,6398.0,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617168,,BAO_0000224,,
2224.0,11889.0,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617169,,BAO_0000224,,
2225.0,4221.0,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617170,,BAO_0000224,,
2226.0,11026.0,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617171,,BAO_0000224,,
2227.0,11866.0,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617172,,BAO_0000224,,
2228.0,4221.0,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617173,,BAO_0000224,,
2229.0,13950.0,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617174,,BAO_0000019,,
2230.0,1263.0,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617175,,BAO_0000224,,
2231.0,13291.0,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617176,,BAO_0000357,,
2232.0,10812.0,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617177,,BAO_0000357,,
2233.0,13020.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617178,,BAO_0000224,,
2234.0,13021.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617179,,BAO_0000224,,
2235.0,13020.0,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617180,,BAO_0000224,,
2236.0,14532.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617181,,BAO_0000357,,
2237.0,13944.0,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617182,,BAO_0000357,,
2238.0,14331.0,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617183,,BAO_0000357,,
2239.0,14118.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617184,,BAO_0000357,,
2240.0,13033.0,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617185,,BAO_0000357,,
2241.0,10321.0,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617186,,BAO_0000357,,
2242.0,12918.0,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617187,,BAO_0000357,,
2243.0,15120.0,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617188,,BAO_0000357,,
2244.0,2613.0,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617189,,BAO_0000218,,
2245.0,13378.0,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0,,,,,104784.0,D,5.0,Autocuration,1.0,,CHEMBL617190,,BAO_0000224,,
2246.0,2331.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0,,,CHO,,104784.0,D,5.0,Autocuration,1.0,,CHEMBL617191,449.0,BAO_0000219,,
2247.0,2331.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,104784.0,D,5.0,Autocuration,1.0,,CHEMBL617192,449.0,BAO_0000219,,
2248.0,2331.0,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0,,,CHO,,104784.0,D,5.0,Autocuration,1.0,,CHEMBL617193,449.0,BAO_0000219,,
2249.0,2331.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0,,,CHO,,104784.0,D,5.0,Autocuration,1.0,,CHEMBL617194,449.0,BAO_0000219,,
2250.0,4170.0,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL617195,,BAO_0000224,,
2251.0,15453.0,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,,,,,104784.0,H,4.0,Autocuration,1.0,,CHEMBL881830,,BAO_0000224,,
2252.0,1479.0,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005.0,H,8.0,Autocuration,1.0,,CHEMBL617196,,BAO_0000357,,
2253.0,11139.0,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617197,,BAO_0000224,,
2254.0,13969.0,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,,,,,17005.0,H,8.0,Expert,1.0,,CHEMBL617198,,BAO_0000357,,
2255.0,13392.0,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,17005.0,H,8.0,Expert,1.0,,CHEMBL873476,,BAO_0000357,,
2256.0,14430.0,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,,,,,17005.0,H,8.0,Expert,1.0,,CHEMBL617199,,BAO_0000019,,
2257.0,13181.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617200,,BAO_0000357,,
2258.0,17200.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL617484,,BAO_0000357,,
2259.0,17200.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617485,,BAO_0000357,,
2260.0,17200.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL617486,,BAO_0000357,,
2261.0,13463.0,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL858022,,BAO_0000357,,
2262.0,6347.0,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617049,449.0,BAO_0000219,,
2263.0,6857.0,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,107.0,D,9.0,Expert,1.0,,CHEMBL617050,449.0,BAO_0000219,,
2264.0,4176.0,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617051,,BAO_0000219,,
2265.0,4176.0,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617052,,BAO_0000219,,
2266.0,4176.0,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617053,,BAO_0000219,,
2267.0,6347.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,,,CHO,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617054,449.0,BAO_0000219,,
2268.0,6347.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,,,CHO,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617055,449.0,BAO_0000219,,
2269.0,15331.0,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL882924,,BAO_0000357,,
2270.0,16146.0,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617056,,BAO_0000357,,
2271.0,15250.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617057,449.0,BAO_0000219,,
2272.0,13631.0,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617058,,BAO_0000219,,
2273.0,3805.0,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617059,,BAO_0000357,,
2274.0,4011.0,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,CHO,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617060,449.0,BAO_0000219,,
2275.0,4012.0,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,,,CHO,,107.0,H,8.0,Expert,1.0,,CHEMBL617061,449.0,BAO_0000219,,
2276.0,6366.0,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,,,L929,,107.0,H,8.0,Expert,1.0,,CHEMBL617062,307.0,BAO_0000219,,
2277.0,15949.0,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107.0,H,8.0,Expert,1.0,,CHEMBL617063,449.0,BAO_0000219,,
2278.0,14093.0,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617064,,BAO_0000019,,
2279.0,13481.0,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617065,,BAO_0000019,,
2280.0,6347.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617066,449.0,BAO_0000219,,
2281.0,6347.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,,,CHO,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617067,449.0,BAO_0000219,,
2282.0,14093.0,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617068,,BAO_0000019,,
2283.0,14093.0,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617069,,BAO_0000019,,
2284.0,13481.0,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617070,,BAO_0000019,,
2285.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617071,,BAO_0000357,,
2286.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL872915,,BAO_0000357,,
2287.0,14755.0,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617072,,BAO_0000357,,
2288.0,16441.0,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617073,,BAO_0000357,,
2289.0,14744.0,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617074,,BAO_0000357,,
2290.0,16659.0,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107.0,H,8.0,Expert,1.0,,CHEMBL617075,449.0,BAO_0000219,,
2291.0,3307.0,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617076,,BAO_0000357,,
2292.0,6857.0,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617077,,BAO_0000019,,
2293.0,5635.0,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617078,,BAO_0000357,,
2294.0,4234.0,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617079,,BAO_0000357,,
2295.0,15527.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617080,,BAO_0000357,,
2296.0,6588.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,107.0,H,8.0,Expert,1.0,,CHEMBL617081,449.0,BAO_0000219,,
2297.0,13631.0,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617082,,BAO_0000219,,
2298.0,17723.0,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617083,,BAO_0000357,,
2299.0,14770.0,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617084,,BAO_0000357,,
2300.0,16293.0,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617085,,BAO_0000357,,
2301.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617086,,BAO_0000357,,
2302.0,12469.0,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617087,,BAO_0000219,,
2303.0,15363.0,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617088,,BAO_0000357,,
2304.0,15363.0,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617089,,BAO_0000357,,
2305.0,16441.0,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617090,,BAO_0000019,,
2306.0,8.0,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617513,,BAO_0000357,,
2307.0,4176.0,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617514,722.0,BAO_0000219,,
2308.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617515,,BAO_0000019,,
2309.0,17200.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617516,,BAO_0000357,,
2310.0,17200.0,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617517,,BAO_0000357,,
2311.0,4013.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107.0,D,9.0,Expert,1.0,,CHEMBL617518,449.0,BAO_0000219,,
2312.0,5088.0,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617519,,BAO_0000357,,
2313.0,5088.0,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617520,,BAO_0000357,,
2314.0,5088.0,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617521,,BAO_0000357,,
2315.0,5088.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617522,,BAO_0000357,,
2316.0,5088.0,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617523,,BAO_0000357,,
2317.0,5088.0,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617524,,BAO_0000357,,
2318.0,9786.0,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617525,,BAO_0000019,,
2319.0,9205.0,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617526,,BAO_0000019,,
2320.0,11257.0,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617527,,BAO_0000224,,
2321.0,9362.0,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617528,,BAO_0000019,,
2322.0,9362.0,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617529,,BAO_0000019,,
2323.0,10590.0,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617530,,BAO_0000224,,
2324.0,10468.0,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617531,,BAO_0000019,,
2325.0,13050.0,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617532,,BAO_0000019,,
2326.0,11624.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617533,,BAO_0000019,,
2327.0,10468.0,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617534,,BAO_0000019,,
2328.0,10330.0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617535,,BAO_0000224,,
2329.0,10062.0,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617536,,BAO_0000224,,
2330.0,11642.0,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617537,,BAO_0000224,,
2331.0,10062.0,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617538,,BAO_0000224,,
2332.0,13427.0,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617539,,BAO_0000219,,
2333.0,12280.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617540,,BAO_0000224,,
2334.0,4101.0,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617541,,BAO_0000224,,
2335.0,10062.0,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617542,,BAO_0000224,,
2336.0,11147.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617543,,BAO_0000224,,
2337.0,2395.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617544,485.0,BAO_0000219,,
2338.0,2395.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617545,485.0,BAO_0000219,,
2339.0,9098.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617413,,BAO_0000019,,
2340.0,9098.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617414,,BAO_0000019,,
2341.0,9098.0,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617415,,BAO_0000019,,
2342.0,9443.0,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617416,,BAO_0000224,,
2343.0,9443.0,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617417,,BAO_0000224,,
2344.0,9699.0,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617418,,BAO_0000019,,
2345.0,9699.0,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617419,,BAO_0000019,,
2346.0,9098.0,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617420,,BAO_0000224,,
2347.0,3070.0,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617421,,BAO_0000224,,
2348.0,9547.0,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617422,,BAO_0000224,,
2349.0,10444.0,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617423,,BAO_0000019,,
2350.0,14617.0,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617424,,BAO_0000019,,
2351.0,14617.0,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617425,,BAO_0000019,,
2352.0,11130.0,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617426,,BAO_0000224,,
2353.0,11130.0,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617427,,BAO_0000218,,
2354.0,14542.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,,Brain,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617428,,BAO_0000221,955.0,
2355.0,2797.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617429,,BAO_0000224,,
2356.0,11332.0,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617430,,BAO_0000019,,
2357.0,11332.0,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617431,,BAO_0000019,,
2358.0,10752.0,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,,Frontal cortex,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617432,,BAO_0000019,1870.0,
2359.0,1185.0,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617433,,BAO_0000224,,
2360.0,1185.0,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617434,,BAO_0000224,,
2361.0,11624.0,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617435,,BAO_0000224,,
2362.0,1344.0,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617436,,BAO_0000019,,
2363.0,15453.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0,,Striatum,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617437,,BAO_0000019,2435.0,
2364.0,11662.0,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617438,,BAO_0000019,,
2365.0,11662.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617439,,BAO_0000019,,
2366.0,10796.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617440,,BAO_0000224,,
2367.0,9069.0,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617441,,BAO_0000224,,
2368.0,8814.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL872918,,BAO_0000019,,
2369.0,8908.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617442,,BAO_0000019,,
2370.0,9098.0,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617443,,BAO_0000019,,
2371.0,9098.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617444,,BAO_0000019,,
2372.0,9098.0,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617445,,BAO_0000019,,
2373.0,9098.0,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617446,,BAO_0000019,,
2374.0,9098.0,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617447,,BAO_0000249,,
2375.0,9098.0,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617448,,BAO_0000019,,
2376.0,9098.0,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617449,,BAO_0000019,,
2377.0,9161.0,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617450,,BAO_0000019,,
2378.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617451,,BAO_0000019,,
2379.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617452,,BAO_0000019,,
2380.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617453,,BAO_0000019,,
2381.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617660,,BAO_0000019,,
2382.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617661,,BAO_0000019,,
2383.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617662,,BAO_0000019,,
2384.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL872919,,BAO_0000019,,
2385.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617663,,BAO_0000019,,
2386.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617664,,BAO_0000019,,
2387.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617665,,BAO_0000019,,
2388.0,9161.0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617666,,BAO_0000019,,
2389.0,12094.0,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617667,,BAO_0000019,,
2390.0,12018.0,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617668,,BAO_0000249,,
2391.0,10394.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617669,,BAO_0000249,,
2392.0,15260.0,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617670,,BAO_0000224,,
2393.0,11624.0,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617671,,BAO_0000224,,
2394.0,13654.0,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617672,,BAO_0000224,,
2395.0,9541.0,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617673,,BAO_0000019,,
2396.0,11933.0,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617674,,BAO_0000224,,
2397.0,15538.0,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617675,,BAO_0000019,,
2398.0,15538.0,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617676,,BAO_0000019,,
2399.0,15538.0,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617677,,BAO_0000019,,
2400.0,8841.0,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617678,,BAO_0000019,,
2401.0,1455.0,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617679,,BAO_0000224,,
2402.0,1455.0,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617680,,BAO_0000224,,
2403.0,11752.0,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617681,,BAO_0000019,,
2404.0,11642.0,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,,Brain,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617682,,BAO_0000221,955.0,
2405.0,12092.0,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617683,,BAO_0000224,,
2406.0,3967.0,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617684,,BAO_0000224,,
2407.0,12771.0,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686.0,D,5.0,Autocuration,1.0,,CHEMBL617685,,BAO_0000224,,
2408.0,11642.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617686,,BAO_0000019,,
2409.0,11628.0,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617687,,BAO_0000224,,
2410.0,13654.0,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617688,,BAO_0000224,,
2411.0,11200.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617689,,BAO_0000019,,
2412.0,11200.0,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617690,,BAO_0000019,,
2413.0,11200.0,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617691,,BAO_0000218,,
2414.0,11200.0,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617692,,BAO_0000218,,
2415.0,11200.0,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617693,,BAO_0000218,,
2416.0,11200.0,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686.0,H,4.0,Autocuration,1.0,,CHEMBL617694,,BAO_0000218,,
2417.0,15436.0,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,,Brain,,,12687.0,H,8.0,Expert,1.0,,CHEMBL857985,,BAO_0000221,955.0,
2418.0,15436.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617695,,BAO_0000019,,
2419.0,14025.0,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617696,,BAO_0000019,,
2420.0,4342.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617697,,BAO_0000357,,
2421.0,13735.0,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617257,,BAO_0000019,,
2422.0,5816.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617258,,BAO_0000357,,
2423.0,14287.0,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617259,,BAO_0000019,,
2424.0,15738.0,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617260,,BAO_0000357,,
2425.0,15738.0,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617261,,BAO_0000357,,
2426.0,15026.0,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617262,,BAO_0000019,,
2427.0,16647.0,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617263,,BAO_0000019,,
2428.0,16647.0,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617264,,BAO_0000019,,
2429.0,13345.0,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617265,,BAO_0000019,,
2430.0,1543.0,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,,,,Membranes,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617266,,BAO_0000249,,
2431.0,12444.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617267,,BAO_0000019,,
2432.0,16404.0,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617268,,BAO_0000019,,
2433.0,16404.0,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,,,CHO,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617269,449.0,BAO_0000219,,
2434.0,15577.0,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617323,,BAO_0000357,,
2435.0,15577.0,Serotonergic activity of the compound.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617324,,BAO_0000357,,
2436.0,2495.0,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617325,,BAO_0000249,,
2437.0,15042.0,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617326,,BAO_0000019,,
2438.0,15026.0,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617327,,BAO_0000249,,
2439.0,12919.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617328,,BAO_0000019,,
2440.0,12919.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617329,,BAO_0000019,,
2441.0,12919.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617330,,BAO_0000019,,
2442.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617331,,BAO_0000357,,
2443.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617332,,BAO_0000357,,
2444.0,4820.0,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617333,,BAO_0000357,,
2445.0,6736.0,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617334,,BAO_0000357,,
2446.0,5163.0,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617335,,BAO_0000357,,
2447.0,5163.0,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617336,,BAO_0000357,,
2448.0,6011.0,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617337,,BAO_0000357,,
2449.0,14294.0,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617338,,BAO_0000357,,
2450.0,5014.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617339,,BAO_0000357,,
2451.0,17066.0,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617340,,BAO_0000357,,
2452.0,17515.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617341,,BAO_0000357,,
2453.0,6736.0,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617342,,BAO_0000357,,
2454.0,5163.0,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617343,,BAO_0000357,,
2455.0,16911.0,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,,,NIH3T3,,107.0,H,8.0,Expert,1.0,,CHEMBL617344,723.0,BAO_0000219,,
2456.0,6841.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617345,,BAO_0000357,,
2457.0,6119.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617346,,BAO_0000357,,
2458.0,3962.0,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617347,,BAO_0000357,,
2459.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617348,,BAO_0000357,,
2460.0,4373.0,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617349,,BAO_0000357,,
2461.0,3962.0,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617350,,BAO_0000019,,
2462.0,1633.0,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL872339,,BAO_0000357,,
2463.0,4373.0,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617351,,BAO_0000357,,
2464.0,6576.0,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617352,,BAO_0000357,,
2465.0,4687.0,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617353,,BAO_0000357,,
2466.0,16946.0,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617354,,BAO_0000357,,
2467.0,14159.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617355,,BAO_0000357,,
2468.0,3032.0,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,107.0,H,8.0,Expert,1.0,,CHEMBL617356,449.0,BAO_0000219,,
2469.0,16655.0,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617357,,BAO_0000357,,
2470.0,13964.0,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617358,,BAO_0000357,,
2471.0,16989.0,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617359,,BAO_0000357,,
2472.0,16117.0,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617360,,BAO_0000357,,
2473.0,16700.0,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL875913,,BAO_0000357,,
2474.0,3269.0,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617361,,BAO_0000357,,
2475.0,1274.0,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL617362,,BAO_0000357,,
2476.0,1317.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617363,,BAO_0000357,,
2477.0,12146.0,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617364,,BAO_0000357,,
2478.0,12652.0,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617365,,BAO_0000224,,
2479.0,12652.0,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617366,,BAO_0000224,,
2480.0,12652.0,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617367,,BAO_0000224,,
2481.0,12652.0,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075.0,H,4.0,Autocuration,1.0,,CHEMBL617368,,BAO_0000224,,
2482.0,16647.0,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617369,,BAO_0000357,,
2483.0,15851.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0,,,HEK293,,227.0,D,9.0,Expert,1.0,,CHEMBL617370,722.0,BAO_0000219,,
2484.0,6857.0,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,227.0,D,9.0,Expert,1.0,,CHEMBL617371,449.0,BAO_0000219,,
2485.0,3805.0,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617372,,BAO_0000357,,
2486.0,6491.0,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,227.0,D,9.0,Expert,1.0,,CHEMBL617373,,BAO_0000357,,
2487.0,14093.0,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617374,,BAO_0000019,,
2488.0,13481.0,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617375,,BAO_0000019,,
2489.0,14093.0,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617376,,BAO_0000019,,
2490.0,14093.0,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617377,,BAO_0000019,,
2491.0,14093.0,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617378,,BAO_0000019,,
2492.0,13481.0,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617379,,BAO_0000019,,
2493.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617380,,BAO_0000357,,
2494.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617381,,BAO_0000357,,
2495.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617382,,BAO_0000357,,
2496.0,12369.0,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617383,,BAO_0000357,,
2497.0,12369.0,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617384,,BAO_0000357,,
2498.0,12369.0,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617385,,BAO_0000357,,
2499.0,14447.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617386,,BAO_0000019,,
2500.0,14447.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617387,,BAO_0000019,,
2501.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617388,723.0,BAO_0000219,,
2502.0,6857.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,,,CHO,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617389,449.0,BAO_0000219,,
2503.0,6857.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,107.0,D,9.0,Expert,1.0,,CHEMBL617390,449.0,BAO_0000219,,
2504.0,5635.0,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,104817.0,H,4.0,Autocuration,1.0,,CHEMBL617391,,BAO_0000224,,
2505.0,12861.0,Binding activity radioligand.,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617392,,BAO_0000357,,
2506.0,12861.0,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617393,,BAO_0000019,,
2507.0,5105.0,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617394,307.0,BAO_0000219,,
2508.0,5104.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107.0,H,8.0,Expert,1.0,,CHEMBL617395,307.0,BAO_0000219,,
2509.0,5105.0,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,,,L929,,107.0,H,8.0,Expert,1.0,,CHEMBL617396,307.0,BAO_0000219,,
2510.0,5105.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,,,L929,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617397,307.0,BAO_0000219,,
2511.0,5254.0,Binding affinity against 5-HT2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617398,,BAO_0000357,,
2512.0,5254.0,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617399,,BAO_0000357,,
2513.0,13267.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617400,722.0,BAO_0000219,,
2514.0,13267.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617401,722.0,BAO_0000219,,
2515.0,14157.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,107.0,D,9.0,Expert,1.0,,CHEMBL617402,722.0,BAO_0000219,,
2516.0,12936.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107.0,D,9.0,Expert,1.0,,CHEMBL617403,722.0,BAO_0000219,,
2517.0,14068.0,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617404,,BAO_0000357,,
2518.0,12936.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107.0,D,9.0,Expert,1.0,,CHEMBL857981,722.0,BAO_0000219,,
2519.0,12936.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107.0,D,9.0,Expert,1.0,,CHEMBL617405,722.0,BAO_0000219,,
2520.0,4540.0,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,107.0,D,9.0,Expert,1.0,,CHEMBL617253,722.0,BAO_0000219,,
2521.0,6166.0,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617254,,BAO_0000357,,
2522.0,17296.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617255,722.0,BAO_0000219,,
2523.0,17296.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617256,722.0,BAO_0000219,,
2524.0,17296.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616874,722.0,BAO_0000219,,
2525.0,15779.0,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0,,,HEK293,,107.0,D,9.0,Expert,1.0,,CHEMBL616875,722.0,BAO_0000219,,
2526.0,14391.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Expert,1.0,,CHEMBL616876,722.0,BAO_0000219,,
2527.0,15851.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,,,HEK293,,107.0,H,8.0,Expert,1.0,,CHEMBL616877,722.0,BAO_0000219,,
2528.0,15851.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,107.0,D,9.0,Expert,1.0,,CHEMBL616878,722.0,BAO_0000219,,
2529.0,3832.0,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,,,HEK293,,107.0,H,8.0,Expert,1.0,,CHEMBL616879,722.0,BAO_0000219,,
2530.0,3833.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,,,HEK293,,107.0,H,8.0,Expert,1.0,,CHEMBL616880,722.0,BAO_0000219,,
2531.0,12936.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107.0,D,9.0,Expert,1.0,,CHEMBL616881,722.0,BAO_0000219,,
2532.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616882,723.0,BAO_0000219,,
2533.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616883,723.0,BAO_0000219,,
2534.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616884,723.0,BAO_0000219,,
2535.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616885,722.0,BAO_0000219,,
2536.0,1883.0,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,,,CHO-K1,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616886,485.0,BAO_0000219,,
2537.0,1883.0,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,107.0,H,8.0,Expert,1.0,,CHEMBL616887,485.0,BAO_0000219,,
2538.0,14875.0,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107.0,D,9.0,Expert,1.0,,CHEMBL616888,,BAO_0000357,,
2539.0,15146.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616889,722.0,BAO_0000219,,
2540.0,5213.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616890,722.0,BAO_0000219,,
2541.0,16404.0,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107.0,D,9.0,Expert,1.0,,CHEMBL616891,449.0,BAO_0000219,,
2542.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616892,722.0,BAO_0000219,,
2543.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,,,HEK293,,107.0,H,8.0,Autocuration,1.0,,CHEMBL616893,722.0,BAO_0000219,,
2544.0,12652.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,,,NIH3T3,,10620.0,H,8.0,Autocuration,1.0,,CHEMBL616894,723.0,BAO_0000219,,
2545.0,4682.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,,,NIH3T3,,107.0,H,8.0,Expert,1.0,,CHEMBL616895,723.0,BAO_0000219,,
2546.0,12652.0,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,,,,,10620.0,H,8.0,Autocuration,1.0,,CHEMBL616896,,BAO_0000019,,
2547.0,4921.0,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,,,,,10621.0,H,8.0,Autocuration,1.0,,CHEMBL617099,,BAO_0000357,,
2548.0,4921.0,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,,,,,10621.0,H,8.0,Autocuration,1.0,,CHEMBL617100,,BAO_0000357,,
2549.0,16312.0,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL884532,,BAO_0000357,,
2550.0,14998.0,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617101,,BAO_0000357,,
2551.0,14025.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617102,,BAO_0000357,,
2552.0,13047.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,107.0,H,8.0,Autocuration,1.0,,CHEMBL617103,,BAO_0000019,,
2553.0,13047.0,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107.0,H,8.0,Expert,1.0,,CHEMBL617104,,BAO_0000357,,
2554.0,1883.0,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL857979,485.0,BAO_0000219,,
2555.0,13463.0,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL857502,,BAO_0000019,,
2556.0,13463.0,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617105,,BAO_0000019,,
2557.0,13463.0,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,,Stomach,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL858021,,BAO_0000019,945.0,
2558.0,13463.0,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12687.0,D,9.0,Expert,1.0,,CHEMBL875910,,BAO_0000019,945.0,
2559.0,13463.0,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617106,,BAO_0000019,,
2560.0,16326.0,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687.0,H,8.0,Expert,1.0,,CHEMBL617107,723.0,BAO_0000219,,
2561.0,14093.0,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617108,,BAO_0000019,,
2562.0,14093.0,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617109,,BAO_0000019,,
2563.0,15740.0,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617110,,BAO_0000357,,
2564.0,16633.0,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617111,,BAO_0000357,,
2565.0,17200.0,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617112,,BAO_0000019,,
2566.0,17133.0,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617113,,BAO_0000357,,
2567.0,17133.0,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617114,,BAO_0000357,,
2568.0,17133.0,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617115,,BAO_0000357,,
2569.0,17200.0,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617116,,BAO_0000219,,
2570.0,15363.0,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617117,,BAO_0000019,,
2571.0,17200.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617118,,BAO_0000357,,
2572.0,17200.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617119,,BAO_0000357,,
2573.0,17200.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617120,,BAO_0000357,,
2574.0,17200.0,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617121,,BAO_0000219,,
2575.0,17200.0,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617122,,BAO_0000219,,
2576.0,17211.0,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617123,,BAO_0000019,,
2577.0,17331.0,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617124,,BAO_0000019,,
2578.0,13565.0,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617600,,BAO_0000249,,
2579.0,13730.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617601,,BAO_0000357,,
2580.0,12416.0,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL882923,,BAO_0000019,,
2581.0,15295.0,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617602,,BAO_0000357,,
2582.0,1742.0,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617603,,BAO_0000019,,
2583.0,15295.0,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617604,,BAO_0000357,,
2584.0,14970.0,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617605,,BAO_0000019,,
2585.0,16693.0,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617606,,BAO_0000019,,
2586.0,14776.0,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617607,,BAO_0000019,,
2587.0,14286.0,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617455,,BAO_0000249,,
2588.0,17200.0,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617456,,BAO_0000019,,
2589.0,15306.0,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617457,,BAO_0000357,,
2590.0,14178.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617458,,BAO_0000357,,
2591.0,14229.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617459,,BAO_0000019,,
2592.0,12884.0,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617460,,BAO_0000357,,
2593.0,13149.0,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617461,,BAO_0000357,,
2594.0,15295.0,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617462,,BAO_0000019,,
2595.0,15740.0,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617463,,BAO_0000357,,
2596.0,15185.0,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617464,,BAO_0000019,,
2597.0,15185.0,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617465,,BAO_0000019,,
2598.0,17529.0,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617466,,BAO_0000019,,
2599.0,14826.0,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617467,,BAO_0000019,,
2600.0,17211.0,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617468,,BAO_0000019,,
2601.0,14826.0,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617469,,BAO_0000019,,
2602.0,14093.0,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617470,,BAO_0000019,,
2603.0,14093.0,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617471,,BAO_0000019,,
2604.0,13246.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12687.0,H,8.0,Expert,1.0,,CHEMBL617472,723.0,BAO_0000219,,
2605.0,13246.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617473,,BAO_0000357,,
2606.0,15436.0,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617474,,BAO_0000019,,
2607.0,15436.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617475,,BAO_0000019,,
2608.0,14442.0,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617476,,BAO_0000221,955.0,
2609.0,12457.0,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617477,,BAO_0000357,,
2610.0,12457.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687.0,H,8.0,Expert,1.0,,CHEMBL617478,723.0,BAO_0000219,,
2611.0,14755.0,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617479,,BAO_0000221,,
2612.0,4707.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617480,,BAO_0000357,,
2613.0,13297.0,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617481,,BAO_0000357,,
2614.0,17331.0,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617482,,BAO_0000019,,
2615.0,4664.0,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617483,,BAO_0000019,,
2616.0,16633.0,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621528,,BAO_0000357,,
2617.0,4664.0,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,NIH3T3,,12687.0,D,9.0,Expert,1.0,,CHEMBL621529,723.0,BAO_0000219,,
2618.0,16133.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL621530,,BAO_0000357,,
2619.0,16133.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL621531,,BAO_0000357,,
2620.0,14060.0,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL621532,,BAO_0000019,,
2621.0,16326.0,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL621533,,BAO_0000357,,
2622.0,16659.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,12687.0,H,8.0,Expert,1.0,,CHEMBL621534,449.0,BAO_0000219,,
2623.0,14776.0,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621535,,BAO_0000019,,
2624.0,13481.0,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621536,,BAO_0000357,,
2625.0,17386.0,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621537,,BAO_0000357,,
2626.0,6611.0,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL621538,,BAO_0000357,,
2627.0,14423.0,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621539,,BAO_0000019,,
2628.0,15412.0,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621540,,BAO_0000019,,
2629.0,15412.0,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621541,,BAO_0000019,,
2630.0,6238.0,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621542,,BAO_0000019,,
2631.0,6648.0,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL621543,,BAO_0000357,,
2632.0,5667.0,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL621544,,BAO_0000357,,
2633.0,6611.0,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL621545,,BAO_0000357,,
2634.0,13481.0,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621546,,BAO_0000357,,
2635.0,13481.0,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL621547,,BAO_0000357,,
2636.0,15558.0,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687.0,H,8.0,Expert,1.0,,CHEMBL618692,723.0,BAO_0000219,,
2637.0,6013.0,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618693,,BAO_0000357,,
2638.0,16633.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL872922,,BAO_0000357,,
2639.0,6013.0,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618694,,BAO_0000357,,
2640.0,6013.0,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL618695,,BAO_0000357,,
2641.0,6013.0,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618696,,BAO_0000357,,
2642.0,6013.0,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL618697,,BAO_0000357,,
2643.0,6013.0,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618892,,BAO_0000357,,
2644.0,6013.0,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618893,,BAO_0000357,,
2645.0,16293.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618894,,BAO_0000357,,
2646.0,17175.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,,,NIH3T3,,12687.0,H,8.0,Expert,1.0,,CHEMBL618895,723.0,BAO_0000219,,
2647.0,13278.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL618896,,BAO_0000357,,
2648.0,3682.0,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618897,,BAO_0000019,5383.0,
2649.0,2014.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618898,,BAO_0000357,,
2650.0,2014.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618899,,BAO_0000357,,
2651.0,4932.0,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618900,,BAO_0000357,,
2652.0,4932.0,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618901,,BAO_0000019,,
2653.0,3935.0,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618902,,BAO_0000357,,
2654.0,5432.0,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,12687.0,D,9.0,Expert,1.0,,CHEMBL618903,,BAO_0000221,10000000.0,
2655.0,15818.0,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618904,,BAO_0000357,,
2656.0,13672.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618905,,BAO_0000357,,
2657.0,13672.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618906,,BAO_0000357,,
2658.0,14749.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,,,NIH3T3,,12687.0,H,8.0,Expert,1.0,,CHEMBL618907,723.0,BAO_0000219,,
2659.0,13462.0,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL618908,,BAO_0000019,,
2660.0,15740.0,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617909,,BAO_0000357,,
2661.0,16647.0,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617910,,BAO_0000019,,
2662.0,13345.0,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,,Brain,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617911,,BAO_0000221,955.0,
2663.0,16740.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL872923,,BAO_0000249,,
2664.0,16740.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617912,,BAO_0000249,,
2665.0,15535.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617913,,BAO_0000019,,
2666.0,16740.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617914,,BAO_0000249,,
2667.0,16740.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617915,,BAO_0000249,,
2668.0,16740.0,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617916,,BAO_0000249,,
2669.0,4795.0,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617917,,BAO_0000019,,
2670.0,8.0,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617918,,BAO_0000019,,
2671.0,8.0,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617919,,BAO_0000019,,
2672.0,17200.0,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617920,,BAO_0000019,,
2673.0,2148.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617921,,BAO_0000019,,
2674.0,13345.0,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0,,,,,105102.0,D,5.0,Expert,1.0,,CHEMBL617922,,BAO_0000224,,
2675.0,5088.0,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617923,,BAO_0000357,,
2676.0,5088.0,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617924,,BAO_0000357,,
2677.0,17133.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617925,,BAO_0000357,,
2678.0,17133.0,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617926,,BAO_0000357,,
2679.0,16532.0,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617927,,BAO_0000357,,
2680.0,15086.0,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617928,,BAO_0000357,,
2681.0,2309.0,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617929,,BAO_0000019,,
2682.0,12953.0,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617930,,BAO_0000019,,
2683.0,12953.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617931,,BAO_0000019,,
2684.0,12953.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617932,,BAO_0000019,,
2685.0,16659.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,,,CHO,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617933,449.0,BAO_0000219,,
2686.0,16740.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617934,,BAO_0000019,,
2687.0,16740.0,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617935,,BAO_0000019,,
2688.0,17133.0,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617936,,BAO_0000357,,
2689.0,17211.0,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617937,,BAO_0000019,,
2690.0,17331.0,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617938,,BAO_0000019,,
2691.0,16633.0,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617939,,BAO_0000218,,
2692.0,16633.0,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617940,,BAO_0000218,,
2693.0,16633.0,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617941,,BAO_0000218,,
2694.0,15026.0,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617942,,BAO_0000357,,
2695.0,15026.0,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617943,,BAO_0000357,,
2696.0,16404.0,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093.0,H,4.0,Expert,1.0,,CHEMBL617944,,BAO_0000224,,
2697.0,16404.0,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093.0,H,4.0,Expert,1.0,,CHEMBL617945,,BAO_0000224,,
2698.0,16404.0,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,105075.0,H,4.0,Expert,1.0,,CHEMBL617946,,BAO_0000224,,
2699.0,16404.0,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617947,,BAO_0000357,,
2700.0,16326.0,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617948,,BAO_0000357,,
2701.0,15847.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL858116,,BAO_0000019,,
2702.0,15847.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617949,,BAO_0000019,,
2703.0,15329.0,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617950,,BAO_0000019,,
2704.0,16404.0,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617951,,BAO_0000019,1515.0,
2705.0,16404.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617952,,BAO_0000019,1515.0,
2706.0,16404.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,,Thoracic aorta,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617953,,BAO_0000019,1515.0,
2707.0,12861.0,Binding activity radioligand.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617954,,BAO_0000357,,
2708.0,12861.0,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617955,,BAO_0000019,,
2709.0,12861.0,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL857071,,BAO_0000019,,
2710.0,12490.0,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,,,,,12687.0,H,8.0,Expert,1.0,,CHEMBL617270,,BAO_0000019,,
2711.0,12827.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,,,N1E-115,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617271,339.0,BAO_0000219,,
2712.0,12827.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,,,N1E-115,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617272,339.0,BAO_0000219,,
2713.0,12918.0,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617273,,BAO_0000019,,
2714.0,12919.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687.0,D,9.0,Expert,1.0,,CHEMBL617274,,BAO_0000019,,
2715.0,17723.0,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617275,,BAO_0000357,,
2716.0,6013.0,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617276,,BAO_0000357,,
2717.0,16293.0,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617277,,BAO_0000357,,
2718.0,3857.0,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617278,,BAO_0000019,,
2719.0,3857.0,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617279,,BAO_0000019,,
2720.0,3857.0,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617280,,BAO_0000019,,
2721.0,15363.0,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617281,,BAO_0000357,,
2722.0,15363.0,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617282,,BAO_0000357,,
2723.0,16441.0,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617283,,BAO_0000019,,
2724.0,16441.0,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617284,,BAO_0000019,,
2725.0,4176.0,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617285,722.0,BAO_0000219,,
2726.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617286,,BAO_0000019,,
2727.0,17200.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,108.0,D,9.0,Expert,1.0,,CHEMBL617287,,BAO_0000357,,
2728.0,5088.0,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617288,,BAO_0000357,,
2729.0,5088.0,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617289,,BAO_0000357,,
2730.0,5088.0,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL872917,,BAO_0000357,,
2731.0,5088.0,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617290,,BAO_0000357,,
2732.0,16659.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617291,449.0,BAO_0000219,,
2733.0,16659.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,,,CHO,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617292,449.0,BAO_0000219,,
2734.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617293,723.0,BAO_0000219,,
2735.0,6857.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,108.0,D,9.0,Expert,1.0,,CHEMBL617294,449.0,BAO_0000219,,
2736.0,3857.0,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617295,,BAO_0000019,,
2737.0,12861.0,Binding activity radioligand.,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617296,,BAO_0000357,,
2738.0,12861.0,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617297,,BAO_0000019,,
2739.0,5104.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,,,CHO,,108.0,H,8.0,Expert,1.0,,CHEMBL617298,449.0,BAO_0000219,,
2740.0,5105.0,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,,,CHO,,108.0,H,8.0,Expert,1.0,,CHEMBL617299,449.0,BAO_0000219,,
2741.0,5105.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,,,CHO,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617300,449.0,BAO_0000219,,
2742.0,5254.0,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617454,,BAO_0000357,,
2743.0,13267.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617505,722.0,BAO_0000219,,
2744.0,14157.0,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,108.0,D,9.0,Expert,1.0,,CHEMBL617506,722.0,BAO_0000219,,
2745.0,12936.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108.0,D,9.0,Expert,1.0,,CHEMBL617507,722.0,BAO_0000219,,
2746.0,14068.0,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617508,,BAO_0000357,,
2747.0,12936.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108.0,D,9.0,Expert,1.0,,CHEMBL857982,722.0,BAO_0000219,,
2748.0,4540.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,108.0,D,9.0,Expert,1.0,,CHEMBL617509,722.0,BAO_0000219,,
2749.0,4540.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0,,,HEK293,,108.0,D,9.0,Expert,1.0,,CHEMBL617510,722.0,BAO_0000219,,
2750.0,6166.0,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617511,,BAO_0000357,,
2751.0,17296.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617512,722.0,BAO_0000219,,
2752.0,17296.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617749,722.0,BAO_0000219,,
2753.0,15779.0,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617750,722.0,BAO_0000219,,
2754.0,15779.0,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617751,722.0,BAO_0000219,,
2755.0,14391.0,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108.0,H,8.0,Expert,1.0,,CHEMBL617752,722.0,BAO_0000219,,
2756.0,15779.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617753,722.0,BAO_0000219,,
2757.0,15851.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,,,HEK293,,108.0,H,8.0,Expert,1.0,,CHEMBL617754,722.0,BAO_0000219,,
2758.0,15851.0,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,108.0,D,9.0,Expert,1.0,,CHEMBL617755,722.0,BAO_0000219,,
2759.0,15779.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617756,722.0,BAO_0000219,,
2760.0,3832.0,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,,,HEK293,,108.0,H,8.0,Expert,1.0,,CHEMBL617757,722.0,BAO_0000219,,
2761.0,3833.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,,,HEK293,,108.0,H,8.0,Expert,1.0,,CHEMBL617758,722.0,BAO_0000219,,
2762.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617759,723.0,BAO_0000219,,
2763.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617760,722.0,BAO_0000219,,
2764.0,1883.0,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,108.0,H,8.0,Expert,1.0,,CHEMBL617761,485.0,BAO_0000219,,
2765.0,4321.0,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108.0,D,9.0,Expert,1.0,,CHEMBL617762,,BAO_0000357,,
2766.0,14875.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617763,,BAO_0000357,,
2767.0,15146.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL857983,722.0,BAO_0000219,,
2768.0,5213.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617764,722.0,BAO_0000219,,
2769.0,16404.0,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,,,HeLa,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617765,308.0,BAO_0000219,,
2770.0,13267.0,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617766,,BAO_0000019,,
2771.0,13267.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,,Hippocampus,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617767,,BAO_0000221,10000000.0,
2772.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617768,722.0,BAO_0000219,,
2773.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,,,HEK293,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617769,722.0,BAO_0000219,,
2774.0,13463.0,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,,,,,11864.0,H,8.0,Autocuration,1.0,,CHEMBL858023,,BAO_0000357,,
2775.0,13463.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864.0,H,8.0,Autocuration,1.0,,CHEMBL617770,,BAO_0000019,945.0,
2776.0,13463.0,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864.0,H,8.0,Autocuration,1.0,,CHEMBL617771,,BAO_0000019,945.0,
2777.0,12652.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,,,A9,,11864.0,H,8.0,Autocuration,1.0,,CHEMBL617772,625.0,BAO_0000219,,
2778.0,4682.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864.0,H,8.0,Autocuration,1.0,,CHEMBL617773,723.0,BAO_0000219,,
2779.0,4682.0,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864.0,H,8.0,Autocuration,1.0,,CHEMBL617850,723.0,BAO_0000219,,
2780.0,4682.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864.0,H,8.0,Autocuration,1.0,,CHEMBL617851,723.0,BAO_0000219,,
2781.0,12652.0,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,,,,,11864.0,H,8.0,Autocuration,1.0,,CHEMBL617852,,BAO_0000019,,
2782.0,13463.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0,,Stomach,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL858024,,BAO_0000019,945.0,
2783.0,13463.0,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12689.0,D,9.0,Expert,1.0,,CHEMBL617853,,BAO_0000019,945.0,
2784.0,13969.0,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617854,,BAO_0000357,,
2785.0,13392.0,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL873477,,BAO_0000357,,
2786.0,13392.0,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617855,,BAO_0000357,,
2787.0,14430.0,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617856,,BAO_0000019,,
2788.0,1742.0,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617857,,BAO_0000019,,
2789.0,14286.0,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617858,,BAO_0000249,,
2790.0,5619.0,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617859,,BAO_0000357,,
2791.0,15086.0,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617860,,BAO_0000357,,
2792.0,12861.0,Binding activity radioligand.,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617861,,BAO_0000357,,
2793.0,12861.0,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617862,,BAO_0000019,,
2794.0,12861.0,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617863,,BAO_0000019,,
2795.0,12827.0,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617864,,BAO_0000249,,
2796.0,12827.0,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617649,,BAO_0000249,,
2797.0,12919.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617650,,BAO_0000019,,
2798.0,12919.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617651,,BAO_0000019,,
2799.0,16429.0,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617652,,BAO_0000357,,
2800.0,773.0,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL857072,,BAO_0000019,,
2801.0,5033.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617653,,BAO_0000357,,
2802.0,12861.0,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687.0,H,8.0,Autocuration,1.0,,CHEMBL617654,,BAO_0000019,,
2803.0,14093.0,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617655,,BAO_0000019,,
2804.0,14970.0,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL617656,,BAO_0000357,,
2805.0,14970.0,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617657,,BAO_0000357,,
2806.0,14970.0,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617658,,BAO_0000357,,
2807.0,14178.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Expert,1.0,,CHEMBL617659,,BAO_0000357,,
2808.0,14178.0,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Expert,1.0,,CHEMBL617838,,BAO_0000357,,
2809.0,14229.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12689.0,D,9.0,Expert,1.0,,CHEMBL617839,,BAO_0000249,,
2810.0,16532.0,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617840,,BAO_0000357,,
2811.0,14826.0,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617841,,BAO_0000019,,
2812.0,17211.0,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL875915,,BAO_0000019,,
2813.0,17211.0,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL617842,,BAO_0000219,,
2814.0,13246.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12689.0,H,8.0,Expert,1.0,,CHEMBL617843,723.0,BAO_0000219,,
2815.0,13246.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL617844,,BAO_0000357,,
2816.0,12457.0,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL617845,,BAO_0000357,,
2817.0,12457.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,,,NIH3T3,,12689.0,H,8.0,Expert,1.0,,CHEMBL617846,723.0,BAO_0000219,,
2818.0,4707.0,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617847,,BAO_0000357,,
2819.0,13297.0,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL617848,,BAO_0000357,,
2820.0,16633.0,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617849,,BAO_0000357,,
2821.0,16133.0,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL621507,,BAO_0000357,,
2822.0,16326.0,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL621508,,BAO_0000357,,
2823.0,14423.0,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621509,,BAO_0000019,,
2824.0,15412.0,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621510,,BAO_0000019,,
2825.0,15412.0,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621511,,BAO_0000019,,
2826.0,15558.0,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,,,A9,,12689.0,H,8.0,Expert,1.0,,CHEMBL621512,625.0,BAO_0000219,,
2827.0,16633.0,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621513,,BAO_0000357,,
2828.0,6013.0,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL621514,,BAO_0000357,,
2829.0,17175.0,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL621515,,BAO_0000219,,
2830.0,12469.0,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621516,,BAO_0000219,,
2831.0,3682.0,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621517,,BAO_0000019,5383.0,
2832.0,4932.0,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621518,,BAO_0000357,,
2833.0,4932.0,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621519,,BAO_0000019,,
2834.0,3935.0,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621520,,BAO_0000357,,
2835.0,15818.0,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621521,,BAO_0000357,,
2836.0,15818.0,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621522,,BAO_0000357,,
2837.0,14749.0,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL621523,,BAO_0000219,,
2838.0,15740.0,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621524,,BAO_0000357,,
2839.0,17133.0,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Expert,1.0,,CHEMBL621525,,BAO_0000357,,
2840.0,16532.0,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL872921,,BAO_0000357,,
2841.0,12369.0,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL621526,,BAO_0000357,,
2842.0,12369.0,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL621527,,BAO_0000219,,
2843.0,2309.0,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Expert,1.0,,CHEMBL617865,,BAO_0000019,,
2844.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617866,,BAO_0000357,,
2845.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617867,,BAO_0000019,,
2846.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617487,,BAO_0000357,,
2847.0,12953.0,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689.0,H,8.0,Expert,1.0,,CHEMBL617488,,BAO_0000357,,
2848.0,17133.0,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617489,,BAO_0000357,,
2849.0,17211.0,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617490,,BAO_0000019,,
2850.0,17211.0,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617491,,BAO_0000019,,
2851.0,14025.0,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617492,,BAO_0000019,,
2852.0,14998.0,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617493,,BAO_0000019,,
2853.0,4342.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617494,,BAO_0000357,,
2854.0,13735.0,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0,,,,,12689.0,D,9.0,Expert,1.0,,CHEMBL617495,,BAO_0000019,,
2855.0,13181.0,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617496,,BAO_0000357,,
2856.0,1883.0,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617497,485.0,BAO_0000219,,
2857.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617498,,BAO_0000357,,
2858.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617499,,BAO_0000357,,
2859.0,14579.0,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689.0,H,8.0,Autocuration,1.0,,CHEMBL617500,,BAO_0000019,,
2860.0,4639.0,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617501,,BAO_0000357,,
2861.0,4820.0,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617502,,BAO_0000357,,
2862.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617503,,BAO_0000357,,
2863.0,14755.0,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617504,,BAO_0000357,,
2864.0,14744.0,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617406,,BAO_0000357,,
2865.0,6857.0,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,227.0,D,9.0,Expert,1.0,,CHEMBL617407,,BAO_0000019,,
2866.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617408,,BAO_0000357,,
2867.0,15363.0,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617409,,BAO_0000357,,
2868.0,15363.0,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617410,,BAO_0000357,,
2869.0,15363.0,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617411,,BAO_0000357,,
2870.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617412,,BAO_0000019,,
2871.0,17200.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,227.0,D,9.0,Expert,1.0,,CHEMBL617774,,BAO_0000357,,
2872.0,15851.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227.0,D,9.0,Expert,1.0,,CHEMBL617775,722.0,BAO_0000219,,
2873.0,15851.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227.0,D,9.0,Expert,1.0,,CHEMBL617776,722.0,BAO_0000219,,
2874.0,6857.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227.0,D,9.0,Expert,1.0,,CHEMBL617777,449.0,BAO_0000219,,
2875.0,6857.0,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227.0,D,9.0,Expert,1.0,,CHEMBL617778,449.0,BAO_0000219,,
2876.0,15779.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617779,722.0,BAO_0000219,,
2877.0,15851.0,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227.0,H,8.0,Expert,1.0,,CHEMBL617780,722.0,BAO_0000219,,
2878.0,15779.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617781,722.0,BAO_0000219,,
2879.0,14157.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227.0,D,9.0,Expert,1.0,,CHEMBL617782,722.0,BAO_0000219,,
2880.0,4540.0,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,227.0,D,9.0,Expert,1.0,,CHEMBL617783,722.0,BAO_0000219,,
2881.0,6166.0,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617784,,BAO_0000357,,
2882.0,15779.0,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617785,722.0,BAO_0000219,,
2883.0,14391.0,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,,,HEK293,,227.0,H,8.0,Expert,1.0,,CHEMBL857984,722.0,BAO_0000219,,
2884.0,3832.0,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,,,HEK293,,227.0,H,8.0,Expert,1.0,,CHEMBL617786,722.0,BAO_0000219,,
2885.0,3833.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,,,HEK293,,227.0,H,8.0,Expert,1.0,,CHEMBL617787,722.0,BAO_0000219,,
2886.0,15851.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227.0,D,9.0,Expert,1.0,,CHEMBL617788,722.0,BAO_0000219,,
2887.0,15851.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,227.0,D,9.0,Expert,1.0,,CHEMBL617789,722.0,BAO_0000219,,
2888.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617790,722.0,BAO_0000219,,
2889.0,1883.0,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,227.0,H,8.0,Expert,1.0,,CHEMBL617791,485.0,BAO_0000219,,
2890.0,4321.0,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227.0,H,8.0,Expert,1.0,,CHEMBL617608,,BAO_0000357,,
2891.0,15146.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617609,722.0,BAO_0000219,,
2892.0,5213.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617610,722.0,BAO_0000219,,
2893.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617611,722.0,BAO_0000219,,
2894.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617612,722.0,BAO_0000219,,
2895.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617613,722.0,BAO_0000219,,
2896.0,14025.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617614,,BAO_0000019,,
2897.0,13463.0,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,,Stomach,,,12688.0,H,8.0,Expert,1.0,,CHEMBL617615,,BAO_0000019,945.0,
2898.0,7259.0,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688.0,H,8.0,Expert,1.0,,CHEMBL858114,,BAO_0000357,945.0,
2899.0,7259.0,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617616,,BAO_0000357,945.0,
2900.0,7185.0,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688.0,D,9.0,Expert,1.0,,CHEMBL617617,,BAO_0000019,945.0,
2901.0,7185.0,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0,,,,,12688.0,D,9.0,Expert,1.0,,CHEMBL875914,,BAO_0000019,,
2902.0,13267.0,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,,Stomach,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617618,,BAO_0000019,945.0,
2903.0,13735.0,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688.0,D,9.0,Expert,1.0,,CHEMBL617619,,BAO_0000357,945.0,
2904.0,15738.0,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,,,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617620,,BAO_0000019,,
2905.0,15738.0,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,,,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617621,,BAO_0000019,,
2906.0,15738.0,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,,,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617622,,BAO_0000019,,
2907.0,12936.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688.0,D,9.0,Expert,1.0,,CHEMBL617623,,BAO_0000357,945.0,
2908.0,12936.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688.0,D,9.0,Expert,1.0,,CHEMBL617624,,BAO_0000357,945.0,
2909.0,12936.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688.0,D,9.0,Expert,1.0,,CHEMBL617625,,BAO_0000357,945.0,
2910.0,12936.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688.0,D,9.0,Expert,1.0,,CHEMBL617626,,BAO_0000357,945.0,
2911.0,16404.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617627,,BAO_0000019,945.0,
2912.0,16404.0,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688.0,H,8.0,Expert,1.0,,CHEMBL617628,,BAO_0000019,945.0,
2913.0,16404.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,,Stomach,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617629,,BAO_0000019,945.0,
2914.0,16404.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,,Stomach,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL858115,,BAO_0000019,945.0,
2915.0,16404.0,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688.0,D,9.0,Expert,1.0,,CHEMBL617630,,BAO_0000019,945.0,
2916.0,16404.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,,Thoracic aorta,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617631,,BAO_0000019,1515.0,
2917.0,7483.0,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617632,,BAO_0000357,,
2918.0,7483.0,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,,,,,12688.0,H,8.0,Expert,1.0,,CHEMBL617633,,BAO_0000357,,
2919.0,7483.0,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617634,,BAO_0000357,,
2920.0,7483.0,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688.0,H,8.0,Autocuration,1.0,,CHEMBL617635,,BAO_0000357,,
2922.0,16404.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688.0,D,9.0,Autocuration,1.0,,CHEMBL617637,,BAO_0000019,945.0,
2923.0,6347.0,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617638,,BAO_0000357,,
2924.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617639,,BAO_0000357,,
2925.0,4373.0,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617640,,BAO_0000357,,
2926.0,4687.0,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617641,,BAO_0000357,,
2927.0,16946.0,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617642,,BAO_0000357,,
2928.0,16633.0,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617643,,BAO_0000357,,
2929.0,16633.0,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617644,,BAO_0000357,,
2930.0,16633.0,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,,,,,227.0,H,8.0,Autocuration,1.0,,CHEMBL617645,,BAO_0000357,,
2931.0,15026.0,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617646,,BAO_0000357,,
2932.0,15738.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617647,,BAO_0000357,,
2933.0,15738.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617648,,BAO_0000357,,
2934.0,15738.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617875,,BAO_0000357,,
2935.0,15738.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617876,,BAO_0000357,,
2936.0,16404.0,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617877,,BAO_0000357,,
2937.0,15026.0,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL617878,,BAO_0000357,,
2938.0,15738.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617879,,BAO_0000357,,
2939.0,16312.0,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617880,,BAO_0000019,,
2940.0,5486.0,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL617881,,BAO_0000357,2435.0,
2941.0,5254.0,Binding affinity against 5-HT1A receptor,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL857073,,BAO_0000357,,
2942.0,3857.0,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,,,CHO,,108.0,H,8.0,Expert,1.0,,CHEMBL617882,449.0,BAO_0000219,,
2943.0,6857.0,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,108.0,D,9.0,Expert,1.0,,CHEMBL617883,449.0,BAO_0000219,,
2944.0,4176.0,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617884,,BAO_0000219,,
2945.0,6347.0,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,,,CHO,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617885,449.0,BAO_0000219,,
2946.0,6347.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,,,CHO,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617886,449.0,BAO_0000219,,
2947.0,16146.0,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108.0,D,9.0,Expert,1.0,,CHEMBL617887,,BAO_0000357,,
2948.0,3805.0,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617888,,BAO_0000357,,
2949.0,3857.0,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617889,,BAO_0000019,,
2950.0,5635.0,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617890,,BAO_0000357,,
2951.0,5635.0,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617891,,BAO_0000357,,
2952.0,5635.0,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617892,,BAO_0000357,,
2953.0,4012.0,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,,,CHO,,108.0,H,8.0,Expert,1.0,,CHEMBL617893,449.0,BAO_0000219,,
2954.0,6366.0,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,,,CHO,,108.0,H,8.0,Expert,1.0,,CHEMBL617894,449.0,BAO_0000219,,
2955.0,15949.0,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108.0,H,8.0,Expert,1.0,,CHEMBL617895,449.0,BAO_0000219,,
2956.0,17211.0,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617896,449.0,BAO_0000219,,
2957.0,6491.0,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0,,,,,108.0,D,9.0,Expert,1.0,,CHEMBL617897,,BAO_0000357,,
2958.0,14093.0,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617898,,BAO_0000019,,
2959.0,13481.0,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617899,,BAO_0000019,,
2960.0,6347.0,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0,,,CHO,,108.0,H,8.0,Expert,1.0,,CHEMBL617900,449.0,BAO_0000219,,
2961.0,14093.0,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617901,,BAO_0000019,,
2962.0,14093.0,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617902,,BAO_0000019,,
2963.0,13481.0,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617903,,BAO_0000019,,
2964.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617904,,BAO_0000357,,
2965.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617905,,BAO_0000357,,
2966.0,14442.0,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617906,,BAO_0000357,,
2967.0,14755.0,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617907,,BAO_0000357,,
2968.0,14744.0,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL617908,,BAO_0000357,,
2969.0,16659.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108.0,H,8.0,Expert,1.0,,CHEMBL620617,449.0,BAO_0000219,,
2970.0,6857.0,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,108.0,D,9.0,Expert,1.0,,CHEMBL620618,,BAO_0000019,,
2971.0,5635.0,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL620619,,BAO_0000357,,
2972.0,4234.0,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108.0,D,9.0,Expert,1.0,,CHEMBL620620,,BAO_0000357,,
2973.0,16209.0,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620621,,BAO_0000357,,
2974.0,5778.0,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104698.0,D,7.0,Autocuration,1.0,,CHEMBL872920,,BAO_0000249,,
2975.0,5094.0,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620622,,BAO_0000223,,
2976.0,809.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL620623,,BAO_0000019,,
2977.0,1578.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620624,,BAO_0000019,,
2978.0,809.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620625,,BAO_0000019,,
2979.0,12469.0,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620626,,BAO_0000219,,
2980.0,14290.0,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621307,,BAO_0000019,,
2981.0,14290.0,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621308,,BAO_0000019,,
2982.0,10609.0,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621309,,BAO_0000223,,
2983.0,10609.0,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621310,,BAO_0000223,,
2984.0,10609.0,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621311,,BAO_0000223,,
2985.0,15253.0,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621502,,BAO_0000249,,
2986.0,15253.0,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621503,,BAO_0000249,,
2987.0,11683.0,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,,,,Membranes,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621504,,BAO_0000249,,
2988.0,12092.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621505,,BAO_0000223,,
2989.0,1946.0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL621506,,BAO_0000019,,
2990.0,11623.0,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619781,,BAO_0000223,,
2991.0,11623.0,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619782,,BAO_0000223,,
2992.0,14788.0,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619783,,BAO_0000019,,
2993.0,5432.0,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL619784,,BAO_0000019,,
2994.0,14826.0,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619785,,BAO_0000249,,
2995.0,2222.0,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619786,,BAO_0000223,,
2996.0,11963.0,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619787,,BAO_0000019,,
2997.0,14145.0,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL872925,,BAO_0000019,,
2998.0,17819.0,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619788,,BAO_0000019,,
2999.0,10394.0,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619789,,BAO_0000249,,
3000.0,10394.0,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619790,,BAO_0000249,,
3001.0,15034.0,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619791,,BAO_0000019,,
3002.0,691.0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619792,,BAO_0000019,,
3003.0,12092.0,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,,,,Membranes,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619793,,BAO_0000249,,
3004.0,11752.0,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL619794,,BAO_0000223,,
3005.0,11752.0,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,,Brain,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619795,,BAO_0000221,955.0,
3006.0,301.0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619796,,BAO_0000019,,
3007.0,16532.0,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620448,,BAO_0000223,,
3008.0,16532.0,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620449,,BAO_0000223,,
3009.0,12092.0,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620450,,BAO_0000223,,
3010.0,11684.0,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620451,,BAO_0000223,,
3011.0,11684.0,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620631,,BAO_0000223,,
3012.0,12953.0,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620632,,BAO_0000019,,
3013.0,12953.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620633,,BAO_0000019,,
3014.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620634,,BAO_0000223,,
3015.0,12861.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620635,,BAO_0000019,,
3016.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620636,,BAO_0000218,,
3017.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620637,,BAO_0000218,,
3018.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620638,,BAO_0000218,,
3019.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620639,,BAO_0000218,,
3020.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620640,,BAO_0000218,,
3021.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620641,,BAO_0000218,,
3022.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620642,,BAO_0000218,,
3023.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620643,,BAO_0000218,,
3024.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620644,,BAO_0000218,,
3025.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620645,,BAO_0000218,,
3026.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620646,,BAO_0000218,,
3027.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620647,,BAO_0000218,,
3028.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620648,,BAO_0000218,,
3029.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620649,,BAO_0000218,,
3030.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620650,,BAO_0000218,,
3031.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620651,,BAO_0000218,,
3032.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL872875,,BAO_0000218,,
3033.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620652,,BAO_0000218,,
3034.0,10609.0,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620653,,BAO_0000019,,
3035.0,12861.0,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL857076,,BAO_0000019,,
3036.0,12861.0,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL620654,,BAO_0000019,,
3037.0,12861.0,Binding activity radioligand.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620655,,BAO_0000223,,
3038.0,10728.0,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,,,,Brain membranes,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620656,,BAO_0000249,,
3039.0,10728.0,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,,,,Brain membranes,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620657,,BAO_0000249,,
3040.0,5163.0,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620658,,BAO_0000357,,
3041.0,5163.0,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620659,,BAO_0000357,,
3042.0,6011.0,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620660,,BAO_0000357,,
3043.0,5014.0,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620661,,BAO_0000357,,
3044.0,5635.0,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620662,,BAO_0000357,,
3045.0,5163.0,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL620663,,BAO_0000357,,
3046.0,6841.0,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620664,,BAO_0000357,,
3047.0,6119.0,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL620665,,BAO_0000357,,
3048.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620666,,BAO_0000357,,
3049.0,1633.0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620667,,BAO_0000357,,
3050.0,1633.0,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL620668,,BAO_0000357,,
3051.0,4373.0,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620669,,BAO_0000357,,
3052.0,6576.0,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL620670,,BAO_0000357,,
3053.0,4687.0,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620671,,BAO_0000357,,
3054.0,12146.0,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620672,,BAO_0000357,,
3055.0,12146.0,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620673,,BAO_0000357,,
3056.0,16946.0,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620674,,BAO_0000357,,
3057.0,14159.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620675,,BAO_0000357,,
3058.0,16700.0,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL620676,,BAO_0000357,,
3059.0,3269.0,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL621382,,BAO_0000357,,
3060.0,1274.0,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108.0,D,9.0,Expert,1.0,,CHEMBL621383,,BAO_0000357,,
3061.0,1317.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL621384,,BAO_0000357,,
3062.0,5834.0,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL621385,,BAO_0000357,,
3063.0,11147.0,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL617989,,BAO_0000357,,
3064.0,14145.0,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Expert,1.0,,CHEMBL617990,,BAO_0000019,,
3065.0,10561.0,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL875085,,BAO_0000221,2116.0,
3066.0,15847.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617991,,BAO_0000019,,
3067.0,15847.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617992,,BAO_0000019,,
3068.0,10561.0,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617993,,BAO_0000221,2116.0,
3069.0,11454.0,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617994,,BAO_0000221,2116.0,
3070.0,4639.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617995,,BAO_0000019,,
3071.0,4639.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617996,,BAO_0000019,,
3072.0,4639.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617997,,BAO_0000019,,
3073.0,4639.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617998,,BAO_0000019,,
3074.0,4639.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617999,,BAO_0000019,,
3075.0,4639.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618000,,BAO_0000019,,
3076.0,15253.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617815,,BAO_0000221,2116.0,
3077.0,15253.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617816,,BAO_0000221,2116.0,
3078.0,11963.0,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617817,,BAO_0000221,2116.0,
3079.0,1946.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617818,,BAO_0000221,2116.0,
3080.0,1946.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617819,,BAO_0000221,2116.0,
3081.0,12045.0,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617820,,BAO_0000223,,
3082.0,1559.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617821,,BAO_0000221,2116.0,
3083.0,273.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617822,,BAO_0000221,2116.0,
3084.0,273.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617823,,BAO_0000221,2116.0,
3085.0,188.0,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617824,,BAO_0000221,2116.0,
3086.0,12919.0,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617825,,BAO_0000221,2116.0,
3087.0,12918.0,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617826,,BAO_0000221,2116.0,
3088.0,1559.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617827,,BAO_0000221,2116.0,
3089.0,273.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617828,,BAO_0000221,2116.0,
3090.0,1559.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617829,,BAO_0000221,2116.0,
3091.0,1559.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617830,,BAO_0000221,2116.0,
3092.0,1559.0,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617831,,BAO_0000221,2116.0,
3093.0,14424.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617832,,BAO_0000221,2116.0,
3094.0,13181.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL617833,,BAO_0000019,,
3095.0,5486.0,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,,,,,51.0,H,8.0,Autocuration,1.0,,CHEMBL617834,,BAO_0000357,,
3096.0,6491.0,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,104714.0,D,5.0,Expert,1.0,,CHEMBL617835,,BAO_0000223,,
3097.0,6013.0,Binding affinity towards 5-HT3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617836,,BAO_0000223,,
3098.0,12861.0,Binding activity radioligand.,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617837,,BAO_0000223,,
3099.0,12861.0,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620392,,BAO_0000019,,
3100.0,5104.0,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620393,,BAO_0000223,,
3101.0,5105.0,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620394,,BAO_0000223,,
3102.0,5104.0,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620395,,BAO_0000223,,
3103.0,3935.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620396,,BAO_0000019,,
3104.0,13657.0,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,,,NG108-15,,105030.0,H,4.0,Expert,1.0,,CHEMBL620582,433.0,BAO_0000219,,
3105.0,10369.0,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL620583,,BAO_0000218,,
3106.0,10369.0,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL620584,,BAO_0000019,,
3107.0,12918.0,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL620585,,BAO_0000224,,
3108.0,12918.0,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL620586,,BAO_0000224,,
3109.0,10369.0,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL620587,,BAO_0000019,,
3110.0,773.0,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL620588,,BAO_0000019,,
3111.0,12918.0,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL620589,,BAO_0000218,,
3112.0,10561.0,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL620590,,BAO_0000219,,
3113.0,12827.0,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL617956,,BAO_0000019,,
3114.0,12827.0,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL617957,,BAO_0000019,,
3115.0,12918.0,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL617958,,BAO_0000224,,
3116.0,273.0,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL617959,,BAO_0000219,,
3117.0,273.0,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL617960,,BAO_0000219,,
3118.0,10561.0,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL617961,,BAO_0000224,,
3119.0,5033.0,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,,,,,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL617962,,BAO_0000219,,
3120.0,16429.0,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,,,N1E-115,,105030.0,H,4.0,Autocuration,1.0,,CHEMBL617963,339.0,BAO_0000219,,
3121.0,10322.0,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,11765.0,H,8.0,Autocuration,1.0,,CHEMBL617964,,BAO_0000019,,
3122.0,14331.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,,,,,11765.0,H,8.0,Autocuration,1.0,,CHEMBL617965,,BAO_0000219,,
3123.0,13462.0,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0,,,,,10630.0,D,9.0,Autocuration,1.0,,CHEMBL617966,,BAO_0000357,,
3124.0,12861.0,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106.0,H,8.0,Autocuration,1.0,,CHEMBL857074,,BAO_0000019,,
3125.0,15086.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL617967,,BAO_0000357,,
3126.0,12861.0,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL617968,,BAO_0000357,,
3127.0,10561.0,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617969,,BAO_0000223,,
3128.0,10561.0,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617970,,BAO_0000223,,
3129.0,10561.0,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617971,,BAO_0000223,,
3130.0,10561.0,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617972,,BAO_0000019,,
3131.0,273.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617973,,BAO_0000019,,
3132.0,273.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617974,,BAO_0000019,,
3133.0,273.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0,,Ileum,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617975,,BAO_0000221,2116.0,
3134.0,273.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617976,,BAO_0000019,,
3135.0,273.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617977,,BAO_0000019,,
3136.0,273.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617978,,BAO_0000019,,
3137.0,273.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617979,,BAO_0000019,,
3138.0,13047.0,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0,,,CHO,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL617980,449.0,BAO_0000219,,
3139.0,1650.0,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617981,,BAO_0000019,,
3140.0,16288.0,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL617982,,BAO_0000019,,
3141.0,16288.0,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL617983,,BAO_0000357,,
3142.0,10254.0,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617984,,BAO_0000019,,
3143.0,14532.0,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617985,,BAO_0000019,,
3144.0,13392.0,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,,,Heart,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617986,,BAO_0000218,948.0,
3145.0,13392.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617987,,BAO_0000019,948.0,
3146.0,13392.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617988,,BAO_0000019,948.0,
3147.0,13392.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617792,,BAO_0000019,948.0,
3148.0,13392.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617793,,BAO_0000019,948.0,
3149.0,13392.0,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617794,,BAO_0000019,,
3150.0,13392.0,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617795,,BAO_0000019,,
3151.0,13392.0,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617796,,BAO_0000019,,
3152.0,13392.0,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617797,,BAO_0000019,,
3153.0,1089.0,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617798,,BAO_0000218,,
3154.0,1089.0,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617799,,BAO_0000218,,
3155.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617800,,BAO_0000218,,
3156.0,11454.0,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617801,,BAO_0000019,,
3157.0,12205.0,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617802,,BAO_0000218,,
3158.0,1089.0,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617803,,BAO_0000019,,
3159.0,5094.0,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617804,,BAO_0000019,,
3160.0,2622.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617805,,BAO_0000019,,
3161.0,245.0,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617806,,BAO_0000223,,
3162.0,14788.0,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617807,,BAO_0000019,,
3163.0,14788.0,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617808,,BAO_0000019,,
3164.0,3020.0,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617809,,BAO_0000249,,
3165.0,1742.0,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617810,,BAO_0000019,,
3166.0,17394.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,,Brain,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617811,,BAO_0000249,955.0,
3167.0,17394.0,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,,Brain,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617812,,BAO_0000221,955.0,
3168.0,17394.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617813,,BAO_0000249,,
3169.0,14286.0,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617814,,BAO_0000249,,
3170.0,14178.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617698,,BAO_0000019,,
3171.0,14178.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617699,,BAO_0000019,,
3172.0,14178.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617700,,BAO_0000019,,
3173.0,14178.0,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617701,,BAO_0000223,,
3174.0,15034.0,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617702,,BAO_0000019,,
3175.0,1089.0,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,,,,Membranes,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617703,,BAO_0000249,,
3176.0,1089.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617704,,BAO_0000019,,
3177.0,16532.0,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617705,,BAO_0000223,,
3178.0,12801.0,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617706,,BAO_0000223,,
3179.0,15194.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,,,NG108-15,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617707,433.0,BAO_0000219,,
3180.0,15194.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,,,NG108-15,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617708,433.0,BAO_0000219,,
3181.0,15194.0,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617709,,BAO_0000019,,
3182.0,15194.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617710,,BAO_0000019,,
3183.0,15194.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL882925,,BAO_0000019,,
3184.0,15194.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617711,,BAO_0000019,,
3185.0,10610.0,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617712,,BAO_0000019,,
3186.0,10355.0,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617713,,BAO_0000019,,
3187.0,691.0,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617714,,BAO_0000019,,
3188.0,10611.0,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617715,,BAO_0000218,,
3189.0,12801.0,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617716,,BAO_0000218,,
3190.0,10609.0,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617717,,BAO_0000218,,
3191.0,11454.0,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617718,,BAO_0000218,,
3192.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617719,,BAO_0000218,,
3193.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617720,,BAO_0000218,,
3194.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL617721,,BAO_0000218,,
3195.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617722,,BAO_0000218,,
3196.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617723,,BAO_0000218,,
3197.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617724,,BAO_0000218,,
3198.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617725,,BAO_0000218,,
3199.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617726,,BAO_0000218,,
3200.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617727,,BAO_0000218,,
3201.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617728,,BAO_0000218,,
3202.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617729,,BAO_0000218,,
3203.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617730,,BAO_0000218,,
3204.0,11454.0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617731,,BAO_0000218,,
3205.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617732,,BAO_0000218,,
3206.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617733,,BAO_0000218,,
3207.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617734,,BAO_0000218,,
3208.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL872874,,BAO_0000218,,
3209.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617735,,BAO_0000218,,
3210.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617736,,BAO_0000218,,
3211.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617737,,BAO_0000218,,
3212.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617738,,BAO_0000218,,
3213.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617739,,BAO_0000218,,
3214.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617740,,BAO_0000218,,
3215.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617741,,BAO_0000218,,
3216.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617742,,BAO_0000218,,
3217.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617743,,BAO_0000218,,
3218.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617744,,BAO_0000218,,
3219.0,11454.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617745,,BAO_0000218,,
3220.0,670.0,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617746,,BAO_0000218,,
3221.0,670.0,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617747,,BAO_0000218,,
3222.0,10321.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL617748,,BAO_0000218,,
3223.0,10321.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618909,,BAO_0000218,,
3224.0,10321.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618910,,BAO_0000218,,
3225.0,10321.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618911,,BAO_0000218,,
3226.0,10321.0,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618912,,BAO_0000218,,
3227.0,10322.0,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618913,,BAO_0000218,,
3228.0,15412.0,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618914,,BAO_0000019,,
3229.0,15412.0,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618915,,BAO_0000019,,
3230.0,15412.0,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL618916,,BAO_0000223,,
3231.0,15412.0,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618917,,BAO_0000019,,
3232.0,15412.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,,Hippocampus,,,104698.0,D,7.0,Intermediate,1.0,,CHEMBL618918,,BAO_0000221,10000000.0,
3233.0,15412.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL618919,,BAO_0000019,,
3234.0,17394.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL618920,,BAO_0000019,,
3235.0,12457.0,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618921,,BAO_0000223,,
3236.0,12457.0,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618922,,BAO_0000019,,
3237.0,12205.0,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618923,,BAO_0000019,,
3238.0,14532.0,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618924,,BAO_0000019,,
3239.0,1122.0,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618925,,BAO_0000019,,
3240.0,5094.0,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618926,,BAO_0000019,,
3241.0,809.0,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL618927,,BAO_0000221,2116.0,
3242.0,809.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL618928,,BAO_0000221,2116.0,
3243.0,14290.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL618929,,BAO_0000221,2116.0,
3244.0,14290.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL618930,,BAO_0000221,2116.0,
3245.0,14290.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL618931,,BAO_0000221,2116.0,
3246.0,14290.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619594,,BAO_0000221,2116.0,
3247.0,14290.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619595,,BAO_0000221,2116.0,
3248.0,13961.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619596,,BAO_0000221,2116.0,
3249.0,13961.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619755,,BAO_0000221,2116.0,
3250.0,809.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619756,,BAO_0000221,2116.0,
3251.0,809.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619757,,BAO_0000221,2116.0,
3252.0,809.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619758,,BAO_0000221,2116.0,
3253.0,14290.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619759,,BAO_0000221,2116.0,
3254.0,14290.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619760,,BAO_0000221,2116.0,
3255.0,14290.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619761,,BAO_0000221,2116.0,
3256.0,14290.0,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619762,,BAO_0000221,2116.0,
3257.0,14290.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619763,,BAO_0000221,2116.0,
3258.0,14290.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL617868,,BAO_0000221,2116.0,
3259.0,15034.0,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL617869,,BAO_0000357,,
3260.0,5094.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL882926,,BAO_0000249,2435.0,
3261.0,5094.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL617870,,BAO_0000249,2435.0,
3262.0,5399.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL617871,,BAO_0000357,2435.0,
3263.0,17394.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL617872,,BAO_0000357,2435.0,
3264.0,17394.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL617873,,BAO_0000357,2435.0,
3265.0,17394.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL617874,,BAO_0000357,2435.0,
3266.0,13961.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619067,,BAO_0000221,2116.0,
3267.0,13961.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619068,,BAO_0000221,2116.0,
3268.0,13961.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619069,,BAO_0000221,2116.0,
3269.0,16946.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619070,,BAO_0000357,,
3270.0,16946.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619071,,BAO_0000357,,
3271.0,15034.0,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619072,,BAO_0000019,,
3272.0,15034.0,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619073,,BAO_0000019,,
3273.0,12918.0,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619074,,BAO_0000019,,
3274.0,16946.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619075,,BAO_0000357,,
3275.0,17394.0,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619076,,BAO_0000357,2435.0,
3276.0,15034.0,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619077,,BAO_0000357,2435.0,
3277.0,5094.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619078,,BAO_0000249,2435.0,
3278.0,5094.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619079,,BAO_0000249,2435.0,
3279.0,17358.0,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619080,,BAO_0000221,2116.0,
3280.0,12953.0,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Expert,1.0,,CHEMBL619081,,BAO_0000357,,
3281.0,12953.0,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619082,,BAO_0000357,,
3282.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619083,,BAO_0000357,,
3283.0,12953.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619084,,BAO_0000357,,
3284.0,273.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL859397,,BAO_0000221,2116.0,
3285.0,12918.0,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619085,,BAO_0000221,2116.0,
3286.0,12919.0,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619086,,BAO_0000221,2116.0,
3287.0,273.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619087,,BAO_0000221,2116.0,
3288.0,273.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619088,,BAO_0000221,2116.0,
3289.0,13181.0,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619089,,BAO_0000357,,
3290.0,13181.0,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619090,,BAO_0000357,,
3291.0,15034.0,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619091,,BAO_0000019,,
3292.0,5033.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619092,,BAO_0000357,,
3293.0,1980.0,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619093,,BAO_0000019,,
3294.0,13181.0,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,HEK293,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619094,722.0,BAO_0000219,,
3295.0,14287.0,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619095,,BAO_0000019,,
3296.0,1317.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL857988,,BAO_0000357,,
3297.0,15316.0,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619096,,BAO_0000357,,
3298.0,16429.0,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619097,,BAO_0000357,2435.0,
3299.0,14818.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0,,Hippocampus,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619098,,BAO_0000221,10000000.0,
3300.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619751,,BAO_0000357,,
3301.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619752,,BAO_0000357,,
3302.0,13961.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL875096,,BAO_0000221,2116.0,
3303.0,5486.0,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,,,,,108.0,H,8.0,Autocuration,1.0,,CHEMBL619004,,BAO_0000357,,
3304.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619005,,BAO_0000357,,
3305.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619006,,BAO_0000019,,
3306.0,4199.0,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,,,HeLa,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619007,308.0,BAO_0000219,,
3307.0,15146.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619008,,BAO_0000357,,
3308.0,5213.0,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619009,,BAO_0000357,,
3309.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,,,HeLa,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619010,308.0,BAO_0000219,,
3310.0,17358.0,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,,,,,10622.0,H,8.0,Autocuration,1.0,,CHEMBL619011,,BAO_0000357,,
3311.0,17358.0,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,,,,,10622.0,H,8.0,Autocuration,1.0,,CHEMBL619012,,BAO_0000357,,
3312.0,16946.0,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,,,,,10622.0,H,8.0,Autocuration,1.0,,CHEMBL619013,,BAO_0000219,,
3313.0,17358.0,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,,,,,10622.0,H,8.0,Autocuration,1.0,,CHEMBL619014,,BAO_0000357,,
3314.0,268.0,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,,Cardiac atrium,,,11249.0,H,8.0,Autocuration,1.0,,CHEMBL857503,,BAO_0000019,2081.0,
3315.0,268.0,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,,Cardiac atrium,,,11249.0,H,8.0,Autocuration,1.0,,CHEMBL619015,,BAO_0000019,2081.0,
3316.0,15086.0,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,11249.0,H,8.0,Autocuration,1.0,,CHEMBL619016,,BAO_0000357,,
3317.0,14875.0,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,,Hippocampus,,,11249.0,H,8.0,Autocuration,1.0,,CHEMBL619017,,BAO_0000221,10000000.0,
3318.0,13267.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0,,Hippocampus,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619018,,BAO_0000221,10000000.0,
3319.0,13047.0,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL619019,,BAO_0000019,,
3320.0,1650.0,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623.0,D,9.0,Expert,1.0,,CHEMBL619020,,BAO_0000357,,
3321.0,567.0,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619021,,BAO_0000019,,
3322.0,17358.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619022,,BAO_0000357,,
3323.0,188.0,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619023,,BAO_0000357,,
3324.0,670.0,lntrinsic activity relative to 5-HT receptor,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619024,,BAO_0000019,,
3325.0,204.0,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619025,,BAO_0000019,,
3326.0,1946.0,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL619026,,BAO_0000019,,
3327.0,6398.0,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619027,,BAO_0000019,,
3328.0,6398.0,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619028,,BAO_0000019,,
3329.0,17358.0,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619029,,BAO_0000019,,
3330.0,6398.0,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619030,,BAO_0000019,,
3331.0,11752.0,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL619031,,BAO_0000357,,
3332.0,809.0,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619032,,BAO_0000019,,
3333.0,14178.0,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623.0,D,9.0,Expert,1.0,,CHEMBL619033,,BAO_0000357,,
3334.0,567.0,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619034,,BAO_0000357,,
3335.0,1946.0,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619035,,BAO_0000357,,
3336.0,1946.0,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619036,,BAO_0000357,,
3337.0,13961.0,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0,,,,,10623.0,D,9.0,Expert,1.0,,CHEMBL619037,,BAO_0000019,,
3338.0,6238.0,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,,Striatum,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619038,,BAO_0000249,2435.0,
3339.0,14290.0,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619039,,BAO_0000249,,
3340.0,14290.0,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL619040,,BAO_0000249,,
3341.0,809.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0,,Striatum,,,10623.0,D,9.0,Expert,1.0,,CHEMBL619041,,BAO_0000019,2435.0,
3342.0,1578.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,,Striatum,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619042,,BAO_0000019,2435.0,
3343.0,16709.0,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,,Striatum,,,10623.0,H,8.0,Expert,1.0,,CHEMBL619043,,BAO_0000249,2435.0,
3344.0,1946.0,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,,Striatum,,,10623.0,H,8.0,Expert,1.0,,CHEMBL619044,,BAO_0000019,2435.0,
3345.0,15253.0,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,,Striatum,,,10623.0,H,8.0,Expert,1.0,,CHEMBL619045,,BAO_0000249,2435.0,
3346.0,4535.0,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623.0,H,8.0,Expert,1.0,,CHEMBL619046,,BAO_0000249,2435.0,
3347.0,13961.0,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL619047,,BAO_0000249,,
3348.0,17358.0,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,,Brain,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619048,,BAO_0000221,955.0,
3349.0,15847.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL859398,,BAO_0000019,,
3350.0,15847.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619049,,BAO_0000019,,
3351.0,670.0,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL857886,,BAO_0000019,,
3352.0,670.0,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL619050,,BAO_0000019,,
3353.0,1317.0,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL620591,,BAO_0000019,,
3354.0,12936.0,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623.0,D,9.0,Expert,1.0,,CHEMBL620592,,BAO_0000357,,
3355.0,4535.0,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623.0,H,8.0,Expert,1.0,,CHEMBL620593,,BAO_0000249,2435.0,
3356.0,14424.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0,,,,,10623.0,D,9.0,Expert,1.0,,CHEMBL620594,,BAO_0000019,,
3357.0,14424.0,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL875079,,BAO_0000019,,
3358.0,14424.0,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL620595,,BAO_0000019,,
3359.0,14424.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0,,,,,10623.0,D,9.0,Expert,1.0,,CHEMBL620596,,BAO_0000019,,
3360.0,14424.0,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL620597,,BAO_0000019,,
3361.0,14424.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL620598,,BAO_0000019,,
3362.0,14424.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,,,,,10623.0,H,8.0,Expert,1.0,,CHEMBL620599,,BAO_0000218,,
3363.0,14424.0,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623.0,H,8.0,Autocuration,1.0,,CHEMBL620600,,BAO_0000019,,
3364.0,1980.0,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620601,,BAO_0000019,,
3365.0,4639.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620602,,BAO_0000019,,
3366.0,17358.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620603,,BAO_0000357,,
3367.0,17358.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620604,,BAO_0000357,,
3368.0,17358.0,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620605,,BAO_0000357,,
3369.0,1558.0,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620606,,BAO_0000357,,
3370.0,17358.0,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620607,,BAO_0000019,,
3371.0,16117.0,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620608,,BAO_0000357,,
3372.0,17358.0,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620609,,BAO_0000019,,
3373.0,17358.0,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620610,,BAO_0000019,,
3374.0,17358.0,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620611,,BAO_0000357,,
3375.0,17358.0,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620612,,BAO_0000357,,
3376.0,17358.0,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620613,,BAO_0000357,,
3377.0,17358.0,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620614,,BAO_0000357,,
3378.0,1274.0,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Expert,1.0,,CHEMBL620615,,BAO_0000357,,
3379.0,10728.0,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698.0,H,6.0,Autocuration,1.0,,CHEMBL857075,,BAO_0000249,,
3380.0,11695.0,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620616,,BAO_0000249,,
3381.0,11695.0,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619411,,BAO_0000249,,
3382.0,12490.0,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619412,,BAO_0000019,,
3383.0,11828.0,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL619413,,BAO_0000019,,
3384.0,12253.0,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,,Hippocampus,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619414,,BAO_0000221,10000000.0,
3385.0,10561.0,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619415,,BAO_0000019,,
3386.0,10561.0,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619416,,BAO_0000019,,
3387.0,14432.0,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619417,,BAO_0000019,,
3388.0,12936.0,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL619418,,BAO_0000223,,
3389.0,1274.0,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL619419,,BAO_0000223,,
3390.0,1980.0,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619420,,BAO_0000019,,
3391.0,670.0,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619421,,BAO_0000249,,
3392.0,968.0,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL619422,,BAO_0000019,,
3393.0,14287.0,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619423,,BAO_0000019,,
3394.0,567.0,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL875080,,BAO_0000019,,
3395.0,13267.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619424,,BAO_0000019,,
3396.0,14826.0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619425,,BAO_0000249,,
3397.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619426,,BAO_0000223,,
3398.0,15194.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL619427,,BAO_0000223,,
3399.0,10394.0,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698.0,D,7.0,Autocuration,1.0,,CHEMBL619645,,BAO_0000223,,
3400.0,13657.0,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,,,,,10576.0,D,9.0,Expert,1.0,,CHEMBL619646,,BAO_0000249,,
3401.0,1879.0,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,,Brain,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL619647,,BAO_0000221,955.0,
3402.0,1879.0,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL619648,,BAO_0000019,,
3403.0,1879.0,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL619165,,BAO_0000019,,
3404.0,204.0,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL620719,,BAO_0000218,,
3405.0,1879.0,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL872924,,BAO_0000019,,
3406.0,1879.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL620720,,BAO_0000357,,
3407.0,1879.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL620721,,BAO_0000019,,
3408.0,1879.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL620722,,BAO_0000019,,
3409.0,10641.0,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620723,,BAO_0000019,,
3410.0,773.0,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,12020.0,H,8.0,Autocuration,1.0,,CHEMBL620724,,BAO_0000019,,
3411.0,11952.0,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL620725,,BAO_0000249,,
3412.0,14145.0,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0,,,,,12020.0,D,9.0,Autocuration,1.0,,CHEMBL620726,,BAO_0000019,,
3413.0,17066.0,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144.0,H,8.0,Expert,1.0,,CHEMBL620727,,BAO_0000357,,
3414.0,6398.0,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620728,,BAO_0000223,,
3415.0,10321.0,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620729,,BAO_0000019,,
3416.0,511.0,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL858288,,BAO_0000019,,
3417.0,4639.0,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620730,,BAO_0000223,,
3418.0,4639.0,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620731,,BAO_0000223,,
3419.0,4639.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620732,,BAO_0000019,,
3420.0,4639.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618042,,BAO_0000019,,
3421.0,4639.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618043,,BAO_0000019,,
3422.0,1558.0,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618044,,BAO_0000223,,
3423.0,268.0,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618045,,BAO_0000019,,
3424.0,2474.0,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618046,,BAO_0000223,,
3425.0,5067.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618047,,BAO_0000019,,
3426.0,5067.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL875084,,BAO_0000019,,
3427.0,5067.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618048,,BAO_0000019,,
3428.0,5067.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618049,,BAO_0000223,,
3429.0,5067.0,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619764,,BAO_0000019,,
3430.0,5067.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619765,,BAO_0000019,,
3431.0,5067.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619766,,BAO_0000019,,
3432.0,5067.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619767,,BAO_0000223,,
3433.0,5067.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619768,,BAO_0000223,,
3434.0,5067.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619769,,BAO_0000019,,
3435.0,5067.0,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619770,,BAO_0000223,,
3436.0,5067.0,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619771,,BAO_0000223,,
3437.0,14331.0,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619772,,BAO_0000219,,
3438.0,5067.0,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619773,,BAO_0000223,,
3439.0,6179.0,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,,,NG108-15,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619774,433.0,BAO_0000219,,
3440.0,4265.0,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL875083,,BAO_0000019,,
3441.0,4265.0,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,,,NG108-15,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL620718,433.0,BAO_0000219,,
3442.0,17358.0,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618127,,BAO_0000223,,
3443.0,17358.0,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618128,,BAO_0000223,,
3444.0,13628.0,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618129,,BAO_0000219,,
3445.0,4612.0,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618130,,BAO_0000223,,
3446.0,17358.0,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618131,,BAO_0000019,,
3447.0,4639.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618132,,BAO_0000019,,
3448.0,4639.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618133,,BAO_0000019,,
3449.0,4639.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618134,,BAO_0000019,,
3450.0,4639.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618135,,BAO_0000019,,
3451.0,511.0,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618136,,BAO_0000223,,
3452.0,1479.0,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618137,,BAO_0000223,,
3453.0,1317.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618138,,BAO_0000223,,
3454.0,12146.0,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618139,,BAO_0000223,,
3455.0,12146.0,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618140,,BAO_0000223,,
3456.0,13969.0,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618141,,BAO_0000223,,
3457.0,13392.0,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108.0,H,8.0,Expert,1.0,,CHEMBL873478,,BAO_0000357,,
3458.0,13392.0,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618142,,BAO_0000223,,
3459.0,14159.0,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618143,,BAO_0000357,,
3460.0,1558.0,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618144,,BAO_0000357,,
3461.0,16655.0,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618145,,BAO_0000357,,
3462.0,13020.0,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618146,,BAO_0000223,,
3463.0,13021.0,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618147,,BAO_0000223,,
3464.0,13020.0,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618148,,BAO_0000223,,
3465.0,10321.0,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618149,,BAO_0000019,,
3466.0,15818.0,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL872927,,BAO_0000357,,
3467.0,15818.0,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618150,,BAO_0000357,,
3468.0,17358.0,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618151,,BAO_0000357,,
3469.0,2222.0,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL875094,,BAO_0000357,,
3470.0,10322.0,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618152,,BAO_0000019,,
3471.0,16117.0,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618153,,BAO_0000357,,
3472.0,17200.0,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618888,,BAO_0000357,,
3473.0,17358.0,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618889,,BAO_0000019,,
3474.0,16700.0,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618890,,BAO_0000357,,
3475.0,1980.0,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL618891,,BAO_0000019,,
3476.0,1980.0,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL619054,,BAO_0000019,,
3477.0,12409.0,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL619055,,BAO_0000223,,
3478.0,4365.0,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL619056,,BAO_0000357,,
3479.0,4365.0,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL619057,,BAO_0000019,,
3480.0,4365.0,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144.0,H,8.0,Autocuration,1.0,,CHEMBL619058,,BAO_0000357,,
3481.0,6769.0,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020.0,D,9.0,Expert,1.0,,CHEMBL619059,,BAO_0000219,,
3482.0,6769.0,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020.0,D,9.0,Expert,1.0,,CHEMBL619060,,BAO_0000219,,
3483.0,6769.0,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020.0,D,9.0,Expert,1.0,,CHEMBL875095,,BAO_0000219,,
3484.0,809.0,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619061,,BAO_0000221,2116.0,
3485.0,809.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619062,,BAO_0000221,2116.0,
3486.0,14290.0,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619063,,BAO_0000019,,
3487.0,17358.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619064,,BAO_0000221,2116.0,
3488.0,17358.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619065,,BAO_0000357,,
3489.0,17358.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0,,Ileum,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL619066,,BAO_0000221,2116.0,
3490.0,17386.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,,Ileum,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619775,,BAO_0000221,2116.0,
3491.0,3269.0,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619776,,BAO_0000357,,
3492.0,7721.0,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841.0,H,4.0,Autocuration,1.0,,CHEMBL619777,,BAO_0000224,,
3493.0,7721.0,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841.0,H,4.0,Autocuration,1.0,,CHEMBL619778,,BAO_0000224,,
3494.0,9117.0,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0,,Ileum,,,104841.0,H,4.0,Autocuration,1.0,,CHEMBL619779,,BAO_0000221,2116.0,
3495.0,7721.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841.0,H,4.0,Autocuration,1.0,,CHEMBL619780,,BAO_0000224,,
3496.0,7721.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841.0,H,4.0,Autocuration,1.0,,CHEMBL619166,,BAO_0000224,,
3497.0,15796.0,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841.0,H,4.0,Autocuration,1.0,,CHEMBL619167,,BAO_0000019,,
3498.0,15796.0,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841.0,H,4.0,Autocuration,1.0,,CHEMBL619168,,BAO_0000019,,
3499.0,15650.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168.0,D,9.0,Expert,1.0,,CHEMBL619169,,BAO_0000219,2081.0,
3500.0,15650.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168.0,D,9.0,Expert,1.0,,CHEMBL619170,,BAO_0000219,2081.0,
3501.0,6866.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,104841.0,D,5.0,Autocuration,1.0,,CHEMBL619171,,BAO_0000019,,
3502.0,15650.0,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0,,Cardiac atrium,,,168.0,D,9.0,Expert,1.0,,CHEMBL619172,,BAO_0000219,2081.0,
3503.0,10063.0,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619173,,BAO_0000019,,
3504.0,12665.0,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619174,,BAO_0000019,,
3505.0,7504.0,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619175,,BAO_0000019,,
3506.0,7504.0,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619176,,BAO_0000224,,
3507.0,7038.0,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619177,,BAO_0000019,,
3508.0,7626.0,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619178,,BAO_0000224,,
3509.0,7626.0,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619179,,BAO_0000224,,
3510.0,7185.0,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,,Stomach,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619180,,BAO_0000019,945.0,
3511.0,7185.0,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,,Stomach,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619181,,BAO_0000019,945.0,
3512.0,7185.0,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619182,,BAO_0000019,,
3513.0,6960.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619183,,BAO_0000224,,
3514.0,6960.0,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619184,,BAO_0000224,,
3515.0,12416.0,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL619185,,BAO_0000221,10000000.0,
3516.0,15753.0,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,,,,,12198.0,H,8.0,Expert,1.0,,CHEMBL619186,,BAO_0000357,,
3517.0,8062.0,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,,,,,104705.0,H,4.0,Autocuration,1.0,,CHEMBL619187,,BAO_0000019,,
3518.0,9036.0,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,104705.0,D,5.0,Autocuration,1.0,,CHEMBL619188,,BAO_0000019,,
3519.0,15067.0,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705.0,D,5.0,Autocuration,1.0,,CHEMBL619189,,BAO_0000224,,
3520.0,15753.0,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0,,Brain,,,12198.0,D,9.0,Expert,1.0,,CHEMBL619190,,BAO_0000019,955.0,
3521.0,15753.0,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0,,Cerebellum,,,12198.0,D,9.0,Expert,1.0,,CHEMBL619191,,BAO_0000221,2037.0,
3522.0,15295.0,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,104705.0,D,5.0,Autocuration,1.0,,CHEMBL619192,,BAO_0000019,,
3523.0,6347.0,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705.0,D,5.0,Autocuration,1.0,,CHEMBL619193,,BAO_0000224,,
3524.0,6763.0,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619194,,BAO_0000019,,
3525.0,12092.0,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,104705.0,D,5.0,Autocuration,1.0,,CHEMBL619195,,BAO_0000224,,
3526.0,1579.0,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0,,,,,104705.0,D,5.0,Autocuration,1.0,,CHEMBL619196,,BAO_0000224,,
3527.0,1579.0,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0,,Stomach,,,104705.0,D,5.0,Autocuration,1.0,,CHEMBL619197,,BAO_0000019,945.0,
3528.0,5963.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121.0,D,9.0,Expert,1.0,,CHEMBL619198,,BAO_0000219,,
3529.0,5963.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121.0,D,9.0,Expert,1.0,,CHEMBL875081,,BAO_0000219,,
3530.0,5030.0,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,,,,,18065.0,H,8.0,Autocuration,1.0,,CHEMBL884712,,BAO_0000357,,
3531.0,15796.0,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,,,,,121.0,H,8.0,Expert,1.0,,CHEMBL884710,,BAO_0000357,,
3532.0,15413.0,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,18065.0,H,8.0,Autocuration,1.0,,CHEMBL619199,,BAO_0000019,,
3533.0,15413.0,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,,,,,18065.0,H,8.0,Autocuration,1.0,,CHEMBL619200,,BAO_0000019,,
3534.0,15413.0,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,,,,,18065.0,H,8.0,Autocuration,1.0,,CHEMBL619201,,BAO_0000019,,
3535.0,12409.0,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,,,,,18065.0,H,8.0,Autocuration,1.0,,CHEMBL619202,,BAO_0000019,,
3536.0,16909.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51.0,D,9.0,Expert,1.0,,CHEMBL619203,449.0,BAO_0000219,,
3537.0,16909.0,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0,,,,,51.0,D,9.0,Expert,1.0,,CHEMBL619204,,BAO_0000019,,
3538.0,15629.0,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL619205,,BAO_0000249,,
3539.0,15629.0,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,,,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL619206,,BAO_0000357,,
3540.0,15629.0,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576.0,H,8.0,Expert,1.0,,CHEMBL619207,,BAO_0000249,,
3541.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL619208,,BAO_0000019,2435.0,
3542.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL619209,,BAO_0000019,2435.0,
3543.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL619210,,BAO_0000019,2435.0,
3544.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL619211,,BAO_0000019,2435.0,
3545.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL619212,,BAO_0000019,2435.0,
3546.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620681,,BAO_0000019,2435.0,
3547.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620682,,BAO_0000019,2435.0,
3548.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620683,,BAO_0000019,2435.0,
3549.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620684,,BAO_0000019,2435.0,
3550.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620685,,BAO_0000019,2435.0,
3551.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620686,,BAO_0000019,2435.0,
3552.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620687,,BAO_0000019,349.0,
3553.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620688,,BAO_0000019,349.0,
3554.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620689,,BAO_0000019,349.0,
3555.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620690,,BAO_0000019,349.0,
3556.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620691,,BAO_0000019,349.0,
3557.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620692,,BAO_0000019,349.0,
3558.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL620693,,BAO_0000019,349.0,
3559.0,1274.0,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Expert,1.0,,CHEMBL620694,,BAO_0000357,,
3560.0,17358.0,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL857986,,BAO_0000019,,
3561.0,14532.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620695,,BAO_0000357,,
3562.0,16989.0,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Expert,1.0,,CHEMBL620696,,BAO_0000357,,
3563.0,17200.0,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620697,,BAO_0000357,,
3564.0,15779.0,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620698,,BAO_0000357,,
3565.0,15779.0,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620699,,BAO_0000357,,
3566.0,15779.0,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620700,,BAO_0000357,,
3567.0,15650.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620701,643.0,BAO_0000219,,
3568.0,15650.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168.0,H,8.0,Autocuration,1.0,,CHEMBL875082,643.0,BAO_0000219,,
3569.0,15650.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620702,643.0,BAO_0000219,,
3570.0,15650.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620703,643.0,BAO_0000219,,
3571.0,17046.0,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168.0,H,8.0,Autocuration,1.0,,CHEMBL620704,673.0,BAO_0000219,,
3572.0,17046.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168.0,H,8.0,Expert,1.0,,CHEMBL620705,673.0,BAO_0000219,,
3573.0,15650.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,,,C6,,168.0,H,8.0,Expert,1.0,,CHEMBL620706,673.0,BAO_0000219,,
3574.0,17046.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,,,C6,,168.0,H,8.0,Expert,1.0,,CHEMBL620707,673.0,BAO_0000219,,
3575.0,17066.0,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,,,,,10624.0,H,8.0,Expert,1.0,,CHEMBL620708,,BAO_0000357,,
3576.0,17200.0,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,,,,,105.0,H,8.0,Autocuration,1.0,,CHEMBL620709,,BAO_0000357,,
3577.0,16146.0,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624.0,D,9.0,Expert,1.0,,CHEMBL620710,,BAO_0000357,,
3578.0,15250.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,,,CHO,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL620711,449.0,BAO_0000219,,
3579.0,6491.0,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10624.0,D,9.0,Expert,1.0,,CHEMBL620712,,BAO_0000357,,
3580.0,17066.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624.0,D,9.0,Expert,1.0,,CHEMBL620713,,BAO_0000357,,
3581.0,17066.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,,,10624.0,D,9.0,Expert,1.0,,CHEMBL620714,,BAO_0000357,,
3582.0,4234.0,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624.0,D,9.0,Expert,1.0,,CHEMBL620715,,BAO_0000357,,
3583.0,6013.0,Binding affinity towards 5-HT5A receptor,B,,,,,,,,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL620716,,BAO_0000357,,
3584.0,17175.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10624.0,H,8.0,Expert,1.0,,CHEMBL620717,,BAO_0000357,,
3585.0,15818.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL618072,,BAO_0000357,,
3586.0,6166.0,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,,,,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL857987,,BAO_0000357,,
3587.0,15779.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL618073,722.0,BAO_0000219,,
3588.0,15779.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL618074,722.0,BAO_0000219,,
3589.0,5213.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,,,HEK293,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL618075,722.0,BAO_0000219,,
3590.0,17066.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625.0,D,9.0,Expert,1.0,,CHEMBL618076,,BAO_0000357,,
3591.0,17066.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625.0,D,9.0,Expert,1.0,,CHEMBL618077,,BAO_0000357,,
3592.0,17066.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625.0,D,9.0,Expert,1.0,,CHEMBL618078,,BAO_0000357,,
3593.0,17066.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625.0,D,9.0,Expert,1.0,,CHEMBL881821,,BAO_0000357,,
3594.0,17066.0,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625.0,D,9.0,Expert,1.0,,CHEMBL618079,,BAO_0000357,,
3595.0,17175.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10625.0,H,8.0,Expert,1.0,,CHEMBL618080,,BAO_0000357,,
3596.0,16190.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL618081,722.0,BAO_0000219,,
3597.0,16190.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10626.0,H,8.0,Autocuration,1.0,,CHEMBL618082,722.0,BAO_0000219,,
3598.0,4820.0,Binding affinity towards 5-HT5a receptor,B,,,,,,,,,10624.0,H,8.0,Expert,1.0,,CHEMBL618083,,BAO_0000357,,
3599.0,17066.0,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624.0,D,9.0,Expert,1.0,,CHEMBL618084,,BAO_0000357,,
3600.0,17066.0,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624.0,H,8.0,Expert,1.0,,CHEMBL618085,,BAO_0000357,,
3601.0,17175.0,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,,,,,10624.0,H,8.0,Expert,1.0,,CHEMBL618086,,BAO_0000357,,
3602.0,16633.0,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL875092,,BAO_0000357,,
3603.0,16633.0,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL618087,,BAO_0000357,,
3604.0,16700.0,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,,,,,10624.0,H,8.0,Autocuration,1.0,,CHEMBL872926,,BAO_0000357,,
3605.0,4639.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618088,,BAO_0000019,,
3606.0,5486.0,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,,,,,104714.0,H,4.0,Autocuration,1.0,,CHEMBL618089,,BAO_0000223,,
3607.0,16146.0,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL618090,,BAO_0000357,,
3608.0,17273.0,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL618091,,BAO_0000357,,
3609.0,17687.0,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL618092,,BAO_0000357,,
3610.0,6491.0,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL618093,,BAO_0000357,,
3611.0,16190.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,,,HeLa,,10627.0,H,8.0,Expert,1.0,,CHEMBL618094,308.0,BAO_0000219,,
3612.0,17066.0,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL618095,,BAO_0000357,,
3613.0,17066.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL875093,,BAO_0000357,,
3614.0,17066.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL618096,,BAO_0000357,,
3615.0,17066.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL618118,,BAO_0000357,,
3616.0,3555.0,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL618119,,BAO_0000357,,
3617.0,5808.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL618120,,BAO_0000357,,
3618.0,6013.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL618121,,BAO_0000357,,
3619.0,15818.0,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,,,HEK293,,10627.0,H,8.0,Expert,1.0,,CHEMBL618122,722.0,BAO_0000219,,
3620.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL618123,,BAO_0000357,,
3621.0,3935.0,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,,,HEK293,,10627.0,H,8.0,Expert,1.0,,CHEMBL618124,722.0,BAO_0000219,,
3622.0,15818.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL618125,,BAO_0000357,,
3623.0,3805.0,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,10627.0,D,9.0,Expert,1.0,,CHEMBL618126,722.0,BAO_0000219,,
3624.0,16441.0,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL618236,,BAO_0000019,,
3625.0,16441.0,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL618237,,BAO_0000019,,
3626.0,6786.0,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,,,COS-7,,10627.0,H,8.0,Expert,1.0,,CHEMBL618238,643.0,BAO_0000219,,
3627.0,4234.0,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL618239,,BAO_0000357,,
3628.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL618240,,BAO_0000019,,
3629.0,17200.0,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL618241,,BAO_0000357,,
3630.0,17451.0,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,,,HEK293,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL859399,722.0,BAO_0000219,,
3631.0,3935.0,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL618242,,BAO_0000019,,
3632.0,5033.0,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL857991,,BAO_0000357,,
3633.0,4540.0,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL619951,,BAO_0000357,,
3634.0,4540.0,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627.0,D,9.0,Expert,1.0,,CHEMBL619952,308.0,BAO_0000219,,
3635.0,4540.0,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627.0,D,9.0,Expert,1.0,,CHEMBL619953,308.0,BAO_0000219,,
3636.0,17296.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL619954,308.0,BAO_0000219,,
3637.0,17296.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL619955,308.0,BAO_0000219,,
3638.0,17296.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL619956,308.0,BAO_0000219,,
3639.0,15779.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL619957,449.0,BAO_0000219,,
3640.0,15779.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL619958,722.0,BAO_0000219,,
3641.0,15779.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,,,HEK293,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620627,722.0,BAO_0000219,,
3642.0,15779.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620628,722.0,BAO_0000219,,
3643.0,15779.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620629,308.0,BAO_0000219,,
3644.0,6166.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620630,,BAO_0000357,,
3645.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620782,308.0,BAO_0000219,,
3646.0,15316.0,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620783,,BAO_0000357,,
3647.0,4199.0,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL620784,,BAO_0000357,,
3648.0,15146.0,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,,,HeLa,,10627.0,H,8.0,Expert,1.0,,CHEMBL620785,308.0,BAO_0000219,,
3649.0,5213.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL857992,,BAO_0000357,,
3650.0,16429.0,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620786,,BAO_0000219,,
3651.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620787,308.0,BAO_0000219,,
3652.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620788,308.0,BAO_0000219,,
3653.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620789,308.0,BAO_0000219,,
3654.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,,,HeLa,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620790,308.0,BAO_0000219,,
3655.0,15250.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,,,CHO,,10628.0,H,8.0,Autocuration,1.0,,CHEMBL620791,449.0,BAO_0000219,,
3656.0,14423.0,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,,,,,10628.0,H,8.0,Autocuration,1.0,,CHEMBL620792,,BAO_0000019,,
3657.0,15086.0,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10628.0,H,8.0,Autocuration,1.0,,CHEMBL620793,,BAO_0000357,,
3658.0,4342.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10628.0,H,8.0,Autocuration,1.0,,CHEMBL620794,,BAO_0000357,,
3659.0,16190.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,10627.0,D,9.0,Autocuration,1.0,,CHEMBL620795,308.0,BAO_0000219,,
3660.0,4820.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL620796,,BAO_0000357,,
3661.0,4639.0,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620797,,BAO_0000357,,
3662.0,17066.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL620798,,BAO_0000019,,
3663.0,6011.0,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620799,,BAO_0000357,,
3664.0,17066.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL620800,,BAO_0000357,,
3665.0,17515.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620801,,BAO_0000357,,
3666.0,5014.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL875100,,BAO_0000357,,
3667.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620802,,BAO_0000357,,
3668.0,17066.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL620803,,BAO_0000019,,
3669.0,17066.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,,,,,10627.0,H,8.0,Expert,1.0,,CHEMBL620804,,BAO_0000019,,
3670.0,4373.0,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620805,,BAO_0000357,,
3671.0,4687.0,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620806,,BAO_0000357,,
3672.0,16946.0,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620807,,BAO_0000357,,
3673.0,16946.0,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620808,,BAO_0000357,,
3674.0,16633.0,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620809,,BAO_0000357,,
3675.0,16633.0,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620810,,BAO_0000357,,
3676.0,17066.0,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627.0,D,9.0,Expert,1.0,,CHEMBL620811,,BAO_0000357,,
3677.0,16700.0,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620812,,BAO_0000357,,
3678.0,3269.0,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620813,,BAO_0000357,,
3679.0,5486.0,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,,,,,10627.0,H,8.0,Autocuration,1.0,,CHEMBL620814,,BAO_0000357,,
3680.0,16146.0,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209.0,D,9.0,Expert,1.0,,CHEMBL620815,,BAO_0000357,,
3681.0,5014.0,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620816,722.0,BAO_0000219,,
3682.0,15463.0,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620817,,BAO_0000357,,
3683.0,3805.0,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620818,,BAO_0000357,,
3684.0,5014.0,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,,,HEK293,,10209.0,H,8.0,Expert,1.0,,CHEMBL620819,722.0,BAO_0000219,,
3685.0,6491.0,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10209.0,D,9.0,Expert,1.0,,CHEMBL620820,,BAO_0000357,,
3686.0,16190.0,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620821,449.0,BAO_0000219,,
3687.0,17066.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209.0,D,9.0,Expert,1.0,,CHEMBL620822,,BAO_0000357,,
3688.0,17066.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209.0,D,9.0,Expert,1.0,,CHEMBL620823,,BAO_0000357,,
3689.0,3555.0,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209.0,D,9.0,Expert,1.0,,CHEMBL620824,,BAO_0000357,,
3690.0,6588.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,10209.0,H,8.0,Expert,1.0,,CHEMBL620825,449.0,BAO_0000219,,
3691.0,15463.0,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL872930,,BAO_0000357,,
3692.0,6013.0,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620826,,BAO_0000357,,
3693.0,16209.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620827,,BAO_0000357,,
3694.0,3935.0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620828,,BAO_0000357,,
3695.0,15818.0,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620829,,BAO_0000357,,
3696.0,5014.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209.0,H,8.0,Expert,1.0,,CHEMBL620830,722.0,BAO_0000219,,
3697.0,16441.0,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL620831,,BAO_0000019,,
3698.0,16441.0,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL620832,,BAO_0000019,,
3699.0,4234.0,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209.0,D,9.0,Expert,1.0,,CHEMBL621548,,BAO_0000357,,
3700.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL621549,,BAO_0000019,,
3701.0,17200.0,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL621550,,BAO_0000357,,
3702.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,,,CHO,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL621551,449.0,BAO_0000219,,
3703.0,17085.0,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL621552,,BAO_0000019,,
3704.0,5104.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL857077,,BAO_0000357,,
3705.0,5104.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL618158,,BAO_0000357,,
3706.0,5033.0,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,10209.0,D,9.0,Expert,1.0,,CHEMBL618159,643.0,BAO_0000219,,
3707.0,5486.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,,,COS-7,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL875101,643.0,BAO_0000219,,
3708.0,4540.0,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,10209.0,D,9.0,Expert,1.0,,CHEMBL618160,722.0,BAO_0000219,,
3709.0,6166.0,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL618161,,BAO_0000357,,
3710.0,17342.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,,,HEK293,,10209.0,H,8.0,Expert,1.0,,CHEMBL618162,722.0,BAO_0000219,,
3711.0,17342.0,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL618163,,BAO_0000357,,
3712.0,17296.0,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL618164,,BAO_0000357,,
3713.0,16429.0,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL618165,,BAO_0000219,,
3714.0,15779.0,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL618166,722.0,BAO_0000219,,
3715.0,15779.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL857989,722.0,BAO_0000219,,
3716.0,15779.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619888,722.0,BAO_0000219,,
3717.0,15779.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619889,722.0,BAO_0000219,,
3718.0,15779.0,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619890,722.0,BAO_0000219,,
3719.0,17451.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,,,CHO,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619891,449.0,BAO_0000219,,
3720.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619892,722.0,BAO_0000219,,
3721.0,4199.0,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,,,HEK293,,10209.0,D,9.0,Expert,1.0,,CHEMBL619893,722.0,BAO_0000219,,
3722.0,4199.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619894,722.0,BAO_0000219,,
3723.0,3680.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,,,HEK293,,10209.0,D,9.0,Intermediate,1.0,,CHEMBL619895,722.0,BAO_0000219,,
3724.0,3680.0,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,,,,,10209.0,D,9.0,Intermediate,1.0,,CHEMBL619896,,BAO_0000357,,
3725.0,15316.0,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,,,COS-7,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619897,643.0,BAO_0000219,,
3726.0,15146.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619898,722.0,BAO_0000219,,
3727.0,5213.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,10209.0,H,8.0,Expert,1.0,,CHEMBL619899,722.0,BAO_0000219,,
3728.0,5213.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619900,722.0,BAO_0000219,,
3729.0,14818.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0,,,HEK293,,10209.0,D,9.0,Expert,1.0,,CHEMBL619901,722.0,BAO_0000219,,
3730.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620580,722.0,BAO_0000219,,
3731.0,14818.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620581,722.0,BAO_0000219,,
3732.0,4829.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,,,HEK293,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620733,722.0,BAO_0000219,,
3733.0,17200.0,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0,,,,,10209.0,D,9.0,Autocuration,1.0,,CHEMBL620734,,BAO_0000357,,
3734.0,17066.0,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0,,,,,10022.0,D,9.0,Expert,1.0,,CHEMBL620735,,BAO_0000357,,
3735.0,14025.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL620736,,BAO_0000019,,
3736.0,15250.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620737,449.0,BAO_0000219,,
3737.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620738,449.0,BAO_0000219,,
3738.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620739,449.0,BAO_0000219,,
3739.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620740,449.0,BAO_0000219,,
3740.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620741,449.0,BAO_0000219,,
3741.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620742,449.0,BAO_0000219,,
3742.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620743,449.0,BAO_0000219,,
3743.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620744,449.0,BAO_0000219,,
3744.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620745,449.0,BAO_0000219,,
3745.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620746,449.0,BAO_0000219,,
3746.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620747,449.0,BAO_0000219,,
3747.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620748,449.0,BAO_0000219,,
3748.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620749,449.0,BAO_0000219,,
3749.0,17066.0,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923.0,H,8.0,Expert,1.0,,CHEMBL620750,,BAO_0000357,,
3750.0,17066.0,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,11923.0,D,9.0,Expert,1.0,,CHEMBL620751,,BAO_0000357,,
3751.0,17386.0,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923.0,H,8.0,Expert,1.0,,CHEMBL620752,,BAO_0000357,,
3752.0,14423.0,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,,,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL872929,,BAO_0000019,,
3753.0,15874.0,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,11923.0,D,9.0,Expert,1.0,,CHEMBL620753,,BAO_0000357,,
3754.0,15874.0,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0,,,,,11923.0,D,9.0,Expert,1.0,,CHEMBL620754,,BAO_0000357,,
3755.0,16372.0,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0,,,CHO,,11923.0,D,9.0,Expert,1.0,,CHEMBL620755,449.0,BAO_0000219,,
3756.0,4622.0,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620756,,BAO_0000357,,
3757.0,15086.0,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620757,,BAO_0000357,,
3758.0,16372.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620758,449.0,BAO_0000219,,
3759.0,16372.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620759,449.0,BAO_0000219,,
3760.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620760,449.0,BAO_0000219,,
3761.0,16372.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,,,CHO,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620761,449.0,BAO_0000219,,
3762.0,17386.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,,Ileum,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620762,,BAO_0000221,2116.0,
3763.0,17386.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,,Ileum,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620763,,BAO_0000221,2116.0,
3764.0,17386.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,,Ileum,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620764,,BAO_0000221,2116.0,
3765.0,5831.0,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,11923.0,D,9.0,Expert,1.0,,CHEMBL857990,,BAO_0000249,,
3766.0,4342.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620765,,BAO_0000357,,
3767.0,17319.0,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,11923.0,H,8.0,Expert,1.0,,CHEMBL620766,,BAO_0000357,,
3768.0,17342.0,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,,Hypothalamus,,,11923.0,H,8.0,Expert,1.0,,CHEMBL620767,,BAO_0000019,1898.0,
3769.0,17342.0,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,11923.0,H,8.0,Autocuration,1.0,,CHEMBL620768,,BAO_0000357,,
3770.0,3680.0,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,,Hypothalamus,,,11923.0,H,8.0,Expert,1.0,,CHEMBL619051,,BAO_0000249,1898.0,
3771.0,3680.0,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923.0,H,8.0,Expert,1.0,,CHEMBL619052,,BAO_0000357,,
3772.0,17319.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923.0,D,9.0,Expert,1.0,,CHEMBL619053,722.0,BAO_0000219,,
3773.0,17319.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923.0,D,9.0,Expert,1.0,,CHEMBL619703,722.0,BAO_0000219,,
3774.0,17319.0,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923.0,D,9.0,Autocuration,1.0,,CHEMBL619704,722.0,BAO_0000219,,
3775.0,4820.0,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL619851,,BAO_0000357,,
3776.0,4639.0,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619852,,BAO_0000357,,
3777.0,6011.0,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619853,,BAO_0000357,,
3778.0,17066.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209.0,D,9.0,Expert,1.0,,CHEMBL619854,,BAO_0000357,,
3779.0,17066.0,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL619855,,BAO_0000357,,
3780.0,17515.0,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619856,,BAO_0000357,,
3781.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619857,,BAO_0000357,,
3782.0,17066.0,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL619858,,BAO_0000019,,
3783.0,4373.0,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619859,,BAO_0000357,,
3784.0,4373.0,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619860,,BAO_0000357,,
3785.0,4687.0,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619861,,BAO_0000357,,
3786.0,17342.0,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL619862,,BAO_0000357,,
3787.0,16946.0,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619863,,BAO_0000357,,
3788.0,16946.0,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619864,,BAO_0000357,,
3789.0,16633.0,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL872928,,BAO_0000357,,
3790.0,16633.0,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619865,,BAO_0000357,,
3791.0,17066.0,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209.0,H,8.0,Expert,1.0,,CHEMBL619866,,BAO_0000357,,
3792.0,16700.0,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,,,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619867,,BAO_0000357,,
3793.0,17386.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,,Ileum,,,10209.0,H,8.0,Autocuration,1.0,,CHEMBL619868,,BAO_0000221,2116.0,
3794.0,14080.0,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619869,,BAO_0000019,,
3795.0,14080.0,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0,,,,,55.0,D,9.0,Expert,1.0,,CHEMBL619870,,BAO_0000019,,
3796.0,409.0,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619871,,BAO_0000357,,
3797.0,409.0,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619872,,BAO_0000357,,
3798.0,409.0,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619873,,BAO_0000357,,
3799.0,11090.0,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55.0,H,8.0,Expert,1.0,,CHEMBL619874,,BAO_0000357,178.0,
3800.0,11090.0,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55.0,H,8.0,Expert,1.0,,CHEMBL619875,,BAO_0000357,178.0,
3801.0,948.0,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619876,,BAO_0000357,,
3802.0,948.0,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619877,,BAO_0000357,,
3803.0,13622.0,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL619878,,BAO_0000219,,
3804.0,13622.0,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619879,,BAO_0000019,178.0,
3805.0,9637.0,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619880,,BAO_0000357,,
3806.0,11320.0,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619881,,BAO_0000357,,
3807.0,11320.0,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL619882,,BAO_0000357,,
3808.0,6838.0,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619883,,BAO_0000357,,
3809.0,17667.0,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0,,Blood,,,55.0,D,9.0,Expert,1.0,,CHEMBL619884,,BAO_0000357,178.0,
3810.0,12703.0,In vitro potency against human 5-Lipoxygenase,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619885,,BAO_0000357,,
3811.0,14312.0,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0,,,,,55.0,D,9.0,Expert,1.0,,CHEMBL619886,,BAO_0000019,,
3812.0,14312.0,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619887,,BAO_0000019,178.0,
3813.0,5364.0,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL875097,,BAO_0000019,,
3814.0,951.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618001,,BAO_0000219,,
3815.0,951.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618002,,BAO_0000219,,
3816.0,951.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618003,,BAO_0000219,,
3817.0,951.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618004,,BAO_0000219,,
3818.0,12365.0,Inhibition of human 5-lipoxygenase in human cells,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618005,,BAO_0000219,,
3819.0,10603.0,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618006,,BAO_0000357,,
3820.0,10501.0,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL875086,,BAO_0000019,,
3821.0,12281.0,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,,Blood,,,55.0,H,8.0,Expert,1.0,,CHEMBL618007,,BAO_0000357,178.0,
3822.0,2567.0,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618008,,BAO_0000357,,
3823.0,2567.0,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618009,,BAO_0000219,,
3824.0,10193.0,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618010,,BAO_0000357,,
3825.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618011,,BAO_0000357,,
3826.0,13623.0,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618012,,BAO_0000357,,
3827.0,12780.0,Tested against 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL882927,,BAO_0000357,,
3828.0,12780.0,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618013,,BAO_0000357,,
3829.0,12780.0,Tested for activity against 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618014,,BAO_0000357,,
3830.0,11966.0,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618015,,BAO_0000357,,
3831.0,5364.0,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618016,,BAO_0000019,,
3832.0,13165.0,Inhibition of Human 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618017,,BAO_0000357,,
3833.0,5364.0,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618018,,BAO_0000019,,
3834.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL875087,,BAO_0000219,,
3835.0,11311.0,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618019,,BAO_0000219,,
3836.0,14863.0,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618020,,BAO_0000019,,
3837.0,14863.0,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618021,,BAO_0000019,,
3838.0,11087.0,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618022,,BAO_0000357,178.0,
3839.0,455.0,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618023,,BAO_0000357,,
3840.0,13183.0,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618024,,BAO_0000357,,
3841.0,10319.0,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL873950,,BAO_0000019,,
3842.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618025,,BAO_0000357,,
3843.0,951.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618026,,BAO_0000219,,
3844.0,951.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618027,,BAO_0000219,,
3845.0,951.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618028,,BAO_0000219,,
3846.0,951.0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618029,,BAO_0000219,,
3847.0,9859.0,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618030,,BAO_0000357,,
3848.0,9859.0,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618031,,BAO_0000357,,
3849.0,9859.0,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618032,,BAO_0000357,,
3850.0,2567.0,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618033,,BAO_0000357,,
3851.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618034,,BAO_0000357,,
3852.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL875088,,BAO_0000357,,
3853.0,949.0,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618035,,BAO_0000019,,
3854.0,949.0,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618036,,BAO_0000019,,
3855.0,10603.0,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618037,,BAO_0000357,,
3856.0,10603.0,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618038,,BAO_0000357,,
3857.0,10603.0,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618761,,BAO_0000019,,
3858.0,10603.0,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618762,,BAO_0000357,,
3859.0,10603.0,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618763,,BAO_0000357,,
3860.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618764,,BAO_0000357,,
3861.0,14580.0,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0,,,,,55.0,D,9.0,Expert,1.0,,CHEMBL618765,,BAO_0000357,,
3862.0,11090.0,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087.0,H,8.0,Expert,1.0,,CHEMBL618766,,BAO_0000357,,
3863.0,11090.0,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087.0,H,8.0,Expert,1.0,,CHEMBL618767,,BAO_0000357,,
3864.0,6339.0,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,,,,,17087.0,H,8.0,Autocuration,1.0,,CHEMBL619380,,BAO_0000357,,
3865.0,6339.0,Inhibitory activity against murine lipoxygenase-2.,B,,,,,,,,,17087.0,H,8.0,Expert,1.0,,CHEMBL619381,,BAO_0000357,,
3866.0,12281.0,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0,,,,,17087.0,D,9.0,Expert,1.0,,CHEMBL619382,,BAO_0000357,,
3867.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,,,,,17087.0,H,8.0,Autocuration,1.0,,CHEMBL619383,,BAO_0000357,,
3868.0,11089.0,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619384,,BAO_0000019,,
3869.0,10091.0,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619385,,BAO_0000019,,
3870.0,14352.0,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL882928,,BAO_0000019,,
3871.0,13329.0,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL619386,,BAO_0000019,,
3872.0,13329.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619387,,BAO_0000019,,
3873.0,13329.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619388,,BAO_0000019,,
3874.0,13329.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619389,,BAO_0000019,,
3875.0,13329.0,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619390,,BAO_0000019,,
3876.0,13329.0,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619391,,BAO_0000019,,
3877.0,13329.0,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619392,,BAO_0000019,,
3878.0,11311.0,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619393,,BAO_0000019,,
3879.0,11311.0,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619394,,BAO_0000019,,
3880.0,105.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619395,702.0,BAO_0000219,,
3881.0,105.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619396,702.0,BAO_0000219,,
3882.0,9138.0,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619397,,BAO_0000357,,
3883.0,9138.0,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619398,,BAO_0000357,,
3884.0,9138.0,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619399,,BAO_0000357,,
3885.0,14427.0,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619400,,BAO_0000357,,
3886.0,13329.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619401,,BAO_0000019,,
3887.0,13329.0,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619402,,BAO_0000019,,
3888.0,14427.0,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0,,,RBL-2H3,,12166.0,D,9.0,Expert,1.0,,CHEMBL619403,663.0,BAO_0000219,,
3889.0,14427.0,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619404,,BAO_0000357,,
3890.0,14427.0,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619405,,BAO_0000357,,
3891.0,10293.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619406,702.0,BAO_0000219,,
3892.0,338.0,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL619407,702.0,BAO_0000219,,
3893.0,303.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619408,,BAO_0000357,,
3894.0,303.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619409,702.0,BAO_0000219,,
3895.0,9247.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619410,702.0,BAO_0000219,,
3896.0,9247.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619753,702.0,BAO_0000219,,
3897.0,137.0,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619754,702.0,BAO_0000219,,
3898.0,11481.0,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619903,,BAO_0000357,,
3899.0,11481.0,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619904,,BAO_0000357,,
3900.0,9029.0,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619905,,BAO_0000357,,
3901.0,1701.0,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619906,,BAO_0000019,,
3902.0,1701.0,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619907,,BAO_0000019,,
3903.0,1701.0,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619908,,BAO_0000019,,
3904.0,1701.0,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619909,,BAO_0000019,,
3905.0,13358.0,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619910,702.0,BAO_0000219,,
3906.0,1175.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL882929,702.0,BAO_0000219,,
3907.0,8797.0,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619911,702.0,BAO_0000219,,
3908.0,8797.0,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619912,,BAO_0000019,,
3909.0,577.0,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL619913,,BAO_0000357,,
3910.0,9295.0,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619914,702.0,BAO_0000219,,
3911.0,9295.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619915,702.0,BAO_0000219,,
3912.0,9295.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619916,702.0,BAO_0000219,,
3913.0,9295.0,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619917,,BAO_0000218,,
3914.0,9295.0,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619918,,BAO_0000357,,
3915.0,216.0,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619919,,BAO_0000218,,
3916.0,11090.0,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL883710,702.0,BAO_0000219,,
3917.0,11090.0,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,,Blood,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619920,,BAO_0000019,178.0,
3918.0,10091.0,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619921,,BAO_0000357,,
3919.0,10274.0,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619922,,BAO_0000019,,
3920.0,13622.0,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619923,,BAO_0000219,,
3921.0,12118.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619924,702.0,BAO_0000219,,
3922.0,12576.0,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619925,,BAO_0000357,,
3923.0,9546.0,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619926,702.0,BAO_0000219,,
3924.0,9521.0,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619927,702.0,BAO_0000219,,
3925.0,10626.0,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619928,702.0,BAO_0000219,,
3926.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619929,702.0,BAO_0000219,,
3927.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL875089,702.0,BAO_0000219,,
3928.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619930,702.0,BAO_0000219,,
3929.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619931,702.0,BAO_0000219,,
3930.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619932,702.0,BAO_0000219,,
3931.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619933,702.0,BAO_0000219,,
3932.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619934,702.0,BAO_0000219,,
3933.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619935,702.0,BAO_0000219,,
3934.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619936,702.0,BAO_0000219,,
3935.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619937,702.0,BAO_0000219,,
3936.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619938,702.0,BAO_0000219,,
3937.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619939,702.0,BAO_0000219,,
3938.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619940,702.0,BAO_0000219,,
3939.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL875090,702.0,BAO_0000219,,
3940.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619941,702.0,BAO_0000219,,
3941.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619942,702.0,BAO_0000219,,
3942.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL883711,702.0,BAO_0000219,,
3943.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619943,702.0,BAO_0000219,,
3944.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619944,702.0,BAO_0000219,,
3945.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619945,702.0,BAO_0000219,,
3946.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619946,702.0,BAO_0000219,,
3947.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619947,702.0,BAO_0000219,,
3948.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619948,702.0,BAO_0000219,,
3949.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619949,702.0,BAO_0000219,,
3950.0,9401.0,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619950,,BAO_0000019,,
3951.0,10325.0,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618050,,BAO_0000019,,
3952.0,1556.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,,,RBL-2H3,,12166.0,H,8.0,Expert,1.0,,CHEMBL875091,663.0,BAO_0000219,,
3953.0,1556.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,,,RBL-2H3,,12166.0,H,8.0,Expert,1.0,,CHEMBL618051,663.0,BAO_0000219,,
3954.0,961.0,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL618052,702.0,BAO_0000219,,
3955.0,6838.0,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618053,,BAO_0000019,,
3956.0,10325.0,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL618054,,BAO_0000019,,
3957.0,9209.0,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL618055,702.0,BAO_0000219,,
3958.0,11520.0,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL618056,702.0,BAO_0000219,,
3959.0,137.0,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618057,,BAO_0000357,,
3960.0,4717.0,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618058,702.0,BAO_0000219,,
3961.0,10636.0,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL618059,702.0,BAO_0000219,,
3962.0,14312.0,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL618060,,BAO_0000019,,
3963.0,1203.0,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618061,702.0,BAO_0000219,,
3964.0,1203.0,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618062,,BAO_0000019,,
3965.0,13622.0,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL618063,702.0,BAO_0000219,,
3966.0,9793.0,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618064,,BAO_0000357,,
3967.0,1143.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL618065,702.0,BAO_0000219,,
3968.0,11854.0,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL618066,702.0,BAO_0000219,,
3969.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618067,702.0,BAO_0000219,,
3970.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618068,702.0,BAO_0000219,,
3971.0,10501.0,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL618069,702.0,BAO_0000219,,
3972.0,12526.0,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL618070,702.0,BAO_0000219,,
3973.0,10034.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL618071,,BAO_0000019,349.0,
3974.0,10034.0,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL619247,,BAO_0000019,349.0,
3975.0,10034.0,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,,,,,10825.0,H,8.0,Autocuration,1.0,,CHEMBL619248,,BAO_0000019,,
3976.0,10046.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL619249,,BAO_0000221,10000000.0,
3977.0,10046.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576.0,H,8.0,Autocuration,1.0,,CHEMBL619250,,BAO_0000221,10000000.0,
3978.0,10046.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL619251,,BAO_0000019,,
3979.0,12079.0,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619252,,BAO_0000019,178.0,
3980.0,12079.0,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619253,,BAO_0000019,178.0,
3981.0,11311.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619254,,BAO_0000219,,
3982.0,12338.0,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,,,,,17140.0,H,8.0,Expert,1.0,,CHEMBL619255,,BAO_0000219,,
3983.0,12143.0,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,,,,,17140.0,H,8.0,Expert,1.0,,CHEMBL619256,,BAO_0000219,,
3984.0,12143.0,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,,,,,17140.0,H,8.0,Autocuration,1.0,,CHEMBL875418,,BAO_0000219,,
3985.0,12143.0,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140.0,H,8.0,Expert,1.0,,CHEMBL619257,,BAO_0000219,,
3986.0,12143.0,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140.0,H,8.0,Autocuration,1.0,,CHEMBL619258,,BAO_0000219,,
3987.0,12365.0,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,,,,,17140.0,H,8.0,Expert,1.0,,CHEMBL619259,,BAO_0000357,,
3988.0,13500.0,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,,,,,17140.0,H,8.0,Expert,1.0,,CHEMBL619260,,BAO_0000357,,
3989.0,12832.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619261,,BAO_0000218,178.0,
3990.0,12832.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619263,,BAO_0000218,178.0,
3991.0,12832.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619264,,BAO_0000218,178.0,
3992.0,12832.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619265,,BAO_0000218,178.0,
3993.0,12832.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619266,,BAO_0000218,178.0,
3994.0,12832.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619902,,BAO_0000218,178.0,
3995.0,12832.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620058,,BAO_0000218,178.0,
3996.0,12832.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620059,,BAO_0000218,178.0,
3997.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620060,,BAO_0000218,178.0,
3998.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620061,,BAO_0000218,178.0,
3999.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620062,,BAO_0000218,178.0,
4000.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620063,,BAO_0000218,178.0,
4001.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620064,,BAO_0000218,178.0,
4002.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620065,,BAO_0000218,178.0,
4003.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620066,,BAO_0000218,178.0,
4004.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620067,,BAO_0000218,178.0,
4005.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620068,,BAO_0000218,178.0,
4006.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620069,,BAO_0000218,178.0,
4007.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620070,,BAO_0000218,178.0,
4008.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620071,,BAO_0000218,178.0,
4009.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620072,,BAO_0000218,178.0,
4010.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620036,,BAO_0000218,178.0,
4011.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL857702,,BAO_0000218,178.0,
4012.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620037,,BAO_0000218,178.0,
4013.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620038,,BAO_0000218,178.0,
4014.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620039,,BAO_0000218,178.0,
4015.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620040,,BAO_0000218,178.0,
4016.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620041,,BAO_0000218,178.0,
4017.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620042,,BAO_0000218,178.0,
4018.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620043,,BAO_0000218,178.0,
4019.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620044,,BAO_0000218,178.0,
4020.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620045,,BAO_0000218,178.0,
4021.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620046,,BAO_0000218,178.0,
4022.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620047,,BAO_0000218,178.0,
4023.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620048,,BAO_0000218,178.0,
4024.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL857703,,BAO_0000218,178.0,
4025.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620049,,BAO_0000218,178.0,
4026.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620050,,BAO_0000218,178.0,
4027.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620051,,BAO_0000218,178.0,
4028.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619213,,BAO_0000218,178.0,
4029.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619214,,BAO_0000218,178.0,
4030.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619804,,BAO_0000218,178.0,
4031.0,12832.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619805,,BAO_0000218,178.0,
4032.0,12832.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619806,,BAO_0000218,178.0,
4033.0,12832.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619807,,BAO_0000218,178.0,
4034.0,12832.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619808,,BAO_0000218,178.0,
4035.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619809,,BAO_0000218,,
4036.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619810,,BAO_0000218,,
4037.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL619811,,BAO_0000218,,
4038.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620769,,BAO_0000218,,
4039.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620770,,BAO_0000218,,
4040.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620771,,BAO_0000218,,
4041.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620772,,BAO_0000218,,
4042.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620773,,BAO_0000218,,
4043.0,9203.0,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620774,,BAO_0000357,,
4044.0,82.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL620775,,BAO_0000357,,
4045.0,11090.0,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620776,,BAO_0000357,,
4046.0,12832.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0,,Blood,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620777,,BAO_0000218,178.0,
4047.0,1065.0,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620778,,BAO_0000357,,
4048.0,1065.0,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620779,,BAO_0000357,,
4049.0,12832.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL621500,,BAO_0000019,,
4050.0,12832.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL621501,,BAO_0000019,,
4051.0,12832.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618098,,BAO_0000019,,
4052.0,10504.0,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618099,,BAO_0000019,,
4053.0,7788.0,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618100,,BAO_0000357,,
4054.0,10001.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618101,,BAO_0000357,,
4055.0,10193.0,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618102,,BAO_0000357,,
4056.0,13243.0,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618103,,BAO_0000357,,
4057.0,13243.0,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618104,,BAO_0000357,,
4058.0,969.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL883712,,BAO_0000219,,
4059.0,10001.0,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618105,,BAO_0000357,,
4060.0,7788.0,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618106,,BAO_0000357,,
4061.0,10001.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618107,,BAO_0000357,,
4062.0,10193.0,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618108,,BAO_0000357,,
4063.0,13243.0,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618109,,BAO_0000357,,
4064.0,13243.0,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618110,,BAO_0000357,,
4065.0,13243.0,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618111,,BAO_0000357,,
4066.0,13243.0,Inhibitory activity uM,F,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618112,,BAO_0000019,,
4067.0,10504.0,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618113,,BAO_0000019,,
4068.0,7788.0,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618114,,BAO_0000357,,
4069.0,10546.0,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,55.0,H,8.0,Expert,1.0,,CHEMBL620871,,BAO_0000221,2116.0,
4070.0,13183.0,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620872,,BAO_0000357,,
4071.0,13183.0,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620873,,BAO_0000357,,
4072.0,2578.0,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL620874,,BAO_0000357,,
4073.0,12780.0,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL620875,,BAO_0000357,,
4074.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620876,,BAO_0000251,2107.0,
4075.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620877,,BAO_0000251,2107.0,
4076.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL857854,,BAO_0000251,2107.0,
4077.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620878,,BAO_0000251,2107.0,
4078.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620879,,BAO_0000251,2107.0,
4079.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620880,,BAO_0000251,2107.0,
4080.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620881,,BAO_0000251,2107.0,
4081.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620882,,BAO_0000251,2107.0,
4082.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620883,,BAO_0000251,2107.0,
4083.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620884,,BAO_0000251,2107.0,
4084.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620885,,BAO_0000251,2107.0,
4085.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620886,,BAO_0000251,2107.0,
4086.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620887,,BAO_0000251,2107.0,
4087.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618039,,BAO_0000251,2107.0,
4088.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618040,,BAO_0000251,2107.0,
4089.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618041,,BAO_0000251,2107.0,
4090.0,7411.0,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618216,,BAO_0000251,2107.0,
4091.0,7411.0,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618217,,BAO_0000251,2107.0,
4092.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618218,,BAO_0000251,2107.0,
4093.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618219,,BAO_0000251,2107.0,
4094.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618220,,BAO_0000251,2107.0,
4095.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618221,,BAO_0000251,2107.0,
4096.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618222,,BAO_0000251,2107.0,
4097.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618223,,BAO_0000251,2107.0,
4098.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618224,,BAO_0000251,2107.0,
4099.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618225,,BAO_0000251,2107.0,
4100.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618226,,BAO_0000251,2107.0,
4101.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618227,,BAO_0000251,2107.0,
4102.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618228,,BAO_0000251,2107.0,
4103.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618229,,BAO_0000251,2107.0,
4104.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618230,,BAO_0000251,2107.0,
4105.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618231,,BAO_0000251,2107.0,
4106.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618232,,BAO_0000251,2107.0,
4107.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618233,,BAO_0000251,2107.0,
4108.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618234,,BAO_0000251,2107.0,
4109.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618235,,BAO_0000251,2107.0,
4110.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618115,,BAO_0000251,2107.0,
4111.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618116,,BAO_0000251,2107.0,
4112.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618117,,BAO_0000251,2107.0,
4113.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619968,,BAO_0000251,2107.0,
4114.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619969,,BAO_0000251,2107.0,
4115.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619970,,BAO_0000251,2107.0,
4116.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619971,,BAO_0000251,2107.0,
4117.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619972,,BAO_0000251,2107.0,
4118.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619973,,BAO_0000251,2107.0,
4119.0,7411.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619974,,BAO_0000251,2107.0,
4120.0,7411.0,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619975,,BAO_0000251,2107.0,
4121.0,7411.0,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619976,,BAO_0000251,,
4122.0,7411.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619977,,BAO_0000251,2107.0,
4123.0,7411.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619978,,BAO_0000251,2107.0,
4124.0,7411.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619979,,BAO_0000251,2107.0,
4125.0,7411.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619980,,BAO_0000251,2107.0,
4126.0,7411.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619981,,BAO_0000251,2107.0,
4127.0,10797.0,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619982,741.0,BAO_0000219,,
4128.0,6881.0,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0,,,BEL-7404 tumor cell line,,80698.0,N,1.0,Intermediate,1.0,,CHEMBL619983,993.0,BAO_0000219,,
4129.0,3838.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL620031,391.0,BAO_0000219,,
4130.0,3838.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL620032,391.0,BAO_0000219,,
4131.0,12981.0,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0,,,V79,,81264.0,N,1.0,Expert,1.0,,CHEMBL620033,505.0,BAO_0000219,,
4132.0,12981.0,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0,,,V79,,81264.0,N,1.0,Expert,1.0,,CHEMBL620034,505.0,BAO_0000219,,
4133.0,7653.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635.0,N,1.0,Intermediate,1.0,,CHEMBL620035,1119.0,BAO_0000219,,
4134.0,7653.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635.0,N,1.0,Intermediate,1.0,,CHEMBL618318,1119.0,BAO_0000219,,
4135.0,7653.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635.0,N,1.0,Intermediate,1.0,,CHEMBL618319,1119.0,BAO_0000219,,
4136.0,7653.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635.0,N,1.0,Intermediate,1.0,,CHEMBL618320,1119.0,BAO_0000219,,
4137.0,7653.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635.0,N,1.0,Intermediate,1.0,,CHEMBL618321,1119.0,BAO_0000219,,
4138.0,7653.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635.0,N,1.0,Intermediate,1.0,,CHEMBL883118,1119.0,BAO_0000219,,
4139.0,17229.0,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL883795,391.0,BAO_0000219,,
4140.0,12858.0,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL618322,391.0,BAO_0000219,,
4141.0,16325.0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL618323,391.0,BAO_0000219,,
4142.0,16325.0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL618324,391.0,BAO_0000219,,
4143.0,5858.0,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL618325,391.0,BAO_0000219,,
4144.0,16325.0,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL875416,391.0,BAO_0000219,,
4145.0,14696.0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL618326,391.0,BAO_0000219,,
4146.0,3786.0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL618327,391.0,BAO_0000219,,
4147.0,14696.0,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619215,391.0,BAO_0000219,,
4148.0,14769.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619216,391.0,BAO_0000219,,
4149.0,15354.0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619217,391.0,BAO_0000219,,
4150.0,14255.0,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619218,391.0,BAO_0000219,,
4151.0,14255.0,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619219,391.0,BAO_0000219,,
4152.0,14255.0,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619220,391.0,BAO_0000219,,
4153.0,14696.0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619221,391.0,BAO_0000219,,
4154.0,12016.0,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619222,391.0,BAO_0000219,,
4155.0,2597.0,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL857454,391.0,BAO_0000219,,
4156.0,12526.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619223,702.0,BAO_0000219,,
4157.0,12526.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619224,702.0,BAO_0000219,,
4158.0,14799.0,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619225,,BAO_0000019,,
4159.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619226,702.0,BAO_0000219,,
4160.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619227,702.0,BAO_0000219,,
4161.0,12767.0,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619228,,BAO_0000357,,
4162.0,10997.0,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619229,,BAO_0000219,,
4163.0,11388.0,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619230,702.0,BAO_0000219,,
4164.0,167.0,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619231,,BAO_0000357,,
4165.0,167.0,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619232,,BAO_0000357,,
4166.0,13744.0,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619233,,BAO_0000357,,
4167.0,1630.0,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619234,,BAO_0000357,,
4168.0,1630.0,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619235,,BAO_0000357,,
4169.0,969.0,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL619236,,BAO_0000019,,
4170.0,13621.0,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619237,702.0,BAO_0000219,,
4171.0,10089.0,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619238,,BAO_0000357,,
4172.0,10193.0,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619239,,BAO_0000357,,
4173.0,11966.0,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619240,,BAO_0000357,,
4174.0,12251.0,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL875417,,BAO_0000019,,
4175.0,211.0,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619241,702.0,BAO_0000219,,
4176.0,12251.0,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619242,,BAO_0000019,,
4177.0,12495.0,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL883796,702.0,BAO_0000219,,
4178.0,414.0,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619243,,BAO_0000357,,
4179.0,414.0,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619244,,BAO_0000357,,
4180.0,10325.0,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619245,,BAO_0000019,,
4181.0,11966.0,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619246,,BAO_0000019,,
4182.0,165.0,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619984,702.0,BAO_0000219,,
4183.0,165.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619985,702.0,BAO_0000219,,
4184.0,165.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619986,702.0,BAO_0000219,,
4185.0,165.0,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL619987,702.0,BAO_0000219,,
4186.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619988,,BAO_0000218,,
4187.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619989,702.0,BAO_0000219,,
4188.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619990,702.0,BAO_0000219,,
4189.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619991,,BAO_0000219,,
4190.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619992,,BAO_0000219,,
4191.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619993,,BAO_0000218,,
4192.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619994,663.0,BAO_0000219,,
4193.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619995,663.0,BAO_0000219,,
4194.0,11311.0,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619996,,BAO_0000019,,
4195.0,11732.0,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619997,,BAO_0000019,,
4196.0,11732.0,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619998,,BAO_0000019,,
4197.0,11087.0,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL619999,,BAO_0000019,,
4198.0,11087.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620000,,BAO_0000019,,
4199.0,11087.0,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620001,702.0,BAO_0000219,,
4200.0,11087.0,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL620002,,BAO_0000357,,
4201.0,496.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620003,702.0,BAO_0000219,,
4202.0,13986.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL620004,702.0,BAO_0000219,,
4203.0,11520.0,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL874063,,BAO_0000357,,
4204.0,10293.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620005,702.0,BAO_0000219,,
4205.0,303.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620006,702.0,BAO_0000219,,
4206.0,303.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620007,702.0,BAO_0000219,,
4207.0,9247.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620008,702.0,BAO_0000219,,
4208.0,9247.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL620009,702.0,BAO_0000219,,
4209.0,9247.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620010,702.0,BAO_0000219,,
4210.0,9247.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620011,702.0,BAO_0000219,,
4211.0,9247.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620677,702.0,BAO_0000219,,
4212.0,9247.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620678,702.0,BAO_0000219,,
4213.0,9247.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620679,702.0,BAO_0000219,,
4214.0,9247.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620680,702.0,BAO_0000219,,
4215.0,11481.0,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL620838,,BAO_0000357,,
4216.0,105.0,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620839,,BAO_0000357,,
4217.0,9029.0,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL620840,,BAO_0000357,,
4218.0,1175.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL620841,702.0,BAO_0000219,,
4219.0,12118.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620842,702.0,BAO_0000219,,
4220.0,12118.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620843,702.0,BAO_0000219,,
4221.0,12118.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620844,702.0,BAO_0000219,,
4222.0,9225.0,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620845,702.0,BAO_0000219,,
4223.0,9401.0,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620846,,BAO_0000019,,
4224.0,137.0,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL873951,,BAO_0000357,,
4225.0,137.0,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620847,,BAO_0000357,,
4226.0,4717.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620848,702.0,BAO_0000219,,
4227.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620849,702.0,BAO_0000219,,
4228.0,10501.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620850,702.0,BAO_0000219,,
4229.0,10501.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620851,702.0,BAO_0000219,,
4230.0,10501.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620852,702.0,BAO_0000219,,
4231.0,12526.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL875098,702.0,BAO_0000219,,
4232.0,14799.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL620853,702.0,BAO_0000219,,
4233.0,14799.0,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620854,,BAO_0000019,,
4234.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620855,702.0,BAO_0000219,,
4235.0,3595.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL839884,702.0,BAO_0000219,,
4236.0,12526.0,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620856,702.0,BAO_0000219,,
4237.0,12526.0,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620857,702.0,BAO_0000219,,
4238.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620858,,BAO_0000019,,
4239.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620859,,BAO_0000019,,
4240.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620860,,BAO_0000019,,
4241.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620861,,BAO_0000019,,
4242.0,9138.0,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,,,,,12166.0,H,8.0,Expert,1.0,,CHEMBL620862,,BAO_0000357,,
4243.0,9138.0,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620863,,BAO_0000357,,
4244.0,11966.0,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620864,,BAO_0000019,,
4245.0,165.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620865,702.0,BAO_0000219,,
4246.0,165.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620866,702.0,BAO_0000219,,
4247.0,11311.0,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620867,663.0,BAO_0000219,,
4248.0,11311.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620868,663.0,BAO_0000219,,
4249.0,11311.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620869,663.0,BAO_0000219,,
4250.0,11311.0,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL873952,,BAO_0000019,,
4251.0,11311.0,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL875099,,BAO_0000357,,
4252.0,11311.0,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620870,663.0,BAO_0000219,,
4253.0,11087.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618261,,BAO_0000019,,
4254.0,11087.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618262,,BAO_0000019,,
4255.0,11087.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619428,,BAO_0000019,,
4256.0,11087.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619429,,BAO_0000019,,
4257.0,11087.0,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL619430,,BAO_0000019,,
4258.0,496.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620017,702.0,BAO_0000219,,
4259.0,496.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620018,702.0,BAO_0000219,,
4260.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620019,702.0,BAO_0000219,,
4261.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620020,702.0,BAO_0000219,,
4262.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620021,702.0,BAO_0000219,,
4263.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620022,702.0,BAO_0000219,,
4264.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620023,702.0,BAO_0000219,,
4265.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620024,702.0,BAO_0000219,,
4266.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620025,702.0,BAO_0000219,,
4267.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620026,702.0,BAO_0000219,,
4268.0,13986.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620027,702.0,BAO_0000219,,
4269.0,13986.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Expert,1.0,,CHEMBL620028,,BAO_0000019,,
4270.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620029,,BAO_0000357,,
4271.0,9295.0,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL620030,,BAO_0000357,,
4272.0,4717.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL875415,702.0,BAO_0000219,,
4273.0,4717.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618256,702.0,BAO_0000219,,
4274.0,11854.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618257,702.0,BAO_0000219,,
4275.0,11854.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618258,702.0,BAO_0000219,,
4276.0,11854.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618259,702.0,BAO_0000219,,
4277.0,10193.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618260,,BAO_0000019,,
4278.0,9295.0,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618215,702.0,BAO_0000219,,
4279.0,9295.0,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618390,702.0,BAO_0000219,,
4280.0,9295.0,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618391,702.0,BAO_0000219,,
4281.0,9295.0,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618392,702.0,BAO_0000219,,
4282.0,165.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618393,702.0,BAO_0000219,,
4283.0,11311.0,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618394,,BAO_0000219,,
4284.0,10489.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0,,,RBL-1,,12166.0,H,8.0,Expert,1.0,,CHEMBL618395,702.0,BAO_0000219,,
4285.0,10489.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL618396,702.0,BAO_0000219,,
4286.0,10489.0,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166.0,D,9.0,Expert,1.0,,CHEMBL858253,702.0,BAO_0000219,,
4287.0,14799.0,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,,,12166.0,D,9.0,Autocuration,1.0,,CHEMBL618397,,BAO_0000019,,
4288.0,9295.0,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0,,,,,12054.0,H,8.0,Autocuration,1.0,,CHEMBL618398,,BAO_0000357,,
4289.0,16811.0,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618399,,BAO_0000019,,
4290.0,168.0,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618400,,BAO_0000357,,
4291.0,6309.0,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618401,,BAO_0000357,,
4292.0,6309.0,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618402,,BAO_0000357,,
4293.0,3092.0,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,,,RBL-1,,55.0,H,8.0,Autocuration,1.0,,CHEMBL876400,702.0,BAO_0000219,,
4294.0,168.0,Inhibitory activity against 5-lipoxygenase.,B,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618403,,BAO_0000357,,
4295.0,168.0,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618404,,BAO_0000357,,
4296.0,168.0,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618405,,BAO_0000357,,
4297.0,168.0,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618406,,BAO_0000357,,
4298.0,12338.0,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,,,,,55.0,H,8.0,Expert,1.0,,CHEMBL618407,,BAO_0000019,,
4299.0,4501.0,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618408,,BAO_0000357,,
4300.0,1132.0,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618409,,BAO_0000357,,
4301.0,2117.0,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618410,,BAO_0000357,,
4302.0,168.0,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618411,,BAO_0000357,,
4303.0,168.0,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,,,,,55.0,H,8.0,Autocuration,1.0,,CHEMBL618412,,BAO_0000357,,
4304.0,13575.0,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,,,RBL-1,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618413,702.0,BAO_0000219,,
4305.0,11089.0,,B,,,,,,,,,12166.0,H,8.0,Autocuration,1.0,,CHEMBL618414,,BAO_0000357,,
4306.0,216.0,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,,,,,10102.0,H,8.0,Autocuration,1.0,,CHEMBL618415,,BAO_0000357,,
4307.0,13165.0,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,,,,,10102.0,H,8.0,Autocuration,1.0,,CHEMBL618416,,BAO_0000019,,
4308.0,3278.0,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102.0,H,8.0,Autocuration,1.0,,CHEMBL876401,,BAO_0000357,,
4309.0,3278.0,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102.0,H,8.0,Expert,1.0,,CHEMBL618417,,BAO_0000357,,
4310.0,11966.0,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,,,,,10102.0,H,8.0,Autocuration,1.0,,CHEMBL618418,,BAO_0000357,,
4311.0,175.0,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,,,,,10102.0,H,8.0,Autocuration,1.0,,CHEMBL618419,,BAO_0000357,,
4312.0,175.0,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,,,,,10102.0,H,8.0,Autocuration,1.0,,CHEMBL618420,,BAO_0000357,,
4313.0,13449.0,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,,,,,10102.0,H,8.0,Autocuration,1.0,,CHEMBL618421,,BAO_0000357,,
4314.0,12014.0,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,,,,,11238.0,H,8.0,Autocuration,1.0,,CHEMBL618422,,BAO_0000019,,
4315.0,12014.0,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,,,,,11238.0,H,8.0,Autocuration,1.0,,CHEMBL618423,,BAO_0000019,,
4316.0,12014.0,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,,,,,11238.0,H,8.0,Autocuration,1.0,,CHEMBL618424,,BAO_0000019,,
4317.0,99.0,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,,,,,100284.0,S,2.0,Intermediate,1.0,,CHEMBL618425,,BAO_0000220,,
4318.0,4349.0,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618426,,BAO_0000019,,
4319.0,4071.0,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0,,,Panel (56 tumour cell lines),,80623.0,N,1.0,Expert,1.0,,CHEMBL618427,390.0,BAO_0000219,,
4320.0,17589.0,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0,,,5637,,80008.0,N,1.0,Expert,1.0,,CHEMBL618428,345.0,BAO_0000219,,
4321.0,15002.0,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0,,,5637,,80008.0,N,1.0,Intermediate,1.0,,CHEMBL618429,345.0,BAO_0000219,,
4322.0,13958.0,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0,,,5637,,80008.0,N,1.0,Intermediate,1.0,,CHEMBL618430,345.0,BAO_0000219,,
4323.0,17589.0,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0,,,5637,,80008.0,N,1.0,Expert,1.0,,CHEMBL618431,345.0,BAO_0000219,,
4324.0,16748.0,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0,,,5637,,80008.0,N,1.0,Expert,1.0,,CHEMBL883799,345.0,BAO_0000219,,
4325.0,16747.0,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008.0,N,1.0,Intermediate,1.0,,CHEMBL618432,345.0,BAO_0000219,,
4326.0,16747.0,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008.0,N,1.0,Intermediate,1.0,,CHEMBL618433,345.0,BAO_0000219,,
4327.0,15285.0,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0,,,,,10443.0,D,9.0,Expert,1.0,,CHEMBL618434,,BAO_0000357,,
4328.0,3726.0,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0,,,CV-1,,240.0,H,8.0,Expert,1.0,,CHEMBL618435,407.0,BAO_0000219,,
4329.0,5033.0,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,,,,,10577.0,H,8.0,Autocuration,1.0,,CHEMBL876402,,BAO_0000357,,
4330.0,11756.0,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,,,,,104698.0,H,6.0,Autocuration,1.0,,CHEMBL618436,,BAO_0000019,,
4331.0,11953.0,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL618437,,BAO_0000218,,
4332.0,5033.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033.0,D,9.0,Intermediate,1.0,,CHEMBL618438,,BAO_0000357,,
4333.0,11347.0,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045.0,H,8.0,Expert,1.0,,CHEMBL883800,,BAO_0000251,,
4334.0,11347.0,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045.0,H,8.0,Expert,1.0,,CHEMBL618439,,BAO_0000251,,
4335.0,1229.0,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL618440,,BAO_0000019,,
4336.0,1229.0,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL618441,,BAO_0000019,,
4337.0,17588.0,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0,,,,,11938.0,H,8.0,Expert,1.0,,CHEMBL618442,,BAO_0000019,,
4338.0,17588.0,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0,,,,,11938.0,H,8.0,Autocuration,1.0,,CHEMBL618443,,BAO_0000019,,
4339.0,17588.0,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0,,,,,11938.0,H,8.0,Expert,1.0,,CHEMBL619158,,BAO_0000019,,
4340.0,17588.0,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0,,,,,11938.0,H,8.0,Autocuration,1.0,,CHEMBL620974,,BAO_0000019,,
4341.0,16485.0,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,,,,,11938.0,H,8.0,Autocuration,1.0,,CHEMBL620975,,BAO_0000357,,
4342.0,4337.0,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL620976,,BAO_0000019,,
4343.0,4112.0,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Expert,1.0,,CHEMBL620977,,BAO_0000019,,
4344.0,16160.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315.0,N,1.0,Intermediate,1.0,,CHEMBL620978,542.0,BAO_0000219,,
4345.0,16160.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315.0,N,1.0,Intermediate,1.0,,CHEMBL620979,542.0,BAO_0000219,,
4346.0,17376.0,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315.0,N,1.0,Expert,1.0,,CHEMBL620980,542.0,BAO_0000219,,
4347.0,17376.0,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315.0,N,1.0,Expert,1.0,,CHEMBL620981,542.0,BAO_0000219,,
4348.0,17376.0,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315.0,N,1.0,Expert,1.0,,CHEMBL620982,542.0,BAO_0000219,,
4349.0,17376.0,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315.0,N,1.0,Expert,1.0,,CHEMBL620983,542.0,BAO_0000219,,
4350.0,3241.0,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775.0,H,4.0,Autocuration,1.0,,CHEMBL620984,,BAO_0000019,,
4351.0,3241.0,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775.0,H,4.0,Autocuration,1.0,,CHEMBL620985,,BAO_0000019,,
4352.0,3725.0,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,,,,,275.0,H,8.0,Expert,1.0,,CHEMBL620986,,BAO_0000357,,
4353.0,10805.0,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0,,,,,50425.0,N,1.0,Expert,1.0,,CHEMBL620987,,BAO_0000218,,
4354.0,10805.0,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0,,,,,50425.0,N,1.0,Expert,1.0,,CHEMBL620988,,BAO_0000218,,
4355.0,10805.0,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425.0,N,1.0,Expert,1.0,,CHEMBL620989,,BAO_0000218,,
4356.0,10805.0,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425.0,N,1.0,Expert,1.0,,CHEMBL620990,,BAO_0000218,,
4357.0,10805.0,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425.0,N,1.0,Intermediate,1.0,,CHEMBL620991,,BAO_0000218,,
4358.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL620992,850.0,BAO_0000218,,
4359.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL620993,850.0,BAO_0000218,,
4360.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL620994,850.0,BAO_0000218,,
4361.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL620995,850.0,BAO_0000218,,
4362.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL620996,850.0,BAO_0000218,,
4363.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL875581,850.0,BAO_0000218,,
4364.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620997,,BAO_0000218,,
4365.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620998,,BAO_0000218,,
4366.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620999,,BAO_0000218,,
4367.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621000,,BAO_0000218,,
4368.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621001,,BAO_0000218,,
4369.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621002,,BAO_0000218,,
4370.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621003,,BAO_0000218,,
4371.0,10685.0,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621004,,BAO_0000218,,
4372.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621005,,BAO_0000218,,
4373.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621006,,BAO_0000218,,
4374.0,10685.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621007,,BAO_0000218,,
4375.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621008,,BAO_0000218,,
4376.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621009,,BAO_0000218,,
4377.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL857705,,BAO_0000218,,
4378.0,10144.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619828,,BAO_0000218,,
4379.0,10685.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619829,,BAO_0000218,,
4380.0,10685.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619830,,BAO_0000218,,
4381.0,10685.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619831,,BAO_0000218,,
4382.0,10685.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619832,,BAO_0000218,,
4383.0,10685.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619833,,BAO_0000218,,
4384.0,10685.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619834,,BAO_0000218,,
4385.0,10685.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619835,,BAO_0000218,,
4386.0,10685.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619836,,BAO_0000218,,
4387.0,8831.0,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL619837,850.0,BAO_0000218,,
4388.0,11704.0,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619838,,BAO_0000218,,
4389.0,11704.0,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619839,,BAO_0000218,,
4390.0,10685.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL619840,850.0,BAO_0000218,,
4391.0,10685.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL619841,850.0,BAO_0000218,,
4392.0,11368.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Expert,1.0,,CHEMBL857704,850.0,BAO_0000218,,
4393.0,11368.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Intermediate,1.0,,CHEMBL619842,850.0,BAO_0000218,,
4394.0,11368.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628.0,N,1.0,Expert,1.0,,CHEMBL619843,850.0,BAO_0000218,,
4395.0,17763.0,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619844,,BAO_0000019,,
4396.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL857855,,BAO_0000251,2107.0,
4397.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619845,,BAO_0000251,2107.0,
4398.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619846,,BAO_0000251,2107.0,
4399.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619847,,BAO_0000251,2107.0,
4400.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619848,,BAO_0000251,2107.0,
4401.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620893,,BAO_0000251,2107.0,
4402.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620894,,BAO_0000251,2107.0,
4403.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620895,,BAO_0000251,2107.0,
4404.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620896,,BAO_0000251,2107.0,
4405.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620897,,BAO_0000251,2107.0,
4406.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620898,,BAO_0000251,2107.0,
4407.0,7411.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620899,,BAO_0000251,2107.0,
4408.0,347.0,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620900,,BAO_0000218,1969.0,
4409.0,3341.0,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620901,,BAO_0000218,,
4410.0,17853.0,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620902,,BAO_0000218,,
4411.0,4514.0,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620903,,BAO_0000218,,
4412.0,6062.0,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620904,,BAO_0000218,,
4413.0,6821.0,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620905,,BAO_0000218,,
4414.0,6057.0,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620906,,BAO_0000218,,
4415.0,5145.0,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875420,,BAO_0000218,,
4416.0,6641.0,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620907,,BAO_0000218,,
4417.0,5472.0,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620908,,BAO_0000218,,
4418.0,4257.0,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620909,,BAO_0000218,,
4419.0,5546.0,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620910,,BAO_0000218,,
4420.0,5334.0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620911,,BAO_0000218,,
4421.0,5334.0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620912,,BAO_0000218,,
4422.0,17509.0,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620913,,BAO_0000218,,
4423.0,6535.0,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620914,,BAO_0000218,,
4424.0,5668.0,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620915,,BAO_0000218,,
4425.0,5922.0,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620916,,BAO_0000218,,
4426.0,5922.0,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620917,,BAO_0000218,,
4427.0,6078.0,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620918,,BAO_0000218,,
4428.0,2661.0,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620919,,BAO_0000218,,
4429.0,3249.0,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620920,,BAO_0000218,1969.0,
4430.0,3249.0,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620921,,BAO_0000218,1969.0,
4431.0,5553.0,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620922,,BAO_0000218,1969.0,
4432.0,1916.0,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620923,,BAO_0000218,,
4433.0,6227.0,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620924,,BAO_0000218,1969.0,
4434.0,4809.0,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620925,,BAO_0000218,,
4435.0,5355.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620926,,BAO_0000218,,
4436.0,5355.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620927,,BAO_0000218,,
4437.0,5355.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620928,,BAO_0000218,,
4438.0,5355.0,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620929,,BAO_0000218,,
4439.0,6221.0,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620930,,BAO_0000218,1969.0,
4440.0,167.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620931,,BAO_0000218,,
4441.0,167.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620932,,BAO_0000218,,
4442.0,4257.0,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620933,,BAO_0000218,,
4443.0,6221.0,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620934,,BAO_0000218,,
4444.0,17667.0,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620935,,BAO_0000218,,
4445.0,17267.0,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620936,,BAO_0000218,,
4446.0,4256.0,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620937,,BAO_0000218,,
4447.0,4256.0,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620938,,BAO_0000218,,
4448.0,17853.0,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620939,,BAO_0000218,,
4449.0,16365.0,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620940,,BAO_0000218,,
4450.0,1916.0,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620941,,BAO_0000218,,
4451.0,5334.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620942,,BAO_0000218,,
4452.0,5334.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620943,,BAO_0000218,,
4453.0,17592.0,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620944,,BAO_0000218,,
4454.0,1399.0,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620945,,BAO_0000218,,
4455.0,4809.0,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620946,,BAO_0000218,,
4456.0,3341.0,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620947,,BAO_0000218,,
4457.0,64.0,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620948,,BAO_0000218,,
4458.0,5005.0,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620949,,BAO_0000218,,
4459.0,5005.0,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620950,,BAO_0000218,,
4460.0,5237.0,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620951,,BAO_0000218,,
4461.0,5237.0,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620952,,BAO_0000218,,
4462.0,5302.0,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875421,,BAO_0000218,,
4463.0,17667.0,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620953,,BAO_0000218,,
4464.0,6161.0,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873491,,BAO_0000218,,
4465.0,6161.0,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620954,,BAO_0000218,,
4466.0,3854.0,Plasma half life determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620955,,BAO_0000218,1969.0,
4467.0,993.0,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618097,,BAO_0000218,1969.0,
4468.0,4514.0,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618268,,BAO_0000218,1969.0,
4469.0,5334.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618269,,BAO_0000218,1969.0,
4470.0,5334.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618270,,BAO_0000218,1969.0,
4471.0,1466.0,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618271,,BAO_0000218,,
4472.0,1466.0,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873493,,BAO_0000218,,
4473.0,5313.0,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621031,,BAO_0000218,,
4474.0,5313.0,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621032,,BAO_0000218,,
4475.0,3880.0,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621033,,BAO_0000218,,
4476.0,3639.0,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621034,,BAO_0000218,1969.0,
4477.0,3880.0,The half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621035,,BAO_0000218,,
4478.0,3918.0,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621036,,BAO_0000218,1969.0,
4479.0,16452.0,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621037,,BAO_0000218,1969.0,
4480.0,17796.0,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619812,,BAO_0000218,,
4481.0,5983.0,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619813,,BAO_0000218,,
4482.0,1466.0,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873335,,BAO_0000218,,
4483.0,16456.0,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619814,,BAO_0000218,,
4484.0,6113.0,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0,,,,,50506.0,N,1.0,Expert,1.0,,CHEMBL619815,,BAO_0000218,,
4485.0,6113.0,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0,,,,,50506.0,N,1.0,Expert,1.0,,CHEMBL619816,,BAO_0000218,,
4486.0,17796.0,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619817,,BAO_0000218,,
4487.0,17796.0,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710.0,N,1.0,Intermediate,1.0,,CHEMBL619818,,BAO_0000218,,
4488.0,5308.0,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619819,,BAO_0000218,1969.0,
4489.0,4877.0,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619820,,BAO_0000218,,
4490.0,4876.0,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875419,,BAO_0000218,,
4491.0,4878.0,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619821,,BAO_0000218,1969.0,
4492.0,5308.0,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619822,,BAO_0000218,,
4493.0,4877.0,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619823,,BAO_0000218,,
4494.0,4876.0,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619824,,BAO_0000218,,
4495.0,4876.0,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619825,,BAO_0000218,,
4496.0,5308.0,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619826,,BAO_0000218,,
4497.0,4877.0,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,Lung,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619827,,BAO_0000218,2048.0,
4498.0,4878.0,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618167,,BAO_0000218,,
4499.0,5689.0,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Blood,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618168,,BAO_0000019,178.0,
4500.0,5689.0,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Brain,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618169,,BAO_0000019,955.0,
4501.0,5689.0,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618170,,BAO_0000019,,
4502.0,5689.0,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Intestine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618171,,BAO_0000019,160.0,
4503.0,5689.0,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Kidney,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618172,,BAO_0000019,2113.0,
4504.0,5689.0,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Liver,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618173,,BAO_0000019,2107.0,
4505.0,5689.0,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618174,,BAO_0000019,,
4506.0,5689.0,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Spleen,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875408,,BAO_0000019,2106.0,
4507.0,14465.0,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL839827,,BAO_0000218,,
4508.0,5689.0,Partition coefficient was measured as -log (counts per min ),A,,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618175,,BAO_0000019,,
4509.0,611.0,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618176,,BAO_0000218,,
4510.0,611.0,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618177,,BAO_0000218,,
4511.0,14465.0,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618178,,BAO_0000218,,
4512.0,4876.0,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618179,,BAO_0000218,,
4513.0,5689.0,Half-life was measured,A,,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873489,,BAO_0000019,,
4514.0,7515.0,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618180,,BAO_0000019,,
4515.0,17667.0,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618181,,BAO_0000218,,
4516.0,17667.0,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618182,,BAO_0000218,,
4517.0,4727.0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618183,,BAO_0000218,,
4518.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618184,,BAO_0000218,,
4519.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618185,,BAO_0000218,,
4520.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618186,,BAO_0000218,,
4521.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618187,,BAO_0000218,,
4522.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618188,,BAO_0000218,,
4523.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875409,,BAO_0000218,,
4524.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618189,,BAO_0000218,,
4525.0,3655.0,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618190,,BAO_0000218,178.0,
4526.0,3655.0,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618191,,BAO_0000218,178.0,
4527.0,3655.0,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618192,,BAO_0000218,178.0,
4528.0,3655.0,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618193,,BAO_0000218,10000001.0,
4529.0,3655.0,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618194,,BAO_0000218,10000001.0,
4530.0,3655.0,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618195,,BAO_0000218,10000001.0,
4531.0,3655.0,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618196,,BAO_0000218,955.0,
4532.0,3655.0,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618197,,BAO_0000218,955.0,
4533.0,3655.0,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618198,,BAO_0000218,955.0,
4534.0,3655.0,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618199,,BAO_0000218,948.0,
4535.0,3655.0,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618200,,BAO_0000218,948.0,
4536.0,3655.0,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618201,,BAO_0000218,948.0,
4537.0,3655.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618202,,BAO_0000218,160.0,
4538.0,3655.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618203,,BAO_0000218,160.0,
4539.0,3655.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618204,,BAO_0000218,160.0,
4540.0,3655.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618205,,BAO_0000218,2113.0,
4541.0,3655.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618206,,BAO_0000218,2113.0,
4542.0,3655.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618207,,BAO_0000218,2113.0,
4543.0,3655.0,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618208,,BAO_0000218,2107.0,
4544.0,3655.0,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618932,,BAO_0000218,2107.0,
4545.0,3655.0,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618933,,BAO_0000218,2107.0,
4546.0,3655.0,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618934,,BAO_0000218,2048.0,
4547.0,3655.0,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618935,,BAO_0000218,2048.0,
4548.0,3655.0,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618936,,BAO_0000218,2048.0,
4549.0,3655.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618937,,BAO_0000218,2385.0,
4550.0,3655.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618938,,BAO_0000218,2385.0,
4551.0,3655.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619104,,BAO_0000218,2385.0,
4552.0,3655.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619105,,BAO_0000218,2106.0,
4553.0,3655.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619106,,BAO_0000218,2106.0,
4554.0,3655.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619107,,BAO_0000218,2106.0,
4555.0,3655.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875410,,BAO_0000218,945.0,
4556.0,3655.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619108,,BAO_0000218,945.0,
4557.0,3655.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619109,,BAO_0000218,945.0,
4558.0,16597.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619110,,BAO_0000218,,
4559.0,16597.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619111,,BAO_0000218,,
4560.0,16597.0,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619112,,BAO_0000218,,
4561.0,16597.0,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619113,,BAO_0000218,,
4562.0,17764.0,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619114,,BAO_0000218,,
4563.0,17764.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619115,,BAO_0000218,,
4564.0,3830.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619116,478.0,BAO_0000219,,
4565.0,3829.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619117,478.0,BAO_0000219,,
4566.0,2040.0,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619118,478.0,BAO_0000219,,
4567.0,15684.0,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619119,478.0,BAO_0000219,,
4568.0,15684.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619120,478.0,BAO_0000219,,
4569.0,15684.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619121,478.0,BAO_0000219,,
4570.0,15684.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619122,478.0,BAO_0000219,,
4571.0,15684.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619123,478.0,BAO_0000219,,
4572.0,15684.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619124,478.0,BAO_0000219,,
4573.0,2859.0,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619125,478.0,BAO_0000219,,
4574.0,5618.0,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL875411,478.0,BAO_0000219,,
4575.0,15684.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619126,478.0,BAO_0000219,,
4576.0,15684.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619127,478.0,BAO_0000219,,
4577.0,15684.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619128,478.0,BAO_0000219,,
4578.0,15684.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619129,478.0,BAO_0000219,,
4579.0,2113.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619130,478.0,BAO_0000219,,
4580.0,2113.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619131,478.0,BAO_0000219,,
4581.0,16745.0,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619132,478.0,BAO_0000219,,
4582.0,16597.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619133,478.0,BAO_0000218,,
4583.0,15684.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619134,478.0,BAO_0000219,,
4584.0,15684.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619135,478.0,BAO_0000219,,
4585.0,2040.0,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619136,478.0,BAO_0000219,,
4586.0,2040.0,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619137,478.0,BAO_0000219,,
4587.0,16165.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL883713,478.0,BAO_0000219,,
4588.0,16165.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL875412,478.0,BAO_0000219,,
4589.0,16597.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619138,478.0,BAO_0000218,,
4590.0,16597.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619262,478.0,BAO_0000218,,
4591.0,3992.0,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619139,478.0,BAO_0000219,,
4592.0,10553.0,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619140,478.0,BAO_0000219,,
4593.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619141,478.0,BAO_0000219,,
4594.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619142,478.0,BAO_0000219,,
4595.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619143,478.0,BAO_0000219,,
4596.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619144,478.0,BAO_0000219,,
4597.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619145,478.0,BAO_0000219,,
4598.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619146,478.0,BAO_0000219,,
4599.0,15569.0,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619147,478.0,BAO_0000219,,
4600.0,17420.0,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619148,478.0,BAO_0000219,,
4601.0,17420.0,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619149,478.0,BAO_0000219,,
4602.0,15099.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619150,478.0,BAO_0000219,,
4603.0,15099.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619151,478.0,BAO_0000219,,
4604.0,17672.0,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL883794,478.0,BAO_0000219,,
4605.0,17672.0,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619152,478.0,BAO_0000219,,
4606.0,17270.0,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619153,478.0,BAO_0000219,,
4607.0,17270.0,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619154,478.0,BAO_0000219,,
4608.0,5574.0,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619155,478.0,BAO_0000219,,
4609.0,2113.0,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619156,478.0,BAO_0000219,,
4610.0,16913.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619157,478.0,BAO_0000219,,
4611.0,16913.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619797,478.0,BAO_0000219,,
4612.0,17839.0,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619798,,BAO_0000218,,
4613.0,6821.0,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619799,,BAO_0000218,,
4614.0,6078.0,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619800,,BAO_0000218,,
4615.0,6535.0,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619801,,BAO_0000218,,
4616.0,4449.0,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619802,,BAO_0000218,,
4617.0,6057.0,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619803,,BAO_0000218,,
4618.0,5922.0,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619965,,BAO_0000218,,
4619.0,5940.0,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619966,,BAO_0000218,,
4620.0,6265.0,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619967,,BAO_0000218,,
4621.0,6265.0,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620073,,BAO_0000218,,
4622.0,6265.0,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620074,,BAO_0000218,,
4623.0,5940.0,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620075,,BAO_0000218,,
4624.0,5940.0,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620076,,BAO_0000218,,
4625.0,4514.0,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620077,,BAO_0000218,,
4626.0,5546.0,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620078,,BAO_0000218,,
4627.0,5553.0,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620079,,BAO_0000218,,
4628.0,6641.0,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620080,,BAO_0000218,,
4629.0,5472.0,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620081,,BAO_0000218,,
4630.0,5668.0,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620082,,BAO_0000218,,
4631.0,5711.0,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620083,,BAO_0000218,,
4632.0,5145.0,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620084,,BAO_0000218,,
4633.0,3443.0,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620085,,BAO_0000218,,
4634.0,3443.0,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL874595,,BAO_0000218,,
4635.0,3249.0,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873352,,BAO_0000218,,
4636.0,3249.0,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620086,,BAO_0000218,,
4637.0,5355.0,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620087,,BAO_0000218,,
4638.0,5355.0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620088,,BAO_0000218,,
4639.0,5355.0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620089,,BAO_0000218,,
4640.0,4809.0,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620090,,BAO_0000218,,
4641.0,4809.0,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620091,,BAO_0000218,,
4642.0,14294.0,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620092,,BAO_0000251,,
4643.0,14294.0,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620093,,BAO_0000251,,
4644.0,14294.0,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620094,,BAO_0000251,,
4645.0,14294.0,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620095,,BAO_0000251,,
4646.0,3443.0,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620096,,BAO_0000218,,
4647.0,3443.0,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620097,,BAO_0000218,,
4648.0,11271.0,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620098,,BAO_0000019,,
4649.0,3443.0,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620099,,BAO_0000218,,
4650.0,3443.0,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620100,,BAO_0000218,,
4651.0,6821.0,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620101,,BAO_0000019,,
4652.0,17267.0,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620102,,BAO_0000019,,
4653.0,5819.0,Half life in monkey plasma,A,,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620103,,BAO_0000366,1969.0,
4654.0,5819.0,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620104,,BAO_0000366,1969.0,
4655.0,1916.0,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL874596,,BAO_0000218,,
4656.0,17509.0,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873490,,BAO_0000218,,
4657.0,1399.0,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620105,,BAO_0000019,,
4658.0,1916.0,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620780,,BAO_0000218,,
4659.0,4809.0,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620781,,BAO_0000218,,
4660.0,5546.0,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620956,,BAO_0000218,,
4661.0,3443.0,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620957,,BAO_0000218,1088.0,
4662.0,3443.0,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620958,,BAO_0000218,1088.0,
4663.0,4257.0,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620959,,BAO_0000218,,
4664.0,6221.0,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620960,,BAO_0000218,,
4665.0,5472.0,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620961,,BAO_0000218,,
4666.0,4727.0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620962,,BAO_0000218,,
4667.0,4727.0,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620963,,BAO_0000218,,
4668.0,4727.0,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620964,,BAO_0000218,,
4669.0,4727.0,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620965,,BAO_0000218,,
4670.0,4727.0,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620966,,BAO_0000218,,
4671.0,4727.0,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0,,Blood,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620967,,BAO_0000221,178.0,
4672.0,1452.0,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620968,,BAO_0000019,,
4673.0,1452.0,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL874597,,BAO_0000019,,
4674.0,1452.0,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620969,,BAO_0000019,,
4675.0,1452.0,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620970,,BAO_0000019,,
4676.0,11706.0,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0,,,,,235.0,D,9.0,Expert,1.0,,CHEMBL620971,,BAO_0000357,,
4677.0,1916.0,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620972,,BAO_0000218,,
4678.0,17791.0,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620973,,BAO_0000019,,
4679.0,7766.0,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618243,,BAO_0000019,,
4680.0,6567.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618244,,BAO_0000019,,
4681.0,6567.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618245,,BAO_0000019,,
4682.0,6567.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618246,,BAO_0000019,,
4683.0,6567.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618247,,BAO_0000019,,
4684.0,17791.0,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618248,,BAO_0000218,,
4685.0,7766.0,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618249,,BAO_0000019,1088.0,
4686.0,6852.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618250,,BAO_0000019,,
4687.0,6852.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL874598,,BAO_0000019,,
4688.0,6852.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618251,,BAO_0000019,,
4689.0,6852.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618252,,BAO_0000019,,
4690.0,6852.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618253,,BAO_0000019,,
4691.0,6852.0,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618254,,BAO_0000019,,
4692.0,6852.0,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618255,,BAO_0000019,,
4693.0,4397.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618983,,BAO_0000251,2107.0,
4694.0,17409.0,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618984,,BAO_0000019,,
4695.0,17409.0,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618985,,BAO_0000019,,
4696.0,17176.0,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618986,,BAO_0000019,,
4697.0,15444.0,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618987,,BAO_0000019,,
4698.0,17267.0,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618988,,BAO_0000019,,
4699.0,5944.0,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618989,,BAO_0000251,2107.0,
4700.0,5668.0,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618990,,BAO_0000251,2107.0,
4701.0,5669.0,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618991,,BAO_0000251,2107.0,
4702.0,5041.0,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876725,,BAO_0000251,,
4703.0,5041.0,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618992,,BAO_0000251,,
4704.0,5041.0,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618993,,BAO_0000251,,
4705.0,5676.0,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618994,,BAO_0000251,2107.0,
4706.0,5944.0,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618995,,BAO_0000251,2107.0,
4707.0,17538.0,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618996,,BAO_0000251,2107.0,
4708.0,6331.0,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618997,,BAO_0000251,2107.0,
4709.0,5948.0,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618998,,BAO_0000251,2107.0,
4710.0,5965.0,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618999,,BAO_0000218,,
4711.0,1916.0,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620223,,BAO_0000218,,
4712.0,5965.0,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620224,,BAO_0000218,,
4713.0,1299.0,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620225,,BAO_0000019,,
4714.0,1299.0,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620226,,BAO_0000019,,
4715.0,7766.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620227,,BAO_0000019,1088.0,
4716.0,7766.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876726,,BAO_0000019,1088.0,
4717.0,7766.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620228,,BAO_0000019,1088.0,
4718.0,7766.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620229,,BAO_0000019,1088.0,
4719.0,17764.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620230,,BAO_0000218,,
4720.0,17764.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620231,,BAO_0000218,,
4721.0,17764.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620232,,BAO_0000218,,
4722.0,17764.0,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620233,,BAO_0000218,,
4723.0,14294.0,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620234,,BAO_0000218,,
4724.0,14294.0,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620235,,BAO_0000218,,
4725.0,14294.0,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620236,,BAO_0000218,,
4726.0,6251.0,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620237,,BAO_0000218,2107.0,
4727.0,17582.0,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620238,,BAO_0000218,,
4728.0,17811.0,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Adrenal gland,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620239,,BAO_0000218,2369.0,
4729.0,17811.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620240,,BAO_0000218,955.0,
4730.0,17811.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620241,,BAO_0000218,955.0,
4731.0,17811.0,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876727,,BAO_0000218,,
4732.0,17811.0,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620242,,BAO_0000218,2113.0,
4733.0,17811.0,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620243,,BAO_0000218,,
4734.0,5288.0,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620244,,BAO_0000218,,
4735.0,2717.0,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620245,,BAO_0000218,1977.0,
4736.0,2717.0,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620246,,BAO_0000218,1977.0,
4737.0,2717.0,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620247,,BAO_0000218,1977.0,
4738.0,17753.0,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620248,,BAO_0000218,1969.0,
4739.0,17753.0,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL873497,,BAO_0000218,1969.0,
4740.0,17753.0,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620249,,BAO_0000218,1969.0,
4741.0,17764.0,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620250,,BAO_0000218,,
4742.0,17764.0,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620251,,BAO_0000218,,
4743.0,17764.0,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620252,,BAO_0000218,,
4744.0,17764.0,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620253,,BAO_0000218,,
4745.0,17764.0,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620254,,BAO_0000218,,
4746.0,17764.0,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620255,,BAO_0000218,,
4747.0,16597.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620256,,BAO_0000218,,
4748.0,2675.0,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876728,,BAO_0000218,,
4749.0,2675.0,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620257,,BAO_0000218,,
4750.0,16597.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620258,,BAO_0000218,,
4751.0,4890.0,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620259,,BAO_0000218,,
4752.0,429.0,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620260,,BAO_0000218,,
4753.0,17837.0,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620261,,BAO_0000218,178.0,
4754.0,16597.0,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620262,,BAO_0000218,,
4755.0,16597.0,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620263,,BAO_0000218,,
4756.0,6619.0,Half life in ob/ob mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620264,,BAO_0000218,,
4757.0,4066.0,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620265,,BAO_0000218,,
4758.0,4239.0,Half-life was measured in mouse,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620266,,BAO_0000218,,
4759.0,5969.0,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620267,,BAO_0000218,,
4760.0,8999.0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619364,,BAO_0000218,,
4761.0,8999.0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619365,,BAO_0000218,,
4762.0,17641.0,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619366,,BAO_0000218,955.0,
4763.0,17641.0,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619367,,BAO_0000218,2113.0,
4764.0,17641.0,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619368,,BAO_0000218,2107.0,
4765.0,17641.0,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619369,,BAO_0000218,2048.0,
4766.0,17641.0,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876729,,BAO_0000218,2106.0,
4767.0,16597.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619370,,BAO_0000218,,
4768.0,4890.0,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619371,,BAO_0000218,,
4769.0,429.0,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619372,,BAO_0000218,,
4770.0,429.0,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620012,,BAO_0000218,,
4771.0,5969.0,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620013,,BAO_0000218,,
4772.0,16913.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL620014,478.0,BAO_0000219,,
4773.0,16913.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL620015,478.0,BAO_0000219,,
4774.0,16913.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621010,478.0,BAO_0000219,,
4775.0,16913.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621011,478.0,BAO_0000219,,
4776.0,16913.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621012,478.0,BAO_0000219,,
4777.0,16913.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621013,478.0,BAO_0000219,,
4778.0,17270.0,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621014,478.0,BAO_0000219,,
4779.0,5618.0,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017.0,N,1.0,Intermediate,1.0,,CHEMBL618154,481.0,BAO_0000219,,
4780.0,17777.0,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL618155,478.0,BAO_0000219,,
4781.0,16112.0,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017.0,N,1.0,Intermediate,1.0,,CHEMBL618156,481.0,BAO_0000219,,
4782.0,15748.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780cisR,,80017.0,N,1.0,Intermediate,1.0,,CHEMBL618157,481.0,BAO_0000219,,
4783.0,6633.0,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618328,478.0,BAO_0000219,,
4784.0,16930.0,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618329,478.0,BAO_0000219,,
4785.0,17496.0,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618330,478.0,BAO_0000219,,
4786.0,12989.0,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL618331,478.0,BAO_0000219,,
4787.0,4840.0,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618332,478.0,BAO_0000219,,
4788.0,12989.0,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL618333,478.0,BAO_0000219,,
4789.0,16745.0,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017.0,N,1.0,Intermediate,1.0,,CHEMBL618334,481.0,BAO_0000219,,
4790.0,16597.0,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL618335,478.0,BAO_0000219,,
4791.0,16547.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0,,,,,11736.0,D,9.0,Expert,1.0,,CHEMBL618336,,BAO_0000019,,
4792.0,16547.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,,,,,11736.0,H,8.0,Expert,1.0,,CHEMBL618337,,BAO_0000019,,
4793.0,16547.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0,,,,,11736.0,D,9.0,Expert,1.0,,CHEMBL618338,,BAO_0000019,,
4794.0,15856.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0,,,HEK293,,278.0,D,9.0,Expert,1.0,,CHEMBL618339,722.0,BAO_0000219,,
4795.0,15856.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0,,,HEK293,,278.0,D,9.0,Expert,1.0,,CHEMBL618340,722.0,BAO_0000219,,
4796.0,16547.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0,,,,,11831.0,D,9.0,Expert,1.0,,CHEMBL618341,,BAO_0000019,,
4797.0,16547.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,,,,,11831.0,H,8.0,Expert,1.0,,CHEMBL618342,,BAO_0000019,,
4798.0,16547.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0,,,,,11831.0,D,9.0,Expert,1.0,,CHEMBL618343,,BAO_0000019,,
4799.0,17402.0,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,,,,,280.0,H,8.0,Expert,1.0,,CHEMBL621038,,BAO_0000357,,
4800.0,11746.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0,,,T-cells,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL621039,574.0,BAO_0000219,,
4801.0,11746.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0,,,T-cells,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL621040,574.0,BAO_0000219,,
4802.0,5455.0,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL621041,455.0,BAO_0000219,,
4803.0,2068.0,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL621042,455.0,BAO_0000219,,
4804.0,2683.0,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL621043,455.0,BAO_0000219,,
4805.0,15313.0,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Expert,1.0,,CHEMBL621044,455.0,BAO_0000219,,
4806.0,13739.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL621045,455.0,BAO_0000219,,
4807.0,13739.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL621046,455.0,BAO_0000219,,
4808.0,14750.0,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL621047,455.0,BAO_0000219,,
4809.0,14777.0,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL621048,797.0,BAO_0000219,,
4810.0,14777.0,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL883798,797.0,BAO_0000219,,
4811.0,17672.0,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL621049,797.0,BAO_0000219,,
4812.0,14368.0,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL621050,797.0,BAO_0000219,,
4813.0,14368.0,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL621051,797.0,BAO_0000219,,
4814.0,13866.0,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL621052,797.0,BAO_0000219,,
4815.0,2545.0,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL621053,797.0,BAO_0000219,,
4816.0,2545.0,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL621054,797.0,BAO_0000219,,
4817.0,6062.0,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621055,,BAO_0000218,,
4818.0,4578.0,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876398,,BAO_0000218,,
4819.0,17592.0,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621056,,BAO_0000218,,
4820.0,5005.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621057,,BAO_0000218,,
4821.0,5005.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621058,,BAO_0000218,,
4822.0,5922.0,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621059,,BAO_0000218,,
4823.0,5355.0,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621060,,BAO_0000218,,
4824.0,5355.0,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621061,,BAO_0000218,,
4825.0,5355.0,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621062,,BAO_0000218,,
4826.0,6057.0,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621063,,BAO_0000218,,
4827.0,5145.0,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621064,,BAO_0000218,,
4828.0,6821.0,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621065,,BAO_0000218,,
4829.0,5334.0,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621066,,BAO_0000218,,
4830.0,5334.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621067,,BAO_0000218,,
4831.0,6641.0,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621068,,BAO_0000218,,
4832.0,2661.0,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876399,,BAO_0000218,,
4833.0,6535.0,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621069,,BAO_0000218,,
4834.0,4809.0,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621070,,BAO_0000218,,
4835.0,6062.0,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621071,,BAO_0000218,,
4836.0,3443.0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621072,,BAO_0000218,,
4837.0,4578.0,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618209,,BAO_0000218,,
4838.0,4809.0,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618210,,BAO_0000218,,
4839.0,11271.0,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618211,,BAO_0000019,,
4840.0,6057.0,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618212,,BAO_0000218,,
4841.0,6057.0,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618213,,BAO_0000019,,
4842.0,17853.0,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618214,,BAO_0000019,,
4843.0,5302.0,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873492,,BAO_0000218,,
4844.0,4257.0,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618272,,BAO_0000218,,
4845.0,4257.0,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618273,,BAO_0000218,,
4846.0,13501.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618274,,BAO_0000218,1969.0,
4847.0,5394.0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618275,,BAO_0000218,,
4848.0,2661.0,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618276,,BAO_0000218,,
4849.0,3341.0,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618277,,BAO_0000019,,
4850.0,3045.0,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618278,,BAO_0000218,,
4851.0,5005.0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618279,,BAO_0000218,1969.0,
4852.0,4847.0,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618280,,BAO_0000019,,
4853.0,4256.0,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618281,,BAO_0000218,,
4854.0,6535.0,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618282,,BAO_0000218,1969.0,
4855.0,6057.0,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618283,,BAO_0000019,,
4856.0,17592.0,Half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618284,,BAO_0000019,,
4857.0,6641.0,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618285,,BAO_0000218,,
4858.0,5472.0,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618286,,BAO_0000019,,
4859.0,6221.0,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618287,,BAO_0000218,,
4860.0,5668.0,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618288,,BAO_0000218,,
4861.0,4809.0,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876393,,BAO_0000218,,
4862.0,5546.0,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618289,,BAO_0000218,,
4863.0,5553.0,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618290,,BAO_0000218,,
4864.0,6078.0,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618291,,BAO_0000019,,
4865.0,5147.0,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618292,,BAO_0000019,,
4866.0,5145.0,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618293,,BAO_0000019,,
4867.0,6062.0,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618294,,BAO_0000218,,
4868.0,5355.0,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618295,,BAO_0000218,,
4869.0,5355.0,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618296,,BAO_0000218,,
4870.0,5355.0,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618297,,BAO_0000218,,
4871.0,7766.0,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618298,,BAO_0000019,1088.0,
4872.0,7766.0,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618299,,BAO_0000019,1088.0,
4873.0,7766.0,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618300,,BAO_0000019,1088.0,
4874.0,7766.0,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618301,,BAO_0000019,1088.0,
4875.0,7766.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618302,,BAO_0000019,1088.0,
4876.0,7766.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876394,,BAO_0000019,1088.0,
4877.0,7766.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618303,,BAO_0000019,1088.0,
4878.0,7766.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618304,,BAO_0000019,1088.0,
4879.0,1916.0,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618305,,BAO_0000218,,
4880.0,16643.0,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618306,,BAO_0000218,,
4881.0,17248.0,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618307,,BAO_0000019,,
4882.0,17248.0,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618308,,BAO_0000019,,
4883.0,6241.0,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618309,,BAO_0000019,,
4884.0,17716.0,Unbound fraction (plasma),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618310,,BAO_0000019,,
4885.0,17605.0,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873353,,BAO_0000366,1969.0,
4886.0,17625.0,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618311,,BAO_0000366,1969.0,
4887.0,17625.0,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618312,,BAO_0000366,1969.0,
4888.0,17747.0,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618313,,BAO_0000366,1969.0,
4889.0,15613.0,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618314,,BAO_0000019,,
4890.0,354.0,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618315,,BAO_0000019,,
4891.0,3741.0,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618316,,BAO_0000019,,
4892.0,3741.0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618317,,BAO_0000019,,
4893.0,3741.0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620138,,BAO_0000019,,
4894.0,17599.0,Partition coefficient (logP),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL858280,,BAO_0000019,,
4895.0,5486.0,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620139,,BAO_0000019,,
4896.0,5600.0,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620140,,BAO_0000251,,
4897.0,14294.0,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620141,,BAO_0000019,,
4898.0,14294.0,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620142,,BAO_0000019,,
4899.0,14294.0,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620143,,BAO_0000019,,
4900.0,14294.0,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620144,,BAO_0000251,,
4901.0,14294.0,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620145,,BAO_0000251,,
4902.0,14294.0,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620146,,BAO_0000251,,
4903.0,6260.0,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620147,,BAO_0000251,2107.0,
4904.0,6187.0,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620148,,BAO_0000251,,
4905.0,6251.0,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620149,,BAO_0000251,2107.0,
4906.0,3246.0,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876412,,BAO_0000019,,
4907.0,17313.0,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619352,,BAO_0000019,,
4908.0,6227.0,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619353,,BAO_0000019,,
4909.0,5530.0,Protein binding in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619354,,BAO_0000019,1969.0,
4910.0,6108.0,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619355,,BAO_0000019,,
4911.0,6108.0,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619356,,BAO_0000019,,
4912.0,2774.0,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619357,,BAO_0000019,,
4913.0,16643.0,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619358,,BAO_0000019,,
4914.0,17582.0,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0,,,Caco-2,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619359,495.0,BAO_0000219,,
4915.0,6838.0,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0,,,Caco-2,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619360,495.0,BAO_0000219,,
4916.0,6108.0,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619361,,BAO_0000019,,
4917.0,6108.0,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619362,,BAO_0000019,,
4918.0,6108.0,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619363,,BAO_0000019,,
4919.0,2146.0,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618942,,BAO_0000019,,
4920.0,4514.0,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618943,,BAO_0000019,,
4921.0,6108.0,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618944,,BAO_0000019,,
4922.0,7766.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618945,,BAO_0000019,1088.0,
4923.0,5969.0,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618946,,BAO_0000218,,
4924.0,3277.0,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876413,,BAO_0000218,,
4925.0,3802.0,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618947,,BAO_0000218,,
4926.0,2862.0,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618948,,BAO_0000218,1969.0,
4927.0,6348.0,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618949,,BAO_0000218,1969.0,
4928.0,17764.0,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618950,,BAO_0000218,,
4929.0,5781.0,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618951,,BAO_0000218,,
4930.0,17764.0,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618952,,BAO_0000218,,
4931.0,4066.0,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618953,,BAO_0000218,,
4932.0,17641.0,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618954,,BAO_0000218,955.0,
4933.0,17641.0,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618955,,BAO_0000218,2113.0,
4934.0,17641.0,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618956,,BAO_0000218,2107.0,
4935.0,17641.0,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618957,,BAO_0000218,2048.0,
4936.0,17764.0,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618958,,BAO_0000218,,
4937.0,17764.0,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618959,,BAO_0000218,,
4938.0,17764.0,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618960,,BAO_0000218,,
4939.0,17764.0,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876723,,BAO_0000218,,
4940.0,17641.0,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618961,,BAO_0000218,2106.0,
4941.0,16597.0,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618962,,BAO_0000218,,
4942.0,16597.0,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618963,,BAO_0000218,,
4943.0,5951.0,Tmax value in IRC mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618964,,BAO_0000218,,
4944.0,5506.0,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618965,,BAO_0000218,,
4945.0,5506.0,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618966,,BAO_0000218,,
4946.0,429.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0,,Urine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618967,,BAO_0000218,1088.0,
4947.0,429.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0,,Urine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618968,,BAO_0000218,1088.0,
4948.0,4066.0,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0,,Urine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618969,,BAO_0000218,1088.0,
4949.0,17734.0,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618970,,BAO_0000218,,
4950.0,17734.0,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618971,,BAO_0000218,,
4951.0,6062.0,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618972,,BAO_0000218,,
4952.0,5969.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618973,,BAO_0000218,,
4953.0,5969.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618974,,BAO_0000218,,
4954.0,5969.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618975,,BAO_0000218,,
4955.0,5980.0,Vd in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618976,,BAO_0000218,,
4956.0,17592.0,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618977,,BAO_0000218,,
4957.0,6348.0,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876724,,BAO_0000218,,
4958.0,17753.0,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618978,,BAO_0000218,,
4959.0,17753.0,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618979,,BAO_0000218,,
4960.0,17753.0,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618980,,BAO_0000218,,
4961.0,4239.0,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618981,,BAO_0000218,,
4962.0,2862.0,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618982,,BAO_0000218,,
4963.0,17734.0,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620150,,BAO_0000218,,
4964.0,2675.0,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620151,,BAO_0000218,,
4965.0,2675.0,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620152,,BAO_0000218,,
4966.0,17837.0,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620153,,BAO_0000218,,
4967.0,5727.0,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876395,,BAO_0000218,,
4968.0,17852.0,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620154,,BAO_0000218,,
4969.0,17764.0,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620155,,BAO_0000218,,
4970.0,16597.0,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620156,,BAO_0000218,,
4971.0,6062.0,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620157,,BAO_0000218,,
4972.0,16438.0,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620158,,BAO_0000218,2113.0,
4973.0,16438.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620159,,BAO_0000218,178.0,
4974.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620160,,BAO_0000218,178.0,
4975.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620161,,BAO_0000218,178.0,
4976.0,10708.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL620162,797.0,BAO_0000219,,
4977.0,16597.0,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL620163,500.0,BAO_0000219,,
4978.0,16062.0,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL620833,500.0,BAO_0000219,,
4979.0,16062.0,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL876396,500.0,BAO_0000219,,
4980.0,16958.0,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL620834,500.0,BAO_0000219,,
4981.0,6700.0,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL620835,500.0,BAO_0000219,,
4982.0,17226.0,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL620836,500.0,BAO_0000219,,
4983.0,6828.0,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL620837,500.0,BAO_0000219,,
4984.0,12314.0,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621017,500.0,BAO_0000219,,
4985.0,13412.0,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL621018,500.0,BAO_0000218,,
4986.0,13299.0,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621019,500.0,BAO_0000219,,
4987.0,17420.0,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621020,500.0,BAO_0000219,,
4988.0,13678.0,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621021,500.0,BAO_0000219,,
4989.0,14171.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,,,A-431,,9.0,H,8.0,Expert,1.0,,CHEMBL621022,500.0,BAO_0000219,,
4990.0,6333.0,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621023,500.0,BAO_0000219,,
4991.0,2356.0,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL621024,500.0,BAO_0000219,,
4992.0,15578.0,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621025,500.0,BAO_0000219,,
4993.0,5126.0,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621026,500.0,BAO_0000219,,
4994.0,6844.0,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621027,500.0,BAO_0000219,,
4995.0,6844.0,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL876397,500.0,BAO_0000219,,
4996.0,4925.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL883797,500.0,BAO_0000219,,
4997.0,4925.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621028,500.0,BAO_0000219,,
4998.0,13978.0,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621029,500.0,BAO_0000219,,
4999.0,16786.0,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621030,500.0,BAO_0000219,,
5000.0,13412.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,,,A-431,,9.0,H,8.0,Expert,1.0,,CHEMBL621147,500.0,BAO_0000219,,
5001.0,17824.0,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621148,500.0,BAO_0000218,,
5002.0,12751.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL621149,500.0,BAO_0000219,,
5003.0,12380.0,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621150,500.0,BAO_0000219,,
5004.0,4959.0,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL621151,500.0,BAO_0000219,,
5005.0,6333.0,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621152,500.0,BAO_0000219,,
5006.0,6333.0,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621153,500.0,BAO_0000219,,
5007.0,6333.0,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL884000,500.0,BAO_0000219,,
5008.0,5296.0,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0,,,,,9.0,D,9.0,Expert,1.0,,CHEMBL621154,,BAO_0000019,,
5009.0,12624.0,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621155,500.0,BAO_0000219,,
5010.0,14926.0,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL621156,500.0,BAO_0000219,,
5011.0,14926.0,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL621157,500.0,BAO_0000219,,
5012.0,14926.0,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,,,A-431,,9.0,H,8.0,Expert,1.0,,CHEMBL621158,500.0,BAO_0000219,,
5013.0,15144.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621159,500.0,BAO_0000219,,
5014.0,15144.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621160,500.0,BAO_0000219,,
5015.0,5245.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621161,500.0,BAO_0000219,,
5016.0,5245.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621162,500.0,BAO_0000219,,
5017.0,5245.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621163,500.0,BAO_0000219,,
5018.0,5245.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621164,500.0,BAO_0000219,,
5019.0,5245.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621165,500.0,BAO_0000219,,
5020.0,5922.0,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619159,,BAO_0000019,,
5021.0,1116.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619160,,BAO_0000366,1969.0,
5022.0,17853.0,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619161,,BAO_0000218,,
5023.0,993.0,Plasma half life in monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619162,,BAO_0000366,1969.0,
5024.0,4514.0,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619163,,BAO_0000366,1969.0,
5025.0,5334.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619164,,BAO_0000218,1969.0,
5026.0,5334.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619320,,BAO_0000218,1969.0,
5027.0,4578.0,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619321,,BAO_0000218,,
5028.0,2661.0,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873336,,BAO_0000218,,
5029.0,5355.0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619322,,BAO_0000218,,
5030.0,5355.0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619323,,BAO_0000218,,
5031.0,5355.0,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619324,,BAO_0000218,,
5032.0,11271.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619325,,BAO_0000019,,
5033.0,11271.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876411,,BAO_0000019,,
5034.0,11271.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619326,,BAO_0000019,,
5035.0,11271.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619327,,BAO_0000019,,
5036.0,11271.0,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619328,,BAO_0000019,,
5037.0,11271.0,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619329,,BAO_0000019,,
5038.0,11271.0,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619330,,BAO_0000019,,
5039.0,11271.0,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619331,,BAO_0000019,,
5040.0,11271.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619332,,BAO_0000019,,
5041.0,11271.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619333,,BAO_0000019,,
5042.0,11271.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619334,,BAO_0000019,,
5043.0,11271.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619335,,BAO_0000019,,
5044.0,11271.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619336,,BAO_0000019,,
5045.0,11271.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619337,,BAO_0000019,,
5046.0,11271.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619338,,BAO_0000019,,
5047.0,11271.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619339,,BAO_0000019,,
5048.0,5809.0,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL619340,,BAO_0000218,,
5049.0,17720.0,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL873496,,BAO_0000218,1969.0,
5050.0,3546.0,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL619341,,BAO_0000218,1969.0,
5051.0,3546.0,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL619342,,BAO_0000218,1969.0,
5052.0,3546.0,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL619343,,BAO_0000218,,
5053.0,3546.0,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL619344,,BAO_0000218,,
5054.0,3546.0,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL619345,,BAO_0000218,,
5055.0,3546.0,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL619346,,BAO_0000218,,
5056.0,3546.0,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL619347,,BAO_0000218,,
5057.0,10625.0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619348,,BAO_0000019,,
5058.0,10625.0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619349,,BAO_0000019,,
5059.0,10625.0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619350,,BAO_0000019,,
5060.0,10625.0,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619351,,BAO_0000019,,
5061.0,10625.0,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875953,,BAO_0000019,,
5062.0,10625.0,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621716,,BAO_0000019,,
5063.0,10625.0,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621717,,BAO_0000019,,
5064.0,10625.0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621718,,BAO_0000019,,
5065.0,3510.0,Area under curve after 1 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621719,,BAO_0000019,,
5066.0,3510.0,Area under curve after 2 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621720,,BAO_0000019,,
5067.0,3510.0,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621721,,BAO_0000218,,
5068.0,7766.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621722,,BAO_0000019,1088.0,
5069.0,7766.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621723,,BAO_0000019,1088.0,
5070.0,7766.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621724,,BAO_0000019,1088.0,
5071.0,7766.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623443,,BAO_0000019,1088.0,
5072.0,7766.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623444,,BAO_0000019,1088.0,
5073.0,7766.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623445,,BAO_0000019,1088.0,
5074.0,7766.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0,,Urine,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623446,,BAO_0000019,1088.0,
5075.0,16643.0,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623447,,BAO_0000251,2107.0,
5076.0,6852.0,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623448,,BAO_0000019,,
5077.0,6852.0,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623449,,BAO_0000019,,
5078.0,6852.0,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623450,,BAO_0000019,,
5079.0,6567.0,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623451,,BAO_0000251,2107.0,
5080.0,6570.0,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623452,,BAO_0000019,,
5081.0,6570.0,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623453,,BAO_0000019,,
5082.0,5237.0,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623454,,BAO_0000251,2107.0,
5083.0,5237.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623455,,BAO_0000251,2107.0,
5084.0,5237.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624371,,BAO_0000251,2107.0,
5085.0,5202.0,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624372,,BAO_0000218,,
5086.0,5481.0,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624373,,BAO_0000019,,
5087.0,5481.0,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624374,,BAO_0000019,,
5088.0,3956.0,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624556,,BAO_0000019,,
5089.0,5074.0,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624557,,BAO_0000366,1969.0,
5090.0,5074.0,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624558,,BAO_0000366,1969.0,
5091.0,4727.0,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0,,Blood,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624559,,BAO_0000221,178.0,
5092.0,5965.0,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624560,,BAO_0000019,,
5093.0,5732.0,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624561,,BAO_0000251,,
5094.0,5819.0,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624562,,BAO_0000366,1969.0,
5095.0,5819.0,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624563,,BAO_0000366,1969.0,
5096.0,1916.0,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624564,,BAO_0000218,,
5097.0,6597.0,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624565,,BAO_0000251,2107.0,
5098.0,5229.0,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875152,,BAO_0000366,1969.0,
5099.0,5229.0,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624566,,BAO_0000366,1969.0,
5100.0,2192.0,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873805,,BAO_0000366,1969.0,
5101.0,3032.0,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624567,,BAO_0000251,2107.0,
5102.0,1916.0,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624568,,BAO_0000218,,
5103.0,17716.0,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624569,,BAO_0000218,,
5104.0,15778.0,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624570,,BAO_0000218,,
5105.0,17313.0,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624571,,BAO_0000019,,
5106.0,4231.0,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624572,,BAO_0000019,,
5107.0,4755.0,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624573,,BAO_0000019,,
5108.0,4755.0,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875153,,BAO_0000019,,
5109.0,16907.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624574,,BAO_0000251,2107.0,
5110.0,10839.0,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624575,,BAO_0000019,,
5111.0,10839.0,Plasma protein binding (human),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624576,,BAO_0000019,,
5112.0,3199.0,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624577,,BAO_0000251,2107.0,
5113.0,1345.0,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0,,Blood,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624578,,BAO_0000221,178.0,
5114.0,4297.0,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622796,,BAO_0000019,1977.0,
5115.0,4297.0,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0,,Serum,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622797,,BAO_0000019,1977.0,
5116.0,4297.0,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622798,,BAO_0000019,,
5117.0,4297.0,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622799,,BAO_0000019,,
5118.0,4231.0,Half life of the in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622800,,BAO_0000366,1969.0,
5119.0,5633.0,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0,,,,S9,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622801,,BAO_0000220,,
5120.0,5633.0,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622802,,BAO_0000251,2107.0,
5121.0,17791.0,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622803,,BAO_0000019,,
5122.0,17791.0,Half life period was evaluated in human,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875154,,BAO_0000019,,
5123.0,3160.0,Half life time in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622804,,BAO_0000366,1969.0,
5124.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622805,,BAO_0000218,955.0,
5125.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622611,,BAO_0000218,948.0,
5126.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622612,,BAO_0000218,948.0,
5127.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875160,,BAO_0000218,2113.0,
5128.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622613,,BAO_0000218,2113.0,
5129.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622614,,BAO_0000218,2113.0,
5130.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622615,,BAO_0000218,2107.0,
5131.0,16438.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622616,,BAO_0000218,2107.0,
5132.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622617,,BAO_0000218,2107.0,
5133.0,16438.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622618,,BAO_0000218,2106.0,
5134.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622619,,BAO_0000218,2106.0,
5135.0,16438.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622620,,BAO_0000218,2106.0,
5136.0,16438.0,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622621,,BAO_0000218,955.0,
5137.0,16438.0,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622622,,BAO_0000218,178.0,
5138.0,16438.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622623,,BAO_0000218,178.0,
5139.0,16438.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622624,,BAO_0000218,178.0,
5140.0,16438.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622625,,BAO_0000218,178.0,
5141.0,16438.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622626,,BAO_0000218,178.0,
5142.0,16438.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622627,,BAO_0000218,178.0,
5143.0,16438.0,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622628,,BAO_0000218,955.0,
5144.0,16438.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622629,,BAO_0000218,955.0,
5145.0,16438.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622630,,BAO_0000218,955.0,
5146.0,16438.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622631,,BAO_0000218,955.0,
5147.0,16438.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622632,,BAO_0000218,955.0,
5148.0,16438.0,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622633,,BAO_0000218,955.0,
5149.0,16438.0,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622634,,BAO_0000218,948.0,
5150.0,16438.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622635,,BAO_0000218,948.0,
5151.0,16438.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875161,,BAO_0000218,948.0,
5152.0,16438.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622636,,BAO_0000218,948.0,
5153.0,16438.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623335,,BAO_0000218,948.0,
5154.0,16438.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623336,,BAO_0000218,948.0,
5155.0,16438.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623337,,BAO_0000218,2113.0,
5156.0,16438.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623338,,BAO_0000218,2113.0,
5157.0,16438.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623339,,BAO_0000218,2113.0,
5158.0,16438.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623524,,BAO_0000218,2113.0,
5159.0,16438.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623525,,BAO_0000218,2113.0,
5160.0,16438.0,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623526,,BAO_0000218,2107.0,
5161.0,16438.0,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623527,,BAO_0000218,2107.0,
5162.0,16438.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623528,,BAO_0000218,2107.0,
5163.0,5245.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL624615,500.0,BAO_0000219,,
5164.0,5245.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621672,500.0,BAO_0000219,,
5165.0,16289.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621673,500.0,BAO_0000218,,
5166.0,16289.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621674,500.0,BAO_0000218,,
5167.0,16093.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL884002,500.0,BAO_0000219,,
5168.0,16825.0,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621850,500.0,BAO_0000219,,
5169.0,4848.0,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL621851,500.0,BAO_0000219,,
5170.0,14827.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL621852,500.0,BAO_0000219,,
5171.0,14827.0,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL621853,500.0,BAO_0000219,,
5172.0,16289.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621854,500.0,BAO_0000218,,
5173.0,16289.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL621855,500.0,BAO_0000218,,
5174.0,16289.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623724,500.0,BAO_0000218,,
5175.0,16289.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623725,500.0,BAO_0000218,,
5176.0,16289.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623726,500.0,BAO_0000218,,
5177.0,16289.0,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL623727,500.0,BAO_0000219,,
5178.0,16289.0,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,,,A-431,,9.0,H,8.0,Expert,1.0,,CHEMBL623728,500.0,BAO_0000219,,
5179.0,16289.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623729,500.0,BAO_0000218,,
5180.0,16289.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623730,500.0,BAO_0000218,,
5181.0,16289.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623731,500.0,BAO_0000218,,
5182.0,14555.0,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623732,500.0,BAO_0000218,,
5183.0,14555.0,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623733,500.0,BAO_0000218,,
5184.0,14555.0,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623734,500.0,BAO_0000218,,
5185.0,14555.0,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623735,500.0,BAO_0000218,,
5186.0,1937.0,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL623736,500.0,BAO_0000219,,
5187.0,13739.0,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL623737,500.0,BAO_0000219,,
5188.0,3558.0,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL623738,500.0,BAO_0000219,,
5189.0,3558.0,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Intermediate,1.0,,CHEMBL875168,500.0,BAO_0000219,,
5190.0,17686.0,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL623739,646.0,BAO_0000219,,
5191.0,5305.0,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623740,646.0,BAO_0000219,,
5192.0,3614.0,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624424,646.0,BAO_0000219,,
5193.0,17229.0,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624425,624.0,BAO_0000219,,
5194.0,15935.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624426,624.0,BAO_0000219,,
5195.0,15935.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624427,624.0,BAO_0000219,,
5196.0,15560.0,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624428,624.0,BAO_0000219,,
5197.0,13891.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624429,624.0,BAO_0000219,,
5198.0,13891.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624620,624.0,BAO_0000219,,
5199.0,13788.0,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624621,624.0,BAO_0000219,,
5200.0,15403.0,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624622,624.0,BAO_0000219,,
5201.0,1009.0,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624623,624.0,BAO_0000219,,
5202.0,1043.0,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL874365,624.0,BAO_0000219,,
5203.0,5858.0,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624624,624.0,BAO_0000219,,
5204.0,5958.0,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624625,624.0,BAO_0000219,,
5205.0,5506.0,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624626,624.0,BAO_0000219,,
5206.0,12781.0,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624627,624.0,BAO_0000219,,
5207.0,14399.0,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL883157,624.0,BAO_0000219,,
5208.0,5958.0,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Expert,1.0,,CHEMBL624628,624.0,BAO_0000219,,
5209.0,3510.0,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624629,,BAO_0000218,,
5210.0,3510.0,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623551,,BAO_0000218,,
5211.0,3510.0,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623552,,BAO_0000218,,
5212.0,3510.0,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623553,,BAO_0000218,,
5213.0,3085.0,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623554,,BAO_0000019,,
5214.0,3085.0,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623555,,BAO_0000019,,
5215.0,3085.0,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623556,,BAO_0000019,,
5216.0,9372.0,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623557,,BAO_0000019,,
5217.0,3085.0,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623558,,BAO_0000019,,
5218.0,3085.0,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623559,,BAO_0000019,,
5219.0,1469.0,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0,,Spleen,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623560,,BAO_0000221,2106.0,
5220.0,4297.0,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623561,,BAO_0000019,,
5221.0,4297.0,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623562,,BAO_0000019,,
5222.0,17585.0,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623563,,BAO_0000019,,
5223.0,1336.0,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0,,Spleen,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623564,,BAO_0000221,2106.0,
5224.0,3085.0,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873806,,BAO_0000019,,
5225.0,2857.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623565,,BAO_0000019,,
5226.0,2857.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623566,,BAO_0000019,,
5227.0,2857.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623567,,BAO_0000019,,
5228.0,1540.0,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623568,,BAO_0000019,,
5229.0,6316.0,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623569,,BAO_0000218,1969.0,
5230.0,17594.0,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623570,,BAO_0000218,1969.0,
5231.0,4953.0,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624254,,BAO_0000218,1969.0,
5232.0,16907.0,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624255,,BAO_0000218,1969.0,
5233.0,16907.0,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624256,,BAO_0000218,1969.0,
5234.0,2959.0,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624257,,BAO_0000218,1969.0,
5235.0,17594.0,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624258,,BAO_0000218,1969.0,
5236.0,5356.0,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875277,,BAO_0000218,,
5237.0,16807.0,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622667,,BAO_0000218,,
5238.0,4527.0,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622668,,BAO_0000218,,
5239.0,4527.0,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622669,,BAO_0000218,,
5240.0,15660.0,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622670,,BAO_0000218,,
5241.0,15660.0,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622671,,BAO_0000218,,
5242.0,5802.0,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622672,,BAO_0000218,,
5243.0,3598.0,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Expert,1.0,,CHEMBL622673,,BAO_0000218,,
5244.0,3598.0,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Expert,1.0,,CHEMBL622674,,BAO_0000218,,
5245.0,5944.0,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622675,,BAO_0000218,,
5246.0,5944.0,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622676,,BAO_0000218,,
5247.0,5944.0,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622677,,BAO_0000218,,
5248.0,5944.0,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622678,,BAO_0000218,,
5249.0,4186.0,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622679,,BAO_0000218,,
5250.0,5007.0,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622680,,BAO_0000218,,
5251.0,5668.0,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622681,,BAO_0000218,,
5252.0,5668.0,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875278,,BAO_0000218,,
5253.0,5006.0,Area under curve was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622682,,BAO_0000218,,
5254.0,5006.0,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622683,,BAO_0000218,,
5255.0,3771.0,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622684,,BAO_0000218,,
5256.0,3771.0,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622685,,BAO_0000218,,
5257.0,3771.0,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622686,,BAO_0000218,,
5258.0,1916.0,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618344,,BAO_0000218,,
5259.0,5302.0,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875582,,BAO_0000218,,
5260.0,5600.0,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618345,,BAO_0000218,,
5261.0,5600.0,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618346,,BAO_0000218,,
5262.0,17764.0,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618347,,BAO_0000218,,
5263.0,4368.0,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618348,,BAO_0000218,,
5264.0,5318.0,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618349,,BAO_0000019,,
5265.0,5318.0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618350,,BAO_0000019,,
5266.0,5318.0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618351,,BAO_0000019,,
5267.0,5318.0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618352,,BAO_0000019,,
5268.0,14518.0,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0,,Blood,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873494,,BAO_0000221,178.0,
5269.0,2209.0,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618353,,BAO_0000366,1969.0,
5270.0,6787.0,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618354,,BAO_0000366,1969.0,
5271.0,4898.0,Half life in human plasma was reported,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875583,,BAO_0000366,1969.0,
5272.0,6072.0,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618355,,BAO_0000019,1977.0,
5273.0,16907.0,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618356,,BAO_0000366,1969.0,
5274.0,5656.0,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618357,,BAO_0000251,,
5275.0,4755.0,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618358,,BAO_0000366,1969.0,
5276.0,17503.0,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0,,Zone of skin,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618359,,BAO_0000221,14.0,
5277.0,12357.0,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618360,,BAO_0000366,1969.0,
5278.0,3076.0,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618361,,BAO_0000019,,
5279.0,6410.0,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618362,,BAO_0000251,2107.0,
5280.0,3741.0,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618363,,BAO_0000366,1969.0,
5281.0,3741.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618364,,BAO_0000366,1969.0,
5282.0,3741.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875584,,BAO_0000366,1969.0,
5283.0,1540.0,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618365,,BAO_0000019,,
5284.0,2905.0,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL873495,,BAO_0000366,1969.0,
5285.0,2905.0,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618366,,BAO_0000366,1969.0,
5286.0,5523.0,Half-life was determined,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618367,,BAO_0000019,,
5287.0,1499.0,Half-life (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618368,,BAO_0000221,178.0,
5288.0,1499.0,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0,,Blood,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618369,,BAO_0000221,178.0,
5289.0,17065.0,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618370,,BAO_0000366,1969.0,
5290.0,6861.0,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618371,,BAO_0000019,,
5291.0,1499.0,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618372,,BAO_0000221,178.0,
5292.0,530.0,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618373,,BAO_0000366,1969.0,
5293.0,1116.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618374,,BAO_0000366,1969.0,
5294.0,6695.0,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618375,,BAO_0000366,1969.0,
5295.0,6695.0,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618376,,BAO_0000366,1969.0,
5296.0,10.0,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618377,,BAO_0000251,2107.0,
5297.0,993.0,Plasma half life in human,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618378,,BAO_0000366,1969.0,
5298.0,15429.0,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618379,,BAO_0000366,1969.0,
5299.0,1675.0,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618380,,BAO_0000366,1969.0,
5300.0,2209.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618381,,BAO_0000366,1969.0,
5301.0,2209.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618382,,BAO_0000366,1969.0,
5302.0,5318.0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618383,,BAO_0000019,,
5303.0,2412.0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618384,,BAO_0000019,,
5304.0,2412.0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618385,,BAO_0000019,,
5305.0,2906.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619099,,BAO_0000366,1969.0,
5306.0,2906.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619100,,BAO_0000366,1969.0,
5307.0,5495.0,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619101,,BAO_0000019,,
5308.0,5495.0,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619102,,BAO_0000019,,
5309.0,4397.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619103,,BAO_0000251,2107.0,
5310.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619268,,BAO_0000218,,
5311.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619269,,BAO_0000218,,
5312.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619270,,BAO_0000218,,
5313.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619271,,BAO_0000218,,
5314.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875585,,BAO_0000218,,
5315.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL619272,,BAO_0000218,,
5316.0,6058.0,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619273,391.0,BAO_0000219,,
5317.0,17708.0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619274,391.0,BAO_0000219,,
5318.0,14017.0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Expert,1.0,,CHEMBL619275,391.0,BAO_0000219,,
5319.0,16818.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619276,391.0,BAO_0000219,,
5320.0,16818.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619277,391.0,BAO_0000219,,
5321.0,16818.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619278,391.0,BAO_0000219,,
5322.0,11970.0,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619279,391.0,BAO_0000219,,
5323.0,12400.0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL858458,391.0,BAO_0000219,,
5324.0,12888.0,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Expert,1.0,,CHEMBL619280,391.0,BAO_0000219,,
5325.0,15300.0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619281,391.0,BAO_0000219,,
5326.0,14769.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619282,391.0,BAO_0000219,,
5327.0,15895.0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619283,391.0,BAO_0000219,,
5328.0,17376.0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619284,391.0,BAO_0000219,,
5329.0,14882.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619285,391.0,BAO_0000219,,
5330.0,14882.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619286,391.0,BAO_0000219,,
5331.0,15176.0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619287,391.0,BAO_0000219,,
5332.0,12696.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL857455,391.0,BAO_0000219,,
5333.0,2496.0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL883801,391.0,BAO_0000219,,
5334.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619288,972.0,BAO_0000219,,
5335.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619289,972.0,BAO_0000219,,
5336.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619290,972.0,BAO_0000219,,
5337.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619291,972.0,BAO_0000219,,
5338.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619292,972.0,BAO_0000219,,
5339.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619293,972.0,BAO_0000219,,
5340.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619294,972.0,BAO_0000219,,
5341.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619295,972.0,BAO_0000219,,
5342.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619296,972.0,BAO_0000219,,
5343.0,11831.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641.0,N,1.0,Intermediate,1.0,,CHEMBL619297,972.0,BAO_0000219,,
5344.0,12782.0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640.0,N,1.0,Intermediate,1.0,,CHEMBL619298,391.0,BAO_0000219,,
5345.0,1229.0,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL619299,,BAO_0000019,,
5346.0,15313.0,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Expert,1.0,,CHEMBL619300,741.0,BAO_0000219,,
5347.0,15313.0,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Expert,1.0,,CHEMBL619301,741.0,BAO_0000219,,
5348.0,11544.0,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619302,741.0,BAO_0000219,,
5349.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619303,741.0,BAO_0000219,,
5350.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619304,741.0,BAO_0000219,,
5351.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL857706,741.0,BAO_0000219,,
5352.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619305,741.0,BAO_0000219,,
5353.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619306,741.0,BAO_0000219,,
5354.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619307,741.0,BAO_0000219,,
5355.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619308,741.0,BAO_0000219,,
5356.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619309,741.0,BAO_0000219,,
5357.0,9424.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL619310,741.0,BAO_0000219,,
5358.0,14769.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619311,624.0,BAO_0000219,,
5359.0,15354.0,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619312,624.0,BAO_0000219,,
5360.0,17445.0,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619313,624.0,BAO_0000219,,
5361.0,4337.0,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619314,624.0,BAO_0000219,,
5362.0,15277.0,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619959,624.0,BAO_0000219,,
5363.0,4812.0,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619960,624.0,BAO_0000219,,
5364.0,4812.0,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619961,624.0,BAO_0000219,,
5365.0,4995.0,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619962,624.0,BAO_0000219,,
5366.0,5847.0,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL875586,624.0,BAO_0000219,,
5367.0,6557.0,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619963,624.0,BAO_0000219,,
5368.0,2597.0,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619964,624.0,BAO_0000219,,
5369.0,6058.0,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620108,624.0,BAO_0000219,,
5370.0,17708.0,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620109,624.0,BAO_0000219,,
5371.0,15176.0,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620110,624.0,BAO_0000219,,
5372.0,15300.0,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620111,624.0,BAO_0000219,,
5373.0,11970.0,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620112,624.0,BAO_0000219,,
5374.0,12400.0,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620113,624.0,BAO_0000219,,
5375.0,12888.0,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Expert,1.0,,CHEMBL620114,624.0,BAO_0000219,,
5376.0,3030.0,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620115,624.0,BAO_0000219,,
5377.0,14769.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620116,624.0,BAO_0000219,,
5378.0,17376.0,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620117,624.0,BAO_0000219,,
5379.0,16558.0,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620118,624.0,BAO_0000219,,
5380.0,5194.0,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620119,624.0,BAO_0000219,,
5381.0,10708.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL620120,624.0,BAO_0000219,,
5382.0,16880.0,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620121,646.0,BAO_0000219,,
5383.0,10196.0,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620122,646.0,BAO_0000219,,
5384.0,10196.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620123,646.0,BAO_0000219,,
5385.0,10196.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620124,646.0,BAO_0000219,,
5386.0,12083.0,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620125,646.0,BAO_0000219,,
5387.0,16464.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620126,646.0,BAO_0000219,,
5388.0,16464.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL883027,646.0,BAO_0000219,,
5389.0,16470.0,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620127,646.0,BAO_0000219,,
5390.0,16470.0,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620128,646.0,BAO_0000219,,
5391.0,16470.0,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620129,646.0,BAO_0000219,,
5392.0,16470.0,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620130,646.0,BAO_0000219,,
5393.0,16582.0,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620131,646.0,BAO_0000219,,
5394.0,15935.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620132,646.0,BAO_0000219,,
5395.0,15935.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620133,646.0,BAO_0000219,,
5396.0,16597.0,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620134,646.0,BAO_0000219,,
5397.0,17376.0,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620135,646.0,BAO_0000219,,
5398.0,16496.0,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620136,646.0,BAO_0000219,,
5399.0,16152.0,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620137,646.0,BAO_0000219,,
5400.0,16152.0,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620268,646.0,BAO_0000219,,
5401.0,16464.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620269,646.0,BAO_0000219,,
5402.0,2288.0,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620270,646.0,BAO_0000219,,
5403.0,17350.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620271,646.0,BAO_0000219,,
5404.0,4090.0,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620272,646.0,BAO_0000219,,
5405.0,4090.0,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620273,646.0,BAO_0000219,,
5406.0,17350.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620274,646.0,BAO_0000219,,
5407.0,4197.0,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620275,646.0,BAO_0000219,,
5408.0,17072.0,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620276,646.0,BAO_0000219,,
5409.0,17072.0,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620277,646.0,BAO_0000219,,
5410.0,5194.0,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620278,646.0,BAO_0000219,,
5411.0,4257.0,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620279,,BAO_0000218,,
5412.0,6123.0,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620280,,BAO_0000218,,
5413.0,1337.0,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620281,,BAO_0000218,,
5414.0,1337.0,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620282,,BAO_0000218,,
5415.0,8833.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621134,,BAO_0000218,,
5416.0,8833.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621135,,BAO_0000218,,
5417.0,8833.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621136,,BAO_0000218,,
5418.0,8833.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621137,,BAO_0000218,,
5419.0,17657.0,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621138,,BAO_0000218,1969.0,
5420.0,17650.0,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875587,,BAO_0000218,1969.0,
5421.0,1977.0,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621139,,BAO_0000218,,
5422.0,1977.0,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621140,,BAO_0000218,,
5423.0,3132.0,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621141,,BAO_0000218,,
5424.0,5473.0,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621142,,BAO_0000218,,
5425.0,5474.0,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621143,,BAO_0000218,,
5426.0,5474.0,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621144,,BAO_0000218,,
5427.0,6062.0,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621145,,BAO_0000218,,
5428.0,4709.0,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621146,,BAO_0000218,,
5429.0,2652.0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622567,,BAO_0000218,,
5430.0,2652.0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622568,,BAO_0000218,,
5431.0,2877.0,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622569,,BAO_0000218,,
5432.0,5444.0,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622570,,BAO_0000218,,
5433.0,5130.0,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622571,,BAO_0000218,1969.0,
5434.0,6265.0,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622572,,BAO_0000218,,
5435.0,4657.0,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622573,,BAO_0000218,,
5436.0,16367.0,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622574,,BAO_0000218,,
5437.0,16367.0,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622575,,BAO_0000218,,
5438.0,9579.0,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622576,,BAO_0000218,,
5439.0,9579.0,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622577,,BAO_0000218,,
5440.0,5983.0,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622578,,BAO_0000218,,
5441.0,6241.0,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622579,,BAO_0000218,,
5442.0,5313.0,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622580,,BAO_0000218,,
5443.0,5313.0,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622581,,BAO_0000218,,
5444.0,6642.0,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622582,,BAO_0000218,,
5445.0,6642.0,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622583,,BAO_0000218,,
5446.0,6641.0,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622584,,BAO_0000218,,
5447.0,6642.0,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622585,,BAO_0000218,,
5448.0,17791.0,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622586,,BAO_0000218,,
5449.0,17655.0,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623281,,BAO_0000218,,
5450.0,17655.0,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623282,,BAO_0000218,,
5451.0,6596.0,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623283,,BAO_0000218,,
5452.0,3880.0,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623284,,BAO_0000218,,
5453.0,16367.0,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623285,,BAO_0000218,,
5454.0,17409.0,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623463,,BAO_0000218,1969.0,
5455.0,17409.0,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875952,,BAO_0000218,1969.0,
5456.0,2959.0,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621705,,BAO_0000218,,
5457.0,13501.0,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621706,,BAO_0000218,,
5458.0,4527.0,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621707,,BAO_0000218,,
5459.0,15145.0,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621708,,BAO_0000218,,
5460.0,4219.0,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621709,,BAO_0000218,,
5461.0,17538.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621710,,BAO_0000218,,
5462.0,17538.0,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621711,,BAO_0000218,,
5463.0,1466.0,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621712,,BAO_0000218,,
5464.0,17650.0,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621713,,BAO_0000218,,
5465.0,3132.0,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621714,,BAO_0000218,,
5466.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621715,,BAO_0000218,,
5467.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Liver,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623717,,BAO_0000218,2107.0,
5468.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Liver,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623718,,BAO_0000218,2107.0,
5469.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Liver,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623719,,BAO_0000218,2107.0,
5470.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623720,,BAO_0000218,,
5471.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623721,,BAO_0000218,,
5472.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623722,,BAO_0000218,2385.0,
5473.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623723,,BAO_0000218,2385.0,
5474.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618543,,BAO_0000218,2385.0,
5475.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618544,,BAO_0000218,2106.0,
5476.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875155,,BAO_0000218,2106.0,
5477.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618545,,BAO_0000218,,
5478.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618546,,BAO_0000218,,
5479.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623529,,BAO_0000218,,
5480.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623530,,BAO_0000218,,
5481.0,2413.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621764,,BAO_0000218,,
5482.0,17827.0,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621765,,BAO_0000019,,
5483.0,17827.0,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621766,,BAO_0000019,2037.0,
5484.0,17827.0,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621767,,BAO_0000019,1870.0,
5485.0,17827.0,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621768,,BAO_0000019,,
5486.0,17827.0,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621769,,BAO_0000019,2435.0,
5487.0,17827.0,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621770,,BAO_0000019,,
5488.0,17827.0,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621771,,BAO_0000019,2037.0,
5489.0,17827.0,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621772,,BAO_0000019,1870.0,
5490.0,17827.0,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621773,,BAO_0000019,,
5491.0,17827.0,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621774,,BAO_0000019,2435.0,
5492.0,17791.0,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621775,,BAO_0000218,,
5493.0,17667.0,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621776,,BAO_0000218,1969.0,
5494.0,17791.0,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621777,,BAO_0000019,,
5495.0,110.0,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL875162,,BAO_0000218,,
5496.0,5781.0,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621778,,BAO_0000218,1969.0,
5497.0,17734.0,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621779,,BAO_0000218,1969.0,
5498.0,17718.0,AUC value was determined after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622479,,BAO_0000218,1969.0,
5499.0,4573.0,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622480,,BAO_0000218,,
5500.0,3277.0,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622481,,BAO_0000218,,
5501.0,2862.0,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622482,,BAO_0000218,,
5502.0,2862.0,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622483,,BAO_0000218,,
5503.0,5951.0,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622484,,BAO_0000218,,
5504.0,17729.0,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622641,,BAO_0000218,,
5505.0,17728.0,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622642,,BAO_0000218,,
5506.0,17728.0,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622643,,BAO_0000218,,
5507.0,17729.0,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622644,,BAO_0000218,,
5508.0,9424.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL622645,741.0,BAO_0000219,,
5509.0,9424.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL622646,741.0,BAO_0000219,,
5510.0,9424.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL621238,741.0,BAO_0000219,,
5511.0,9424.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL621239,741.0,BAO_0000219,,
5512.0,9424.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL621240,741.0,BAO_0000219,,
5513.0,9424.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL621241,741.0,BAO_0000219,,
5514.0,9424.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL621242,741.0,BAO_0000219,,
5515.0,9424.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620350,741.0,BAO_0000219,,
5516.0,9424.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620351,741.0,BAO_0000219,,
5517.0,9424.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620352,741.0,BAO_0000219,,
5518.0,9424.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620353,741.0,BAO_0000219,,
5519.0,9424.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620354,741.0,BAO_0000219,,
5520.0,9424.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620355,741.0,BAO_0000219,,
5521.0,9424.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620356,741.0,BAO_0000219,,
5522.0,9424.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620357,741.0,BAO_0000219,,
5523.0,9424.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620358,741.0,BAO_0000219,,
5524.0,9424.0,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Expert,1.0,,CHEMBL620359,741.0,BAO_0000219,,
5525.0,11544.0,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620360,741.0,BAO_0000219,,
5526.0,17378.0,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620361,741.0,BAO_0000219,,
5527.0,17378.0,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620362,741.0,BAO_0000219,,
5528.0,17079.0,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620363,741.0,BAO_0000219,,
5529.0,17079.0,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433.0,N,1.0,Intermediate,1.0,,CHEMBL620364,741.0,BAO_0000219,,
5530.0,13466.0,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0,,,833K,,80647.0,N,1.0,Intermediate,1.0,,CHEMBL620365,854.0,BAO_0000219,,
5531.0,13466.0,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0,,,833K,,80647.0,N,1.0,Intermediate,1.0,,CHEMBL620366,854.0,BAO_0000219,,
5532.0,2392.0,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0,,,833K,,80647.0,N,1.0,Expert,1.0,,CHEMBL620367,854.0,BAO_0000219,,
5533.0,2392.0,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0,,,833K,,80647.0,N,1.0,Intermediate,1.0,,CHEMBL620368,854.0,BAO_0000219,,
5534.0,6608.0,Inhibitory activity against caspase-1,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620369,,BAO_0000019,,
5535.0,10199.0,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0,,,,,45.0,H,8.0,Autocuration,1.0,,CHEMBL620370,,BAO_0000357,,
5536.0,17749.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0,,,8701-BC,,80648.0,N,1.0,Intermediate,1.0,,CHEMBL620371,705.0,BAO_0000219,,
5537.0,17749.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0,,,8701-BC,,80648.0,N,1.0,Intermediate,1.0,,CHEMBL620372,705.0,BAO_0000219,,
5538.0,1229.0,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL876492,,BAO_0000019,,
5539.0,1229.0,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL620373,,BAO_0000019,,
5540.0,1229.0,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,,,,,22226.0,U,0.0,Intermediate,1.0,,CHEMBL620374,,BAO_0000019,,
5541.0,6390.0,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620375,,BAO_0000019,,
5542.0,16219.0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL857902,,BAO_0000019,,
5543.0,16219.0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620376,,BAO_0000019,,
5544.0,17043.0,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,,,,,11922.0,H,8.0,Autocuration,1.0,,CHEMBL620377,,BAO_0000357,,
5545.0,6929.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0,,,KB ,,81115.0,N,1.0,Intermediate,1.0,,CHEMBL620378,324.0,BAO_0000219,,
5546.0,6929.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0,,,KB ,,81115.0,N,1.0,Intermediate,1.0,,CHEMBL620379,324.0,BAO_0000219,,
5547.0,7083.0,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620380,,BAO_0000219,,
5548.0,12446.0,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0,,,9L,,80653.0,N,1.0,Intermediate,1.0,,CHEMBL884006,392.0,BAO_0000219,,
5549.0,15345.0,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0,,,9L,,80653.0,N,1.0,Expert,1.0,,CHEMBL620381,392.0,BAO_0000219,,
5550.0,15345.0,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0,,,9L,,80653.0,N,1.0,Expert,1.0,,CHEMBL620382,392.0,BAO_0000219,,
5551.0,6301.0,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620383,646.0,BAO_0000219,,
5552.0,4833.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL876493,646.0,BAO_0000219,,
5553.0,4833.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620384,646.0,BAO_0000219,,
5554.0,4833.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620385,646.0,BAO_0000219,,
5555.0,13330.0,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620386,646.0,BAO_0000219,,
5556.0,17517.0,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,25.0,D,9.0,Expert,1.0,,CHEMBL620387,646.0,BAO_0000219,,
5557.0,17517.0,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0,,,A549,,25.0,D,9.0,Expert,1.0,,CHEMBL621404,646.0,BAO_0000219,,
5558.0,14425.0,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621405,646.0,BAO_0000219,,
5559.0,14425.0,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621406,646.0,BAO_0000219,,
5560.0,5228.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621407,646.0,BAO_0000219,,
5561.0,5351.0,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621408,646.0,BAO_0000219,,
5562.0,12198.0,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL885345,646.0,BAO_0000219,,
5563.0,13891.0,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621409,646.0,BAO_0000219,,
5564.0,5677.0,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL876034,646.0,BAO_0000219,,
5565.0,13788.0,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621410,646.0,BAO_0000219,,
5566.0,13384.0,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621411,646.0,BAO_0000219,,
5567.0,6726.0,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621412,646.0,BAO_0000219,,
5568.0,3455.0,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621413,646.0,BAO_0000219,,
5569.0,5726.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621414,646.0,BAO_0000219,,
5570.0,5726.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621415,646.0,BAO_0000219,,
5571.0,3936.0,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621416,646.0,BAO_0000219,,
5572.0,14991.0,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621417,646.0,BAO_0000219,,
5573.0,5243.0,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621418,646.0,BAO_0000219,,
5574.0,12858.0,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621419,646.0,BAO_0000219,,
5575.0,6776.0,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621420,646.0,BAO_0000219,,
5576.0,16558.0,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL875823,646.0,BAO_0000219,,
5577.0,4583.0,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621421,646.0,BAO_0000219,,
5578.0,13514.0,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621422,646.0,BAO_0000219,,
5579.0,15166.0,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL884014,646.0,BAO_0000219,,
5580.0,13873.0,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621423,646.0,BAO_0000219,,
5581.0,6447.0,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621424,646.0,BAO_0000219,,
5582.0,2068.0,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621425,646.0,BAO_0000219,,
5583.0,1863.0,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621426,646.0,BAO_0000219,,
5584.0,13873.0,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621427,646.0,BAO_0000219,,
5585.0,13873.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621428,646.0,BAO_0000219,,
5586.0,13873.0,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621429,646.0,BAO_0000219,,
5587.0,579.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621430,646.0,BAO_0000219,,
5588.0,579.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621431,646.0,BAO_0000219,,
5589.0,4584.0,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621432,646.0,BAO_0000219,,
5590.0,5421.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621433,646.0,BAO_0000219,,
5591.0,5421.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL875824,646.0,BAO_0000219,,
5592.0,5421.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621434,646.0,BAO_0000219,,
5593.0,5421.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621435,646.0,BAO_0000219,,
5594.0,14188.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621436,646.0,BAO_0000219,,
5595.0,14188.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621437,646.0,BAO_0000219,,
5596.0,15354.0,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621438,646.0,BAO_0000219,,
5597.0,14253.0,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621439,646.0,BAO_0000219,,
5598.0,13873.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621440,646.0,BAO_0000219,,
5599.0,3043.0,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621441,,BAO_0000218,,
5600.0,3045.0,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621442,,BAO_0000218,,
5601.0,3022.0,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621443,,BAO_0000218,,
5602.0,4453.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621444,,BAO_0000218,,
5603.0,1696.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625133,,BAO_0000218,,
5604.0,5045.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625134,,BAO_0000218,,
5605.0,5356.0,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625135,,BAO_0000218,,
5606.0,17764.0,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625136,,BAO_0000218,,
5607.0,6448.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625137,,BAO_0000218,,
5608.0,1475.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625138,,BAO_0000218,,
5609.0,3788.0,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625139,,BAO_0000218,,
5610.0,3639.0,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL872264,,BAO_0000218,,
5611.0,13397.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625140,,BAO_0000218,,
5612.0,2137.0,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624436,,BAO_0000218,,
5613.0,2959.0,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624437,,BAO_0000218,,
5614.0,6448.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL872261,,BAO_0000218,,
5615.0,6084.0,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624438,,BAO_0000218,,
5616.0,3639.0,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624439,,BAO_0000218,1969.0,
5617.0,6316.0,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624440,,BAO_0000218,,
5618.0,5238.0,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624441,,BAO_0000218,,
5619.0,17796.0,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624442,,BAO_0000218,1969.0,
5620.0,2652.0,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624443,,BAO_0000218,,
5621.0,5654.0,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624444,,BAO_0000218,,
5622.0,6621.0,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624445,,BAO_0000218,,
5623.0,6505.0,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624446,,BAO_0000218,,
5624.0,5802.0,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624447,,BAO_0000218,,
5625.0,17267.0,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624448,,BAO_0000218,,
5626.0,4521.0,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624449,,BAO_0000218,,
5627.0,6535.0,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624450,,BAO_0000218,,
5628.0,6535.0,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875942,,BAO_0000218,,
5629.0,6535.0,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624451,,BAO_0000218,,
5630.0,5542.0,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624452,,BAO_0000218,,
5631.0,5199.0,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624453,,BAO_0000218,,
5632.0,16907.0,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624454,,BAO_0000218,,
5633.0,16907.0,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624455,,BAO_0000218,,
5634.0,16367.0,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624456,,BAO_0000218,,
5635.0,5505.0,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624457,,BAO_0000218,,
5636.0,6215.0,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624458,,BAO_0000218,,
5637.0,1466.0,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624459,,BAO_0000218,,
5638.0,5007.0,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164.0,S,2.0,Intermediate,1.0,,CHEMBL624460,,BAO_0000251,2107.0,
5639.0,5007.0,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164.0,S,2.0,Intermediate,1.0,,CHEMBL624461,,BAO_0000251,2107.0,
5640.0,16452.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875943,,BAO_0000218,,
5641.0,16452.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624462,,BAO_0000218,,
5642.0,16452.0,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624463,,BAO_0000218,,
5643.0,6221.0,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624464,,BAO_0000218,,
5644.0,5007.0,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624465,,BAO_0000218,,
5645.0,5668.0,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624466,,BAO_0000218,,
5646.0,5668.0,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624467,,BAO_0000218,,
5647.0,5668.0,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624468,,BAO_0000218,,
5648.0,15660.0,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624469,,BAO_0000218,,
5649.0,15660.0,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624470,,BAO_0000218,,
5650.0,5983.0,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624471,,BAO_0000218,,
5651.0,5600.0,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624472,,BAO_0000218,,
5652.0,17764.0,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622775,,BAO_0000218,,
5653.0,6039.0,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622776,,BAO_0000218,,
5654.0,6039.0,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622777,,BAO_0000218,,
5655.0,6039.0,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622778,,BAO_0000218,,
5656.0,4368.0,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622779,,BAO_0000218,,
5657.0,4305.0,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622780,,BAO_0000218,,
5658.0,1918.0,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622781,,BAO_0000218,1969.0,
5659.0,6005.0,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622782,,BAO_0000218,,
5660.0,4839.0,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622783,,BAO_0000218,1969.0,
5661.0,4239.0,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622784,,BAO_0000218,,
5662.0,17729.0,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622785,,BAO_0000218,,
5663.0,17728.0,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622786,,BAO_0000218,,
5664.0,5302.0,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622787,,BAO_0000218,,
5665.0,5506.0,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875949,,BAO_0000218,,
5666.0,5506.0,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622788,,BAO_0000218,,
5667.0,17764.0,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622789,,BAO_0000218,,
5668.0,17764.0,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622790,,BAO_0000218,,
5669.0,17764.0,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622791,,BAO_0000218,,
5670.0,17764.0,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622792,,BAO_0000218,,
5671.0,17764.0,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622793,,BAO_0000218,,
5672.0,17753.0,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622794,,BAO_0000218,,
5673.0,17753.0,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622795,,BAO_0000218,,
5674.0,17753.0,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621803,,BAO_0000218,,
5675.0,3132.0,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621804,,BAO_0000218,,
5676.0,3132.0,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621805,,BAO_0000218,,
5677.0,17837.0,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621806,,BAO_0000218,,
5678.0,17837.0,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621807,,BAO_0000218,,
5679.0,6062.0,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621808,,BAO_0000218,,
5680.0,4066.0,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621809,,BAO_0000218,,
5681.0,16597.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621810,,BAO_0000218,,
5682.0,14239.0,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875164,,BAO_0000218,,
5683.0,14239.0,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621811,,BAO_0000218,,
5684.0,4890.0,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621812,,BAO_0000218,,
5685.0,429.0,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621813,,BAO_0000218,,
5686.0,429.0,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621814,,BAO_0000218,,
5687.0,5969.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621815,,BAO_0000218,,
5688.0,5969.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621816,,BAO_0000218,,
5689.0,5969.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621817,,BAO_0000218,,
5690.0,6091.0,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621818,,BAO_0000218,,
5691.0,6091.0,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621819,,BAO_0000218,,
5692.0,6091.0,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621820,,BAO_0000218,,
5693.0,6091.0,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621821,,BAO_0000218,,
5694.0,6178.0,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621822,,BAO_0000218,,
5695.0,6178.0,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619474,,BAO_0000218,,
5696.0,6619.0,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619475,,BAO_0000218,,
5697.0,6619.0,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619476,,BAO_0000218,,
5698.0,3760.0,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619477,,BAO_0000218,,
5699.0,3760.0,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619478,,BAO_0000218,,
5700.0,3760.0,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619479,,BAO_0000218,,
5701.0,3760.0,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619480,,BAO_0000218,,
5702.0,3192.0,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619481,,BAO_0000218,,
5703.0,3192.0,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619482,,BAO_0000218,,
5704.0,2675.0,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619483,,BAO_0000218,,
5705.0,2675.0,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619484,,BAO_0000218,,
5706.0,16597.0,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619485,,BAO_0000218,1969.0,
5707.0,16597.0,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619486,,BAO_0000218,1969.0,
5708.0,16597.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619487,,BAO_0000218,,
5709.0,17734.0,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619488,,BAO_0000218,,
5710.0,7767.0,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620106,,BAO_0000218,178.0,
5711.0,15345.0,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,,,9L,,80653.0,N,1.0,Intermediate,1.0,,CHEMBL620107,392.0,BAO_0000219,,
5712.0,2181.0,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620283,,BAO_0000019,,
5713.0,2181.0,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL875176,,BAO_0000219,,
5714.0,2181.0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620284,,BAO_0000219,,
5715.0,2181.0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL623515,,BAO_0000219,,
5716.0,10486.0,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL623516,,BAO_0000019,,
5717.0,10486.0,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL623517,,BAO_0000019,,
5718.0,15508.0,Partition coefficient (logD6.5),A,,,,,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL857878,,BAO_0000019,,
5719.0,5242.0,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL623518,478.0,BAO_0000219,,
5720.0,16167.0,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL624195,455.0,BAO_0000219,,
5721.0,4782.0,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL624196,500.0,BAO_0000219,,
5722.0,16093.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9.0,D,9.0,Expert,1.0,,CHEMBL624197,500.0,BAO_0000219,,
5723.0,2596.0,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL624198,624.0,BAO_0000219,,
5724.0,2596.0,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL621287,624.0,BAO_0000219,,
5725.0,3239.0,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL621288,624.0,BAO_0000219,,
5726.0,1847.0,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL876496,624.0,BAO_0000219,,
5727.0,10553.0,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL621289,624.0,BAO_0000219,,
5728.0,16219.0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL621290,,BAO_0000019,,
5729.0,16219.0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL621291,,BAO_0000019,,
5730.0,16219.0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL621292,,BAO_0000019,,
5731.0,16219.0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL621293,,BAO_0000019,,
5732.0,4782.0,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621294,646.0,BAO_0000219,,
5733.0,11805.0,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621295,646.0,BAO_0000219,,
5734.0,11805.0,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL884007,646.0,BAO_0000219,,
5735.0,2007.0,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621296,646.0,BAO_0000219,,
5736.0,4594.0,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621297,646.0,BAO_0000219,,
5737.0,6018.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL839828,646.0,BAO_0000219,,
5738.0,6018.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620397,646.0,BAO_0000219,,
5739.0,3599.0,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620398,646.0,BAO_0000219,,
5740.0,2551.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620399,646.0,BAO_0000219,,
5741.0,16132.0,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620400,646.0,BAO_0000219,,
5742.0,16132.0,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620401,646.0,BAO_0000219,,
5743.0,2551.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620402,646.0,BAO_0000219,,
5744.0,2551.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620403,646.0,BAO_0000219,,
5745.0,11913.0,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620404,,BAO_0000218,,
5746.0,12621.0,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,,,,,,104694.0,H,4.0,Autocuration,1.0,,CHEMBL620405,,BAO_0000218,,
5747.0,12621.0,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694.0,H,4.0,Autocuration,1.0,,CHEMBL620406,,BAO_0000218,,
5748.0,12621.0,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,,,,,,104694.0,H,4.0,Autocuration,1.0,,CHEMBL620407,,BAO_0000218,,
5749.0,12621.0,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694.0,H,4.0,Autocuration,1.0,,CHEMBL620408,,BAO_0000218,,
5750.0,12621.0,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,,,,,,104694.0,H,4.0,Autocuration,1.0,,CHEMBL620409,,BAO_0000218,,
5751.0,3600.0,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Expert,1.0,,CHEMBL620410,624.0,BAO_0000219,,
5752.0,1796.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620411,,BAO_0000019,,
5753.0,1796.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620412,,BAO_0000019,,
5754.0,1796.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL876596,,BAO_0000019,,
5755.0,16464.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Expert,1.0,,CHEMBL620413,622.0,BAO_0000219,,
5756.0,16464.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Intermediate,1.0,,CHEMBL620414,622.0,BAO_0000219,,
5757.0,16464.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Intermediate,1.0,,CHEMBL620415,622.0,BAO_0000219,,
5758.0,13617.0,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620416,646.0,BAO_0000219,,
5759.0,4584.0,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620417,646.0,BAO_0000219,,
5760.0,13799.0,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620418,646.0,BAO_0000219,,
5761.0,16726.0,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620419,646.0,BAO_0000219,,
5762.0,16109.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620420,646.0,BAO_0000219,,
5763.0,16109.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620421,646.0,BAO_0000219,,
5764.0,15474.0,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620422,646.0,BAO_0000219,,
5765.0,6851.0,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620423,646.0,BAO_0000219,,
5766.0,17534.0,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620424,646.0,BAO_0000219,,
5767.0,2621.0,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620425,646.0,BAO_0000219,,
5768.0,830.0,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620426,646.0,BAO_0000219,,
5769.0,14255.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620427,646.0,BAO_0000219,,
5770.0,14255.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620428,646.0,BAO_0000219,,
5771.0,1590.0,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620429,646.0,BAO_0000219,,
5772.0,6146.0,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620430,646.0,BAO_0000219,,
5773.0,17427.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL839887,646.0,BAO_0000219,,
5774.0,5280.0,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620431,646.0,BAO_0000219,,
5775.0,16786.0,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL884010,646.0,BAO_0000219,,
5776.0,5895.0,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620538,646.0,BAO_0000219,,
5777.0,14297.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620539,646.0,BAO_0000219,,
5778.0,17824.0,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623373,646.0,BAO_0000218,,
5779.0,14368.0,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623374,646.0,BAO_0000219,,
5780.0,14368.0,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623375,646.0,BAO_0000219,,
5781.0,14254.0,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623376,646.0,BAO_0000219,,
5782.0,15897.0,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623377,646.0,BAO_0000219,,
5783.0,13866.0,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623378,646.0,BAO_0000219,,
5784.0,13370.0,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623379,646.0,BAO_0000219,,
5785.0,4862.0,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623380,646.0,BAO_0000219,,
5786.0,4862.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623381,646.0,BAO_0000219,,
5787.0,4862.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623382,646.0,BAO_0000219,,
5788.0,15970.0,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623383,646.0,BAO_0000219,,
5789.0,17713.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL623384,646.0,BAO_0000219,,
5790.0,4833.0,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623385,646.0,BAO_0000219,,
5791.0,13736.0,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL623386,646.0,BAO_0000219,,
5792.0,4312.0,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL884105,646.0,BAO_0000219,,
5793.0,5421.0,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623387,646.0,BAO_0000219,,
5794.0,5421.0,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621568,646.0,BAO_0000219,,
5795.0,14717.0,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621569,646.0,BAO_0000219,,
5796.0,4634.0,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621570,646.0,BAO_0000219,,
5797.0,1149.0,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621571,646.0,BAO_0000219,,
5798.0,5421.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621572,646.0,BAO_0000219,,
5799.0,5421.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621573,646.0,BAO_0000219,,
5800.0,5421.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621574,646.0,BAO_0000219,,
5801.0,3320.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621575,646.0,BAO_0000219,,
5802.0,3320.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621576,646.0,BAO_0000219,,
5803.0,3320.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621577,646.0,BAO_0000219,,
5804.0,3320.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621578,646.0,BAO_0000219,,
5805.0,3320.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621579,646.0,BAO_0000219,,
5806.0,5726.0,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621580,646.0,BAO_0000219,,
5807.0,17800.0,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621581,,BAO_0000218,,
5808.0,5985.0,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621582,,BAO_0000218,,
5809.0,5530.0,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621583,,BAO_0000218,,
5810.0,5530.0,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621584,,BAO_0000218,,
5811.0,4839.0,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621585,,BAO_0000218,1969.0,
5812.0,3639.0,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621586,,BAO_0000218,,
5813.0,4838.0,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875835,,BAO_0000218,,
5814.0,4137.0,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621587,,BAO_0000218,,
5815.0,5017.0,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621588,,BAO_0000218,1969.0,
5816.0,17538.0,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621589,,BAO_0000218,2107.0,
5817.0,6161.0,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621590,,BAO_0000218,,
5818.0,6161.0,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621591,,BAO_0000218,,
5819.0,1696.0,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621592,,BAO_0000218,,
5820.0,6762.0,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621593,,BAO_0000218,,
5821.0,5932.0,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621594,,BAO_0000218,1969.0,
5822.0,6305.0,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621595,,BAO_0000218,,
5823.0,4942.0,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621596,,BAO_0000218,,
5824.0,4219.0,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621597,,BAO_0000218,,
5825.0,17853.0,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621598,,BAO_0000218,,
5826.0,4514.0,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621599,,BAO_0000218,,
5827.0,6448.0,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875836,,BAO_0000218,,
5828.0,6227.0,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621600,,BAO_0000218,,
5829.0,6227.0,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621601,,BAO_0000218,,
5830.0,6062.0,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618474,,BAO_0000218,,
5831.0,6821.0,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618475,,BAO_0000218,,
5832.0,4709.0,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624524,,BAO_0000218,,
5833.0,4521.0,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624525,,BAO_0000218,,
5834.0,5374.0,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624526,,BAO_0000218,,
5835.0,6057.0,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624527,,BAO_0000218,,
5836.0,4727.0,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624528,,BAO_0000218,,
5837.0,5145.0,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624529,,BAO_0000218,,
5838.0,17657.0,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624530,,BAO_0000218,,
5839.0,17657.0,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624531,,BAO_0000218,,
5840.0,5145.0,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624532,,BAO_0000218,,
5841.0,6642.0,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624533,,BAO_0000218,,
5842.0,6641.0,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624534,,BAO_0000218,,
5843.0,6642.0,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624535,,BAO_0000218,,
5844.0,5472.0,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624536,,BAO_0000218,,
5845.0,5472.0,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624537,,BAO_0000218,,
5846.0,5472.0,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624538,,BAO_0000218,,
5847.0,5472.0,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624539,,BAO_0000218,,
5848.0,4257.0,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624540,,BAO_0000218,,
5849.0,6679.0,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624541,,BAO_0000218,,
5850.0,5546.0,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624542,,BAO_0000218,,
5851.0,6348.0,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624543,,BAO_0000218,,
5852.0,5474.0,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624544,,BAO_0000218,,
5853.0,6316.0,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624545,,BAO_0000218,1969.0,
5854.0,17594.0,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624546,,BAO_0000218,,
5855.0,17594.0,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875957,,BAO_0000218,,
5856.0,5802.0,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624547,,BAO_0000218,,
5857.0,6535.0,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624548,,BAO_0000218,,
5858.0,6535.0,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624549,,BAO_0000218,,
5859.0,1466.0,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624550,,BAO_0000218,1969.0,
5860.0,6505.0,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621613,,BAO_0000218,,
5861.0,5668.0,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621614,,BAO_0000218,,
5862.0,5668.0,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623431,,BAO_0000218,,
5863.0,5668.0,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623432,,BAO_0000218,,
5864.0,5600.0,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623433,,BAO_0000218,,
5865.0,17764.0,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623434,,BAO_0000218,,
5866.0,6123.0,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623435,,BAO_0000218,,
5867.0,6123.0,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623436,,BAO_0000218,,
5868.0,6757.0,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875958,,BAO_0000218,,
5869.0,16907.0,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623437,,BAO_0000218,,
5870.0,7767.0,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623438,,BAO_0000218,178.0,
5871.0,7767.0,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623439,,BAO_0000218,178.0,
5872.0,7767.0,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623440,,BAO_0000218,10000001.0,
5873.0,7767.0,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623441,,BAO_0000218,10000001.0,
5874.0,7767.0,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623442,,BAO_0000218,10000001.0,
5875.0,7767.0,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623469,,BAO_0000218,,
5876.0,7767.0,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623470,,BAO_0000218,,
5877.0,7767.0,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623471,,BAO_0000218,,
5878.0,7767.0,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623472,,BAO_0000218,948.0,
5879.0,7767.0,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623473,,BAO_0000218,948.0,
5880.0,7767.0,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623474,,BAO_0000218,948.0,
5881.0,7767.0,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623475,,BAO_0000218,2113.0,
5882.0,7767.0,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623476,,BAO_0000218,2113.0,
5883.0,7767.0,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623477,,BAO_0000218,2113.0,
5884.0,7767.0,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621896,,BAO_0000218,160.0,
5885.0,7767.0,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621897,,BAO_0000218,160.0,
5886.0,7767.0,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621898,,BAO_0000218,160.0,
5887.0,7767.0,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621899,,BAO_0000218,2107.0,
5888.0,7767.0,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621900,,BAO_0000218,2107.0,
5889.0,7767.0,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621901,,BAO_0000218,2107.0,
5890.0,7767.0,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621902,,BAO_0000218,2048.0,
5891.0,7767.0,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621903,,BAO_0000218,2048.0,
5892.0,7767.0,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622587,,BAO_0000218,2048.0,
5893.0,7767.0,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620285,,BAO_0000218,2385.0,
5894.0,7767.0,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875285,,BAO_0000218,2385.0,
5895.0,7767.0,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620286,,BAO_0000218,2385.0,
5896.0,7767.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620287,,BAO_0000218,,
5897.0,7767.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620288,,BAO_0000218,,
5898.0,7767.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620289,,BAO_0000218,,
5899.0,7767.0,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620290,,BAO_0000218,160.0,
5900.0,7767.0,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620291,,BAO_0000218,160.0,
5901.0,7767.0,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620292,,BAO_0000218,160.0,
5902.0,7767.0,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620293,,BAO_0000218,2106.0,
5903.0,7767.0,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL620294,,BAO_0000218,2106.0,
5904.0,7767.0,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618614,,BAO_0000218,2106.0,
5905.0,7767.0,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618615,,BAO_0000218,945.0,
5906.0,7767.0,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618616,,BAO_0000218,945.0,
5907.0,2036.0,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Expert,1.0,,CHEMBL618617,622.0,BAO_0000219,,
5908.0,2357.0,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Intermediate,1.0,,CHEMBL618618,622.0,BAO_0000219,,
5909.0,1457.0,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0,,,A204,,80014.0,N,1.0,Intermediate,1.0,,CHEMBL618619,623.0,BAO_0000219,,
5910.0,4379.0,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618620,478.0,BAO_0000219,,
5911.0,1093.0,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL618621,455.0,BAO_0000219,,
5912.0,12152.0,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL618622,455.0,BAO_0000219,,
5913.0,16464.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Expert,1.0,,CHEMBL618623,797.0,BAO_0000219,,
5914.0,16464.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL618624,797.0,BAO_0000219,,
5915.0,16582.0,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Expert,1.0,,CHEMBL618625,797.0,BAO_0000219,,
5916.0,16464.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL618626,797.0,BAO_0000219,,
5917.0,10413.0,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL618627,797.0,BAO_0000219,,
5918.0,6418.0,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL618628,797.0,BAO_0000219,,
5919.0,17134.0,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Expert,1.0,,CHEMBL618629,797.0,BAO_0000219,,
5920.0,16132.0,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Expert,1.0,,CHEMBL618630,797.0,BAO_0000219,,
5921.0,16132.0,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL618631,797.0,BAO_0000219,,
5922.0,16780.0,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019.0,N,1.0,Intermediate,1.0,,CHEMBL618632,797.0,BAO_0000219,,
5923.0,4085.0,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852.0,N,1.0,Expert,1.0,,CHEMBL618633,500.0,BAO_0000219,,
5924.0,1276.0,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619315,624.0,BAO_0000219,,
5925.0,3498.0,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Expert,1.0,,CHEMBL619316,624.0,BAO_0000219,,
5926.0,1169.0,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619317,624.0,BAO_0000219,,
5927.0,4450.0,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619318,624.0,BAO_0000219,,
5928.0,3311.0,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619319,624.0,BAO_0000219,,
5929.0,4461.0,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619739,624.0,BAO_0000219,,
5930.0,3311.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619740,624.0,BAO_0000219,,
5931.0,3311.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL883158,624.0,BAO_0000219,,
5932.0,1457.0,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL884012,624.0,BAO_0000219,,
5933.0,3664.0,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619741,624.0,BAO_0000219,,
5934.0,15895.0,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0,,,A498,,80021.0,N,1.0,Intermediate,1.0,,CHEMBL619742,624.0,BAO_0000219,,
5935.0,11843.0,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL876610,646.0,BAO_0000219,,
5936.0,11843.0,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619743,646.0,BAO_0000219,,
5937.0,17705.0,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619744,646.0,BAO_0000219,,
5938.0,17705.0,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619745,646.0,BAO_0000219,,
5939.0,4369.0,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619746,646.0,BAO_0000219,,
5940.0,4369.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619747,646.0,BAO_0000219,,
5941.0,4369.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619748,646.0,BAO_0000219,,
5942.0,4369.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619749,646.0,BAO_0000219,,
5943.0,4369.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619750,646.0,BAO_0000219,,
5944.0,4369.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624014,646.0,BAO_0000219,,
5945.0,4369.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624015,646.0,BAO_0000219,,
5946.0,4787.0,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL885344,646.0,BAO_0000219,,
5947.0,4787.0,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623224,646.0,BAO_0000219,,
5948.0,6513.0,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL623225,646.0,BAO_0000219,,
5949.0,6690.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622698,646.0,BAO_0000219,,
5950.0,6690.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622699,646.0,BAO_0000219,,
5951.0,12263.0,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL622700,646.0,BAO_0000219,,
5952.0,1054.0,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622701,646.0,BAO_0000219,,
5953.0,1359.0,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622702,646.0,BAO_0000219,,
5954.0,3547.0,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622703,646.0,BAO_0000219,,
5955.0,5771.0,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL622704,646.0,BAO_0000219,,
5956.0,14425.0,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622705,646.0,BAO_0000219,,
5957.0,14425.0,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622706,646.0,BAO_0000219,,
5958.0,14425.0,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622707,646.0,BAO_0000219,,
5959.0,14425.0,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622708,646.0,BAO_0000219,,
5960.0,5280.0,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622709,646.0,BAO_0000219,,
5961.0,15176.0,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622710,646.0,BAO_0000219,,
5962.0,15300.0,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622711,646.0,BAO_0000219,,
5963.0,17824.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622712,646.0,BAO_0000218,,
5964.0,17824.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622713,646.0,BAO_0000218,,
5965.0,17824.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622714,646.0,BAO_0000218,,
5966.0,17824.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622715,646.0,BAO_0000218,,
5967.0,17824.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622716,646.0,BAO_0000218,,
5968.0,17824.0,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622717,646.0,BAO_0000219,,
5969.0,17528.0,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622718,646.0,BAO_0000218,,
5970.0,6870.0,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL622719,646.0,BAO_0000219,,
5971.0,6870.0,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622720,646.0,BAO_0000219,,
5972.0,6870.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622721,646.0,BAO_0000219,,
5973.0,6870.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622722,646.0,BAO_0000219,,
5974.0,16726.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL876030,646.0,BAO_0000219,,
5975.0,6170.0,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620206,646.0,BAO_0000219,,
5976.0,6583.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620207,646.0,BAO_0000219,,
5977.0,6583.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620208,646.0,BAO_0000219,,
5978.0,6583.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620209,646.0,BAO_0000219,,
5979.0,6583.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620210,646.0,BAO_0000219,,
5980.0,6583.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621639,646.0,BAO_0000219,,
5981.0,17321.0,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621640,646.0,BAO_0000219,,
5982.0,17528.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621641,646.0,BAO_0000219,,
5983.0,12888.0,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL621642,646.0,BAO_0000219,,
5984.0,4312.0,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621643,646.0,BAO_0000219,,
5985.0,4312.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621644,646.0,BAO_0000219,,
5986.0,4312.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621645,646.0,BAO_0000219,,
5987.0,17737.0,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621646,646.0,BAO_0000219,,
5988.0,6630.0,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621647,646.0,BAO_0000219,,
5989.0,6630.0,Synergism with tolmetin in A549 cells,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621648,646.0,BAO_0000219,,
5990.0,6630.0,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621649,646.0,BAO_0000219,,
5991.0,6630.0,Antagonism of indomethacin in A549 cells,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621650,646.0,BAO_0000219,,
5992.0,6630.0,Antagonism of sulindac in A549 cells,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621651,646.0,BAO_0000219,,
5993.0,6630.0,Antagonism of tolmetin in A549 cells,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621652,646.0,BAO_0000219,,
5994.0,6630.0,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621653,646.0,BAO_0000219,,
5995.0,6630.0,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621654,646.0,BAO_0000219,,
5996.0,6630.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL621655,646.0,BAO_0000219,,
5997.0,16907.0,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621656,,BAO_0000218,,
5998.0,5944.0,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621657,,BAO_0000218,,
5999.0,5944.0,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621658,,BAO_0000218,,
6000.0,5944.0,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621659,,BAO_0000218,,
6001.0,5944.0,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621660,,BAO_0000218,,
6002.0,2959.0,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621661,,BAO_0000218,,
6003.0,6241.0,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621662,,BAO_0000218,,
6004.0,6241.0,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621663,,BAO_0000218,,
6005.0,2652.0,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621664,,BAO_0000218,,
6006.0,1806.0,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621665,,BAO_0000218,1969.0,
6007.0,1806.0,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621666,,BAO_0000218,1969.0,
6008.0,1021.0,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621667,,BAO_0000218,,
6009.0,1021.0,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876738,,BAO_0000218,,
6010.0,1021.0,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621668,,BAO_0000218,,
6011.0,5444.0,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621669,,BAO_0000218,,
6012.0,5444.0,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621670,,BAO_0000218,,
6013.0,5444.0,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621671,,BAO_0000218,,
6014.0,5444.0,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622360,,BAO_0000218,,
6015.0,5444.0,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622361,,BAO_0000218,,
6016.0,5130.0,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622362,,BAO_0000218,1969.0,
6017.0,3249.0,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622363,,BAO_0000218,1969.0,
6018.0,5473.0,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622364,,BAO_0000218,1969.0,
6019.0,5474.0,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622365,,BAO_0000218,1969.0,
6020.0,4657.0,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622533,,BAO_0000218,1969.0,
6021.0,3031.0,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622534,,BAO_0000218,,
6022.0,4527.0,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622535,,BAO_0000218,,
6023.0,4186.0,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876739,,BAO_0000218,,
6024.0,5007.0,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622536,,BAO_0000218,,
6025.0,3132.0,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622537,,BAO_0000218,1969.0,
6026.0,5006.0,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622538,,BAO_0000218,,
6027.0,4727.0,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627867,,BAO_0000218,,
6028.0,1916.0,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627868,,BAO_0000218,,
6029.0,1918.0,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627869,,BAO_0000218,1969.0,
6030.0,3045.0,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627870,,BAO_0000218,,
6031.0,9579.0,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627871,,BAO_0000218,1969.0,
6032.0,9579.0,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627872,,BAO_0000218,1969.0,
6033.0,933.0,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627873,,BAO_0000218,1969.0,
6034.0,17839.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627874,,BAO_0000218,1969.0,
6035.0,17839.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627875,,BAO_0000218,1969.0,
6036.0,17839.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627876,,BAO_0000218,1969.0,
6037.0,17839.0,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627877,,BAO_0000218,1969.0,
6038.0,6348.0,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627878,,BAO_0000218,1969.0,
6039.0,16367.0,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627879,,BAO_0000218,1969.0,
6040.0,1337.0,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875355,,BAO_0000218,1969.0,
6041.0,1337.0,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627880,,BAO_0000218,1969.0,
6042.0,5199.0,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627881,,BAO_0000218,1969.0,
6043.0,17650.0,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627882,,BAO_0000218,1969.0,
6044.0,6679.0,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL627883,,BAO_0000218,1969.0,
6045.0,5356.0,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL628526,,BAO_0000218,1969.0,
6046.0,5356.0,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL628527,,BAO_0000218,1969.0,
6047.0,6227.0,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL628528,,BAO_0000218,1969.0,
6048.0,6227.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL628529,,BAO_0000218,1969.0,
6049.0,6227.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL628530,,BAO_0000218,1969.0,
6050.0,6227.0,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625243,,BAO_0000218,1969.0,
6051.0,3598.0,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Expert,1.0,,CHEMBL625244,,BAO_0000218,1969.0,
6052.0,4368.0,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625245,,BAO_0000218,,
6053.0,6265.0,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625246,,BAO_0000218,,
6054.0,7767.0,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625247,,BAO_0000218,945.0,
6055.0,7767.0,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625248,,BAO_0000218,1088.0,
6056.0,7767.0,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625249,,BAO_0000218,1088.0,
6057.0,7767.0,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625250,,BAO_0000218,1088.0,
6058.0,17811.0,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625251,,BAO_0000218,,
6059.0,17811.0,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875356,,BAO_0000218,,
6060.0,17827.0,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625252,,BAO_0000218,,
6061.0,17827.0,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625253,,BAO_0000218,178.0,
6062.0,17827.0,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625254,,BAO_0000218,,
6063.0,17827.0,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625255,,BAO_0000218,,
6064.0,17827.0,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625256,,BAO_0000218,,
6065.0,17827.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625257,,BAO_0000218,178.0,
6066.0,17827.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625258,,BAO_0000218,178.0,
6067.0,17827.0,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625259,,BAO_0000218,,
6068.0,17827.0,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625260,,BAO_0000218,,
6069.0,17827.0,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625261,,BAO_0000218,,
6070.0,17827.0,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625262,,BAO_0000218,,
6071.0,17827.0,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622639,,BAO_0000218,,
6072.0,17257.0,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622640,,BAO_0000218,,
6073.0,17257.0,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622812,,BAO_0000218,,
6074.0,17257.0,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622813,,BAO_0000218,,
6075.0,17257.0,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622814,,BAO_0000218,,
6076.0,17827.0,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622815,,BAO_0000218,,
6077.0,3760.0,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625342,,BAO_0000218,,
6078.0,3760.0,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625343,,BAO_0000218,,
6079.0,17409.0,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL877591,,BAO_0000218,,
6080.0,17409.0,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625344,,BAO_0000218,,
6081.0,2675.0,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625345,,BAO_0000218,,
6082.0,2675.0,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625346,,BAO_0000218,,
6083.0,3132.0,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625347,,BAO_0000218,,
6084.0,3132.0,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625348,,BAO_0000218,,
6085.0,16597.0,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625349,,BAO_0000218,,
6086.0,2862.0,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625350,,BAO_0000218,,
6087.0,17764.0,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL882952,,BAO_0000218,,
6088.0,846.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625351,,BAO_0000218,955.0,
6089.0,846.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625352,,BAO_0000218,955.0,
6090.0,846.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL877592,,BAO_0000218,955.0,
6091.0,846.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625353,,BAO_0000218,955.0,
6092.0,846.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL625354,,BAO_0000218,955.0,
6093.0,846.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL626019,,BAO_0000218,955.0,
6094.0,846.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL626020,,BAO_0000218,948.0,
6095.0,846.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL626021,,BAO_0000218,948.0,
6096.0,846.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL626022,,BAO_0000218,948.0,
6097.0,846.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL626192,,BAO_0000218,948.0,
6098.0,1276.0,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626193,646.0,BAO_0000219,,
6099.0,3498.0,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL626194,646.0,BAO_0000219,,
6100.0,1169.0,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626195,646.0,BAO_0000219,,
6101.0,4450.0,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626196,646.0,BAO_0000219,,
6102.0,358.0,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626197,646.0,BAO_0000219,,
6103.0,358.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626198,646.0,BAO_0000219,,
6104.0,358.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626199,646.0,BAO_0000219,,
6105.0,358.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626200,646.0,BAO_0000219,,
6106.0,358.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626201,646.0,BAO_0000219,,
6107.0,358.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626202,646.0,BAO_0000219,,
6108.0,358.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626203,646.0,BAO_0000219,,
6109.0,15167.0,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL626204,646.0,BAO_0000219,,
6110.0,4139.0,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624701,646.0,BAO_0000219,,
6111.0,833.0,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624702,646.0,BAO_0000219,,
6112.0,15718.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL624703,646.0,BAO_0000219,,
6113.0,12373.0,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624704,646.0,BAO_0000219,,
6114.0,637.0,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624705,646.0,BAO_0000219,,
6115.0,14867.0,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL624706,646.0,BAO_0000219,,
6116.0,4461.0,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624707,646.0,BAO_0000219,,
6117.0,5406.0,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624708,646.0,BAO_0000219,,
6118.0,4457.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624709,646.0,BAO_0000219,,
6119.0,1386.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL884107,646.0,BAO_0000219,,
6120.0,3265.0,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624710,646.0,BAO_0000219,,
6121.0,2359.0,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624711,646.0,BAO_0000219,,
6122.0,4457.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624712,646.0,BAO_0000219,,
6123.0,12454.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL624713,646.0,BAO_0000219,,
6124.0,1481.0,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624714,646.0,BAO_0000219,,
6125.0,1750.0,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624715,646.0,BAO_0000219,,
6126.0,5065.0,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624716,646.0,BAO_0000219,,
6127.0,808.0,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619505,646.0,BAO_0000219,,
6128.0,16364.0,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619506,646.0,BAO_0000219,,
6129.0,1847.0,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619507,646.0,BAO_0000219,,
6130.0,1747.0,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619508,646.0,BAO_0000219,,
6131.0,1003.0,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619509,646.0,BAO_0000219,,
6132.0,15313.0,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619510,646.0,BAO_0000219,,
6133.0,3122.0,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619511,646.0,BAO_0000219,,
6134.0,16049.0,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619512,646.0,BAO_0000219,,
6135.0,17134.0,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619513,646.0,BAO_0000219,,
6136.0,6406.0,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619514,646.0,BAO_0000219,,
6137.0,627.0,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619515,646.0,BAO_0000219,,
6138.0,12307.0,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619516,646.0,BAO_0000219,,
6139.0,17861.0,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL884005,646.0,BAO_0000219,,
6140.0,6682.0,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619517,646.0,BAO_0000219,,
6141.0,6663.0,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619518,646.0,BAO_0000219,,
6142.0,2454.0,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619519,646.0,BAO_0000219,,
6143.0,14709.0,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL876489,646.0,BAO_0000219,,
6144.0,15718.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619520,646.0,BAO_0000219,,
6145.0,15718.0,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619521,646.0,BAO_0000219,,
6146.0,17130.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619522,646.0,BAO_0000219,,
6147.0,17130.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619523,646.0,BAO_0000219,,
6148.0,17130.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619524,646.0,BAO_0000219,,
6149.0,17130.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619525,646.0,BAO_0000219,,
6150.0,6630.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619526,646.0,BAO_0000219,,
6151.0,16726.0,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619527,646.0,BAO_0000219,,
6152.0,17846.0,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619528,646.0,BAO_0000219,,
6153.0,3415.0,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619529,646.0,BAO_0000219,,
6154.0,3415.0,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619530,646.0,BAO_0000219,,
6155.0,5609.0,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL876490,646.0,BAO_0000219,,
6156.0,17206.0,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619531,646.0,BAO_0000219,,
6157.0,17206.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619532,646.0,BAO_0000219,,
6158.0,17206.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619533,646.0,BAO_0000219,,
6159.0,17206.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619534,646.0,BAO_0000219,,
6160.0,17206.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620164,646.0,BAO_0000219,,
6161.0,17206.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620165,646.0,BAO_0000219,,
6162.0,16295.0,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620166,646.0,BAO_0000219,,
6163.0,16825.0,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620167,646.0,BAO_0000219,,
6164.0,3439.0,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL620168,646.0,BAO_0000219,,
6165.0,10870.0,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620338,646.0,BAO_0000219,,
6166.0,4845.0,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620339,646.0,BAO_0000219,,
6167.0,5822.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620340,646.0,BAO_0000219,,
6168.0,5822.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620341,646.0,BAO_0000219,,
6169.0,5822.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL876491,646.0,BAO_0000219,,
6170.0,16381.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620342,646.0,BAO_0000219,,
6171.0,16381.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620343,646.0,BAO_0000219,,
6172.0,16381.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620344,646.0,BAO_0000219,,
6173.0,5609.0,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620345,646.0,BAO_0000219,,
6174.0,4644.0,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620346,646.0,BAO_0000219,,
6175.0,4644.0,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620347,646.0,BAO_0000219,,
6176.0,4644.0,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620348,646.0,BAO_0000219,,
6177.0,4644.0,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620349,646.0,BAO_0000219,,
6178.0,5822.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL618667,646.0,BAO_0000219,,
6179.0,3415.0,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL618668,646.0,BAO_0000219,,
6180.0,16726.0,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL876031,646.0,BAO_0000219,,
6181.0,17206.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL618759,646.0,BAO_0000219,,
6182.0,17206.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL618760,646.0,BAO_0000219,,
6183.0,17206.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619000,646.0,BAO_0000219,,
6184.0,17206.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619001,646.0,BAO_0000219,,
6185.0,17206.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619002,646.0,BAO_0000219,,
6186.0,17206.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619003,646.0,BAO_0000219,,
6187.0,17206.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619597,646.0,BAO_0000219,,
6188.0,17206.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619598,646.0,BAO_0000219,,
6189.0,17206.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619599,646.0,BAO_0000219,,
6190.0,17206.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619600,646.0,BAO_0000219,,
6191.0,16726.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619601,646.0,BAO_0000219,,
6192.0,17206.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619602,646.0,BAO_0000219,,
6193.0,17206.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619603,646.0,BAO_0000219,,
6194.0,17206.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619604,646.0,BAO_0000219,,
6195.0,17206.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619605,646.0,BAO_0000219,,
6196.0,6084.0,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619606,,BAO_0000218,,
6197.0,6084.0,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876032,,BAO_0000218,,
6198.0,4809.0,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619607,,BAO_0000218,,
6199.0,5983.0,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619608,,BAO_0000218,,
6200.0,6251.0,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619609,,BAO_0000218,,
6201.0,5932.0,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619610,,BAO_0000218,1969.0,
6202.0,4273.0,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619611,,BAO_0000218,178.0,
6203.0,5313.0,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619612,,BAO_0000218,,
6204.0,5313.0,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619613,,BAO_0000218,,
6205.0,6221.0,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619614,,BAO_0000218,178.0,
6206.0,4709.0,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619615,,BAO_0000218,,
6207.0,167.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619616,,BAO_0000218,,
6208.0,6241.0,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619617,,BAO_0000218,1969.0,
6209.0,344.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619618,,BAO_0000218,,
6210.0,344.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876033,,BAO_0000218,,
6211.0,344.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619619,,BAO_0000218,,
6212.0,2189.0,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619620,,BAO_0000218,,
6213.0,2189.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619621,,BAO_0000218,1088.0,
6214.0,2189.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619622,,BAO_0000218,1088.0,
6215.0,2189.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618874,,BAO_0000218,1088.0,
6216.0,4257.0,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618875,,BAO_0000218,,
6217.0,6221.0,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618876,,BAO_0000218,,
6218.0,6215.0,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618877,,BAO_0000218,,
6219.0,17267.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618878,,BAO_0000218,,
6220.0,6621.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618879,,BAO_0000218,,
6221.0,3854.0,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618880,,BAO_0000218,,
6222.0,3854.0,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618881,,BAO_0000218,,
6223.0,5007.0,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618882,,BAO_0000218,,
6224.0,4333.0,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624226,,BAO_0000218,,
6225.0,4333.0,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624227,,BAO_0000218,1969.0,
6226.0,5006.0,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624228,,BAO_0000218,,
6227.0,5199.0,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624229,,BAO_0000218,,
6228.0,4368.0,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624230,,BAO_0000218,,
6229.0,3771.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624231,,BAO_0000218,,
6230.0,4953.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624232,,BAO_0000218,,
6231.0,5064.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625127,,BAO_0000218,,
6232.0,17657.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625128,,BAO_0000218,,
6233.0,17796.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621675,,BAO_0000218,,
6234.0,17853.0,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621676,,BAO_0000218,,
6235.0,4521.0,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621677,,BAO_0000218,,
6236.0,4521.0,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621678,,BAO_0000218,,
6237.0,5006.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621679,,BAO_0000218,,
6238.0,16365.0,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621680,,BAO_0000218,,
6239.0,1916.0,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621681,,BAO_0000218,,
6240.0,1918.0,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876740,,BAO_0000218,,
6241.0,4239.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621682,,BAO_0000218,,
6242.0,6505.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621683,,BAO_0000218,,
6243.0,5334.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621684,,BAO_0000218,,
6244.0,5334.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621685,,BAO_0000218,,
6245.0,4809.0,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621686,,BAO_0000218,,
6246.0,6348.0,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621687,,BAO_0000218,,
6247.0,6005.0,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621688,,BAO_0000218,,
6248.0,17804.0,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621689,,BAO_0000218,,
6249.0,3184.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621690,,BAO_0000218,,
6250.0,1806.0,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621691,,BAO_0000218,,
6251.0,1806.0,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875941,,BAO_0000218,,
6252.0,1806.0,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621692,,BAO_0000218,,
6253.0,4839.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621693,,BAO_0000218,,
6254.0,5017.0,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621694,,BAO_0000218,,
6255.0,846.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621695,,BAO_0000218,948.0,
6256.0,846.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621696,,BAO_0000218,948.0,
6257.0,846.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621697,,BAO_0000218,2113.0,
6258.0,846.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621698,,BAO_0000218,2113.0,
6259.0,846.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623420,,BAO_0000218,2113.0,
6260.0,846.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623421,,BAO_0000218,2113.0,
6261.0,846.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623422,,BAO_0000218,2113.0,
6262.0,846.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623423,,BAO_0000218,2113.0,
6263.0,846.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623424,,BAO_0000218,2107.0,
6264.0,846.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623425,,BAO_0000218,2107.0,
6265.0,846.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623426,,BAO_0000218,2107.0,
6266.0,846.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623427,,BAO_0000218,2107.0,
6267.0,846.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623428,,BAO_0000218,2107.0,
6268.0,846.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875947,,BAO_0000218,2107.0,
6269.0,846.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623429,,BAO_0000218,2048.0,
6270.0,846.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623430,,BAO_0000218,2048.0,
6271.0,846.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622588,,BAO_0000218,2048.0,
6272.0,846.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622589,,BAO_0000218,2048.0,
6273.0,846.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622751,,BAO_0000218,2048.0,
6274.0,846.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622752,,BAO_0000218,2048.0,
6275.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622753,42.0,BAO_0000218,,
6276.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622647,42.0,BAO_0000218,,
6277.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875163,42.0,BAO_0000218,,
6278.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622648,42.0,BAO_0000218,,
6279.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622649,42.0,BAO_0000218,,
6280.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622650,42.0,BAO_0000218,955.0,
6281.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622651,42.0,BAO_0000218,955.0,
6282.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622652,42.0,BAO_0000218,955.0,
6283.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622653,42.0,BAO_0000218,955.0,
6284.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622654,42.0,BAO_0000218,955.0,
6285.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622655,42.0,BAO_0000218,948.0,
6286.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622656,42.0,BAO_0000218,948.0,
6287.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622657,42.0,BAO_0000218,948.0,
6288.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622658,42.0,BAO_0000218,948.0,
6289.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622659,42.0,BAO_0000218,948.0,
6290.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624630,42.0,BAO_0000218,2113.0,
6291.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624631,42.0,BAO_0000218,2113.0,
6292.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624632,42.0,BAO_0000218,2113.0,
6293.0,17130.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624633,646.0,BAO_0000219,,
6294.0,17130.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624634,646.0,BAO_0000219,,
6295.0,17130.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624635,646.0,BAO_0000219,,
6296.0,17130.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624636,646.0,BAO_0000219,,
6297.0,3263.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL857055,646.0,BAO_0000219,,
6298.0,6663.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL624637,646.0,BAO_0000219,,
6299.0,6663.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL624638,646.0,BAO_0000219,,
6300.0,6663.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL874366,646.0,BAO_0000219,,
6301.0,6663.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL624639,646.0,BAO_0000219,,
6302.0,6663.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL624640,646.0,BAO_0000219,,
6303.0,6663.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624641,646.0,BAO_0000219,,
6304.0,6663.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624642,646.0,BAO_0000219,,
6305.0,6663.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624643,646.0,BAO_0000219,,
6306.0,6663.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624644,646.0,BAO_0000219,,
6307.0,6663.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL624645,646.0,BAO_0000219,,
6308.0,3983.0,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619445,646.0,BAO_0000219,,
6309.0,11141.0,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL839886,646.0,BAO_0000219,,
6310.0,5076.0,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619446,646.0,BAO_0000219,,
6311.0,3311.0,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619447,646.0,BAO_0000219,,
6312.0,3311.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619448,646.0,BAO_0000219,,
6313.0,3311.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619449,646.0,BAO_0000219,,
6314.0,5076.0,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619450,646.0,BAO_0000219,,
6315.0,4150.0,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619451,646.0,BAO_0000219,,
6316.0,2150.0,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619452,646.0,BAO_0000219,,
6317.0,4644.0,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619453,646.0,BAO_0000219,,
6318.0,263.0,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL874367,646.0,BAO_0000219,,
6319.0,11333.0,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619454,646.0,BAO_0000219,,
6320.0,11333.0,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619455,646.0,BAO_0000219,,
6321.0,15895.0,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619456,646.0,BAO_0000219,,
6322.0,16677.0,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0,,,,,50191.0,N,1.0,Expert,1.0,,CHEMBL619457,,BAO_0000218,,
6323.0,10624.0,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192.0,N,1.0,Intermediate,1.0,,CHEMBL619458,,BAO_0000218,,
6324.0,16717.0,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274.0,N,1.0,Expert,1.0,,CHEMBL619459,,BAO_0000218,,
6325.0,16717.0,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274.0,N,1.0,Expert,1.0,,CHEMBL619460,,BAO_0000218,,
6326.0,5513.0,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0,,,,,50416.0,N,1.0,Intermediate,1.0,,CHEMBL619461,,BAO_0000218,,
6327.0,15962.0,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0,,,,,50416.0,N,1.0,Intermediate,1.0,,CHEMBL619462,,BAO_0000218,,
6328.0,15962.0,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416.0,N,1.0,Intermediate,1.0,,CHEMBL620388,,BAO_0000218,,
6329.0,15962.0,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416.0,N,1.0,Intermediate,1.0,,CHEMBL620389,,BAO_0000218,,
6330.0,15962.0,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416.0,N,1.0,Intermediate,1.0,,CHEMBL620390,,BAO_0000218,,
6331.0,16717.0,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416.0,N,1.0,Expert,1.0,,CHEMBL620391,,BAO_0000218,,
6332.0,16717.0,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416.0,N,1.0,Expert,1.0,,CHEMBL621073,,BAO_0000218,,
6333.0,8117.0,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL621074,,BAO_0000218,,
6334.0,8117.0,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL621075,,BAO_0000218,,
6335.0,15472.0,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL619554,,BAO_0000218,,
6336.0,15472.0,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL619555,,BAO_0000218,,
6337.0,16443.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169.0,N,1.0,Intermediate,1.0,,CHEMBL619556,,BAO_0000218,,
6338.0,16443.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169.0,N,1.0,Intermediate,1.0,,CHEMBL619557,,BAO_0000218,,
6339.0,16443.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169.0,N,1.0,Intermediate,1.0,,CHEMBL619558,,BAO_0000218,,
6340.0,17206.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619559,646.0,BAO_0000219,,
6341.0,17206.0,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619560,646.0,BAO_0000219,,
6342.0,16381.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619561,646.0,BAO_0000219,,
6343.0,16381.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619562,646.0,BAO_0000219,,
6344.0,16381.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619563,646.0,BAO_0000219,,
6345.0,16381.0,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL857457,646.0,BAO_0000219,,
6346.0,17206.0,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619564,646.0,BAO_0000219,,
6347.0,16325.0,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619565,646.0,BAO_0000219,,
6348.0,10708.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619566,646.0,BAO_0000218,,
6349.0,10708.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619567,646.0,BAO_0000218,,
6350.0,17376.0,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619568,646.0,BAO_0000219,,
6351.0,17376.0,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619569,646.0,BAO_0000219,,
6352.0,17488.0,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619570,646.0,BAO_0000219,,
6353.0,17404.0,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619571,646.0,BAO_0000218,,
6354.0,10958.0,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619572,646.0,BAO_0000219,,
6355.0,17099.0,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619573,646.0,BAO_0000219,,
6356.0,17099.0,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619574,646.0,BAO_0000219,,
6357.0,4096.0,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619575,646.0,BAO_0000219,,
6358.0,4096.0,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL619576,646.0,BAO_0000219,,
6359.0,4096.0,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619577,646.0,BAO_0000219,,
6360.0,2525.0,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619578,646.0,BAO_0000219,,
6361.0,2525.0,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL884009,646.0,BAO_0000219,,
6362.0,5302.0,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619579,646.0,BAO_0000219,,
6363.0,16325.0,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619580,646.0,BAO_0000219,,
6364.0,16939.0,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619581,646.0,BAO_0000219,,
6365.0,17229.0,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619582,646.0,BAO_0000219,,
6366.0,17380.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619583,646.0,BAO_0000219,,
6367.0,17380.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL876502,646.0,BAO_0000219,,
6368.0,1903.0,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619584,646.0,BAO_0000219,,
6369.0,3838.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619585,646.0,BAO_0000219,,
6370.0,14696.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619586,646.0,BAO_0000219,,
6371.0,3838.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619587,646.0,BAO_0000219,,
6372.0,1522.0,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619588,646.0,BAO_0000219,,
6373.0,12400.0,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619589,646.0,BAO_0000219,,
6374.0,14696.0,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619590,646.0,BAO_0000219,,
6375.0,14769.0,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619591,646.0,BAO_0000219,,
6376.0,14696.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619592,646.0,BAO_0000219,,
6377.0,1888.0,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL619593,646.0,BAO_0000219,,
6378.0,12016.0,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620217,646.0,BAO_0000219,,
6379.0,6058.0,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620218,646.0,BAO_0000219,,
6380.0,17708.0,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620219,646.0,BAO_0000219,,
6381.0,12301.0,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL620220,646.0,BAO_0000219,,
6382.0,11970.0,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL625141,646.0,BAO_0000219,,
6383.0,11818.0,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Expert,1.0,,CHEMBL625142,646.0,BAO_0000219,,
6384.0,12400.0,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL625143,646.0,BAO_0000219,,
6385.0,3381.0,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL625144,646.0,BAO_0000219,,
6386.0,17376.0,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL622474,646.0,BAO_0000219,,
6387.0,10708.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A549,,80682.0,N,1.0,Intermediate,1.0,,CHEMBL884104,646.0,BAO_0000219,,
6388.0,2964.0,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL622475,,BAO_0000219,,
6389.0,5005.0,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224.0,U,0.0,Intermediate,1.0,,CHEMBL622476,,BAO_0000218,,
6390.0,6229.0,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875831,,BAO_0000218,,
6391.0,6229.0,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622477,,BAO_0000218,,
6392.0,5374.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622478,,BAO_0000218,,
6393.0,5374.0,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623172,,BAO_0000218,,
6394.0,6265.0,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623173,,BAO_0000218,,
6395.0,5654.0,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623174,,BAO_0000218,,
6396.0,5654.0,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623175,,BAO_0000218,,
6397.0,16456.0,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623340,,BAO_0000218,,
6398.0,5302.0,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623341,,BAO_0000218,,
6399.0,3624.0,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623342,,BAO_0000218,,
6400.0,16452.0,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623343,,BAO_0000218,,
6401.0,5802.0,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623344,,BAO_0000218,,
6402.0,3598.0,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Expert,1.0,,CHEMBL623345,,BAO_0000218,,
6403.0,17839.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875832,,BAO_0000218,,
6404.0,6762.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623346,,BAO_0000218,,
6405.0,6821.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623347,,BAO_0000218,,
6406.0,6821.0,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623348,,BAO_0000218,,
6407.0,5210.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623349,,BAO_0000218,,
6408.0,6227.0,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623350,,BAO_0000218,,
6409.0,761.0,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623351,,BAO_0000218,,
6410.0,761.0,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623352,,BAO_0000218,,
6411.0,761.0,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623353,,BAO_0000218,,
6412.0,16907.0,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875833,,BAO_0000218,,
6413.0,5474.0,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623354,,BAO_0000218,,
6414.0,6535.0,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623355,,BAO_0000218,,
6415.0,6535.0,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623356,,BAO_0000218,,
6416.0,3352.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623357,,BAO_0000218,,
6417.0,6168.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623358,,BAO_0000218,,
6418.0,5988.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623359,,BAO_0000218,,
6419.0,4942.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623360,,BAO_0000218,,
6420.0,4942.0,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623361,,BAO_0000218,,
6421.0,14541.0,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623362,,BAO_0000218,,
6422.0,4449.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623363,,BAO_0000218,,
6423.0,6057.0,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623364,,BAO_0000218,,
6424.0,5600.0,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875834,,BAO_0000218,,
6425.0,5542.0,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623365,,BAO_0000218,,
6426.0,5542.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623366,,BAO_0000218,,
6427.0,5546.0,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623367,,BAO_0000218,,
6428.0,4514.0,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623368,,BAO_0000218,,
6429.0,3624.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623369,,BAO_0000218,,
6430.0,3854.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623370,,BAO_0000218,,
6431.0,5836.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623371,,BAO_0000218,,
6432.0,5940.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623372,,BAO_0000218,,
6433.0,6168.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621351,,BAO_0000218,,
6434.0,6227.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621352,,BAO_0000218,,
6435.0,6251.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621353,,BAO_0000218,,
6436.0,6448.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621354,,BAO_0000218,,
6437.0,6647.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621355,,BAO_0000218,,
6438.0,5940.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621356,,BAO_0000218,,
6439.0,933.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621357,,BAO_0000218,,
6440.0,5210.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621358,,BAO_0000218,,
6441.0,6642.0,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621359,,BAO_0000218,,
6442.0,6641.0,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621360,,BAO_0000218,,
6443.0,6642.0,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621361,,BAO_0000218,,
6444.0,5472.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621362,,BAO_0000218,,
6445.0,5985.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621363,,BAO_0000218,,
6446.0,15660.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621364,,BAO_0000218,,
6447.0,5530.0,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621166,,BAO_0000218,,
6448.0,5530.0,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621167,,BAO_0000218,,
6449.0,6305.0,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621168,,BAO_0000218,,
6450.0,5210.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621169,,BAO_0000218,,
6451.0,5238.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875950,,BAO_0000218,,
6452.0,5668.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621170,,BAO_0000218,,
6453.0,5668.0,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621171,,BAO_0000218,,
6454.0,5668.0,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621172,,BAO_0000218,,
6455.0,6084.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621173,,BAO_0000218,,
6456.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621174,42.0,BAO_0000218,2113.0,
6457.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621175,42.0,BAO_0000218,2113.0,
6458.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621176,42.0,BAO_0000218,2107.0,
6459.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621177,42.0,BAO_0000218,2107.0,
6460.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621178,42.0,BAO_0000218,2107.0,
6461.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621179,42.0,BAO_0000218,2107.0,
6462.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621180,42.0,BAO_0000218,2107.0,
6463.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875951,42.0,BAO_0000218,2048.0,
6464.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621181,42.0,BAO_0000218,2048.0,
6465.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621182,42.0,BAO_0000218,2048.0,
6466.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621183,42.0,BAO_0000218,2048.0,
6467.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621184,42.0,BAO_0000218,2048.0,
6468.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621185,42.0,BAO_0000218,,
6469.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621186,42.0,BAO_0000218,,
6470.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621187,42.0,BAO_0000218,,
6471.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621188,42.0,BAO_0000218,,
6472.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621189,42.0,BAO_0000218,,
6473.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621190,42.0,BAO_0000218,2106.0,
6474.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618520,42.0,BAO_0000218,2106.0,
6475.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621739,42.0,BAO_0000218,2106.0,
6476.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621740,42.0,BAO_0000218,2106.0,
6477.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621741,42.0,BAO_0000218,2106.0,
6478.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621742,42.0,BAO_0000218,,
6479.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621743,42.0,BAO_0000218,,
6480.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621744,42.0,BAO_0000218,,
6481.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621745,42.0,BAO_0000218,,
6482.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621746,42.0,BAO_0000218,,
6483.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621747,42.0,BAO_0000218,,
6484.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621748,42.0,BAO_0000218,,
6485.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621749,42.0,BAO_0000218,,
6486.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621750,42.0,BAO_0000218,,
6487.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621751,42.0,BAO_0000218,,
6488.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621752,42.0,BAO_0000218,948.0,
6489.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621753,42.0,BAO_0000218,948.0,
6490.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875955,42.0,BAO_0000218,948.0,
6491.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621754,42.0,BAO_0000218,948.0,
6492.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621755,42.0,BAO_0000218,948.0,
6493.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621756,42.0,BAO_0000218,2107.0,
6494.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624199,42.0,BAO_0000218,2107.0,
6495.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624200,42.0,BAO_0000218,2107.0,
6496.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624375,42.0,BAO_0000218,2107.0,
6497.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624376,42.0,BAO_0000218,2107.0,
6498.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624377,42.0,BAO_0000218,2048.0,
6499.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624378,42.0,BAO_0000218,2048.0,
6500.0,12269.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067.0,N,1.0,Intermediate,1.0,,CHEMBL857901,,BAO_0000218,,
6501.0,12269.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067.0,N,1.0,Intermediate,1.0,,CHEMBL875274,,BAO_0000218,,
6502.0,12269.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067.0,N,1.0,Intermediate,1.0,,CHEMBL624379,,BAO_0000218,,
6503.0,12269.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067.0,N,1.0,Intermediate,1.0,,CHEMBL624380,,BAO_0000218,,
6504.0,10624.0,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192.0,N,1.0,Intermediate,1.0,,CHEMBL624381,,BAO_0000218,,
6505.0,17216.0,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714.0,N,1.0,Intermediate,1.0,,CHEMBL624382,,BAO_0000218,,
6506.0,17216.0,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714.0,N,1.0,Intermediate,1.0,,CHEMBL624383,,BAO_0000218,,
6507.0,9560.0,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL624384,,BAO_0000218,,
6508.0,9560.0,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL624385,,BAO_0000218,,
6509.0,9560.0,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL624386,,BAO_0000218,,
6510.0,9560.0,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL624387,,BAO_0000218,,
6511.0,9560.0,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL624388,,BAO_0000218,,
6512.0,9560.0,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL624389,,BAO_0000218,,
6513.0,9560.0,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL624390,,BAO_0000218,,
6514.0,9560.0,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296.0,N,1.0,Intermediate,1.0,,CHEMBL875275,,BAO_0000218,,
6515.0,114.0,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0,,,,,50056.0,N,1.0,Intermediate,1.0,,CHEMBL624391,,BAO_0000218,,
6516.0,114.0,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0,,,,,50056.0,N,1.0,Intermediate,1.0,,CHEMBL623636,,BAO_0000218,,
6517.0,10841.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623637,,BAO_0000218,,
6518.0,10841.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623638,,BAO_0000218,,
6519.0,10841.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623639,,BAO_0000218,,
6520.0,10841.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623640,,BAO_0000218,,
6521.0,10841.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623641,,BAO_0000218,,
6522.0,10841.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623642,,BAO_0000218,,
6523.0,10841.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623643,,BAO_0000218,,
6524.0,10841.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623644,,BAO_0000218,,
6525.0,10841.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623645,,BAO_0000218,,
6526.0,10841.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623646,,BAO_0000218,,
6527.0,10841.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623647,,BAO_0000218,,
6528.0,10841.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0,,,,,50532.0,N,1.0,Intermediate,1.0,,CHEMBL623648,,BAO_0000218,,
6529.0,8117.0,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623649,,BAO_0000218,,
6530.0,8117.0,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623650,,BAO_0000218,,
6531.0,9560.0,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623651,,BAO_0000218,,
6532.0,9560.0,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Expert,1.0,,CHEMBL623652,,BAO_0000218,,
6533.0,9560.0,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623653,,BAO_0000218,,
6534.0,9560.0,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623654,,BAO_0000218,,
6535.0,9560.0,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623655,,BAO_0000218,,
6536.0,9560.0,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623656,,BAO_0000218,,
6537.0,9560.0,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Expert,1.0,,CHEMBL623657,,BAO_0000218,,
6538.0,9560.0,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623658,,BAO_0000218,,
6539.0,9560.0,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623659,,BAO_0000218,,
6540.0,9560.0,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623660,,BAO_0000218,,
6541.0,9560.0,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366.0,N,1.0,Intermediate,1.0,,CHEMBL623661,,BAO_0000218,,
6542.0,10986.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL875281,,BAO_0000218,,
6543.0,10986.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL623662,,BAO_0000218,,
6544.0,10986.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL623663,,BAO_0000218,,
6545.0,10986.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL623664,,BAO_0000218,,
6546.0,10986.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL623665,,BAO_0000218,,
6547.0,10708.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A673,,80023.0,N,1.0,Intermediate,1.0,,CHEMBL621856,165.0,BAO_0000219,,
6548.0,10708.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A704,,80661.0,N,1.0,Intermediate,1.0,,CHEMBL620432,645.0,BAO_0000219,,
6549.0,416.0,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL620433,,BAO_0000219,,
6550.0,14354.0,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Intermediate,1.0,,CHEMBL620434,625.0,BAO_0000219,,
6551.0,14354.0,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Intermediate,1.0,,CHEMBL620435,625.0,BAO_0000219,,
6552.0,5116.0,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0,,,A9,,80024.0,N,1.0,Intermediate,1.0,,CHEMBL620436,625.0,BAO_0000219,,
6553.0,5116.0,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0,,,A9,,80024.0,N,1.0,Intermediate,1.0,,CHEMBL876597,625.0,BAO_0000219,,
6554.0,15694.0,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0,,,Human ovarian carcinoma cell line,,81037.0,N,1.0,Expert,1.0,,CHEMBL620437,874.0,BAO_0000219,,
6555.0,13038.0,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Expert,1.0,,CHEMBL620438,625.0,BAO_0000219,,
6556.0,13038.0,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Expert,1.0,,CHEMBL620439,625.0,BAO_0000219,,
6557.0,10923.0,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Expert,1.0,,CHEMBL619657,625.0,BAO_0000219,,
6558.0,10923.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Intermediate,1.0,,CHEMBL619658,625.0,BAO_0000219,,
6559.0,10923.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Intermediate,1.0,,CHEMBL619659,625.0,BAO_0000219,,
6560.0,10923.0,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,,,,,10649.0,H,8.0,Expert,1.0,,CHEMBL619660,,BAO_0000019,,
6561.0,10923.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Intermediate,1.0,,CHEMBL619661,625.0,BAO_0000219,,
6562.0,10923.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024.0,N,1.0,Intermediate,1.0,,CHEMBL619662,625.0,BAO_0000219,,
6563.0,8158.0,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0,,,AA6,,80663.0,N,1.0,Intermediate,1.0,,CHEMBL619663,975.0,BAO_0000219,,
6564.0,15494.0,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619664,,BAO_0000219,,
6565.0,15494.0,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0,,,,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL619665,,BAO_0000219,,
6566.0,12348.0,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662.0,N,1.0,Intermediate,1.0,,CHEMBL883244,974.0,BAO_0000219,,
6567.0,12348.0,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662.0,N,1.0,Intermediate,1.0,,CHEMBL884011,974.0,BAO_0000219,,
6568.0,2726.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0,,,AA5,,80662.0,N,1.0,Intermediate,1.0,,CHEMBL619666,974.0,BAO_0000219,,
6569.0,2726.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0,,,U-937,,80566.0,N,1.0,Intermediate,1.0,,CHEMBL619667,379.0,BAO_0000219,,
6570.0,10747.0,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0,,,UV4,,80578.0,N,1.0,Intermediate,1.0,,CHEMBL619668,274.0,BAO_0000219,,
6571.0,11005.0,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL619669,185.0,BAO_0000219,,
6572.0,12687.0,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL876608,185.0,BAO_0000219,,
6573.0,12687.0,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619670,185.0,BAO_0000219,,
6574.0,12687.0,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619671,185.0,BAO_0000219,,
6575.0,12687.0,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619672,185.0,BAO_0000219,,
6576.0,12687.0,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619673,185.0,BAO_0000219,,
6577.0,13436.0,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619674,185.0,BAO_0000219,,
6578.0,13435.0,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619675,185.0,BAO_0000219,,
6579.0,13302.0,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619676,185.0,BAO_0000219,,
6580.0,12687.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619677,185.0,BAO_0000219,,
6581.0,12687.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619678,185.0,BAO_0000219,,
6582.0,12687.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL619679,185.0,BAO_0000219,,
6583.0,12878.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL619680,185.0,BAO_0000219,,
6584.0,12878.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL621457,185.0,BAO_0000219,,
6585.0,14367.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL876609,185.0,BAO_0000219,,
6586.0,14367.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL621458,185.0,BAO_0000219,,
6587.0,12398.0,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hampster,36483.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL621459,185.0,BAO_0000219,,
6588.0,12878.0,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL621460,185.0,BAO_0000219,,
6589.0,13820.0,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL621461,185.0,BAO_0000219,,
6590.0,13436.0,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL621462,185.0,BAO_0000219,,
6591.0,6084.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621463,,BAO_0000218,,
6592.0,5711.0,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621464,,BAO_0000218,,
6593.0,4353.0,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621465,,BAO_0000218,,
6594.0,4353.0,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621466,,BAO_0000218,,
6595.0,17800.0,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621467,,BAO_0000218,,
6596.0,3994.0,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621468,,BAO_0000218,,
6597.0,3994.0,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876734,,BAO_0000218,,
6598.0,5145.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618476,,BAO_0000218,,
6599.0,16452.0,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618477,,BAO_0000218,,
6600.0,16452.0,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618478,,BAO_0000218,,
6601.0,5983.0,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618479,,BAO_0000218,,
6602.0,4273.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618480,,BAO_0000218,,
6603.0,12500.0,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618481,,BAO_0000218,,
6604.0,12500.0,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618482,,BAO_0000218,1969.0,
6605.0,3639.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618483,,BAO_0000218,,
6606.0,3880.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618484,,BAO_0000218,,
6607.0,4838.0,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618485,,BAO_0000218,,
6608.0,15600.0,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618486,,BAO_0000218,,
6609.0,17248.0,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618487,,BAO_0000218,,
6610.0,17248.0,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618488,,BAO_0000218,,
6611.0,17248.0,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876735,,BAO_0000218,,
6612.0,17443.0,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618489,,BAO_0000218,,
6613.0,4186.0,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618490,,BAO_0000218,,
6614.0,3749.0,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618491,,BAO_0000218,,
6615.0,3249.0,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618492,,BAO_0000218,,
6616.0,3022.0,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873354,,BAO_0000218,,
6617.0,3749.0,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618493,,BAO_0000218,,
6618.0,2517.0,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618494,,BAO_0000218,,
6619.0,2517.0,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Heart,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618495,,BAO_0000218,948.0,
6620.0,2517.0,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Kidney,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618496,,BAO_0000218,2113.0,
6621.0,2517.0,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Liver,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618497,,BAO_0000218,2107.0,
6622.0,2517.0,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Lung,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618498,,BAO_0000218,2048.0,
6623.0,2517.0,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Spleen,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618499,,BAO_0000218,2106.0,
6624.0,3639.0,LogP in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876736,,BAO_0000218,,
6625.0,6227.0,Partition coefficient (logP),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618500,,BAO_0000218,,
6626.0,6227.0,Partition coefficient in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL857831,,BAO_0000218,,
6627.0,17764.0,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618501,,BAO_0000218,,
6628.0,4809.0,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618502,,BAO_0000218,,
6629.0,5600.0,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618503,,BAO_0000218,,
6630.0,14294.0,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618504,,BAO_0000218,,
6631.0,14294.0,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618505,,BAO_0000218,,
6632.0,14294.0,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618506,,BAO_0000218,,
6633.0,6251.0,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618507,,BAO_0000218,2107.0,
6634.0,3748.0,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876737,,BAO_0000218,,
6635.0,2713.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618508,,BAO_0000218,,
6636.0,6512.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618509,,BAO_0000218,,
6637.0,6679.0,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618510,,BAO_0000218,,
6638.0,3749.0,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618511,,BAO_0000218,,
6639.0,3749.0,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618512,,BAO_0000218,,
6640.0,6742.0,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618513,,BAO_0000218,,
6641.0,6227.0,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618514,,BAO_0000218,,
6642.0,6874.0,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620052,,BAO_0000218,,
6643.0,2877.0,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620053,,BAO_0000218,1969.0,
6644.0,12500.0,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620054,,BAO_0000218,1969.0,
6645.0,12500.0,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620055,,BAO_0000218,1969.0,
6646.0,4709.0,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620056,,BAO_0000218,,
6647.0,5542.0,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620057,,BAO_0000218,2107.0,
6648.0,17594.0,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618939,,BAO_0000218,,
6649.0,2652.0,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618940,,BAO_0000218,,
6650.0,17764.0,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618941,,BAO_0000218,,
6651.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624473,42.0,BAO_0000218,2048.0,
6652.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624474,42.0,BAO_0000218,2048.0,
6653.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624475,42.0,BAO_0000218,2048.0,
6654.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624476,42.0,BAO_0000218,,
6655.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623478,42.0,BAO_0000218,,
6656.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623479,42.0,BAO_0000218,,
6657.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623480,42.0,BAO_0000218,,
6658.0,6599.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623481,42.0,BAO_0000218,,
6659.0,17641.0,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623482,,BAO_0000218,955.0,
6660.0,17641.0,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623483,,BAO_0000218,2113.0,
6661.0,17641.0,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623484,,BAO_0000218,2107.0,
6662.0,17641.0,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623485,,BAO_0000218,2048.0,
6663.0,17641.0,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623486,,BAO_0000218,2106.0,
6664.0,17852.0,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623487,,BAO_0000218,,
6665.0,17764.0,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623488,,BAO_0000218,,
6666.0,17837.0,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623489,,BAO_0000218,,
6667.0,2675.0,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875157,,BAO_0000218,,
6668.0,2675.0,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623490,,BAO_0000218,,
6669.0,4239.0,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623491,,BAO_0000218,,
6670.0,17753.0,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623492,,BAO_0000218,,
6671.0,17753.0,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623493,,BAO_0000218,,
6672.0,17753.0,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623494,,BAO_0000218,,
6673.0,17753.0,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623495,,BAO_0000218,,
6674.0,5727.0,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623496,,BAO_0000218,,
6675.0,2862.0,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623497,,BAO_0000218,,
6676.0,5980.0,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623498,,BAO_0000218,1969.0,
6677.0,17592.0,Clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623499,,BAO_0000218,,
6678.0,17718.0,Clearance value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623500,,BAO_0000218,,
6679.0,16597.0,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623501,,BAO_0000218,,
6680.0,17384.0,Calculated partition coefficient (clogP),P,,,,,,,,,22229.0,U,0.0,Intermediate,1.0,,CHEMBL875158,,BAO_0000100,,
6681.0,6062.0,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623502,,BAO_0000218,,
6682.0,17734.0,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623503,,BAO_0000218,,
6683.0,6348.0,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623504,,BAO_0000218,,
6684.0,5969.0,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623505,,BAO_0000218,,
6685.0,5969.0,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623506,,BAO_0000218,,
6686.0,5969.0,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623507,,BAO_0000218,,
6687.0,16597.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623508,,BAO_0000218,,
6688.0,5781.0,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623509,,BAO_0000218,,
6689.0,17764.0,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875159,,BAO_0000218,,
6690.0,17641.0,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623510,,BAO_0000218,955.0,
6691.0,17641.0,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623511,,BAO_0000218,2113.0,
6692.0,17641.0,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623512,,BAO_0000218,2107.0,
6693.0,17641.0,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623513,,BAO_0000218,2048.0,
6694.0,17764.0,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623514,,BAO_0000218,,
6695.0,17764.0,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622609,,BAO_0000218,,
6696.0,17764.0,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622610,,BAO_0000218,,
6697.0,17764.0,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621823,,BAO_0000218,,
6698.0,17764.0,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621824,,BAO_0000218,,
6699.0,17641.0,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621825,,BAO_0000218,2106.0,
6700.0,16597.0,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621826,,BAO_0000218,,
6701.0,16597.0,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621827,,BAO_0000218,,
6702.0,5727.0,Cmax value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621828,,BAO_0000218,,
6703.0,5951.0,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621829,,BAO_0000218,,
6704.0,5506.0,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621830,,BAO_0000218,,
6705.0,5506.0,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621831,,BAO_0000218,,
6706.0,14239.0,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621832,,BAO_0000218,1969.0,
6707.0,4890.0,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624579,,BAO_0000218,1969.0,
6708.0,429.0,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624580,,BAO_0000218,,
6709.0,10986.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL624581,,BAO_0000218,,
6710.0,10986.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL624582,,BAO_0000218,,
6711.0,10986.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535.0,N,1.0,Intermediate,1.0,,CHEMBL624583,,BAO_0000218,,
6712.0,13227.0,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018.0,N,1.0,Intermediate,1.0,,CHEMBL624584,455.0,BAO_0000219,,
6713.0,4481.0,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12512.0,D,9.0,Expert,1.0,,CHEMBL624585,,BAO_0000249,,
6714.0,16931.0,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0,,,,,114.0,D,9.0,Expert,1.0,,CHEMBL875165,,BAO_0000019,,
6715.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619490,449.0,BAO_0000219,,
6716.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619491,449.0,BAO_0000219,,
6717.0,3850.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,,,CHO,,114.0,H,8.0,Expert,1.0,,CHEMBL619492,449.0,BAO_0000219,,
6718.0,3850.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,,,CHO,,114.0,H,8.0,Expert,1.0,,CHEMBL619493,449.0,BAO_0000219,,
6719.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619494,449.0,BAO_0000219,,
6720.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619495,449.0,BAO_0000219,,
6721.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619496,449.0,BAO_0000219,,
6722.0,3850.0,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0,,,CHO,,114.0,D,9.0,Expert,1.0,,CHEMBL619497,449.0,BAO_0000219,,
6723.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619498,449.0,BAO_0000219,,
6724.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619499,449.0,BAO_0000219,,
6725.0,3850.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,,,CHO,,114.0,H,8.0,Expert,1.0,,CHEMBL619500,449.0,BAO_0000219,,
6726.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619501,449.0,BAO_0000219,,
6727.0,3850.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114.0,H,8.0,Expert,1.0,,CHEMBL619502,449.0,BAO_0000219,,
6728.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619503,449.0,BAO_0000219,,
6729.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL619504,449.0,BAO_0000219,,
6730.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL621298,449.0,BAO_0000219,,
6731.0,3850.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,,,CHO,,114.0,H,8.0,Expert,1.0,,CHEMBL621299,449.0,BAO_0000219,,
6732.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL621300,449.0,BAO_0000219,,
6733.0,3850.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114.0,H,8.0,Autocuration,1.0,,CHEMBL621301,449.0,BAO_0000219,,
6734.0,3850.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114.0,H,8.0,Expert,1.0,,CHEMBL621302,449.0,BAO_0000219,,
6735.0,12680.0,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0,,,A10,,80013.0,N,1.0,Intermediate,1.0,,CHEMBL621303,164.0,BAO_0000219,,
6736.0,1313.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0,,,A10,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL621304,164.0,BAO_0000219,,
6737.0,1313.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0,,,A10,,22226.0,U,0.0,Autocuration,1.0,,CHEMBL621305,164.0,BAO_0000219,,
6738.0,17567.0,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013.0,N,1.0,Intermediate,1.0,,CHEMBL621306,164.0,BAO_0000219,,
6739.0,17567.0,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013.0,N,1.0,Intermediate,1.0,,CHEMBL618444,164.0,BAO_0000219,,
6740.0,11819.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013.0,N,1.0,Intermediate,1.0,,CHEMBL618445,164.0,BAO_0000219,,
6741.0,13436.0,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618446,185.0,BAO_0000219,,
6742.0,12687.0,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618447,185.0,BAO_0000219,,
6743.0,12651.0,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618448,185.0,BAO_0000219,,
6744.0,13300.0,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618449,185.0,BAO_0000219,,
6745.0,15296.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618637,185.0,BAO_0000219,,
6746.0,15328.0,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618638,185.0,BAO_0000219,,
6747.0,13302.0,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618639,185.0,BAO_0000219,,
6748.0,14367.0,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL618640,185.0,BAO_0000219,,
6749.0,17002.0,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL618641,185.0,BAO_0000219,,
6750.0,13436.0,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618642,185.0,BAO_0000219,,
6751.0,13435.0,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL618643,185.0,BAO_0000219,,
6752.0,10503.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL884013,185.0,BAO_0000219,,
6753.0,10503.0,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL622723,185.0,BAO_0000219,,
6754.0,10503.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL622724,185.0,BAO_0000219,,
6755.0,15090.0,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL622725,185.0,BAO_0000219,,
6756.0,10368.0,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL622726,185.0,BAO_0000219,,
6757.0,12651.0,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL622727,185.0,BAO_0000219,,
6758.0,12687.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL622728,185.0,BAO_0000219,,
6759.0,12687.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL622729,185.0,BAO_0000219,,
6760.0,12687.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL622730,185.0,BAO_0000219,,
6761.0,1890.0,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL622731,185.0,BAO_0000219,,
6762.0,10747.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL622732,185.0,BAO_0000219,,
6763.0,10747.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Intermediate,1.0,,CHEMBL622733,185.0,BAO_0000219,,
6764.0,11616.0,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL622734,,BAO_0000218,,
6765.0,11616.0,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL622735,185.0,BAO_0000219,,
6766.0,3471.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618746,185.0,BAO_0000219,,
6767.0,3471.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618747,185.0,BAO_0000219,,
6768.0,3471.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620540,185.0,BAO_0000219,,
6769.0,3471.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620541,185.0,BAO_0000219,,
6770.0,3471.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620542,185.0,BAO_0000219,,
6771.0,3471.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620543,185.0,BAO_0000219,,
6772.0,3471.0,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618832,185.0,BAO_0000219,,
6773.0,11616.0,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL618833,185.0,BAO_0000219,,
6774.0,2656.0,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618834,185.0,BAO_0000219,,
6775.0,10518.0,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618835,185.0,BAO_0000219,,
6776.0,10518.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618836,185.0,BAO_0000219,,
6777.0,10518.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618837,185.0,BAO_0000219,,
6778.0,10518.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618838,185.0,BAO_0000219,,
6779.0,16156.0,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618839,185.0,BAO_0000219,,
6780.0,2656.0,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618840,185.0,BAO_0000219,,
6781.0,11005.0,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618841,,BAO_0000019,,
6782.0,11942.0,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618842,185.0,BAO_0000219,,
6783.0,2128.0,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618843,185.0,BAO_0000219,,
6784.0,16907.0,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618844,,BAO_0000218,,
6785.0,16907.0,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618845,,BAO_0000218,,
6786.0,9579.0,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618846,,BAO_0000218,,
6787.0,9579.0,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618847,,BAO_0000218,,
6788.0,9579.0,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618848,,BAO_0000218,,
6789.0,9579.0,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618849,,BAO_0000218,,
6790.0,16907.0,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618850,,BAO_0000218,,
6791.0,16907.0,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618851,,BAO_0000218,,
6792.0,3184.0,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873815,,BAO_0000218,,
6793.0,5017.0,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618852,,BAO_0000218,1969.0,
6794.0,6821.0,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618853,,BAO_0000218,,
6795.0,17839.0,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618854,,BAO_0000218,,
6796.0,17267.0,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618855,,BAO_0000218,,
6797.0,4727.0,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0,,Blood,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618856,,BAO_0000218,178.0,
6798.0,5238.0,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875827,,BAO_0000218,,
6799.0,4942.0,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618857,,BAO_0000218,,
6800.0,6505.0,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618858,,BAO_0000218,,
6801.0,5130.0,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618859,,BAO_0000218,,
6802.0,1475.0,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618860,,BAO_0000218,,
6803.0,17804.0,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618861,,BAO_0000218,,
6804.0,17804.0,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622539,,BAO_0000218,,
6805.0,6084.0,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622540,,BAO_0000218,,
6806.0,6084.0,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873803,,BAO_0000218,,
6807.0,5542.0,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873804,,BAO_0000218,,
6808.0,5542.0,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624311,,BAO_0000218,,
6809.0,6084.0,Half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624312,,BAO_0000218,,
6810.0,6241.0,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624313,,BAO_0000218,,
6811.0,1916.0,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624314,,BAO_0000218,,
6812.0,6621.0,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624315,,BAO_0000218,,
6813.0,1696.0,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624316,,BAO_0000218,1969.0,
6814.0,17800.0,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624317,,BAO_0000218,,
6815.0,17657.0,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624318,,BAO_0000218,,
6816.0,17657.0,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624319,,BAO_0000218,,
6817.0,4239.0,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624496,,BAO_0000218,,
6818.0,5985.0,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624497,,BAO_0000218,,
6819.0,9932.0,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624498,,BAO_0000218,,
6820.0,5199.0,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624499,,BAO_0000218,,
6821.0,5199.0,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624500,,BAO_0000218,1969.0,
6822.0,1475.0,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624501,,BAO_0000218,1969.0,
6823.0,1475.0,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623666,,BAO_0000218,1969.0,
6824.0,1475.0,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623667,,BAO_0000218,1969.0,
6825.0,6316.0,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623668,,BAO_0000218,,
6826.0,4883.0,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623669,,BAO_0000218,,
6827.0,4727.0,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623670,,BAO_0000218,,
6828.0,1916.0,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623671,,BAO_0000218,,
6829.0,1337.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875945,,BAO_0000218,178.0,
6830.0,1337.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623672,,BAO_0000218,178.0,
6831.0,6265.0,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623673,,BAO_0000218,,
6832.0,4809.0,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623674,,BAO_0000218,,
6833.0,5983.0,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623675,,BAO_0000218,,
6834.0,5313.0,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL872526,,BAO_0000218,,
6835.0,5313.0,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623676,,BAO_0000218,,
6836.0,17650.0,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623677,,BAO_0000218,1969.0,
6837.0,5199.0,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623678,,BAO_0000218,1969.0,
6838.0,933.0,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623679,,BAO_0000218,1969.0,
6839.0,16367.0,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623680,,BAO_0000218,,
6840.0,6348.0,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623681,,BAO_0000218,1969.0,
6841.0,6316.0,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623682,,BAO_0000218,,
6842.0,6215.0,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623683,,BAO_0000218,,
6843.0,3598.0,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Expert,1.0,,CHEMBL623684,,BAO_0000218,,
6844.0,4527.0,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622745,,BAO_0000218,,
6845.0,17764.0,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622746,,BAO_0000218,,
6846.0,5969.0,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622747,,BAO_0000218,,
6847.0,5969.0,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622748,,BAO_0000218,,
6848.0,4573.0,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622749,,BAO_0000218,,
6849.0,3277.0,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622750,,BAO_0000218,1969.0,
6850.0,17734.0,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623411,,BAO_0000218,1969.0,
6851.0,3132.0,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875946,,BAO_0000218,1969.0,
6852.0,3132.0,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623412,,BAO_0000218,1969.0,
6853.0,6348.0,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623413,,BAO_0000218,1969.0,
6854.0,17729.0,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623414,,BAO_0000218,1969.0,
6855.0,17729.0,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623415,,BAO_0000218,1969.0,
6856.0,17729.0,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623416,,BAO_0000218,1969.0,
6857.0,17728.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623417,,BAO_0000218,1969.0,
6858.0,17728.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623418,,BAO_0000218,1969.0,
6859.0,17728.0,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623419,,BAO_0000218,1969.0,
6860.0,4066.0,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622816,,BAO_0000218,,
6861.0,6178.0,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623313,,BAO_0000218,,
6862.0,6178.0,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623314,,BAO_0000218,,
6863.0,3760.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876788,,BAO_0000218,,
6864.0,3760.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623315,,BAO_0000218,,
6865.0,3760.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623316,,BAO_0000218,,
6866.0,3760.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623317,,BAO_0000218,,
6868.0,5961.0,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623319,,BAO_0000218,,
6869.0,6137.0,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623320,,BAO_0000218,,
6870.0,3802.0,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623321,,BAO_0000218,,
6871.0,3535.0,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623322,,BAO_0000218,,
6872.0,3535.0,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623323,,BAO_0000218,,
6873.0,3535.0,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623324,,BAO_0000218,,
6874.0,3535.0,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623325,,BAO_0000218,,
6875.0,3535.0,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623326,,BAO_0000218,,
6876.0,3535.0,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623327,,BAO_0000218,,
6877.0,2862.0,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623328,,BAO_0000218,1969.0,
6878.0,2675.0,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623329,,BAO_0000218,1969.0,
6879.0,2675.0,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623330,,BAO_0000218,1969.0,
6880.0,5399.0,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL876789,,BAO_0000218,,
6893.0,11819.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013.0,N,1.0,Expert,1.0,,CHEMBL623333,164.0,BAO_0000219,,
6894.0,11819.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013.0,N,1.0,Expert,1.0,,CHEMBL623334,164.0,BAO_0000219,,
6895.0,11819.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013.0,N,1.0,Expert,1.0,,CHEMBL627536,164.0,BAO_0000219,,
6896.0,11819.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013.0,N,1.0,Expert,1.0,,CHEMBL627537,164.0,BAO_0000219,,
6897.0,16361.0,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0,,,A10,,80013.0,N,1.0,Intermediate,1.0,,CHEMBL627538,164.0,BAO_0000219,,
6898.0,2288.0,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL884106,393.0,BAO_0000219,,
6899.0,10404.0,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL625294,393.0,BAO_0000219,,
6900.0,14790.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL625295,393.0,BAO_0000219,,
6901.0,14790.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL625296,393.0,BAO_0000219,,
6902.0,14253.0,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Expert,1.0,,CHEMBL625297,393.0,BAO_0000219,,
6903.0,13617.0,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Expert,1.0,,CHEMBL625298,393.0,BAO_0000219,,
6904.0,1003.0,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL625960,393.0,BAO_0000219,,
6905.0,830.0,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL625961,393.0,BAO_0000219,,
6906.0,12307.0,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL625962,393.0,BAO_0000219,,
6907.0,14254.0,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL624717,393.0,BAO_0000219,,
6908.0,13370.0,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL624718,393.0,BAO_0000219,,
6909.0,14790.0,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL624719,393.0,BAO_0000219,,
6910.0,3614.0,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A121,,80655.0,N,1.0,Intermediate,1.0,,CHEMBL624720,393.0,BAO_0000219,,
6911.0,2664.0,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Intermediate,1.0,,CHEMBL624721,622.0,BAO_0000219,,
6912.0,2037.0,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Expert,1.0,,CHEMBL624722,622.0,BAO_0000219,,
6913.0,14539.0,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Intermediate,1.0,,CHEMBL877597,622.0,BAO_0000219,,
6914.0,2836.0,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Intermediate,1.0,,CHEMBL624723,622.0,BAO_0000219,,
6915.0,10708.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A 172,,80012.0,N,1.0,Intermediate,1.0,,CHEMBL624724,622.0,BAO_0000219,,
6916.0,8975.0,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0,,,,,104729.0,H,4.0,Autocuration,1.0,,CHEMBL624725,,BAO_0000224,,
6917.0,7645.0,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,,,,A2,,80656.0,N,1.0,Intermediate,1.0,,CHEMBL624726,1085.0,BAO_0000219,,
6918.0,11377.0,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0,,,,,104713.0,D,5.0,Autocuration,1.0,,CHEMBL857535,,BAO_0000224,,
6919.0,13528.0,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0,,,A204,,80014.0,N,1.0,Expert,1.0,,CHEMBL624727,623.0,BAO_0000219,,
6920.0,10160.0,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0,,,A204,,80014.0,N,1.0,Expert,1.0,,CHEMBL624728,623.0,BAO_0000219,,
6921.0,15144.0,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2058,,80015.0,N,1.0,Intermediate,1.0,,CHEMBL624729,404.0,BAO_0000219,,
6922.0,13160.0,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657.0,N,1.0,Intermediate,1.0,,CHEMBL624730,973.0,BAO_0000219,,
6923.0,12898.0,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657.0,N,1.0,Intermediate,1.0,,CHEMBL624731,973.0,BAO_0000219,,
6924.0,13069.0,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657.0,N,1.0,Intermediate,1.0,,CHEMBL624732,973.0,BAO_0000219,,
6925.0,15984.0,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657.0,N,1.0,Intermediate,1.0,,CHEMBL883245,973.0,BAO_0000219,,
6926.0,15564.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657.0,N,1.0,Intermediate,1.0,,CHEMBL624733,973.0,BAO_0000219,,
6927.0,15564.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657.0,N,1.0,Intermediate,1.0,,CHEMBL624734,973.0,BAO_0000219,,
6928.0,15564.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657.0,N,1.0,Intermediate,1.0,,CHEMBL624735,973.0,BAO_0000219,,
6929.0,4720.0,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621780,478.0,BAO_0000219,,
6930.0,16112.0,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL877598,478.0,BAO_0000219,,
6931.0,16597.0,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL621781,478.0,BAO_0000219,,
6932.0,16378.0,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621782,478.0,BAO_0000219,,
6933.0,16085.0,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL621783,478.0,BAO_0000219,,
6934.0,16317.0,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621784,478.0,BAO_0000219,,
6935.0,15748.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621785,478.0,BAO_0000219,,
6936.0,16597.0,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL621968,478.0,BAO_0000219,,
6937.0,16597.0,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL621969,478.0,BAO_0000219,,
6938.0,16597.0,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL621970,478.0,BAO_0000219,,
6939.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621971,478.0,BAO_0000219,,
6940.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621972,478.0,BAO_0000219,,
6941.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL884108,478.0,BAO_0000219,,
6942.0,15296.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623826,,BAO_0000019,,
6943.0,10251.0,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623827,185.0,BAO_0000219,,
6944.0,10251.0,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623828,185.0,BAO_0000219,,
6945.0,10251.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623829,185.0,BAO_0000219,,
6946.0,10251.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623830,185.0,BAO_0000219,,
6947.0,11858.0,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623831,,BAO_0000019,,
6948.0,11858.0,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623832,185.0,BAO_0000219,,
6949.0,11616.0,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hampster,36483.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL623833,185.0,BAO_0000219,,
6950.0,11616.0,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL623834,185.0,BAO_0000219,,
6951.0,10518.0,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623835,185.0,BAO_0000219,,
6952.0,11396.0,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623836,185.0,BAO_0000219,,
6953.0,10518.0,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL623837,185.0,BAO_0000219,,
6954.0,11616.0,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089.0,N,1.0,Expert,1.0,,CHEMBL623838,185.0,BAO_0000219,,
6955.0,14837.0,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,,,,,12675.0,H,8.0,Autocuration,1.0,,CHEMBL623839,,BAO_0000019,,
6956.0,14837.0,Number of binding sites (n) of isolated serum protein AAG,F,,,,,,,,,12675.0,H,8.0,Autocuration,1.0,,CHEMBL623840,,BAO_0000019,,
6957.0,16037.0,Association constant for binding to AATT duplex,B,,,,,,,,,22222.0,M,3.0,Intermediate,1.0,,CHEMBL623841,,BAO_0000225,,
6958.0,16597.0,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0,,,ABAE,,100090.0,N,1.0,Expert,1.0,,CHEMBL623842,416.0,BAO_0000219,,
6959.0,8831.0,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0,,,AC755,,80668.0,N,1.0,Intermediate,1.0,,CHEMBL623843,1064.0,BAO_0000218,,
6960.0,13419.0,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0,,,,,102444.0,D,9.0,Expert,1.0,,CHEMBL618669,,BAO_0000218,,
6961.0,13419.0,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0,,,,,102444.0,D,9.0,Expert,1.0,,CHEMBL618670,,BAO_0000218,,
6962.0,15778.0,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,,,,,69.0,H,8.0,Autocuration,1.0,,CHEMBL618671,,BAO_0000357,,
6963.0,15778.0,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,,,,,69.0,H,8.0,Autocuration,1.0,,CHEMBL618672,,BAO_0000357,,
6964.0,12988.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669.0,N,1.0,Intermediate,1.0,,CHEMBL618673,978.0,BAO_0000219,,
6965.0,12988.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669.0,N,1.0,Intermediate,1.0,,CHEMBL618674,978.0,BAO_0000219,,
6966.0,12988.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618675,998.0,BAO_0000219,,
6967.0,12988.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618676,998.0,BAO_0000219,,
6968.0,12988.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618677,998.0,BAO_0000219,,
6969.0,11843.0,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618678,626.0,BAO_0000219,,
6970.0,16939.0,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618679,626.0,BAO_0000219,,
6971.0,4782.0,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618680,626.0,BAO_0000219,,
6972.0,6310.0,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Expert,1.0,,CHEMBL618681,626.0,BAO_0000219,,
6973.0,6310.0,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618682,626.0,BAO_0000219,,
6974.0,12858.0,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618683,626.0,BAO_0000219,,
6975.0,17380.0,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618684,626.0,BAO_0000219,,
6976.0,5858.0,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618685,626.0,BAO_0000219,,
6977.0,3838.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL876499,626.0,BAO_0000219,,
6978.0,3838.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618686,626.0,BAO_0000219,,
6979.0,5406.0,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618687,626.0,BAO_0000219,,
6980.0,4071.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618688,626.0,BAO_0000219,,
6981.0,4071.0,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Expert,1.0,,CHEMBL618689,626.0,BAO_0000219,,
6982.0,4071.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618690,626.0,BAO_0000219,,
6983.0,15002.0,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL618691,626.0,BAO_0000219,,
6984.0,14769.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL619373,626.0,BAO_0000219,,
6985.0,13958.0,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL884008,626.0,BAO_0000219,,
6986.0,1665.0,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL619374,626.0,BAO_0000219,,
6987.0,15354.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL619375,626.0,BAO_0000219,,
6988.0,15354.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL619376,626.0,BAO_0000219,,
6989.0,13978.0,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL619377,626.0,BAO_0000219,,
6990.0,6798.0,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL619378,626.0,BAO_0000219,,
6991.0,2959.0,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL872527,,BAO_0000218,,
6992.0,9932.0,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876500,,BAO_0000218,,
6993.0,5546.0,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619379,,BAO_0000218,,
6994.0,16907.0,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619538,,BAO_0000218,,
6995.0,16907.0,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619539,,BAO_0000218,,
6996.0,4257.0,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619540,,BAO_0000218,,
6997.0,4305.0,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619541,,BAO_0000218,,
6998.0,5472.0,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619542,,BAO_0000218,,
6999.0,6062.0,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619543,,BAO_0000218,,
7000.0,3598.0,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Expert,1.0,,CHEMBL619544,,BAO_0000218,,
7001.0,12500.0,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619545,,BAO_0000218,,
7002.0,12500.0,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619546,,BAO_0000218,,
7003.0,6227.0,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619547,,BAO_0000218,,
7004.0,6227.0,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619548,,BAO_0000218,,
7005.0,4219.0,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619549,,BAO_0000218,,
7006.0,1696.0,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619550,,BAO_0000218,,
7007.0,5542.0,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876501,,BAO_0000218,,
7008.0,5199.0,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619551,,BAO_0000218,,
7009.0,6348.0,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619552,,BAO_0000218,,
7010.0,4727.0,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619553,,BAO_0000218,,
7011.0,16367.0,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618722,,BAO_0000218,,
7012.0,2652.0,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618723,,BAO_0000218,,
7013.0,16452.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618724,,BAO_0000218,,
7014.0,16452.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618725,,BAO_0000218,,
7015.0,16452.0,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618726,,BAO_0000218,,
7016.0,5334.0,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618727,,BAO_0000218,,
7017.0,4239.0,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624233,,BAO_0000218,,
7018.0,4709.0,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624234,,BAO_0000218,,
7019.0,5600.0,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624235,,BAO_0000218,,
7020.0,6057.0,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624236,,BAO_0000218,,
7021.0,5654.0,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624237,,BAO_0000218,,
7022.0,5505.0,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624238,,BAO_0000218,,
7023.0,4527.0,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624239,,BAO_0000218,,
7024.0,4521.0,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875829,,BAO_0000218,,
7025.0,4521.0,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624240,,BAO_0000218,,
7026.0,15660.0,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624241,,BAO_0000218,,
7027.0,15660.0,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624242,,BAO_0000218,,
7028.0,6679.0,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624243,,BAO_0000218,,
7029.0,5145.0,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624244,,BAO_0000218,,
7030.0,6821.0,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624245,,BAO_0000218,,
7031.0,4137.0,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624246,,BAO_0000218,,
7032.0,5334.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624247,,BAO_0000218,,
7033.0,15660.0,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624248,,BAO_0000218,,
7034.0,6642.0,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624249,,BAO_0000218,,
7035.0,6641.0,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624250,,BAO_0000218,,
7036.0,6642.0,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624251,,BAO_0000218,,
7037.0,11659.0,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624252,,BAO_0000218,,
7038.0,6448.0,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624253,,BAO_0000218,,
7039.0,5474.0,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624950,,BAO_0000218,,
7040.0,1466.0,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624951,,BAO_0000218,,
7041.0,6535.0,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875830,,BAO_0000218,,
7042.0,6535.0,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624952,,BAO_0000218,,
7043.0,17764.0,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624953,,BAO_0000218,,
7044.0,6215.0,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624954,,BAO_0000218,,
7045.0,6505.0,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624955,,BAO_0000218,,
7046.0,3639.0,Vss was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624956,,BAO_0000218,,
7047.0,3639.0,Vss in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625129,,BAO_0000218,,
7048.0,6062.0,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625130,,BAO_0000218,,
7049.0,4942.0,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625131,,BAO_0000218,,
7050.0,17796.0,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625132,,BAO_0000218,,
7051.0,4883.0,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL872263,,BAO_0000218,,
7060.0,17837.0,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624336,,BAO_0000218,,
7061.0,17729.0,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624337,,BAO_0000218,,
7062.0,17729.0,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624338,,BAO_0000218,,
7063.0,4239.0,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624339,,BAO_0000218,,
7064.0,17592.0,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624340,,BAO_0000218,,
7065.0,6348.0,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624341,,BAO_0000218,,
7066.0,2801.0,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624342,,BAO_0000218,,
7067.0,2801.0,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624343,,BAO_0000218,,
7068.0,17718.0,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624344,,BAO_0000218,,
7069.0,5727.0,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624345,,BAO_0000218,,
7070.0,5302.0,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624346,,BAO_0000218,,
7071.0,3598.0,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Expert,1.0,,CHEMBL624347,,BAO_0000218,,
7072.0,5961.0,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624348,,BAO_0000218,,
7074.0,6091.0,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622754,,BAO_0000218,,
7075.0,6091.0,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622755,,BAO_0000218,,
7076.0,5711.0,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622756,,BAO_0000218,,
7077.0,17728.0,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622757,,BAO_0000218,,
7078.0,17728.0,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622758,,BAO_0000218,,
7079.0,3802.0,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622759,,BAO_0000218,,
7080.0,3802.0,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622760,,BAO_0000218,,
7081.0,14029.0,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622761,,BAO_0000218,1969.0,
7082.0,14029.0,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622762,,BAO_0000218,1969.0,
7083.0,14029.0,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622763,,BAO_0000218,1969.0,
7084.0,14029.0,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622764,,BAO_0000218,1969.0,
7085.0,14029.0,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622765,,BAO_0000218,1969.0,
7086.0,17753.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622766,,BAO_0000218,,
7087.0,17753.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622767,,BAO_0000218,,
7088.0,17753.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622768,,BAO_0000218,,
7089.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875948,,BAO_0000218,178.0,
7090.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622769,,BAO_0000218,178.0,
7091.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622770,,BAO_0000218,178.0,
7092.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622771,,BAO_0000218,178.0,
7093.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622772,,BAO_0000218,178.0,
7094.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622773,,BAO_0000218,178.0,
7095.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL622774,,BAO_0000218,178.0,
7096.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621725,,BAO_0000218,10000001.0,
7097.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621726,,BAO_0000218,10000001.0,
7098.0,15608.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621727,478.0,BAO_0000219,,
7099.0,3290.0,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622413,478.0,BAO_0000219,,
7100.0,2859.0,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622414,478.0,BAO_0000219,,
7101.0,15688.0,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622415,478.0,BAO_0000219,,
7102.0,5642.0,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL884001,478.0,BAO_0000219,,
7103.0,6633.0,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622416,478.0,BAO_0000219,,
7104.0,3906.0,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622417,478.0,BAO_0000219,,
7105.0,6788.0,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622590,478.0,BAO_0000219,,
7106.0,17582.0,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622591,478.0,BAO_0000219,,
7107.0,17764.0,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622592,478.0,BAO_0000219,,
7108.0,17764.0,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622593,478.0,BAO_0000219,,
7109.0,17764.0,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622594,478.0,BAO_0000219,,
7110.0,2815.0,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622595,478.0,BAO_0000219,,
7111.0,16930.0,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622596,478.0,BAO_0000219,,
7112.0,17777.0,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622597,478.0,BAO_0000219,,
7113.0,17777.0,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622598,478.0,BAO_0000219,,
7114.0,16936.0,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,,,104766.0,D,5.0,Autocuration,1.0,,CHEMBL622599,,BAO_0000019,,
7115.0,13759.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622600,478.0,BAO_0000219,,
7116.0,13759.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622601,478.0,BAO_0000219,,
7117.0,13759.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622602,478.0,BAO_0000219,,
7118.0,13759.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622603,478.0,BAO_0000219,,
7119.0,15292.0,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622604,478.0,BAO_0000219,,
7120.0,15292.0,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622605,478.0,BAO_0000219,,
7121.0,15069.0,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL622606,478.0,BAO_0000219,,
7122.0,15069.0,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619463,478.0,BAO_0000219,,
7123.0,14073.0,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619464,478.0,BAO_0000219,,
7124.0,14553.0,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619465,478.0,BAO_0000219,,
7125.0,13040.0,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619466,478.0,BAO_0000219,,
7126.0,6891.0,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619467,478.0,BAO_0000219,,
7127.0,15569.0,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619468,478.0,BAO_0000219,,
7128.0,14190.0,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619469,478.0,BAO_0000219,,
7129.0,15014.0,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL619470,478.0,BAO_0000219,,
7130.0,15014.0,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619471,478.0,BAO_0000219,,
7131.0,17496.0,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619472,478.0,BAO_0000219,,
7132.0,13617.0,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL619473,478.0,BAO_0000219,,
7133.0,13617.0,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL874368,478.0,BAO_0000219,,
7134.0,13617.0,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL884003,478.0,BAO_0000219,,
7135.0,13617.0,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622690,478.0,BAO_0000219,,
7136.0,17672.0,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622691,478.0,BAO_0000219,,
7137.0,4544.0,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL622692,478.0,BAO_0000219,,
7138.0,4544.0,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL623406,478.0,BAO_0000219,,
7139.0,16317.0,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL884004,478.0,BAO_0000219,,
7140.0,15099.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL623407,478.0,BAO_0000219,,
7141.0,13978.0,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL623408,478.0,BAO_0000219,,
7142.0,12989.0,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL623409,478.0,BAO_0000219,,
7143.0,5574.0,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL623410,478.0,BAO_0000219,,
7144.0,13528.0,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL623576,478.0,BAO_0000219,,
7145.0,12782.0,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623577,626.0,BAO_0000219,,
7146.0,14255.0,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623578,626.0,BAO_0000219,,
7147.0,16364.0,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623579,626.0,BAO_0000219,,
7148.0,17376.0,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Expert,1.0,,CHEMBL623580,626.0,BAO_0000219,,
7149.0,12016.0,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623581,626.0,BAO_0000219,,
7150.0,6058.0,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL857456,626.0,BAO_0000219,,
7151.0,17708.0,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623582,626.0,BAO_0000219,,
7152.0,15176.0,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623583,626.0,BAO_0000219,,
7153.0,2806.0,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623584,626.0,BAO_0000219,,
7154.0,15300.0,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623585,626.0,BAO_0000219,,
7155.0,16364.0,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623586,626.0,BAO_0000219,,
7156.0,13859.0,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623587,626.0,BAO_0000219,,
7157.0,11970.0,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL875279,626.0,BAO_0000219,,
7158.0,2450.0,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623588,626.0,BAO_0000219,,
7159.0,12696.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623589,626.0,BAO_0000219,,
7160.0,12400.0,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623590,626.0,BAO_0000219,,
7161.0,12888.0,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Expert,1.0,,CHEMBL623591,626.0,BAO_0000219,,
7162.0,3156.0,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623592,626.0,BAO_0000219,,
7163.0,3381.0,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623593,626.0,BAO_0000219,,
7164.0,16747.0,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL623594,626.0,BAO_0000219,,
7165.0,16748.0,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Expert,1.0,,CHEMBL621833,626.0,BAO_0000219,,
7166.0,12062.0,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL621834,626.0,BAO_0000219,,
7167.0,14769.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL621835,626.0,BAO_0000219,,
7168.0,15895.0,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL621836,626.0,BAO_0000219,,
7169.0,17376.0,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL621837,626.0,BAO_0000219,,
7170.0,14882.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL875280,626.0,BAO_0000219,,
7171.0,14882.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL621838,626.0,BAO_0000219,,
7172.0,15661.0,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0,,,ACHN,,80025.0,N,1.0,Intermediate,1.0,,CHEMBL621839,626.0,BAO_0000219,,
7173.0,9680.0,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621840,,BAO_0000019,,
7174.0,14579.0,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,,,,,10647.0,H,8.0,Autocuration,1.0,,CHEMBL621841,,BAO_0000019,,
7175.0,17290.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0,,,HEL,,50529.0,N,1.0,Expert,1.0,,CHEMBL622979,468.0,BAO_0000218,,
7176.0,17290.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0,,,,,50529.0,N,1.0,Intermediate,1.0,,CHEMBL876595,,BAO_0000218,,
7177.0,15891.0,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159.0,H,8.0,Autocuration,1.0,,CHEMBL620221,,BAO_0000357,,
7178.0,15890.0,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159.0,H,8.0,Autocuration,1.0,,CHEMBL620222,,BAO_0000357,,
7179.0,3801.0,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0,,,ADDP cell line,,80670.0,N,1.0,Intermediate,1.0,,CHEMBL620506,979.0,BAO_0000219,,
7180.0,9222.0,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671.0,N,1.0,Intermediate,1.0,,CHEMBL620507,980.0,BAO_0000219,,
7181.0,9222.0,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671.0,N,1.0,Intermediate,1.0,,CHEMBL620508,980.0,BAO_0000219,,
7182.0,7257.0,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671.0,N,1.0,Intermediate,1.0,,CHEMBL620509,980.0,BAO_0000219,,
7183.0,7257.0,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671.0,N,1.0,Intermediate,1.0,,CHEMBL620510,980.0,BAO_0000219,,
7184.0,7257.0,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0,,,ADJ/PC6,,80671.0,N,1.0,Intermediate,1.0,,CHEMBL620511,980.0,BAO_0000219,,
7185.0,8084.0,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671.0,N,1.0,Intermediate,1.0,,CHEMBL620512,980.0,BAO_0000219,,
7186.0,14943.0,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620513,,BAO_0000019,,
7187.0,14943.0,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620514,,BAO_0000019,,
7188.0,14943.0,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620515,,BAO_0000019,,
7189.0,10524.0,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL620516,,BAO_0000218,,
7190.0,3546.0,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620517,,BAO_0000218,1969.0,
7191.0,3546.0,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620518,,BAO_0000218,1969.0,
7192.0,3546.0,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL620519,,BAO_0000218,,
7193.0,3546.0,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621386,,BAO_0000218,,
7194.0,3546.0,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621387,,BAO_0000218,,
7195.0,3184.0,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621388,,BAO_0000218,,
7196.0,16456.0,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621389,,BAO_0000218,,
7197.0,4809.0,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621390,,BAO_0000218,,
7198.0,4219.0,Calculated partition coefficient (clogP),P,,,,,,,,,22229.0,U,0.0,Intermediate,1.0,,CHEMBL621391,,BAO_0000100,,
7199.0,3748.0,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621392,,BAO_0000218,,
7200.0,3132.0,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621393,,BAO_0000218,,
7201.0,4219.0,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621394,,BAO_0000218,,
7202.0,16907.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621395,,BAO_0000218,2107.0,
7203.0,6057.0,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621396,,BAO_0000218,,
7204.0,6057.0,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621397,,BAO_0000218,,
7205.0,17853.0,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621398,,BAO_0000218,,
7206.0,3639.0,pKa was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618818,,BAO_0000218,,
7207.0,14541.0,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618819,,BAO_0000218,,
7208.0,16456.0,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618820,,BAO_0000218,,
7209.0,16456.0,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873810,,BAO_0000218,,
7210.0,2652.0,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876606,,BAO_0000218,,
7211.0,3624.0,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618821,,BAO_0000218,,
7212.0,1337.0,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618822,,BAO_0000218,178.0,
7213.0,1337.0,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618823,,BAO_0000218,178.0,
7214.0,4709.0,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618824,,BAO_0000218,,
7215.0,15660.0,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618825,,BAO_0000218,,
7216.0,5302.0,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618826,,BAO_0000218,,
7217.0,17791.0,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618827,,BAO_0000218,,
7218.0,6348.0,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618828,,BAO_0000218,,
7219.0,4257.0,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618829,,BAO_0000218,,
7220.0,3771.0,Half-life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618830,,BAO_0000218,,
7221.0,6305.0,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL618831,,BAO_0000218,,
7222.0,13501.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619489,,BAO_0000218,1969.0,
7223.0,17594.0,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619649,,BAO_0000218,,
7224.0,3045.0,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876607,,BAO_0000218,,
7225.0,3043.0,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619650,,BAO_0000218,,
7226.0,4839.0,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619651,,BAO_0000218,,
7227.0,4839.0,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619652,,BAO_0000218,,
7228.0,5802.0,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619653,,BAO_0000218,,
7229.0,17839.0,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619654,,BAO_0000218,,
7230.0,4219.0,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619655,,BAO_0000218,,
7231.0,13966.0,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619656,,BAO_0000218,178.0,
7232.0,3994.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873812,,BAO_0000218,1969.0,
7233.0,3994.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621365,,BAO_0000218,1969.0,
7234.0,4453.0,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621366,,BAO_0000218,,
7235.0,6535.0,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621367,,BAO_0000218,1969.0,
7236.0,6535.0,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621368,,BAO_0000218,1969.0,
7237.0,6535.0,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621369,,BAO_0000218,1969.0,
7238.0,3132.0,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621370,,BAO_0000218,1969.0,
7239.0,5374.0,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621371,,BAO_0000218,,
7240.0,5007.0,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621372,,BAO_0000218,,
7241.0,16907.0,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621373,,BAO_0000218,1969.0,
7242.0,6057.0,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621374,,BAO_0000218,,
7243.0,5006.0,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621375,,BAO_0000218,,
7244.0,5473.0,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621376,,BAO_0000218,,
7245.0,4368.0,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619624,,BAO_0000218,,
7246.0,6448.0,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL875840,,BAO_0000218,,
7247.0,4353.0,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619625,,BAO_0000218,,
7248.0,4353.0,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619626,,BAO_0000218,,
7249.0,4353.0,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619627,,BAO_0000218,,
7250.0,4353.0,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873817,,BAO_0000218,,
7251.0,6265.0,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619628,,BAO_0000218,,
7252.0,5006.0,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619629,,BAO_0000218,,
7253.0,5356.0,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619630,,BAO_0000218,,
7254.0,405.0,Half life in rat,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619631,,BAO_0000218,,
7255.0,6642.0,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL619632,,BAO_0000218,,
7256.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619633,,BAO_0000218,10000001.0,
7257.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875841,,BAO_0000218,10000001.0,
7258.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619634,,BAO_0000218,10000001.0,
7259.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619635,,BAO_0000218,10000001.0,
7260.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619636,,BAO_0000218,10000001.0,
7261.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619637,,BAO_0000218,10000004.0,
7262.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619638,,BAO_0000218,10000004.0,
7263.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619639,,BAO_0000218,10000004.0,
7264.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619640,,BAO_0000218,10000004.0,
7265.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619641,,BAO_0000218,10000004.0,
7266.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619642,,BAO_0000218,10000004.0,
7267.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619643,,BAO_0000218,10000004.0,
7268.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL619644,,BAO_0000218,948.0,
7269.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621112,,BAO_0000218,948.0,
7270.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621113,,BAO_0000218,948.0,
7271.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621114,,BAO_0000218,948.0,
7272.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621115,,BAO_0000218,948.0,
7273.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621116,,BAO_0000218,948.0,
7274.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621117,,BAO_0000218,948.0,
7275.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621118,,BAO_0000218,2113.0,
7276.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621119,,BAO_0000218,2113.0,
7277.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621120,,BAO_0000218,2113.0,
7278.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621757,,BAO_0000218,2113.0,
7279.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621758,,BAO_0000218,2113.0,
7280.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621759,,BAO_0000218,2113.0,
7281.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621760,,BAO_0000218,2113.0,
7282.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621761,,BAO_0000218,2107.0,
7283.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621762,,BAO_0000218,2107.0,
7284.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL621763,,BAO_0000218,2107.0,
7285.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624502,,BAO_0000218,2107.0,
7286.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624503,,BAO_0000218,2107.0,
7287.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624504,,BAO_0000218,2107.0,
7288.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624505,,BAO_0000218,2107.0,
7289.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624506,,BAO_0000218,2048.0,
7290.0,5895.0,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL624507,478.0,BAO_0000219,,
7291.0,6338.0,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL624508,478.0,BAO_0000219,,
7292.0,15163.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL624509,478.0,BAO_0000219,,
7293.0,15163.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL624510,478.0,BAO_0000219,,
7294.0,15000.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL875956,478.0,BAO_0000219,,
7295.0,15000.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL839885,478.0,BAO_0000219,,
7296.0,14729.0,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL624511,478.0,BAO_0000219,,
7297.0,17270.0,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL624512,478.0,BAO_0000219,,
7298.0,5685.0,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL624513,478.0,BAO_0000219,,
7299.0,3563.0,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL624514,478.0,BAO_0000219,,
7300.0,17753.0,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618547,478.0,BAO_0000218,,
7301.0,16317.0,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618548,478.0,BAO_0000219,,
7302.0,16936.0,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618549,478.0,BAO_0000219,,
7303.0,3801.0,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618550,478.0,BAO_0000219,,
7304.0,6181.0,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL618551,478.0,BAO_0000219,,
7305.0,5318.0,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618552,478.0,BAO_0000219,,
7306.0,4840.0,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618553,478.0,BAO_0000219,,
7307.0,15748.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618554,478.0,BAO_0000219,,
7308.0,15748.0,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618555,478.0,BAO_0000219,,
7309.0,15748.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,,,A2780cisR,,80017.0,N,1.0,Intermediate,1.0,,CHEMBL618556,481.0,BAO_0000219,,
7310.0,15748.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,,,A2780cisR,,80017.0,N,1.0,Intermediate,1.0,,CHEMBL618557,481.0,BAO_0000219,,
7311.0,15748.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,,,A2780cisR,,80017.0,N,1.0,Intermediate,1.0,,CHEMBL618558,481.0,BAO_0000219,,
7312.0,15748.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,,,A2780cisR,,80017.0,N,1.0,Intermediate,1.0,,CHEMBL618559,481.0,BAO_0000219,,
7313.0,17753.0,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618560,478.0,BAO_0000218,,
7314.0,17753.0,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618561,478.0,BAO_0000218,,
7315.0,16936.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618562,478.0,BAO_0000219,,
7316.0,16936.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618563,478.0,BAO_0000219,,
7317.0,16936.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618564,478.0,BAO_0000219,,
7318.0,16936.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618565,478.0,BAO_0000219,,
7319.0,17528.0,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618566,478.0,BAO_0000218,,
7320.0,6633.0,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL618567,478.0,BAO_0000219,,
7321.0,15000.0,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL618568,478.0,BAO_0000219,,
7322.0,17528.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL618569,478.0,BAO_0000219,,
7323.0,16936.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621857,478.0,BAO_0000219,,
7324.0,16936.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621858,478.0,BAO_0000219,,
7325.0,16936.0,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621859,478.0,BAO_0000219,,
7326.0,16936.0,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621860,478.0,BAO_0000219,,
7327.0,16936.0,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621861,478.0,BAO_0000219,,
7328.0,16936.0,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL621862,478.0,BAO_0000219,,
7329.0,16936.0,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621863,478.0,BAO_0000219,,
7330.0,16936.0,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621864,478.0,BAO_0000219,,
7331.0,16936.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621865,478.0,BAO_0000219,,
7332.0,17737.0,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621866,478.0,BAO_0000219,,
7333.0,17764.0,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0,,,A2780,,81034.0,N,1.0,Expert,1.0,,CHEMBL621867,478.0,BAO_0000219,,
7334.0,3830.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL621868,478.0,BAO_0000219,,
7335.0,3829.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034.0,N,1.0,Intermediate,1.0,,CHEMBL875282,478.0,BAO_0000219,,
7336.0,3546.0,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621869,,BAO_0000218,,
7337.0,3546.0,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621870,,BAO_0000218,,
7338.0,5668.0,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621871,,BAO_0000019,,
7339.0,3443.0,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621243,,BAO_0000218,1969.0,
7340.0,3443.0,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621244,,BAO_0000218,1969.0,
7341.0,4256.0,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621245,,BAO_0000218,,
7342.0,4256.0,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621246,,BAO_0000218,,
7343.0,4256.0,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621247,,BAO_0000218,,
7344.0,4256.0,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618386,,BAO_0000218,,
7345.0,1916.0,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618387,,BAO_0000218,,
7346.0,5302.0,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618388,,BAO_0000218,,
7347.0,4257.0,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618389,,BAO_0000218,,
7348.0,5355.0,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618574,,BAO_0000019,,
7349.0,5355.0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618575,,BAO_0000019,,
7350.0,5355.0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618576,,BAO_0000019,,
7351.0,6078.0,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618577,,BAO_0000218,,
7352.0,6078.0,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876487,,BAO_0000218,,
7353.0,6062.0,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618578,,BAO_0000218,,
7354.0,2661.0,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618579,,BAO_0000218,,
7355.0,2661.0,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618580,,BAO_0000019,,
7356.0,5394.0,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618581,,BAO_0000218,,
7357.0,4397.0,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618582,,BAO_0000218,,
7358.0,17509.0,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618583,,BAO_0000218,,
7359.0,17509.0,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618584,,BAO_0000218,,
7360.0,6641.0,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618585,,BAO_0000218,,
7361.0,5355.0,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618586,,BAO_0000218,,
7362.0,3443.0,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618587,,BAO_0000218,,
7363.0,3443.0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618588,,BAO_0000218,,
7364.0,17409.0,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618589,,BAO_0000019,,
7365.0,17409.0,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618590,,BAO_0000019,,
7366.0,1052.0,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL872262,,BAO_0000218,,
7367.0,13501.0,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618591,,BAO_0000218,,
7368.0,17509.0,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618592,,BAO_0000218,,
7369.0,5394.0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL876488,,BAO_0000218,,
7370.0,2661.0,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618593,,BAO_0000218,,
7371.0,11219.0,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618594,,BAO_0000218,,
7372.0,3045.0,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL618595,,BAO_0000218,,
7373.0,17796.0,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621469,,BAO_0000019,,
7374.0,1399.0,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621470,,BAO_0000218,,
7375.0,2661.0,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621471,,BAO_0000218,,
7376.0,5005.0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621472,,BAO_0000218,1969.0,
7377.0,17267.0,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621473,,BAO_0000218,,
7378.0,6535.0,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621474,,BAO_0000218,,
7379.0,5922.0,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621475,,BAO_0000218,,
7380.0,6221.0,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL621476,,BAO_0000218,,
7381.0,5668.0,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624290,,BAO_0000218,,
7382.0,5355.0,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624291,,BAO_0000218,,
7383.0,5355.0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624292,,BAO_0000218,,
7384.0,5355.0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624293,,BAO_0000218,,
7385.0,4578.0,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624294,,BAO_0000218,,
7386.0,17592.0,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224.0,U,0.0,Autocuration,1.0,,CHEMBL624295,,BAO_0000218,,
7387.0,6641.0,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624296,,BAO_0000218,,
7388.0,6642.0,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624297,,BAO_0000218,,
7389.0,16367.0,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624298,,BAO_0000218,,
7390.0,5472.0,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624299,,BAO_0000218,,
7391.0,5474.0,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624300,,BAO_0000218,,
7392.0,5654.0,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624301,,BAO_0000218,,
7393.0,6227.0,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624302,,BAO_0000218,,
7394.0,6227.0,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876026,,BAO_0000218,,
7395.0,6221.0,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624303,,BAO_0000218,,
7396.0,4527.0,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624304,,BAO_0000218,,
7397.0,5668.0,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624305,,BAO_0000218,,
7398.0,5668.0,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624306,,BAO_0000218,,
7399.0,3854.0,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624307,,BAO_0000218,,
7400.0,5505.0,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624308,,BAO_0000218,,
7401.0,6251.0,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624309,,BAO_0000218,,
7402.0,1918.0,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624310,,BAO_0000218,,
7403.0,5546.0,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625003,,BAO_0000218,,
7404.0,4809.0,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625004,,BAO_0000218,,
7405.0,6215.0,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625005,,BAO_0000218,,
7406.0,4527.0,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873813,,BAO_0000218,,
7407.0,17594.0,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625006,,BAO_0000218,,
7408.0,17839.0,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625007,,BAO_0000218,,
7409.0,17839.0,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876027,,BAO_0000218,,
7410.0,17839.0,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625008,,BAO_0000218,,
7411.0,17839.0,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625009,,BAO_0000218,,
7412.0,5210.0,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625010,,BAO_0000218,1969.0,
7413.0,5210.0,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL625011,,BAO_0000218,,
7414.0,2959.0,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621553,,BAO_0000218,,
7415.0,4137.0,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621554,,BAO_0000218,,
7416.0,5064.0,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621555,,BAO_0000218,,
7417.0,5147.0,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621556,,BAO_0000218,,
7418.0,5145.0,Half-life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621557,,BAO_0000218,,
7419.0,6123.0,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621558,,BAO_0000218,,
7420.0,6123.0,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621559,,BAO_0000218,,
7421.0,4333.0,Half-life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621560,,BAO_0000218,,
7422.0,4333.0,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL876028,,BAO_0000218,,
7423.0,12500.0,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621561,,BAO_0000218,1969.0,
7424.0,12500.0,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621562,,BAO_0000218,1969.0,
7425.0,6005.0,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621563,,BAO_0000218,,
7426.0,6062.0,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621564,,BAO_0000218,,
7427.0,17650.0,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621565,,BAO_0000218,,
7428.0,5530.0,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621566,,BAO_0000218,,
7429.0,5530.0,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL621567,,BAO_0000218,,
7430.0,5600.0,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL622978,,BAO_0000218,,
7431.0,6039.0,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL873814,,BAO_0000218,,
7432.0,6039.0,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623219,,BAO_0000218,,
7433.0,6039.0,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624477,,BAO_0000218,,
7434.0,6227.0,t1/2 in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624478,,BAO_0000218,,
7435.0,14541.0,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624479,,BAO_0000218,,
7436.0,4521.0,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL624480,,BAO_0000218,,
7437.0,4521.0,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623595,,BAO_0000218,,
7438.0,6679.0,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623596,,BAO_0000218,,
7439.0,1116.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0,,Plasma,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623597,,BAO_0000218,1969.0,
7440.0,5444.0,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623598,,BAO_0000218,,
7441.0,5444.0,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623599,,BAO_0000218,,
7442.0,17853.0,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623600,,BAO_0000218,,
7443.0,4353.0,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623601,,BAO_0000218,,
7444.0,16452.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623602,,BAO_0000218,,
7445.0,16452.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623603,,BAO_0000218,,
7446.0,16452.0,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588.0,N,1.0,Intermediate,1.0,,CHEMBL623604,,BAO_0000218,,
7447.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623605,,BAO_0000218,2048.0,
7448.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623606,,BAO_0000218,2048.0,
7449.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623607,,BAO_0000218,2048.0,
7450.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623608,,BAO_0000218,2048.0,
7451.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623609,,BAO_0000218,2048.0,
7452.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623610,,BAO_0000218,2048.0,
7453.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623611,,BAO_0000218,2385.0,
7454.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623612,,BAO_0000218,2385.0,
7455.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623613,,BAO_0000218,2385.0,
7456.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623614,,BAO_0000218,2385.0,
7457.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623615,,BAO_0000218,2385.0,
7458.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623616,,BAO_0000218,2385.0,
7459.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623617,,BAO_0000218,2385.0,
7460.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL875944,,BAO_0000218,14.0,
7461.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623618,,BAO_0000218,14.0,
7462.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623619,,BAO_0000218,14.0,
7463.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623620,,BAO_0000218,14.0,
7464.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623621,,BAO_0000218,14.0,
7465.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623622,,BAO_0000218,14.0,
7466.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623623,,BAO_0000218,14.0,
7467.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL623624,,BAO_0000218,2106.0,
7468.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618521,,BAO_0000218,2106.0,
7469.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618522,,BAO_0000218,2106.0,
7470.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618523,,BAO_0000218,2106.0,
7471.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618524,,BAO_0000218,2106.0,
7472.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL618525,,BAO_0000218,2106.0,
7473.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624586,,BAO_0000218,2106.0,
7474.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624587,,BAO_0000218,945.0,
7475.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624588,,BAO_0000218,945.0,
7476.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624589,,BAO_0000218,945.0,
7477.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624590,,BAO_0000218,945.0,
7478.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624591,,BAO_0000218,945.0,
7479.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624592,,BAO_0000218,945.0,
7480.0,10107.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594.0,N,1.0,Intermediate,1.0,,CHEMBL624593,,BAO_0000218,945.0,
7481.0,4689.0,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624594,,BAO_0000218,,
7482.0,4950.0,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624595,,BAO_0000218,,
7483.0,5328.0,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624596,,BAO_0000218,,
7484.0,406.0,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624597,,BAO_0000218,,
7485.0,12500.0,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624598,,BAO_0000218,,
7486.0,12500.0,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624599,,BAO_0000218,,
7487.0,5247.0,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL875166,,BAO_0000218,,
7488.0,4186.0,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624600,,BAO_0000218,1969.0,
7489.0,4186.0,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624601,,BAO_0000218,1969.0,
7490.0,6647.0,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624602,,BAO_0000218,,
7491.0,6484.0,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624603,,BAO_0000218,,
7492.0,3249.0,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624604,,BAO_0000218,,
7493.0,6281.0,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624605,,BAO_0000218,1969.0,
7494.0,3307.0,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624606,,BAO_0000218,,
7495.0,12058.0,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624607,,BAO_0000218,178.0,
7496.0,8833.0,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624608,,BAO_0000218,,
7497.0,3193.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624609,,BAO_0000218,178.0,
7498.0,3193.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624610,,BAO_0000218,178.0,
7499.0,3193.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624611,,BAO_0000218,178.0,
7500.0,3193.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624612,,BAO_0000218,178.0,
7501.0,3193.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL875167,,BAO_0000218,178.0,
7502.0,3193.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624613,,BAO_0000218,178.0,
7503.0,3193.0,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624614,,BAO_0000218,178.0,
7504.0,5960.0,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,,,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624392,,BAO_0000218,,
7505.0,13950.0,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624393,,BAO_0000218,955.0,
7506.0,13950.0,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624394,,BAO_0000218,955.0,
7507.0,13950.0,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624395,,BAO_0000218,955.0,
7508.0,13950.0,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624396,,BAO_0000218,955.0,
7509.0,13950.0,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624397,,BAO_0000218,955.0,
7510.0,13950.0,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624398,,BAO_0000218,2046.0,
7511.0,13950.0,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624399,,BAO_0000218,2046.0,
7512.0,13950.0,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624400,,BAO_0000218,2046.0,
7513.0,13950.0,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624401,,BAO_0000218,2046.0,
7514.0,13950.0,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624402,,BAO_0000218,2046.0,
7515.0,9866.0,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624403,,BAO_0000218,178.0,
7516.0,9866.0,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624404,,BAO_0000218,178.0,
7517.0,9866.0,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624405,,BAO_0000218,178.0,
7518.0,9866.0,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624406,,BAO_0000218,10000001.0,
7519.0,9866.0,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624407,,BAO_0000218,10000001.0,
7520.0,9866.0,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL624408,,BAO_0000218,10000001.0,
7521.0,9866.0,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL618644,,BAO_0000218,948.0,
7522.0,9866.0,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL618645,,BAO_0000218,948.0,
7523.0,9866.0,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597.0,N,1.0,Intermediate,1.0,,CHEMBL618646,,BAO_0000218,948.0,
